<SEC-DOCUMENT>0001776985-24-000091.txt : 20241104
<SEC-HEADER>0001776985-24-000091.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104065719
ACCESSION NUMBER:		0001776985-24-000091
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		241420717

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kq32024quarterlyrepo.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iaf38ecbe53f34a5bb80825157a1b3446_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF NOVEMBER 2024</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On November 4, 2024, BioNTech SE (the &#8220;Company&#8221;) provided a development update and reported its financial results for the three and nine months ended September 30, 2024. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three and nine months ended September 30, 2024, are attached hereto as Exhibit 99.1. In addition, an English translation of the Company&#8217;s current Articles of Association, which were registered with the commercial register (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of the local court (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Amtsgericht</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of Mainz, Germany effective as of August 30, 2024, is attached hereto as Exhibit 99.2. Exhibits 99.1 and 99.2 shall be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and incorporated by reference herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; November 4, 2024</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline"><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">Quarterly Report for the Three </a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">and </a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">Nine</a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline"> </a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">Months Ended </a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">September</a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline"> 3</a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">0</a><a href="bnt_2024q3ex99x1quarterlyr.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:124%;text-decoration:underline">, 2024</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.2</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="a992biontechsearticlesofas.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Articles of Association of the Registrant</a></font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bnt_2024q3ex99x1quarterlyr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i58ee89399d9d45f4ac20dcae213591ea_1"></div><div style="min-height:64.63pt;width:100%"><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><img alt="biontech_logoxforestgreen2.jpg" src="biontech_logoxforestgreen2.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:377px"></div></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><img alt="a230530_ihub-labxshootingx.jpg" src="a230530_ihub-labxshootingx.jpg" style="height:430px;margin-bottom:5pt;vertical-align:text-bottom;width:642px"></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%">BioNTech SE</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Quarterly Report of BioNTech SE for the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><br>three and nine months ended September 30, 2024</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A C T I N G    T O G E T H E R    &#8212;    C R E A T I N G    S Y N E R G I E S</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2476"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c&#47;o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:35.43pt;text-align:right"><font><br></font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_320"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED <br>FINANCIAL STATEMENTS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.467%"><tr><td style="width:1.0%"></td><td style="width:6.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_315" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Profit or Loss</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_315" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_310" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Comprehensive Income</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_310" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_305" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Financial Position</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_305" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_300" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Changes in Stockholders</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_300" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">&#8217;</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_300" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"> </a><a href="#i58ee89399d9d45f4ac20dcae213591ea_300" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Equity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_300" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim <a href="#i58ee89399d9d45f4ac20dcae213591ea_295" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Condensed Consolidated Statements of Cash Flows</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_295" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected Explanatory <a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Notes to the Unaudited Interim Condensed Consolidated </a></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Financial Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_366" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_433" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Corporate Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_433" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_438" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Basis of Preparation, Significant Accounting Policies and further </a></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_438" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Accounting Topics</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_438" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_446" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Revenues from Contracts with Customers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_446" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_882" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Income and Expenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_882" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">I</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">ncome Tax</a>es</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_484" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Intangible Assets</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_549755815327" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_490" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Financial Assets and Financial Liabilities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_490" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_738" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Issued Capital and Reserves</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_738" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_524" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Share-Based Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_524" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_2599" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Provisions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_2599" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_530" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Contingencies</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_530" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_536" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Related Party Disclosures</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_536" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%">OPERATING AND FINANCIAL REVIEW <br>AND PROSPECTS</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.934%"><tr><td style="width:1.0%"></td><td style="width:95.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_547" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Operating Results</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_547" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_632" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Liquidity and Capital Resources</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_632" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_549755815136" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_673"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">U</a><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">naudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_315"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Condensed Consolidated Statements of Profit or Loss</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:35.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,244.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">895.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,561.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,340.0</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(178.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(161.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(297.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(420.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(550.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(497.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,642.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,205.3)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(44.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(132.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(139.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(420.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(370.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating expenses </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(410.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(719.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(239.6)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,462.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">164.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">498.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Profit &#47; (Loss) before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">158.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">227.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(978.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">522.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(66.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.5)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">198.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">160.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(924.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">472.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Earnings &#47; (Loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings &#47; (loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.82</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.67</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.83)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.96</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted earnings &#47; (loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.81</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.66</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.83)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.94</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (please see Note 4.2 for further details).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_310"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Condensed Consolidated Statements of Comprehensive Income</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:42.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">198.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">160.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(924.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">472.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain &#47; (loss) on cash flow hedges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net other comprehensive income &#47; (loss) that may be reclassified to profit or loss in subsequent periods </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain &#47; (loss) on equity instruments designated at fair value through other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(108.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net other comprehensive income &#47; (loss) that will not be reclassified to profit or loss in subsequent periods</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(108.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive loss, net of tax </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(96.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.8)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Comprehensive income &#47; (loss), net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">186.8</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">152.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,021.4)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">471.6</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_305"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.833%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Condensed Consolidated Statements of Financial Position</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:56.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.700%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, </font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other intangible assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">873.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">804.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">917.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">757.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,332.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,176.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83.4</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,915.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,479.0</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">357.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade and other receivables </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,155.7</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,084.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,885.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">285.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179.1</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,624.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,663.7</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current assets </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18,486.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,527.3</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22,401.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23,006.3</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity and liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">248.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital reserve</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,373.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,229.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retained earnings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,838.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,763.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other reserves </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,336.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(984.6)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,114.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,245.9</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">206.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">191.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">376.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398.5</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">764.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">689.9</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">762.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">354.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">241.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">415.2</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">525.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">731.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">236.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">149.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,522.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,070.5</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,286.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,760.4</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total equity and liabilities </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22,401.2</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23,006.3</font></td></tr></table></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_300"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.864%"><tr><td style="width:1.0%"></td><td style="width:5.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Condensed Consolidated Statements of Changes in Stockholders&#8217;&#160;Equity</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:0.07pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.964%"><tr><td style="width:1.0%"></td><td style="width:20.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.211%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.348%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;, unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital reserve</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retained earnings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other reserves </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total equity </font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,828.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18,833.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(848.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,055.6</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">472.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">472.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">472.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">471.6</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Treasury shares used for acquisition of business combination</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share repurchase program</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(731.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(738.5)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,228.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,305.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(904.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,866.8</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">248.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,229.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,763.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(984.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,245.9</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(924.8)</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(924.8)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(96.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(96.6)</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(924.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(96.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,021.4)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(255.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(110.0)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">248.6</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,373.0</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8.8)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18,838.5</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,336.8)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,114.5</font></td></tr></table></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_295"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:55.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">198.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">160.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(924.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">472.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(39.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(54.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50.5</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Profit &#47; (Loss) before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">158.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">227.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(978.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">522.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjustments to reconcile profit before tax to net cash flows&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">132.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104.6</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payment expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">77.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(35.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(77.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(364.3)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gain) &#47; Loss on disposal of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.6</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Finance income excluding foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(156.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(148.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(498.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(357.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Finance expense excluding foreign exchange differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government grants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3.0)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized (gain) &#47; loss on derivative instruments at fair value through profit or loss</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">196.7</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Working capital adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decrease &#47; (Increase) in trade and other receivables, contract assets and other assets</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(830.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">631.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,267.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,662.0</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decrease in inventories</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Decrease) &#47; Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(25.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">590.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(293.9)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest received and realized gains from cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">73.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">166.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest paid and realized losses from cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax received &#47; (paid), net</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(190.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(417.8)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(134.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(143.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(761.2)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government grants received</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash flows from &#47; (used in) operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(638.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">811.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">671.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,520.5</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(53.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(219.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(165.6)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from sale of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.8)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of intangible assets and right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(97.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(141.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(348.9)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition of subsidiaries and businesses, net of cash acquired</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(336.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(336.9)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investment in other financial assets</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,958.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,047.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10,301.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,710.2)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from maturity of other financial assets</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,898.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">303.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,974.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">303.0</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash flows used in investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(142.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,232.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,687.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,259.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.1</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Repayment of loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.1)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments related to lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(36.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28.0)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share repurchase program</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(301.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(737.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash flows used in financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(311.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(38.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(765.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net decrease in cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(788.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(732.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,055.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(504.6)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in cash and cash equivalents resulting from exchange rate differences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125.3</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in cash and cash equivalents resulting from other valuation effects</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at the beginning of the period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,376.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,166.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,663.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,875.1</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and cash equivalents as of September 30</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,624.6</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13,495.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,624.6</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13,495.8</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Adjustments to prior-year figures relate to reclassifications within the cash flows from operating and investing activities, respectively.</font></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_366"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_433"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. Corporate Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE is a limited company incorporated and domiciled in Germany. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying unaudited interim condensed consolidated financial statements present the financial position and the results of operation of BioNTech&#160;SE and its subsidiaries and have been prepared on a going concern basis in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board. References to the &#8220;Company&#8221;, &#8220;BioNTech&#8221;, &#8220;Group&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical need and major global health burden. Our fully integrated model combines decades of research in immunology, translational drug discovery and development, a technology agnostic innovation engine, GMP manufacturing, and commercial capabilities to rapidly discover, develop and commercialize our marketed product and other candidate vaccines and therapies. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational mRNA vaccines and therapeutics, cell and gene therapies, targeted antibodies and small molecule immunomodulators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024 were authorized for issuance in accordance with a resolution of the Audit Committee of our Supervisory Board on October&#160;31, 2024.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_438"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:17pt;text-align:justify;text-indent:-17.01pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Basis of Preparation, Significant Accounting Policies and further Accounting Topics</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Preparation and Principles of Consolidation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024 have been prepared in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the audited consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and accompanying notes included in our Annual Report on Form 20-F as of and for the year ended December 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare and present our unaudited interim condensed consolidated financial statements in Euros and round numbers to millions of Euros. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024 include BioNTech SE and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Judgments, Estimates and Assumptions and Accounting Policies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited interim condensed consolidated financial statements requires our management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. This includes but is not limited to our judgment relating to our collaboration with Pfizer, Inc., or Pfizer, as described under the subheading &#8220;Pfizer Agreement Characteristics&#8221; in Note 3 to our audited consolidated financial statements as of and for the year ended December 31, 2023. In order to determine our share of the collaboration partner&#8217;s gross profits, we used certain information from the collaboration partner, including revenues from the sale of products and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain other sharable expense items, some of which is based on preliminary data shared between the partners.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This further includes but is not limited to judgments relating to the impairment tests of our goodwill and intangible assets, as the outcome of these tests is highly dependent on management&#8217;s assumptions regarding future cash flow projections, which require significant judgments and assumptions about future developments. They can be affected by a variety of factors, including but not limited to peak sales assumptions, clinical trial success rates and&#47;or estimation of weighted-average cost of capital. Changes to the assumptions underlying our goodwill and intangible assets impairment assessments could require material adjustments to the carrying amount of our recognized goodwill and intangible assets and may lead to impairment charges recognized in our condensed consolidated statements of profit or loss. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continually evaluates judgments and estimates, including those related to contingencies, revenues and expenses. Management bases its judgments and estimates on parameters available at the time when the unaudited interim condensed consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Such changes are reflected in the assumptions when they occur. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2023, except for income taxes, which are accounted for using the expected annual tax rate in our unaudited interim condensed consolidated financial statements (see Note 5).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we recognize acquired contractual rights to cash flows from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies as royalty assets. Since we do not own the intellectual property or have the right to commercialize the underlying products, royalty assets are recognized as financial assets measured at fair value through profit and loss. We recognize day one gains and losses only when the fair value is evidenced by a quoted price in an active market for the same instrument or is based on a valuation technique that only uses data from observable markets. In all other cases, we defer the difference between the fair value at initial recognition and the transaction price. After initial recognition, we recognize that deferred difference as a gain or loss only to the extent that it arises from a change in a factor that market participants would take into account when pricing the asset or liability.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standards Applied for the First Time</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IFRS standards applied for the first time as of January 1, 2024, as disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2023, had no impact on our unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_446"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Revenues from Contracts with Customers</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2004"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregated information on revenues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the disaggregation of our revenues from contracts with customers&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,113.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">885.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,310.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,306.7</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">251.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33.3</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,244.8</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">895.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,561.1</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,340.0</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 Vaccine Revenues</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2024, and 2023, COVID-19 vaccine revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide, mainly comprising our share of </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the collaboration partner&#8217;s gross profit derived from sales in the collaboration partner&#8217;s territory. Overall, our COVID-19 vaccine revenues amounted to &#8364;1,113.9&#160;million and &#8364;1,310.0&#160;million during the three and nine months ended September&#160;30, 2024, respectively. During the three and nine months ended September&#160;30, 2023, COVID-19 vaccine revenues amounted to &#8364;885.0&#160;million and &#8364;2,306.7&#160;million, respectively. The year-to-date change compared to the comparative prior year period was mainly due to lower revenues from the sales of our COVID-19 vaccines worldwide resulting from lower sales demand during the nine months ended September&#160;30, 2024. During the three months ended September&#160;30, 2024, our sales were higher compared to the prior year period, which were largely driven by the earlier approvals received for our variant-adapted COVID-19 vaccines in 2024. Our COVID-19 vaccine revenues are subject to seasonal effects in the fall &#47; winter of the northern hemisphere. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Revenues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2024, our other revenues were mainly derived from a pandemic preparedness contract with the German government effectively supplemented in the three months ended March 31, 2024.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from contracts with customers were recognized as follows&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Timing of revenue recognition</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goods and services transferred at a point in time</font></td><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">247.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">184.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">301.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">410.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goods and services transferred over time</font></td><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">124.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">3.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">231.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">12.7</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model </font><font style="background-color:#ffffff;color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">873.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">707.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">1,027.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">1,916.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,244.8</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">895.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,561.1</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,340.0</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales based on the share of the collaboration partners&#8217; gross profit.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_882"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Income and Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_454"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1 General Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2017"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of sales increased by &#8364;17.1&#160;million, or 11%, from &#8364;161.8&#160;million during the three months ended September&#160;30, 2023 to &#8364;178.9&#160;million during the three months ended September&#160;30, 2024, and decreased by &#8364;122.9&#160;million, or 29%, from &#8364;420.7&#160;million&#160;during the nine months ended September&#160;30, 2023 to &#8364;297.8&#160;million during the nine months ended September&#160;30, 2024. While we recognized lower cost of sales from our decreased COVID-19 vaccine sales in our </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">territories, particularly Germany, changes in our cost of sales were additionally impacted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by expenses arising from inventory write-downs to net realizable value amounting to &#8364;39.7&#160;million and &#8364;103.3&#160;million during the three and nine months ended September&#160;30, 2024, respectively, compared to &#8364;46.2&#160;million and &#8364;96.1&#160;million during the three and nine months ended September&#160;30, 2023, respectively (adjustments to prior-year figures relate to reclassifications). The inventories valued at net realizable value in our consolidated statement of financial position as of September&#160;30, 2024 take contractual compensation payments into consideration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses increased by &#8364;52.4&#160;million, or 11%, from &#8364;497.9&#160;million during the three months ended September&#160;30, 2023 to &#8364;550.3&#160;million during the three months ended September&#160;30, 2024, and increased by &#8364;437.1&#160;million, or 36%, from &#8364;1,205.3&#160;million&#160;during the nine months ended September&#160;30, 2023 to &#8364;1,642.4&#160;million during the nine months ended September&#160;30, 2024. The increase was mainly driven by advancing key pipeline candidates, such as our antibody drug conjugate, or ADC, antibody and individualized cancer-immunotherapy product candidates. Further contributions to the increase came from higher personnel expenses resulting from an increase in headcount.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and Administrative Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses decreased by &#8364;6.7&#160;million, or 5%, from &#8364;139.1&#160;million during the three months ended September&#160;30, 2023 to &#8364;132.4&#160;million during the three months ended September&#160;30, 2024, and increased by &#8364;49.6&#160;million, or 13%, from &#8364;370.7&#160;million&#160;during the nine months ended September&#160;30, 2023 to &#8364;420.3&#160;million during the nine months ended September&#160;30, 2024. The year-to-date increase compared to the comparative prior year period was primarily due to increased headcount and higher personnel expenses as a result. A reduction in external services led to a slight decrease in total general and administrative expenses during the three months ended September&#160;30, 2024, compared to the comparative prior year period. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_912"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2 Other Operating Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2044"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses recognized during the three and nine months ended September&#160;30, 2024, and 2023, are shown in the following table&#58; </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual disputes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">365.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">605.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation costs</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on derivative instruments at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">213.8</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">410.9</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">36.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">719.9</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">239.6</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Adjustments to prior-year figures relate to reclassifying legal costs in connection with certain litigation as other operating expenses, rather than general and administrative expenses, to reflect changes in reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2024, other operating expenses increased compared to each of the three and nine months ended September 30, 2023, primarily due to expenses incurred in connection with contractual disputes (see Note 10).</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_471"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.3 Other Operating Income</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2065"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income recognized during the three and nine months ended September&#160;30, 2024, and 2023, are shown in the following table&#58; </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Grants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.7</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.9</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on derivative instruments at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.7</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71.8</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.1</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.5</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.9</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56.3</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">27.8</font></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">103.0</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">105.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign exchange differences in the prior year comparative period included in operating income primarily arose from remeasuring our U.S. dollar-denominated trade receivables, which mainly relate to our COVID-19 collaboration with Pfizer, our U.S. dollar-denominated trade payables and our U.S. dollar-denominated other financial liabilities, which mainly relate to obligations incurred from our license agreements.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the amount of our grants deferred in our unaudited interim condensed consolidated financial statements amounted to &#8364;86.5&#160;million compared to &#8364;5.9&#160;million as of December&#160;31,&#160;2023.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_477"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.4 Finance Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2087"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finance result recognized during the three and nine months ended September&#160;30, 2024, and 2023, is shown in the following table&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance result</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">156.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">156.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">498.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">363.2</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains from financial instruments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">498.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">357.4</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4.5)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange differences, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total finance result</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">148.2</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">154.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">484.0</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">358.7</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2024, and 2023, the finance result was mainly derived from returns such as interests and sales resulting from our financial investments as well as fair value adjustments of our money market funds.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_484"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Income Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2024 and 2023, income taxes were calculated based on the best estimate of the weighted average annual income tax rates expected for the full financial years (estimated annual effective income tax rates) on ordinary income before tax adjusted by the tax effect of any discrete items. The income tax asset represents the portion of prepayments for corporate income taxes and trade taxes in Germany that have been estimated for the full financial year 2024 but not yet offset by income tax expenses calculated for the nine months ended September&#160;30, 2024. For the nine months ended September&#160;30, 2024, our effective income tax rate was approximately 5.5%. For the nine months ended September&#160;30, 2023, our effective income tax rate was approximately 9.7%. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the effective income tax rate was mainly driven by the expected negative result for 2024 and management&#8217;s assessment of the requirements in IAS 12, including on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. Thus, in countries where the requirements of IAS 12 were not fulfilled, no deferred tax asset was recognized. Such assessment takes into account the fact that there is an inherent risk of failure in pharmaceutical development and uncertainty of approvals that depend on external regulatory agencies&#8217; opinions. As of September&#160;30, 2024, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future, fulfilling the requirements set out by IAS 12. In accordance with IAS 12, a total deferred tax income of &#8364;38.2&#160;million was recognized in the interim condensed consolidated statements of profit or loss with respect to share-based payment programs during the nine months ended September 30, 2024. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the mandatory exception to recognizing and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes. Furthermore, we reviewed the corporate structure in light of the introduction of Pillar Two Model Rules in various jurisdictions. Since the Group&#8217;s relevant effective tax rate calculated for Pillar Two Purposes is mainly above 15% in all jurisdictions in which it operates, it has been determined that the Group is not materially subject to Pillar Two &#8220;top-up&#8221; taxes. Therefore, the consolidated financial statements for the three and nine months ended September&#160;30, 2024 do not include further information otherwise required by paragraphs 88B and 88C of IAS 12.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2120"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income taxes recognized during the three and nine months ended September&#160;30, 2024, and 2023, are shown in the following table&#58; </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87.5</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(52.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37.0)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income taxes expenses &#47; (income) </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(39.4)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">66.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(54.1)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50.5</font></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_549755815327"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Other Intangible Assets </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We examine the existence of indications of impairment using various factors, particularly deviations from sales forecasts and the analysis of changes in medium-term planning. The identification of indications of impairment takes place with the involvement of the responsible departments, taking external and internal information sources into consideration.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2024, the U.S. Food and Drug Administration, or FDA, lifted the partial clinical hold that was placed on the Phase 1 trial of our partner, MediLink Therapeutics (Suzhou) Co., Ltd, or MediLink,  evaluating BNT326&#47;YL202 (NCT05653752), which was announced on June 17, 2024. BNT326&#47;YL202 is a Human Epidermal Growth Factor Receptor 3, or HER3,-targeting antibody-drug conjugate, or ADC, candidate that is being developed in collaboration between us and MediLink. Trial recruitment was re-initiated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this information, we determined that the triggering event previously identified during the three months ended June 30, 2024 in connection with the asset related to the product candidate BNT326&#47;YL202 no longer existed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partner OncoC4, Inc., or OncoC4, collaborating in the development of a next-generation anti-CTLA-4 antibody candidate, or BNT316&#47;ONC-392 (gotistobart), decided to proactively pause enrollment of new patients in the OncoC4-sponsored two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 (NCT05671510), and informed the FDA of a possible variance in population results for further alignment. The decision was based on the recent assessment of the trial data by the independent data monitoring committee. The trial evaluates the efficacy and safety of the antibody candidate BNT316&#47;ONC-392 as monotherapy in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. Patients already enrolled in this trial continue to receive treatments. In addition, trials evaluating BNT316&#47;ONC-392 in other indications remain unaffected. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this information, during the three months ended September 30, 2024, we identified a triggering event in connection with the asset related to the product candidate BNT316&#47;ONC-392 and performed an impairment test. As a result of the analysis, we did not identify an impairment for this asset.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_490"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Financial Assets and Financial Liabilities</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:30.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Carrying amount</font></div></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Fair value</font></div></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Non-current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 1 (Fair value)</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 2 (Fair value)</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 3 (Fair value)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,350.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,350.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,350.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,350.2</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at fair value through OCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.2</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">131.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">131.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">131.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">131.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at amortized costs</font><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,078.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,137.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,215.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,215.2</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,745.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,745.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,745.0</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash at banks and on hand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">529.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">529.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">529.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trade and other receivables </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">988.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">988.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">988.0</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.9</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently measured at fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6.2</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43.3</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently measured at amortized costs</font><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">762.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">762.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">762.6</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">235.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">236.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">236.4</font></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently not measured according to IFRS 9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">206.3</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">243.7</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">243.7</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #becd32;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fair values for financial assets and liabilities at amortized costs are not disclosed as the book values represent a reasonable approximation. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2024, the non-listed and listed equity investments increased by &#8364;80.5&#160;million compared to year-end 2023 mainly due to our investment in Autolus Therapeutics plc in February 2024 and offsetting subsequent fair value changes amounting to &#8364;(108.3)&#160;million in the first half of 2024.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional developments in our financial assets and liabilities mainly resulted from growth and reallocation of existing capital. This led to a decrease of &#8364;2,095.9&#160;million in security investments subsequently measured at fair value through profit and loss (money market funds) and an increase of &#8364;2,225.5&#160;million in security investments subsequently measured at amortized costs (e.g. bonds, commercial paper) compared to year-end 2023.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:31.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.005%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Carrying amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Non-current</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 1 (Fair value)</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 2 (Fair value)</font></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Level 3 (Fair value)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at fair value through profit or loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,446.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,446.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,446.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,446.1</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at fair value through OCI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">27.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26.0</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial assets subsequently measured at amortized costs</font><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,885.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,104.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,989.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,989.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Security investments disclosed as cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,764.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,764.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,764.5</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash at banks and on hand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">453.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">453.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">453.1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trade and other receivables </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,155.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,155.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,155.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18.6</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently measured at fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Foreign exchange forward contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.4</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38.8</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently measured at amortized costs</font><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loans and borrowings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.3</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trade payables and other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">354.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">354.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">354.0</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">414.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">414.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">414.9</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Financial liabilities subsequently not measured according to IFRS 9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">188.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">216.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">216.7</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair values for financial assets and liabilities at amortized costs are not disclosed as the book values represent a reasonable approximation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity investments designated at Fair Value through OCI</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain &#47; (loss) on equity instruments designated at fair value through other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(108.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.7</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(108.3)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</font></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of fair values</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. </font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:20.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.752%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Type</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Valuation technique</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant unobservable inputs</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward exchange contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Actual and forecasted results</font></div><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Net Asset Value</font></div><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Cash position</font></div><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Nature and pricing indication of latest financing round</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Listed equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices on an active market.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n&#47;a</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent </font></div><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">consideration</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Expected future payments</font></div><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Applied cost of capital</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Royalty assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of expected future cash flows.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Expected future cash flows</font></div><div style="padding-left:8.5pt;text-indent:-8.51pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.51pt">Applied cost of capital</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Values (Level 3)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the recurring fair value measurement of contingent consideration and royalty assets as well as the effect of the measurements on our unaudited interim condensed consolidated statements of profit or loss for the current period.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:56.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Royalty assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contingent consideration</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6.1)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.7)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net effect on profit or loss - Finance income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(38.8)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(38.8)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37.7</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-right:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Disposals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net effect on profit or loss - Finance income &#47; (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net deferred effects on other non-financial liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change in fair value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="border-right:1pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(43.3)</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-right:1pt solid #bece33;padding:0 1pt"></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sensitivity of the fair values of contingent consideration to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:31.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.513%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Input factor</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in assumptions</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in fair value with increasing input factor <br>(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in fair value with decreasing input factor <br>(in millions &#8364;)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash flow projections</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="border-top:1pt solid #005a64;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sensitivity of the fair values of royalty assets to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty assets</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:31.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.513%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Input factor</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in assumptions</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in fair value with increasing input factor <br>(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in fair value with decreasing input factor <br>(in millions &#8364;)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash flow projections</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #005a64;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="border-top:1pt solid #005a64;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.4)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of non-listed equity investments would, for example, increase (decrease) if the price of the latest financing round of the respective investment were to increase (decrease) and the overall company value were higher (lower).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No changes have occurred regarding our risk management activities as disclosed in the notes to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2023. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_738"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Issued Capital and Reserves</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the number of shares outstanding was 239,739,752. This amount excludes 8,812,448&#160;shares held in treasury. As of December 31, 2023, the number of shares outstanding was 237,725,735, excluding 10,826,465 shares held in treasury.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_524"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. Share-Based Payments</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2154"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer Grant (Equity-Settled)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description of Share-Based Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we granted Prof. Ugur Sahin, M.D., an option to purchase 4,374,963 of our ordinary shares, subject to his continued employment with us, under the ESOP 2019 program. All of these option rights vested and became exercisable in 2023, and were exercised on August 9, 2024 with an exercise price for each option of &#8364;13.74 ($15.00) calculated using the foreign exchange rate published by the German Central Bank (Deutsche Bundesbank) on the exercise date and by applying the effective exercise cap and the maximum cap mechanism as disclosed in the notes to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2023. The closing price of one American Depositary Share, or ADS, representing one ordinary share of BioNTech on Nasdaq on the settlement date converted from U.S. Dollars to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#8364;73.68 and led to an intrinsic value of the exercised options of &#8364;259.5&#160;million.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory Board determined in August 2024 that settlements under the ESOP would be made by delivery of ordinary shares (in the form of ADSs) equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from the exercise. The respective </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of ADSs was settled with treasury shares. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from and withheld upon the exercise amounted to &#8364;123.2&#160;million and were paid by us in September 2024 in cash directly to the respective authorities. The settlement mechanism decision neither changed the rights as such nor changed the classification of the grant as equity-settled. As a result of the settlement, no additional share-based payments under IFRS 2 were recorded in this quarter. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2599"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. Provisions</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:58.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.904%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #bece33;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bece33;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2024</font></td><td colspan="3" style="border-top:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual disputes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">605.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Obligations from onerous CMO contracts</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80.2</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79.7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">740.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">278.1</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">731.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269.3</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.8</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed ongoing contractual disputes with licensors and collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under the respective agreements. Our current provisions as of September 30, 2024 included &#8364;605.0&#160;million related to such disputes. Significant judgment has been applied when considering the circumstances of these matters and the ultimate outcomes remain subject to significant uncertainties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, our current provisions included &#8364;50.7&#160;million&#160;(&#8364;80.2&#160;million as of December 31, 2023) of obligations for production capacities derived from contracts with contract manufacturing organizations, or CMOs, that became redundant. The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December 31, 2023. The related expenses were recognized in cost of sales in our consolidated statements of profit or loss. The change of &#8364;29.5&#160;million compared to December 31, 2023 related entirely to consumption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, our current provisions included &#8364;84.3 million in other obligations mainly comprising cost share effects as well as inventor remunerations (&#8364;79.7 million as of December 31, 2023, mainly comprising inventor remunerations as well as customs and duties). The change of &#8364;4.6&#160;million compared to December 31, 2023 related mainly to additions.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_530"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. Contingencies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingencies include, but are not limited to, intellectual property disputes and contractual disputes regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under the respective agreements, product-related disputes and actions by or on behalf of our shareholders. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the normal course and conduct of our business, we may be involved in proceedings with third parties about considering, for example, the use and&#47;or remuneration for use of such third party&#8217;s intellectual property. As of September&#160;30, 2024, none of the intellectual property-related considerations outlined below, of which we have either been notified, or for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to ongoing contractual disputes with licensors and collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under our agreements. We have recorded provisions for such matters to the extent that an economic outflow is deemed probable. As of September 30, 2024, certain amounts do not fulfill the criteria for recording a provision and represent contingencies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to an increasing number of product-related disputes. Our product liability claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics&#47;package leaflet) as well as label warnings and reliance thereon, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific evidence and findings, actual and provable defectiveness and injury, and other matters. These complexities vary from matter to matter. As of September&#160;30, 2024, none of these claims fulfill the criteria for recording a provision. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently subject to certain claims by or on behalf of our shareholders. As of September 30, 2024, these claims do not fulfill the criteria for recording a provision.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and&#47;or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and&#47;or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with IAS 37.92, we believe disclosure regarding the estimates of financial impact or regarding uncertainty as to the amount or maturity of provisions and contingent liabilities for certain legal cases would be prejudicial to us, and therefore we are omitting such disclosure herefrom. This is so as to not compromise the results of the proceedings or our interests.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pending matters to which we are a party are discussed below.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alnylam Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &#38; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#8216;933 Patent, is infringed by the cationic lipid used in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#8216;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &#38; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#8216;979 Patent, which is a continuation of the &#8216;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &#38; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479&#59; 11,633,480&#59; 11,612,657&#59; and 11,590,229, all of which are continuations of the &#8216;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the lawsuits have been consolidated into a single proceeding, which is currently expected to go to trial in July 2025.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Alnylam&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CureVac Proceedings</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infringement Proceedings &#8211; EP&#8217;122, DE&#8217;961, DE&#8216;974, DE&#8217;575, and EP&#8217;668</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP1857122B1, or EP&#8217;122, and three Utility </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or EP&#8217;668, to its German lawsuit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the D&#252;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#8217;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668) pending validity decisions in the DE&#8217;961, DE&#8217;974, and DE&#8217;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#8217;668 opposition proceedings before the Opposition Division of the European Patent Office, or the EPO. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668. On December 28, 2023, the D&#252;sseldorf Regional Court stayed the infringement proceedings as to EP&#8217;122 until a final appellate decision is rendered as to the validity of EP&#8217;122 by the Federal Court of Justice. On June 7, 2024, CureVac waived DE&#8217;575 and withdrew this utility model from the infringement proceedings. On July 2, 2024, the EPO Opposition Division issued a preliminary opinion noting that it believes EP&#8217;668 is likely invalid, and set an oral hearing for March 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infringement Proceedings &#8211; EP&#8217;755, DE&#8217;123, and DE&#8217;130</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP4023755B1, or EP&#8217;755, and two Utility Models DE202021004123U1, and DE202021004130U1. On June 7, 2024, CureVac waived DE&#8217;123 and withdrew this utility model from the infringement proceedings. A hearing on infringement with respect to EP&#8217;755 and DE&#8217;130 that was scheduled to occur in the D&#252;sseldorf Regional Court on September 10, 2024 was rescheduled for July 2025. On July 24, 2024, the EPO Opposition Division issued a preliminary opinion noting that it believes EP&#8217;755 is likely invalid, and set an oral hearing for May 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nullity Proceedings &#8211; EP&#8217;122</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that EP&#8217;122 is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#8217;122 nullity action in support of the validity of EP&#8217;122. The preliminary opinion did not address any infringement of EP&#8217;122. The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#8217;122. On April 30, 2024, the Federal Patent Court issued a judgment containing its written reasons for nullifying EP&#8217;122. On May 7, 2024, CureVac appealed the judgment, which is currently pending.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation Proceedings &#8211; DE&#8217;961, DE&#8216;974, and DE&#8217;575</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;974 is likely to be cancelled. On January 23, 2024, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;961 is likely to be cancelled. On March 7, 2024, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;575 is likely to be cancelled. On June 6, 2024, CureVac submitted a written statement to the German Patent and Trademark Office waiving DE&#8217;575. On June 12, 2024, we withdrew our request for cancellation of DE&#8217;575. On June 25 and 26, 2024, the German Patent and Trademark Office heard oral arguments regarding DE&#8217;961 and DE&#8217;974, and at the conclusion of the hearing on June 26, 2024, confirmed that both DE&#8217;961 and DE&#8217;974 were cancelled.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation Proceedings&#8211; DE&#8217;123 and DE&#8217;130</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we filed cancellation actions seeking the cancellation of German Utility Models DE&#8217;123 and DE&#8217;130 in the German Patent and Trademark Office. On June 6, 2024, CureVac submitted a written statement to the German Patent and Trademark Office waiving DE&#8217;123. On June 12, 2024, we withdrew our request for cancellation of DE&#8217;123. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. Patent Nos. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,135,312&#59; 11,149,278&#59; and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070&#59; 11,286,492&#59; 11,345,920&#59; 11,471,525&#59; 11,576,966&#59; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910. In June 2024, CureVac voluntarily dismissed with prejudice its claims of infringement with respect to the &#8216;493, &#8216;525, and &#8216;966 patents. Currently, a three-week trial is scheduled to begin in early March 2025. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against EP&#8217;122 and EP&#8217;668  in the Business and Property Courts of England and Wales, in the UK High Court of Justice, or the UK High Court. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#8217;122 and EP&#8217;668 patents in the Business and Property Courts of England and Wales. On December 18, 2023, we and Pfizer amended our pleadings to add a claim for revocation and declarations of invalidity and non-infringement with respect to EP&#8217;755. The UK High Court held a trial on EP&#8217;668 and EP&#8217;755 between July 10, 2024 and July 24, 2024. On October 8, 2024, the UK High Court released a judgment finding both EP&#8217;668 and EP&#8217;755 invalid. The UK High Court is expected to hold a hearing before the end of the fourth quarter of 2024, during which hearing CureVac may apply for the right to appeal the judgment as to EP&#8217;668 and EP&#8217;755. On October 25, 2024, CureVac agreed to a final and unappealable revocation of the UK designation of EP&#8217;122 and to discontinue its counterclaim for infringement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and utility models and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVac&#8217;s claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna Proceedings</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement of two European patents, 3590949B1, or EP&#8217;949, and 3718565B1, or EP&#8217;565. On November 7, 2023, the Opposition Division of the EPO revoked EP&#8217;565 after a one-day oral hearing, and on December 7, 2023, it issued its written decision revoking EP&#8217;565. On December 8, 2023, the Opposition Division issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. As a result of those developments in the EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025. On February 7, 2024, Moderna appealed the Opposition Division&#8217;s revocation decision on EP&#8217;565, and the appeal is currently pending. On May 16, 2024, the Opposition Division decided that EP&#8217;949  is valid, in amended form, and issued its written decision regarding the same on July 8, 2024. BioNTech appealed this decision, and the appeal is currently pending. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit asserting </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, and Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales, in the UK High Court. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of EP&#8217;949 and EP&#8217;565.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK High Court held a trial between April 22, 2024, and May 21, 2024. On July 2, 2024, the UK High Court released two judgments. The first judgment concerns the validity of EP&#8217;949 and EP&#8217;565. In this first </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, the UK High Court found that EP&#8217;565 is invalid and therefore not infringed, while EP&#8217;949 is valid and infringed. The second judgment concerns whether Moderna&#8217;s October 2020 commitment not to &#8220;enforce &#91;its&#93; COVID-19 related patents against those making vaccines intended to combat the pandemic,&#8221; or the Patent Pledge, amounted to a consent under UK law to carry out any acts that would otherwise amount to patent infringement. With respect to this judgment, the UK High Court found that Moderna&#8217;s Patent Pledge amounted to consent to carry out activities that might otherwise infringe its patents prior to March 2022, but not after March 2022. A hearing before the UK High Court is scheduled for September 25, 2024, where the parties are expected to apply for the right to appeal. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK High Court held a hearing on September 25, 2024, during which the Court granted Pfizer and BioNTech permission to appeal its judgment regarding the validity of EP&#8217;949, and denied Moderna permission to appeal its judgment regarding validity of EP&#8217;565. No party sought permission to appeal the UK High Court&#8217;s judgment on the patent pledge.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. District Court Litigation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit in the U.S. District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of U.S. Patent Nos. 10,898,574&#59; 10,702,600 and 10,933,127 and seeking monetary relief. On April 12, 2024, the U.S. District Court for the District of Massachusetts stayed the litigation pending resolution of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent Nos. 10,702,600 and 10,933,127.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inter Partes Review</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board, or the PTAB. On March 6, 2024, the PTAB issued decisions instituting </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings on all challenged claims of U.S. Patent Nos. 10,702,600 and 10,933,127. An oral hearing on the merits is scheduled to occur in December 2024. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8216;949 and EP&#8217;565. The District Court of the Hague held a hearing on October 6, 2023, on infringement and validity with respect to EP&#8217;949. On December 6, 2023, the Court found EP&#8217;949 to be invalid. On March 5, 2024, Moderna appealed this decision, and the appeal is pending. The EP&#8217;565 case has been stayed pending the outcome of Moderna&#8217;s appeal of the Opposition Division&#8217;s revocation of EP&#8217;565.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the High Court of Ireland. On February 26, 2024, the High Court of Ireland stayed the lawsuit pending the final determination of the EPO opposition proceedings for EP&#8217;949 and EP&#8217;565 (in each case including any appeals). </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the Brussels Dutch-speaking Enterprise Court. On May 29, 2024, the parties filed a joint request to stay the proceedings, which was entered by the Enterprise Court.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arbutus and Genevant Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus&#58; U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GlaxoSmithKline Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, or GSK, filed a lawsuit against Pfizer and us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware alleging that the cationic lipid used in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes U.S. Patent Nos. 11,638,693&#59; 11,638,694&#59; 11,666,534&#59; 11,766,401&#59; and 11,786,467&#59; and seeking monetary relief. On August 14, 2024, GSK filed an amended complaint to assert infringement of three additional patents, U.S. Patent Nos. 11,759,422&#59; 11,655,475&#59; and 11,851,660. This proceeding is currently pending.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of GlaxoSmithKline&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">adewig Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we and certain of our officers and directors were named as defendants in a securities class action complaint captioned Ladewig v. BioNTech SE filed in the U.S. District Court for the Central District of California brought on behalf of a putative class of investors who purchased our securities from March 30, 2022 through October 13, 2023. Plaintiffs allege that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, by stating that we were &#8220;well positioned&#8221; to remain a &#8220;market leader&#8221; in vaccines for the prevention of COVID-19 and by purportedly overstating demand for Comirnaty. Plaintiffs further allege that we failed to adapt our inventory to reflect the emergence of new COVID variants. On July 15, 2024, the case was transferred to the U.S. District Court for the Southern District of New York. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the allegations to be without merit and intend to vigorously defend our Company in this lawsuit. We cannot reasonably estimate the maximum potential exposure or the range of possible loss for this matter. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_536"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. Related Party Disclosures</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and a beneficial owner of our ordinary shares. Entities controlled by ATHOS KG mainly provide rental and property management activities and sell property, plant and equipment to us. The total amount of transactions with </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG or entities controlled by them had no significant impact on our unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024, compared to the details disclosed in Note 21 to our audited consolidated financial statements included in our Annual Report on Form 20-F as of and for the year ended December 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Management Board and the Supervisory Board of BioNTech SE  are related parties as key management personnel having authority and responsibility for planning, directing, and controlling the activities of BioNTech SE  directly or indirectly. Information with regard to transactions with a member of BioNTech SE&#8217;s management is disclosed in Note 9.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1131"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Operating and Financial Review and Prospects</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, unless stated or the context otherwise requires, references to the &#8220;Company&#8221;, &#8220;BioNTech&#8221;, &#8220;Group&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries. The following &#8220;Operating and Financial Review and Prospects&#8221; should be read together with the unaudited interim condensed consolidated financial statements and related notes as presented above. The following discussion is based on our financial information prepared in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described in the &#8220;Risk Factors&#8221; section further below. Please also see &#8220;Forward-Looking Statements&#8221; included elsewhere in this quarterly report for the three and nine months ended September&#160;30, 2024. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_547"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Results</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_581"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, or AI, and machine learning, or ML, capabilities to discover, develop and commercialize our marketed product and product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational messenger ribonucleic acid, or mRNA vaccines, protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates, or ADCs), cell therapies and small molecules.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect each platform to yield a pipeline of product candidates for further development. Our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases. We aim to expand this status into other disease areas in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we endeavor to address the continuum of cancer disease. The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient&#8217;s cancer is unique and within one patient&#8217;s tumor, every cell is different. Addressing these two challenges is the core of our strategy. To augment anti-tumor activity and to counteract resistance mechanisms we seek to combine compounds with non-overlapping, synergistic mechanisms of action.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In infectious diseases, our product strategy is rooted in global social responsibility and our goal of contributing to equitable access to medicine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach has generated a robust and diversified product pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed product, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1509"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social, and Governance (ESG) </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech was founded out of a responsibility to patients and to society and this is still the vision that drives the Company. It gives grounds for BioNTech&#8217;s enhanced responsibility&#58; for translating the Company&#8217;s science into the health of people worldwide and contributing to equitable access to innovative medicines, for environmental and climate protection, for respecting human rights and for fostering the full potential of all employees. BioNTech recognizes its responsibility as a corporate citizen and is committed to supporting its local communities and beyond through donations, sponsorships and volunteer activities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech&#8217;s performance on environmental, social, and governance matters is regularly assessed by external rating agencies. BioNTech retained its &#8220;Prime&#8221; status from ISS ESG in the recently published assessment </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results for 2024, placing BioNTech in the top 10% of all companies rated in the Pharmaceuticals and Biotechnology sector. In addition, BioNTech improved its overall rating from a B- to a B in the overall Corporate Rating 2024 on a scale from D- (lowest rating) to A+ (highest rating). ISS has extended its ESG Quality Score by the two categories &#8220;Social&#8221; and &#8220;Environment&#8221;, where BioNTech currently is rated with a 2 and 1 respectively. These scores indicate a company&#8217;s transparency with a focus on social and environmental matters on a scale from 1 (high disclosure) to 10 (low disclosure). Furthermore, BioNTech achieved a 5 in the &#34;Governance&#8221; dimension of the ISS Quality Score on a risk scale ranging from 1 (low risk) to 10 (high risk). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the results of the yearly S&#38;P Corporate Sustainability Assessment (S&#38;P CSA) have been published recently&#58; BioNTech received 52 out of 100 possible points in the 2024 assessment. Since 2022, BioNTech has been actively engaging in the comprehensive S&#38;P CSA rating process and has been listed as a participating company. For the third time in a row, the Company was able to significantly improve its result (2023&#58; 45&#47;100 points&#59; 2022&#58; 32&#47;100 points). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech&#8217;s CSR Management, including the fields of action and the material CSR topics, is presented in detail in the separate 2023 Sustainability Report and made available online at www.biontech.com. More information about BioNTech&#8217;s performance in selected ESG ratings, BioNTech&#8217;s Human Rights Statement as well as further relevant information and material can also be found on the Company&#8217;s website. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_560"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketed Product&#58; </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comirnaty</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, our COVID-19 Vaccine Program (BNT162) </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 vaccination has played an important role in saving lives and livelihoods across the world. Our commercial product, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was the first-ever approved mRNA-based product, and, to our knowledge, remains the fastest ever developed prophylactic vaccine from viral sampling to approval. As of December 2023, our COVID-19 vaccine products have been authorized or approved for emergency or temporary use or granted marketing authorization in more than 180 countries and regions worldwide. Our efforts have resulted in more than 4.8 billion doses shipped globally. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Pfizer, we are the Marketing Authorization Holder in the United States, the European Union, or EU, the UK, Canada and other countries. Additionally, we are the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries for the COVID-19 vaccine program. Pfizer has marketing and distribution rights worldwide apart from Greater China, Germany, and T&#252;rkiye. We have the marketing and distribution rights to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany and T&#252;rkiye.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, Fosun Pharma has marketing and distribution rights in Mainland China, Hong Kong Special Administrative Region, or SAR, Macau SAR and Taiwan region.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Commercial Updates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2024, we conducted the required preparation activities for COVID-19 vaccine adaptation and for the commercial launch of SARS-CoV-2 variant-adapted vaccines for the 2024&#47;2025 vaccination season.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024&#47;2025 fall and winter formulation for all eligible populations is available in multiple presentations&#58; as pre-filled syringes, multi-dose vials and single-dose vials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that as SARS-CoV-2 continues to evolve, and the risk of severe COVID-19 disease and deaths persists, particularly for high-risk populations, there will be continued demand for primary and seasonal vaccinations, especially for at-risk and immunocompromised groups. We also expect to continue the transition from an advanced purchase agreement environment to commercial market ordering in more geographies, driven by updated regulatory recommendations to adapt COVID-19 vaccines to newly circulating variants or sublineages of SARS-CoV-2.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B. Clinical Development, Regulatory and Manufacturing Updates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omicron JN.1 sublineages currently account for the majority of COVID-19 cases globally and are antigenically distant from prior circulating SARS-CoV-2 lineages, including Omicron XBB.1.5, Omicron BA.4&#47;BA.5 and the original SARS-CoV-2 strain. Although Omicron XBB.1.5-adapted monovalent vaccines provided some protection against a range of outcomes from JN.1-related COVID-19 disease, evidence </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suggests that vaccines better matched to currently circulating sublineages should provide improved protection against symptomatic and severe COVID-19 disease.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the World Health Organization, or WHO, and the European Medicines Agency, or the EMA, followed by other health authorities, provided guidance highlighting evidence that updated vaccines targeting Omicron JN.1 or JN.1 sublineages may contribute to maintaining protection against COVID-19 during the upcoming fall and winter season. On June 27, 2024, the Committee for Medicinal Products for Human Use, or CHMP, of the EMA recommended marketing authorization for our and Pfizer&#8217;s Omicron JN.1-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. The adaptation was based on the recommendation from the WHO Technical Advisory Group on COVID-19 Vaccine Composition and the EMA&#8217;s Emergency Task Force, or ETF, to update COVID-19 vaccines to target the SARS-CoV-2 variant JN.1 for the 2024&#47;2025 fall and winter vaccination campaign. On July 3, 2024, the European Commission, or EC, adopted an EC Decision in accordance with the CHMP&#8217;s recommendation. Shortly following the EC decision, the updated vaccine was made available for shipment to EU member states. On the same date, July 3, 2024, the EC adopted an EC Decision that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be administered concomitantly with seasonal influenza vaccine in individuals 12 years of age and older and authorized a new presentation for the 30-mcg adapted vaccine, namely glass pre-filled syringe (refrigerated storage conditions). The EC also authorized glass pre-filled syringes, a new presentation of the vaccine that allows for refrigerated storage conditions. On September 19, 2024, the CHMP of the EMA also recommended marketing authorization for our and Pfizer&#8217;s Omicron KP.2-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 in individuals six months of age and older. Following the EC&#8217;s approval on September 26, 2024, we and Pfizer began shipments of our Omicron KP.2-adapted COVID-19 vaccine to EU member states that have specifically ordered this formulation with availability varying based on individual country government requests and national recommendations.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the U.S. Food and Drug Administration&#8217;s, or FDA&#8217;s, Vaccines and Related Biological Products Advisory Committee, or VRBPAC, issued guidance recommending the manufacturing of a JN.1-adapted monovalent COVID-19 vaccine for the 2024&#47;2025 fall and winter seasons. On June 13, 2024, the FDA announced the KP.2 strain as the preferred JN.1-lineage for COVID-19 vaccines, if feasible. In June 2024, we and Pfizer submitted a regulatory application to the FDA for an Omicron JN.1-adapted monovalent vaccine and initiated a rolling supplemental Biologics Licensing Application, or sBLA, for an Omicron KP.2-adapted monovalent vaccine. On August 22, 2024, the FDA approved the sBLA for the companies&#8217; Omicron KP.2-adapted 2024-2025 formula COVID-19 vaccine for individuals 12 years of age and older and granted emergency use authorization for individuals six months through 11 years of age. This season&#8217;s Pfizer and BioNTech COVID-19 vaccine was shipped promptly following approval and was made available in pharmacies, hospitals, and clinics across the U.S. On October 10, 2024, FDA approved the sBLA to include safety and immunogenicity data from a study in which individuals 18 through 64 years of age received COMIRNATY concomitantly with a seasonal influenza vaccine.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2024, the UK&#8217;s Medicines and Healthcare products Regulatory Agency, or MHRA, approved the companies&#8217; Omicron JN.1-adapted vaccine and on October 10, 2024, the companies&#8217; KP.2 adapted vaccine was also approved by the MHRA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer have been manufacturing the Omicron JN.1-adapted monovalent COVID-19 vaccine at risk to ensure supply readiness ahead of the upcoming fall and winter seasons when the demand for COVID-19 vaccination is expected to increase. We and Pfizer intend to continue to monitor the evolving epidemiology of COVID-19 and remain prepared to develop modified vaccine formulas as the data support and as regulatory agencies recommend.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The companies&#8217; regulatory filings have been based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the Pfizer-BioNTech COVID-19 vaccines. These applications also included manufacturing and non-clinical data showing that the KP.2- and JN.1-adapted monovalent COVID-19 vaccine generates a substantially improved response against multiple Omicron JN.1 sublineages, including KP.2, KP.3, and other currently circulating sublineages, compared with the companies&#8217; Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2790"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline of Product Candidates&#58; Third Quarter of 2024 and Post Period-End Updates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our authorized product and clinical product candidates, organized by platform and indication.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Oncology</font></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Drug class </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Platform</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Product candidate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Indication (target)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 1&#47;2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">BioNTech </font></div><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">rights</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:700;line-height:133%;position:relative;top:-1.75pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Collaborator&#47;Partner</font></td></tr><tr style="height:5pt"><td colspan="3" rowspan="30" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">mRNA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">FixVac</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT111&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Advanced, R&#47;R melanoma</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Fully owned</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:400;line-height:120%;position:relative;top:-1.75pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT113&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Metastatic &#47; R&#47;R HPV16+ head and neck cancer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT116&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">1L metastatic NSCLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Advanced&#47;metastatic NSCLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">iNeST</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT122 &#47; RO7198457 (autogene cevumeran) </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">1L advanced melanoma</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Genentech </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:400;line-height:133%;position:relative;top:-1.75pt;vertical-align:baseline">(3)</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Adjuvant colorectal cancer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Adjuvant pancreatic ductal adenocarcinoma</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">RiboMabs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT142&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (CD3&#215;CLDN6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">RiboCytokines</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT152 + BNT153</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (IL-7, IL-2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="6" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Cell <br>therapies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">CAR T cells + CARVac</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT211</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (CLDN6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Neoantigen-based T cells</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT221</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Refractory metastatic melanoma</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="57" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Protein-based therapeutics</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="36" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Next-generation</font></div><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">immune checkpoint modulators&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT311 &#47; GEN1046 (acasunlimab)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">aPD(L)1-R&#47;R metastatic NSCLC (PD-L1&#215;4-1BB)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="15" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="15" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Genmab</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT312 &#47; GEN1042</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (CD40&#215;4-1BB)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT314 &#47; GEN1059</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (EpCAM&#215;4-1BB)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT315 &#47; GEN1055</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (OX40)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT322 &#47; GEN1056</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT316 &#47; ONC-392 (gotistobart)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">aPD(L)1-R&#47;R metastatic NSCLC (CTLA-4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">OncoC4</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Platinum-resistant ovarian cancer (CTLA-4) </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Metastatic castration-resistant prostate cancer (CTLA-4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (CTLA-4) </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT327&#47;PM8002</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">1L&#47;2L+ ES-SCLC (PD-L1 x VEGF-A)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Biotheus</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">1L&#47;2L metastatic TNBC (PD-L1 x VEGF-A)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT327&#47;PM8002 + BNT325&#47;DB-1305</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Biotheus &#47; Duality Biologics</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Targeted cancer antibodies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT321 </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Adjuvant pancreatic ductal adenocarcinoma (sLea)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Metastatic pancreatic cancer (sLea)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="15" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Antibody-drug conjugates</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT323 &#47; DB-1303 (trastuzumab pamirtecan)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">HR+&#47;HER2-low metastatic breast cancer (HER2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="12" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Duality Biologics</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (HER2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT324 &#47; DB-1311</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (B7H3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT325 &#47; DB-1305</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (TROP2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT326 &#47; YL202</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (HER3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">MediLink Therapeutics</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">SMI</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:700;line-height:133%;position:relative;top:-1.75pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Toll-like receptor binding</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT411</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Multiple solid tumors (TLR7)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Infectious Diseases</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Drug class </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Product candidate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Indication</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 1&#47;2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Phase 3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Commercial</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">BioNTech rights</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:700;line-height:133%;position:relative;top:-1.75pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">Collaborator&#47;Partner</font></td></tr><tr style="height:5pt"><td colspan="3" rowspan="30" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:133%">mRNA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT162b2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="9" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">COVID-19</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Pfizer<br>Fosun Pharma</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#005a64;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT162b5&#47;6&#47;7</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT162b + BNT162b4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT162b2+BNT161</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">COVID-19 &#8211; Influenza combination</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Pfizer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT161</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Influenza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Collaboration</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Pfizer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT163</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">HSV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">University of Pennsylvania</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT164</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Tuberculosis</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:400;line-height:120%;position:relative;top:-1.75pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Funded by Bill &#38; Melinda Gates Foundation</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT165</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Malaria</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT166</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Mpox</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Funded by CEPI</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:3.25pt;font-weight:400;line-height:133%;position:relative;top:-1.75pt;vertical-align:baseline"> (7)</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT167</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Shingles</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Collaboration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Pfizer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:133%">Protein-based therapeutics</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">BNT331</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Bacterial vaginosis</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:133%">Fully owned</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #005a64;border-top:1pt solid #005a64;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#3c9673;padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:10pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dashed #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For further details about BioNTech&#8217;s rights, see the discussions elsewhere in this quarterly report.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">FixVac</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Genentech, a member of the Roche Group.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Small Molecule Immunomodulators.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Out-licensed to Pfizer.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 1 clinical trials are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa).</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Coalition for Epidemic Preparedness Innovations, or CEPI.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Oncology Programs </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. mRNA Product Candidates in Oncology</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA-based cancer vaccine product candidates contain our pharmacologically optimized-backbone equipped uridine mRNA, or uRNA, delivered in our proprietary RNA-LPX formulation for intravenous administration. Proprietary RNA-LPX protects RNA from degradation by RNAse and delivers antigen-encoding RNA into antigen-presenting cells in lymphoid organs. These product candidates trigger innate and adaptive immune responses. Our mRNA-based cancer vaccine portfolio includes our FixVac and iNeST technology approaches.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a) FixVac</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our wholly owned, systemically administered, off-the-shelf mRNA-based cancer immunotherapy approach, from which we are developing several first-in-human and potential first-in-class product candidates. Our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates encode shared tumor-antigens that have been identified as frequently expressed across patients with a specific cancer type. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT111 in advanced melanoma.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized Phase 2 clinical trial (BNT111-01&#59; NCT04526899) is being conducted in collaboration with Regeneron Pharmaceuticals Inc., or Regeneron, to evaluate BNT111 in combination with cemiplimab in 184 enrolled patients with anti-PD-(L)1 refractory&#47;relapsed, unresectable Stage III or IV melanoma. The primary endpoint is objective response rate, or ORR. Secondary endpoints include duration of response, or DOR, disease control rate, or DCR, time to response, or TTR, progression-free survival, or PFS, overall survival, or OS, and safety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2024, we announced that the trial met its primary efficacy outcome measure, demonstrating a statistically significant improvement in ORR in patients treated with BNT111 in combination with  cemiplimab, as compared to a historical control in this indication and setting. The ORR in the cemiplimab monotherapy arm was in line with the historical control of anti-PD-(L)1 or anti-CTLA-4 treatments in this patient group. The treatment was generally well tolerated and the safety profile of BNT111 in combination with cemiplimab in this trial was consistent with previous clinical trials assessing BNT111 in combination with anti-PD-(L)1-containing treatments. The Phase 2 trial will </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue as planned to further assess the secondary endpoints which were not mature at the time of the primary analysis. We plan to present these data at an upcoming medical conference in 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT113 in Human Papilloma Virus 16-positive, or HPV16+, head and neck cancer.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A global, randomized Phase 2 clinical trial (AHEAD-MERIT&#59; NCT04534205) is being conducted to evaluate BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment in patients with unresectable, recurrent or metastatic, PD-L1+, HPV16+ head and neck squamous cell carcinoma, or HNSCC. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, an exploratory analysis of antitumor activity (15 patients) and immunogenicity from the safety run-in of AHEAD-MERIT was presented at the 2024 Congress of the European Society of Medical Oncology, or ESMO. The ORR was found to be 40.0% as assessed by blinded independent central review, or BICR, and 33.3% as assessed by the investigator, and a medium PFS, or mPFS, of 3.9 months as per BICR and 6.0 months as per investigator. BNT113 was observed to induce </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T-cell responses against HPV16 E6 and E7 oncoproteins. The combination of BNT113 and pembrolizumab was well tolerated. Treatment emergent adverse events, or TEAEs,  were mostly grade 1 and 2. In summary, the safety run-in cohort of the ongoing AHEAD-MERIT trial supported the tolerability of BNT113 and clinical activity in combination with pembrolizumab was observed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, also at ESMO, results were presented from an investigator-sponsored Phase 1&#47;2 dose escalation clinical trial (HARE-40&#59; NCT03418480) evaluating BNT113 alone in the post-adjuvant and metastatic settings in patients with HPV16+ head and neck and other cancers. BNT113 was shown to induce immune responses in patients in the adjuvant and end-stage clinical settings and to be overall well tolerated with a manageable safety profile.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT116 in advanced non-small-cell lung cancer, or NSCLC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, controlled Phase 2 clinical trial (EMPOWERVAX Lung 1&#59; NCT05557591) is being conducted to evaluate BNT116 in combination with cemiplimab versus cemiplimab alone as first-line treatment of patients with advanced NSCLC whose tumors express PD-L1 in &#8805; 50% of their tumor cells. The primary objective of the Phase 2 trial is to assess the ORR per blinded-independent review committee. Secondary endpoints include other measures of clinical activity per investigator assessment, OS, and safety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1 clinical trial (LuCa-MERIT-1&#59; NCT05142189) is being conducted to evaluate the safety, tolerability and preliminary efficacy of BNT116 alone and in combination with cemiplimab in patients who have progressed on prior anti-PD-(L)1 inhibitor treatment or are not eligible for chemotherapy, in patients with unresectable stage III NSCLC who have undergone chemoradiotherapy and also in the neoadjuvant and adjuvant settings in patients with resectable stage II and III NSCLC, or in combination with docetaxel in patients who have received prior anti-PD-(L)1 inhibitor therapy and platinum-based chemotherapy. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A data update is expected to be presented at the 2024 Society for Immunotherapy of Cancer, or SITC, Annual Meeting, taking place from November 6 to November 10, 2024 in Houston, Texas, U.S. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b) Autogene Cevumeran (BNT122&#47;RO7198457), an Individualized Neoantigen Specific Immunotherapy, or iNeST</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene cevumeran (BNT122&#47;RO7198457) is an individualized cancer immunotherapy product candidate based on up to 20 specific neoantigens that are present on a patient&#8217;s tumor and it is manufactured on-demand. iNeST is partnered with Genentech, a member of the Roche Group, as part of a 50&#58;50 collaboration in which development costs and future profits are shared for all trials, excluding trial BNT122-01 in adjuvant colorectal cancer, which is fully funded and being executed by BioNTech. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene Cevumeran (BNT122&#47;RO7198457) in high-risk muscle-invasive urothelial carcinoma, or MIUC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, double-blind, multi-site Phase 2 clinical trial (IMCODE-004&#59; NCT06534983) evaluating autogene cevumeran as an adjuvant treatment with nivolumab in patients with high-risk MIUC has been initiated. The trial is expected to enroll approximately 360 patients to evaluate the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efficacy of autogene cevumeran in combination with nivolumab compared to nivolumab alone. The primary endpoint for the study is investigator-assessed disease-free survival, or DFS. Secondary objectives include OS and safety. The trial has been initiated in Australia, Canada, Germany, Italy and the U.S. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene Cevumeran (BNT122&#47;RO7198457) in adjuvant colorectal cancer.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, multi-site, open-label Phase 2 clinical trial (BNT122-01&#59; NCT04486378) evaluating autogene cevumeran as an adjuvant treatment of circulating tumor DNA, or ctDNA, positive, surgically resected Stage II (high risk)&#47;Stage III colorectal cancer, or CRC, is ongoing. The trial is expected to enroll about 200 patients to evaluate the efficacy of autogene cevumeran compared to watchful waiting after surgery and chemotherapy, which is the current standard of care for these high-risk patients. The primary endpoint for the study is DFS. Secondary objectives include OS and safety. BioNTech plans to disclose interim data from the ongoing Phase 2 clinical trial in Stage II (high-risk)&#47; Stage III ctDNA+ adjuvant CRC, which is projected for late 2025 or 2026.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene Cevumeran (BNT122&#47;RO7198457) in pancreatic ductal adenocarcinoma, or PDAC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized Phase 2 clinical trial (IMCODE003&#59; NCT05968326) evaluating the safety and efficacy of autogene cevumeran in combination with atezolizumab followed by standard-of-care chemotherapy (mFOLFIRINOX) in patients with resected PDAC compared to chemotherapy alone is recruiting. The Phase 2 study is expected to enroll 260 patients with resected PDAC who have not received prior systemic anti-cancer treatment and showed no evidence of disease after surgery. The primary endpoint is DFS. Secondary endpoints include OS and safety.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene Cevumeran (BNT122&#47;RO7198457) in first-line melanoma.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized Phase 2 clinical trial (IMCODE001&#59; NCT03815058) evaluating the efficacy and safety of autogene cevumeran in combination with pembrolizumab versus pembrolizumab alone as first-line in patients with previously untreated advanced melanoma is fully enrolled and follow-up is ongoing. The primary endpoint is PFS and the readout will be event-driven. Secondary endpoints include ORR, OS, DOR and safety.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Autogene Cevumeran (BNT122&#47;RO7198457) in multiple solid tumors.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An open-label Phase 1 monotherapy clinical trial (NCT03289962) evaluating autogene cevumeran alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, including patients with melanoma, NSCLC, bladder cancer, colorectal cancer, triple negative breast cancer, or TNBC, renal cancer, head and neck cancer and sarcomas as well as other solid tumors is fully enrolled and follow-up is ongoing. A manuscript is expected to be published in 2024. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c) RiboMab</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidate is an mRNA that encodes cancer cell targeting antibodies. This fully-owned product candidate is nucleoside-modified to minimize immunogenicity and our improved mRNA backbone designs with the aim of maximizing protein expression. Our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidate is formulated using liver-targeting lipid nanoparticles, or LNPs, for intravenous delivery. This RNA-LNP technology is designed to address the challenges of recombinantly expressed proteins, including limited serum half-life and manufacturing process challenges.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT142 in multiple solid tumors.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BNT142 encodes a T-cell engaging bispecific antibody targeting Claudin 6, or CLDN6. An open-label, multi-site Phase 1&#47;2 clinical trial (NCT05262530) in patients with CLDN6-positive advanced solid tumors that have exhausted available standard therapy or are not eligible for such available therapy is ongoing.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:line-through">d</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) RiboCytokines</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates are based on the same nucleoside-modified mRNA-LNP technology as the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ribomabs </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and encode cytokines.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT152+BNT153 in multiple solid tumors.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BNT152 encodes IL-7, and BNT153 encodes IL-2. An open-label, multi-site, first-in-human Phase 1 clinical trial (NCT04710043) in multiple solid tumor indications is ongoing to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of a combination of BNT152 and BNT153. The clinical trial consists of two parts&#58; Part 1, the separate mono dose escalation of BNT152 and BNT153, was completed in May 2023, in which a maximum tolerated dose was defined for each product. Part 2 is currently investigating the combination treatment of BNT152 and BNT153.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Oncology Cell Therapy Product Candidates</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a) Chimeric antigen receptor, or CAR, T-cell therapy </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> CAR-T</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT211 consists of two investigational medicinal products&#58; our first CAR-T-cell product candidate, which targets CLDN6-positive solid tumors, in combination with an mRNA named CARVac encoding CLDN6. The CAR-T cells are equipped with a second-generation CAR of high sensitivity and specificity for the tumor-specific carcino-embryonic antigen CLDN6. CARVac is intended to support </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion of transferred CAR-T cells to increase their persistence and efficacy. As with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST, CARVac is also based on a pharmacologically optimized-backbone equipped uRNA delivered in our proprietary RNA-LPX formulation. BNT211 has been granted Priority Medicines Designation by the EMA for the third- or later-line treatment of testicular germ cell tumors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human, open-label, multi-site Phase 1 dose escalation and dose expansion basket trial (NCT04503278) is being conducted to evaluate CLDN6 CAR-T cells as monotherapy or in combination with CLDN6 CARVac in patients with CLDN6-positive relapsed or refractory solid tumors, including ovarian cancers and testicular germ cell tumors, is ongoing. The primary outcome measure of the trial is safety, with secondary efficacy outcome measures to include ORR, DCR and DOR.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, data from the ongoing trial were presented at ESMO which showed encouraging signs of antitumor activity across indications. Among patients who received dose levels of 1x10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR T cells or above after lymphodepletion with or without CARVac, ORR was observed to be 41.7% for patients with testicular cancer and 58.3% for those with ovarian cancer. CARVac was shown to improve CAR-T persistence in some patients. The data also suggest that the safety profile of CLDN6 CAR T cells with and without CARVac is consistent with the previously published effects of CAR T therapies and that repeated CARVac administration does not significantly increase toxicity.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A pivotal Phase 2 in patients with testicular germ cell tumors is planned to start in 2025 based on encouraging activity observed in this patient group.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b) Neoantigen-Targeting T-Cell therapy</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT221 is our autologous, fully individualized, polyspecific T-cell therapy directed against selected sets of individual neoantigens. BNT221 is based on expanded neoantigen-specific memory T-cells and induced naive T cells.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1 dose escalation clinical trial (NCT04625205) in patients with checkpoint inhibitor unresponsive or refractory metastatic melanoma is ongoing. </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first portion of the trial consists of a monotherapy dose escalation of BNT221, for which recruitment and treatment of patients is complete. The findings from this portion of the study have been submitted to a peer-reviewed journal and a manuscript is expected to be published in 2025. The second portion of the study is currently ongoing to evaluate BNT221 in combination with anti-PD-1 therapy as advanced line treatment. Major objectives of this study include evaluation of the safety and feasibility of administering BNT221 alone and in combination with a PD-1 directed therapy, as well as evaluations of immunogenicity and preliminary efficacy.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Antibody Product Candidates in Oncology</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a) Next-Generation Immunomodulators</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing, in collaboration with our partners, antibodies that are designed to function as mono- or bispecific immunomodulators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT311&#47;GEN1046 (acasunlimab) is a potential first-in-class bispecific antibody combining PD-L1 checkpoint inhibition with 4-1BB stimulation. BNT311&#47;GEN1046 (acasunlimab) is being developed &#91;by Genmab A&#47;S, or Genmab,&#93; for the treatment of solid tumors and is currently being evaluated in multiple clinical trials. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 2, multi-site, randomized, open-label clinical trial (NCT05117242) of BNT311&#47;GEN1046 (acasunlimab) as monotherapy and in combination with pembrolizumab in patients with relapsed&#47;refractory metastatic NSCLC and a tumor PD-L1 expression of tumor proportion score, or TPS, of &#8805;1% after treatment with standard of care therapy with an immune checkpoint inhibitor is ongoing. The primary endpoint is ORR according to Response Evaluation Criteria in Solid Tumors, or RECIST v1.1. Secondary endpoints include DOR, TTR, PFS, OS and safety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2 open-label, single-arm clinical trial (NCT03917381) with multiple expansion cohorts evaluating BNT311&#47;GEN1046 (acasunlimab) as monotherapy and in combination therapies in patients with solid tumors is ongoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1 open-label, dose escalation clinical trial (NCT04937153) in Japan evaluating the safety and pharmacokinetics of BNT311&#47;GEN1046 (acasunlimab) as monotherapy and in combination with pembrolizumab in patients with multiple solid tumors is ongoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2024, we announced that while the emerging clinical profile of BNT311&#47;GEN1046 (acasunlimab) is encouraging, for reasons relating to portfolio strategy, we opted not to participate in the further development of the program, including a planned Phase 3 trial. In the event that the program is commercialized, we will retain a tiered single-digit royalty on any potential sales. We and Genmab will continue our collaboration on other programs under the existing agreements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT312&#47;GEN1042, BNT314&#47;GEN1059, BNT315&#47;GEN1055 and BNT322&#47;GEN1056 are being developed in collaboration with Genmab.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT312&#47;GEN1042 is a novel, agonistic, bispecific antibody that combines targeting and conditional activation of the costimulatory molecules CD40 and 4-1BB on immune cells. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2 clinical trial (NCT04083599) is enrolling patients to evaluate BNT312&#47;GEN1042 in combination with pembrolizumab with or without chemotherapy across various solid tumors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1 clinical trial (NCT06057038) is recruiting in Japan to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of BNT312&#47;GEN1042 monotherapy and in combination with pembrolizumab with or without chemotherapy in patients with multiple solid tumors.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT314&#47;GEN1059 is a potential first-in-class bispecific antibody product candidate designed to boost antitumor immune responses through epithelial cell adhesion molecule-, or EpCAM-, dependent 4-1BB agonistic activity.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A BioNTech-sponsored first-in-human Phase 1&#47;2 clinical trial (NCT06150183) is being conducted to investigate the safety and preliminary antitumor activity of BNT314&#47;GEN1059 alone and in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumors. A Trial-in-Progress poster from this trial was presented at the 2024 ESMO Congress. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT315&#47;GEN1055 is an OX40 agonist antibody designed to induce OX40 clustering independently of Fc&#947;R-mediated crosslinking to enhance antitumor T-cell responses.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1&#47;2 clinical trial (NCT06391775) is being conducted to investigate the safety and preliminary antitumor activity of BNT315&#47;GEN1055 in patients with advanced or metastatic solid tumors.</font></div><div style="padding-left:20.69pt;text-indent:0.43pt"><font><br></font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT322&#47;GEN1056 is an antibody product candidate being co-developed with Genmab for the treatment of solid tumors and for use in combination with other products. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1 clinical trial (NCT05586321) in patients with advanced solid tumors is ongoing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT327&#47;PM8002 is a bispecific antibody candidate combining PD-L1 checkpoint inhibition with vascular endothelial growth factor A, or VEGF-A, neutralization  being developed in collaboration with Biotheus Inc., or Biotheus. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2024, the first patient was dosed in a multi-site, open-label Phase 2 clinical trial (NCT06449222) to evaluate the safety, efficacy, and pharmacokinetics of BNT327&#47;PM8002 at two dose levels in combination with chemotherapy in the first- and second-line treatment of patients with locally advanced&#47;metastatic TNBC. The study is recruiting in the U.S., Australia and the UK. A Phase 3 clinical trial in first-line TNBC is expected to start in 2025.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, the first patient was dosed in a multi-site, open-label Phase 2 clinical trial (NCT06449209) to evaluate BNT327&#47;PM8002 in combination with chemotherapy in patients with untreated extensive-stage small-cell lung cancer, or ES-SCLC, and in patients with small-cell lung cancer, or SCLC, that progressed after first- or second-line treatment. The study is recruiting in the U.S. and the UK. A Phase 3 clinical trial in first-line SCLC is expected to start in 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, a Phase 2&#47;3 clinical trial in first-line NSCLC is expected to start in 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cohort evaluating BNT327&#47;PM8002 and BNT325&#47;DB-1305 combination treatment as part of a Phase 1&#47;2 clinical trial (NCT05438329) is recruiting. Additional trials with BNT327 and other antibody drug conjugates, or ADCs, combinations are planned to start in 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, at the ESMO Congress, data were presented from three clinical trials evaluating BNT327&#47;PM8002 in patients with advanced TNBC, epidermal growth factor receptor-, or EGFR, mutated NSCLC and renal cell carcinoma, or RCC.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Data from the ongoing open-label, single-arm Phase 1&#47;2 clinical trial (NCT05918133) evaluating the safety and efficacy of BNT327&#47;PM8002 in combination with nab-paclitaxel as first-line treatment in advanced or metastatic TNBC were reported. The 42 patients were observed to have an ORR of 78.6%, a confirmed ORR, or cORR, of 73.8% with disease control rate of 95.2%, a median progression-free survival, or mPFS, of 13.5 months and a median duration of response, or mDoR, of 11.7 months. Among the 42 patients treated, 38 patients had available PD-L1 expression results assessed by means of a PD-L1 immunohistochemistry, or IHC, E1L3N assay. cORR was observed to be 76.9% in 13 patients with PD-L1 combined positive scores, or CPS, &#60;1, 56.3% in the 16 patients with PD-L1 1&#8804;CPS&#60;10, and 100% in the nine patients with PD-L1 CPS&#8805;10. Any-grade and grade &#8805;3 treatment-related adverse events, or TRAEs, of the combination regimen occurred in 100% and 57.1% of patients, respectively. TRAEs leading to treatment discontinuation occurred in 4.8% of patients. The most common TRAEs included neutropenia, leukocytopenia, anemia, proteinuria and alopecia. In summary, first line treatment of locally advanced&#47;metastatic TNBC with BNT327&#47;PM8002 in combination with nab-paclitaxel was observed to be associated with clinically meaningful antitumor activity regardless of PD-L1 status and manageable toxicity with no new safety signals observed beyond those typically described for anti-PD-(L)1 therapies, anti-VEGF therapies and chemotherapy.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Data from a Phase 2 clinical trial (NCT05756972) evaluating BNT327&#47;PM8002 in combination with carboplatin and pemetrexed in patients with advanced EGFR-mutated NSCLC who progressed after EGFR-tyrosine kinase inhibitor, or TKI, treatment were reported. The 64 patients were observed to have an ORR of 60.9%, a cORR of 57.8% and DCR of 95.3%. In the 28 patients with PD-L1 tumor proportion score, or TPS, &#60;1%, the ORR was observed to be 46.4% and DCR was observed to 92.9%. In the 23 patients with TPS 1-49%, the ORR was observed to be 60.9% and DCR was observed to be 100%. Among the 13 patients with TPS &#8805;50%, the ORR was observed to be 92.3% and DCR was observed to be 92.3%. Any-grade TRAEs occurred in 98.4% patients and grade &#8805; 3 TRAEs occurred in 60.9% of patients. Nine patients discontinued BNT327&#47;PM8002 and&#47;or chemotherapy administration due to TRAEs, plus one case of TRAE-related to death. In summary, we believe that the observations of BNT327&#47;PM8002 in combination with chemotherapy in </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR-mutated NSCLC patients that progressed on prior EGFR-TKI therapy showed encouraging anti-tumor activity independent of PD-L1 expression levels with a positive correlation seen between higher tumor PD-L1 expression levels and overall response rates, and a generally manageable safety profile. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Data from an open-label, multiple cohort, dose-expansion, monotherapy Phase 1&#47;2 clinical trial (NCT05918445) were reported. 28 patients with clear cell RCC, or ccRCC, who progressed after combination of anti-PD-(L)1 and VEGF-TKI therapy or VEGF-TKI monotherapy, were observed to have an ORR of 25%, a DCR of 82.1%, a mPFS of 10.9 months and mDOR of 19.6 months. The 22 patients with previously untreated non-clear cell RCC, or nccRCC, were observed to have an ORR of 36.4%, DCR of 90.9%, mPFS of 15.1 months. Any-grade and grade &#8805;3 TRAEs of the combination regimen occurred in 100% and 41.5% of patients, respectively. TRAEs leading to treatment discontinuation occurred in 1.9% of patients. In summary, we believe BNT327&#47;PM8002 monotherapy was observed to have encouraging anti-tumor activity and a manageable safety profile in patients with previously untreated advanced nccRCC or previously treated advanced ccRCC.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data in first-line TNBC are expected to be presented at the San Antonio Breast Cancer Symposium, taking place from December 10 to December 13, 2024 in San Antonio, Texas, U.S. Additional data are expected to be presented in 2025. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT316&#47;ONC-392 (gotistobart) is an anti-cytotoxic T-lymphocyte associated protein 4, or CTLA-4, monoclonal antibody candidate being developed in collaboration with OncoC4, Inc., or OncoC4. BNT316&#47;ONC-392 (gotistobart) is designed to offer a differentiated safety profile that may allow for higher dosing and longer duration of treatment both as monotherapy and in combination with other therapies. The program received Fast Track designation from the FDA in 2022.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">In October 2024, we were informed by our partner OncoC4 that the FDA has placed a partial clinical hold on the two-stage, open-label, randomized Phase 3 trial PRESERVE-003 (NCT05671510). We and OncoC4 understand that the partial clinical hold is due to varying results between patient populations. The trial evaluates the efficacy and safety of the antibody candidate BNT316&#47;ONC-392 as monotherapy in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. A recent assessment of the trial data by the independent data monitoring committee identified a possible variance in population results. Consequently, we and OncoC4 decided to proactively pause enrollment of new patients and informed the FDA of the possible variance for further alignment. While we and OncoC4 are assessing next steps for the ongoing trial with BNT316&#47;ONC-392 in NSCLC, patients already enrolled in the trial will continue to receive treatment. The trials below evaluating BNT316&#47;ONC-392 in other indications remain unaffected.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 2 clinical trial (PRESERVE-004&#59; NCT05446298) is being conducted to evaluate BNT316&#47;ONC-392 (gotistobart) therapy in combination with pembrolizumab in patients with platinum-resistant ovarian cancer, or PROC. The clinical trial is designed to evaluate multiple doses of BNT316&#47;ONC-392 (gotistobart) in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy. The primary endpoints are ORR and safety. Secondary endpoints include DOR, DCR, PFS and OS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, preliminary data from the Phase 2 (PRESERVE-004&#59; NCT05446298) clinical trial evaluating BNT316&#47;ONC-392 (gotistobart) in combination with pembrolizumab in patients with PROC were presented at ESMO. 33 and 29 patients in 1 mg&#47;kg and 2 mg&#47;kg BNT316&#47;ONC-392 (gotistobart) dose groups, respectively, were observed to have an unconfirmed ORR of 25% and 27.6%, respectively. Grade &#8805;3 TEAEs related to either drug were observed in 45.5% and 41.4% patients in the 1 mg&#47;kg and 2 mg&#47;kg groups, respectively. In summary, these data suggest encouraging preliminary clinical activity and a manageable tolerability profile with no new safety signals detected.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 2 clinical trial (PRESERVE-006&#59; NCT05682443) is being conducted to evaluate the safety and efficacy of BNT316&#47;ONC-392 (gotistobart) in combination with lutetium Lu-177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer, or mCRPC, who have disease progressed on androgen receptor pathway inhibition. The trial is expected to enroll approximately 144 patients at clinical trial sites in the U.S. The primary endpoint is PFS.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1&#47;2 open-label dose escalation clinical trial (PRESERVE-001&#59; NCT04140526) is being conducted to evaluate BNT316&#47;ONC-392 (gotistobart) as a single agent and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b) Targeted Cancer Antibodies &#38; Antibody-Drug Conjugates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT321 is a fully human immunoglobulin G1, monoclonal antibody product candidate targeting sialyl Lewis A, or sLea, an epitope on CA19-9 that is expressed in pancreatic and other solid tumors that plays a role in tumor adhesion and metastasis formation, and is a marker of an aggressive cancer phenotype.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An open-label, multi-site, non-randomized dose escalation and expansion Phase 1 clinical trial (NCT02672917) is being conducted to evaluate BNT321 monotherapy and in combination with modified FOLFIRINOX in pancreatic cancer and other CA19-9 expressing solid tumors. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2 trial (NCT06069778) is being conducted to evaluate the safety, tolerability, and efficacy of BNT321 in combination with mFOLFIRINOX as an adjuvant therapy following curative resection in patients with PDAC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT323&#47;DB-1303 (trastuzumab pamirtecan) is a topoisomerase-1 inhibitor-based human epidermal growth factor receptor 2-, or HER2-, targeted ADC candidate being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd., or DualityBio. The program has been granted Fast Track designation and Breakthrough Therapy Designation by the FDA for the treatment of advanced endometrial cancer in patients who progressed on or after treatment with immune checkpoint inhibitors. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An ongoing randomized, multi-site, open-label, pivotal Phase 3 clinical trial (DYNASTY-Breast02&#59; NCT06018337) is recruiting to evaluate BNT323&#47;DB-1303 versus the investigator&#8217;s choice of chemotherapy in advanced or metastatic hormone receptor positive, or HR+, HER2-low breast cancer subjects whose disease has progressed on at least two lines of prior endocrine therapy or within six months of first-line endocrine therapy and cyclin-dependent 4&#47;6, or CDK4&#47;6, inhibitor and no prior chemotherapy. The first patient was dosed in January 2024. The trial aims to enroll approximately 532 patients. The primary endpoint is PFS. Secondary endpoints include OS, ORR, DCR, DOR and safety, as well as patient-reported outcomes. In September 2024, a Trial-in-Progress poster was presented at the 2024 ESMO Congress.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Topline data from the ongoing Phase 3 in patients with HR+ and HER2-low metastatic breast cancer who have progressed on hormone therapy and&#47;or CDK4&#47;6 inhibition is expected in 2026.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A multi-site, non-randomized, open-label, multiple dose, first-in-human Phase 1&#47;2 clinical trial (NCT05150691) is being conducted to evaluate BNT323&#47;DB-1303 in patients with advanced&#47;unresectable, recurrent, or metastatic HER2-expressing solid tumors. A potential registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with advanced&#47;recurrent endometrial carcinoma has completed enrollment. Data from this cohort are expected in 2025. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A confirmatory Phase 3 trial (NCT06340568) to evaluate BNT323&#47;DB-1303 in patients with advanced endometrial cancer is in planning.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT324&#47;DB-1311 is a topoisomerase-1 inhibitor-based B7H3-targeted ADC candidate being developed in collaboration with DualityBio. This program has been granted Fast Track designation by the FDA for the treatment of advanced&#47;unresectable mCRPC in patients who progressed on or after standard systemic regimens.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human, open-label Phase 1&#47;2 clinical trial (NCT05914116) is being conducted to evaluate BNT324&#47;DB-1311 in patients with advanced solid tumors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2024, we and DualityBio received Orphan Drug Designation for BNT324&#47;DB-1311 from the FDA for the treatment of advanced or metastatic esophageal squamous cell carcinoma. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first preliminary data from this trial will be presented at the 2024 ESMO Asia Congress, taking place from December 6 to December 8, 2024 in Singapore.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT325&#47;DB-1305 is a topoisomerase-1 inhibitor-based TROP2-targeted ADC candidate being developed in collaboration with DualityBio. The program has been granted Fast Track designation by the FDA for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received one to three prior systemic treatment regimens. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2 clinical trial (NCT05438329) is being conducted to evaluate BNT325&#47;DB-1305 in patients with advanced solid tumors is ongoing. As part of this clinical trial, BNT325&#47;DB-1305 is being studied in combination with BNT327&#47;PM8002 across multiple cohorts.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT326&#47;YL202 is a topoisomerase-1 inhibitor-based HER3-targeted ADC candidate being developed in collaboration with MediLink Therapeutics (Suzhou) Co., Ltd, or MediLink. HER3 is a target that is overexpressed in various cancer types, such as NSCLC and breast cancer and is closely associated with tumor metastasis and disease progression. Furthermore, HER3 expression is upregulated after frontline drug therapy, making it an adequate target for cancer treatment resistance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A multi-site, international, open-label, first-in-human Phase 1 clinical trial (NCT05653752), sponsored by MediLink, is being conducted to evaluate BNT326&#47;YL202 as a later-line treatment in patients with locally advanced or metastatic EGFR-mutated NSCLC or HR-positive and HER2-negative breast cancer. On August 15, 2024, the FDA lifted the partial clinical hold that was placed on this trial, initially announced on June 17, 2024. Trial recruitment has been reinitiated and clinical development will focus on dose levels no higher than 3 mg&#47;kg, where the safety profile was manageable and encouraging clinical activity was observed.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Small Molecule Immunomodulator Candidates in Oncology</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT411 is a small molecule TLR7 agonist product candidate. BNT411 is designed to activate both the adaptive and innate immune system through the TLR7 pathway.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2, first-in-human, open-label, dose escalation trial (NCT04101357) with expansion cohorts evaluating safety, pharmacokinetics, progression of disease and preliminary efficacy of BNT411 as monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-na&#239;ve ES-SCLC has been discontinued. Final data of the trial have been gathered and evaluated to be compiled into a clinical study report and are expected to be presented at SITC and published in a scientific journal.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B. Infectious Disease Programs</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Next-generation COVID-19 Vaccine </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT162b5&#47;6&#47;7 &#8211; This is one of multiple vaccine candidates with an engineered design aimed to increase the magnitude and breadth of antibody neutralization response to better protect against COVID-19. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, active controlled, observer-blind Phase 2 clinical trial (NCT04368728) to evaluate the safety, tolerability and immunogenicity of a stabilized spike antigen vaccine candidate has been completed and data are being gathered.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT162b2 + BNT162b4 &#8211; The aim of this program is to develop a vaccine candidate that enhances and broadens SARS-CoV-2 T-cell responses. BNT162b4 is a next-generation COVID-19 vaccine candidate component designed to elicit T-cell immunity across epitopes. BNT162b4 encodes variant-conserved, immunogenic segments of the SARS-CoV-2 nucleocapsid, membrane, and ORF1ab proteins, targeting diverse human leukocyte antigen alleles. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1 clinical trial (NCT05541861) to evaluate the safety, tolerability and immunogenicity of BNT162b4 in combination with BNT162b2 is ongoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both programs are being developed in collaboration with Pfizer.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. COVID-19 &#8211; Influenza Combination mRNA Vaccine Program &#8211; BNT162b2 + BNT161</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2024, we and Pfizer announced top-line results from the Phase 3 clinical trial (NCT06178991) evaluating the companies&#8217; mRNA combination vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. In this trial, the vaccine candidate was compared to a licensed influenza vaccine and the companies&#8217; licensed COVID-19 vaccine given at </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the same visit. The primary immunogenicity objectives were to demonstrate that the antibody responses to influenza (hemagglutination inhibition) and to SARS-CoV-2 (neutralizing titer) elicited by the combination vaccine candidate were non-inferior to standard of care. The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines. No safety signals with the combination vaccine have been identified in an ongoing safety data review. We and Pfizer are evaluating adjustments to the candidate and intend to discuss next steps with health authorities.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Influenza Vaccine Program &#8211; BNT161</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Pfizer entered into an agreement to collaborate on an mRNA program in influenza for an initial period of three years, which ended in 2021. Pfizer has since had the sole responsibility, authority and control of the development, manufacturing and commercialization of all candidates and products related to the program. Upon potential approval and commercialization, BioNTech is eligible to receive a royalty on Pfizer&#8217;s sales. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Herpes Simplex Virus, or HSV, Vaccine Program &#8211; BNT163</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research collaboration with the University of Pennsylvania under which we have the exclusive option to develop and commercialize mRNA vaccine candidates against up to 10 infectious disease indications. As part of this collaboration, we are developing an HSV vaccine candidate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human, controlled, dose-escalation Phase 1 clinical trial (NCT05432583) evaluating the safety, tolerability and immunogenicity of BNT163, an HSV vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, is ongoing. Dose escalation Part A has been completed. Part B (safety and dose evaluation) has completed enrollment across sites in the U.S.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Tuberculosis Vaccine Program &#8211; BNT164</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaborated with the Bill &#38; Melinda Gates Foundation since 2019 to develop vaccine candidates aimed at preventing tuberculosis infection and disease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two randomized, controlled, dose-finding Phase 1 clinical trials (NCT05537038, Germany and NCT05547464, Republic of South Africa) evaluating BNT164 are fully enrolled. Both clinical trials are designed to assess the safety, reactogenicity, and immunogenicity of mRNA vaccine candidates against tuberculosis. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Malaria Vaccine Program &#8211; BNT165</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our malaria program aims to develop a well-tolerated and highly effective mRNA vaccine with durable immunity to prevent blood-stage malaria infection, thereby reducing morbidity and mortality as well as onward transmission. We plan to assess several vaccine candidates, featuring known targets such as circumsporozoite protein, conserved, immunogenic segments of liver stage-expressed proteins, as well as other antigens.</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1 clinical trial (NCT05581641) to evaluate the safety, tolerability and exploratory immunogenicity of the vaccine candidate BNT165b1, the first candidate from our BNT165 program, has been completed. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, dose escalation Phase 1&#47;2 trial (NCT06069544) to evaluate the safety, tolerability, immunogenicity and efficacy of a second investigational RNA-based vaccine candidate is ongoing, with Part A, focusing on safety and immunogenicity, being fully enrolled and Part B, evaluating efficacy in a controlled human malaria infection model, due to start in 2025. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Mpox Vaccine Program &#8211; BNT166</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fully-owned BNT166 program aims to deliver an effective, well-tolerated and accessible vaccine for the prevention of mpox. The multivalent BNT166 mRNA vaccine candidates encode surface antigens that are expressed in the two infectious forms of the mpox virus to efficiently fight virus replication and infectivity. The program is supported through a partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI, to provide equitable access to the vaccine, if successfully developed and approved, in low- and middle-income countries.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1&#47;2 trial clinical trial (NCT05988203) evaluating the safety, tolerability, reactogenicity and immunogenicity of two mRNA-based multivalent vaccine candidates is ongoing. The trial aims to enroll 64 healthy participants with and without prior history of known or suspected smallpox vaccination. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Shingles Vaccine Program &#8211; BNT167</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Pfizer to develop the first mRNA-based vaccine candidate against shingles (also known as herpes zoster). While there are currently approved vaccines for shingles, the goal is to develop an mRNA vaccine candidate that potentially shows high efficacy and better tolerability and is more efficient to produce globally.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, controlled, dose-selection Phase 1&#47;2 clinical trial (NCT05703607) to evaluate the safety, tolerability, and immunogenicity of BNT167 in up to 900 healthy volunteers 50 through 69 years of age is ongoing. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Bacterial Vaginosis &#8211; BNT331</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech R&#38;D (Austria) GmbH, a wholly owned subsidiary of BioNTech SE, is focused on developing novel anti-bacterial drugs to treat persistent bacterial infections. Its development programs are based on our proprietary LysinBuilder platform, which allows for the targeted development of precision anti-bacterials. Our development pipeline focuses on chronic bacterial infections where antibiotics fail to cure or destroy the natural microbiomes. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A two-part, randomized, double-blind Phase 1 clinical trial (NCT06469164) is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BNT331 in healthy women and women diagnosed with bacterial vaginosis. It also aims to explore the efficacy of BNT331 in women diagnosed with bacterial vaginosis. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2822"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows our unaudited interim condensed consolidated statements of profit or loss for each period presented&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,244.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">895.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,561.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,340.0</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(178.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(161.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(297.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(420.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(550.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(497.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,642.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,205.3)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(44.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(132.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(139.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(420.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(370.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating expenses </font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(410.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(719.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(239.6)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">73.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,462.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">164.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">498.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363.2</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Profit &#47; (Loss) before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">158.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">227.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(978.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">522.9</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(66.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.5)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit &#47; (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">198.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">160.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(924.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">472.4</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Earnings &#47; (Loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings &#47; (loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.82</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.67</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.83)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.96</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted earnings &#47; (loss) per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.81</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.66</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.83)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.94</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (please see Note 4.2 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important financial and operating terms and concepts are described in Item 5 of our Annual Report on Form 20-F as of and for the year ended December 31, 2023.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_608"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the three and nine months ended September&#160;30, 2024, and 2023</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_923"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1576"></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,113.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">885.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,244.8</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">895.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">349.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">39</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1542"></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,310.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,306.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(996.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">251.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">654</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,561.1</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,340.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(778.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(33)</font></td></tr></table></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1549"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Revenues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 vaccine revenues increased by &#8364;228.9&#160;million, or 26%, from &#8364;885.0&#160;million during the three months ended September&#160;30, 2023 to &#8364;1,113.9&#160;million during the three months ended September&#160;30, 2024, and decreased by &#8364;996.7&#160;million, or 43%, from &#8364;2,306.7&#160;million during the nine months ended September&#160;30, 2023, to &#8364;1,310.0&#160;million during the nine months ended September&#160;30, 2024, in line with a lower COVID-19 vaccine market demand. During the three months ended September&#160;30, 2024, our sales were higher compared to the prior year period, which were largely driven by the earlier approvals received for our variant-adapted COVID-19 vaccines in 2024. Our COVID-19 vaccine revenues are subject to seasonal effects in the fall &#47; winter of the northern hemisphere. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2024, our other revenues were mainly derived from a pandemic preparedness contract with the German government effectively supplemented in the three months ended March 31, 2024.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_931"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1566"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of sales increased by &#8364;17.1 million, or 11%, from &#8364;161.8 million during the three months ended September&#160;30, 2023 to &#8364;178.9 million during the three months ended September&#160;30, 2024, and decreased by &#8364;122.9 million, or 29%, from &#8364;420.7 million during the nine months ended September&#160;30, 2023 to &#8364;297.8 million during the nine months ended September&#160;30, 2024. While we recognized lower cost of sales from our decreased COVID-19 vaccine sales in our </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">territories, particularly Germany, changes in our cost of sales were additionally impacted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by expenses arising from inventory write-downs to net realizable value amounting to &#8364;39.7&#160;million and &#8364;103.3&#160;million during the three and nine months ended September&#160;30, 2024, respectively, compared to &#8364;46.2&#160;million and &#8364;96.1&#160;million during the three and nine months ended September&#160;30, 2023, respectively (adjustments to prior-year figures relate to reclassifications).</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_950"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1607"></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-COVID-19 vaccine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">437.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">550.3</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">497.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1614"></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:49.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.119%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8364;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-COVID-19 vaccine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #bece33;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,642.4</font></td><td colspan="3" style="border-bottom:1pt solid #bece33;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,205.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">437.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">36</font></td></tr></table></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1621"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses increased by &#8364;52.4 million, or 11%, from &#8364;497.9 million during the three months ended September&#160;30, 2023 to &#8364;550.3 million during the three months ended September&#160;30, 2024, and increased by &#8364;437.1 million, or 36%, from &#8364;1,205.3 million during the nine months ended September&#160;30, 2023 to &#8364;1,642.4 million during the nine months ended September&#160;30, 2024. The increase was mainly driven by advancing key pipeline candidates, such as our antibody drug conjugate, or ADC, antibody and individualized cancer-immunotherapy product candidates. Further contributions to the increase came from higher personnel expenses resulting from an increase in headcount.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_942"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and Administrative Expenses</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1649"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses decreased by &#8364;6.7&#160;million, or 5%, from &#8364;139.1&#160;million during the three months ended September&#160;30, 2023 to &#8364;132.4&#160;million during the three months ended September&#160;30, 2024, and increased by &#8364;49.6&#160;million, or 13%, from &#8364;370.7&#160;million during the nine months ended September&#160;30, 2023 to &#8364;420.3&#160;million during the nine months ended September&#160;30, 2024. The year-to-date increase compared to the comparative prior year period was primarily due to increased headcount and higher personnel expenses as a result. A reduction in external services led to a slight decrease in total general and administrative expenses during the three months ended September&#160;30, 2024, compared to the comparative prior year period. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_958"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Operating Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1676"></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total other operating result decreased by &#8364;345.6 million from a negative operating result of &#8364;9.0 million during the three months ended September&#160;30, 2023 to a negative operating result of &#8364;354.6 million during the three months ended September&#160;30, 2024 and decreased by &#8364;482.5 million from a negative operating result of &#8364;134.4 million during the nine months ended September&#160;30, 2023 to a negative operating result of &#8364;616.9 million during the nine months ended September&#160;30, 2024. This is primarily due to expenses incurred in connection with contractual disputes (see Note 10 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report).</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_967"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance Result</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1703"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total finance result decreased by &#8364;6.1&#160;million from &#8364;154.3&#160;million during the three months ended September&#160;30, 2023, to &#8364;148.2&#160;million during the three months ended September&#160;30, 2024, and increased by &#8364;125.3&#160;million from &#8364;358.7&#160;million during the nine months ended September&#160;30, 2023, to &#8364;484.0&#160;million during the nine months ended September&#160;30, 2024. During the three and nine months ended September&#160;30, 2024, and 2023, our finance result mainly derived from returns such as interests and sales resulting from our financial investments as well as fair value adjustments of our money market funds.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_975"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes decreased by &#8364;106.2&#160;million from &#8364;66.8&#160;million of accrued tax expenses during the three months ended September&#160;30, 2023, to &#8364;39.4&#160;million of realized tax income during the three months ended September&#160;30, 2024, and increased by &#8364;104.6&#160;million from &#8364;50.5&#160;million of accrued tax expenses during the nine months ended September&#160;30, 2023, to &#8364;54.1&#160;million of realized tax income during the nine months ended September&#160;30, 2024. The effective income tax rate for the nine months ended September&#160;30, 2024 was approximately 5.5% and approximately 9.7% for the nine months ended September&#160;30, 2023. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_614"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions that occurred during the three and nine months ended September&#160;30, 2024, and 2023, are explained in Note 12 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report. </font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_619"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited interim condensed consolidated financial statements for the three and nine months ended September&#160;30, 2024, have been prepared in accordance with IAS 34 Interim Financial Reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and the use of estimates are explained in Note 2 to the unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report and further discussed in Note 3 to our audited consolidated financial statements of our Annual Report on Form 20-F as of and for the year ended December 31, 2023.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_626"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the normal course and conduct of our business, we may be involved in proceedings with third parties regarding, among other things, intellectual property disputes, contractual disputes, including the interpretation of each party&#8217;s obligations or the amounts payable under the respective agreements, product-related disputes, and actions by or on behalf of our shareholders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and&#47;or our cash flows in the period in which the amounts are accrued or paid. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pending matters to which we are a party are discussed below.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alnylam Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &#38; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#8216;933 Patent, is infringed by the cationic lipid used in Comirnaty, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#8216;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &#38; Upjohn Co. LLC in the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#8216;979 Patent, which is a continuation of the &#8216;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &#38; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479&#59; 11,633,480&#59; 11,612,657&#59; and 11,590,229, all of which are continuations of the &#8216;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the lawsuits have been consolidated into a single proceeding, which is currently expected to go to trial in July 2025.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CureVac Proceedings</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infringement Proceedings &#8211; EP&#8217;122, DE&#8217;961, DE&#8216;974, DE&#8217;575, and EP&#8217;668</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP1857122B1, or EP&#8217;122, and three Utility Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or EP&#8217;668, to its German lawsuit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the D&#252;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#8217;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668) pending validity decisions in the DE&#8217;961, DE&#8217;974, and DE&#8217;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#8217;668 opposition proceedings before the Opposition Division of the European Patent Office, or the EPO. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668. On December 28, 2023, the D&#252;sseldorf Regional Court stayed the infringement proceedings as to EP&#8217;122 until a final appellate decision is rendered as to the validity of EP&#8217;122 by the Federal Court of Justice. On June 7, 2024, CureVac waived DE&#8217;575 and withdrew this utility model from the infringement proceedings. On July 2, 2024, the EPO Opposition Division issued a preliminary opinion noting that it believes EP&#8217;668 is likely invalid, and set an oral hearing for March 2025.</font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infringement Proceedings &#8211; EP&#8217;755, DE&#8217;123, and DE&#8217;130</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP4023755B1, or EP&#8217;755, and two Utility Models DE202021004123U1, and DE202021004130U1. On June 7, 2024, CureVac waived DE&#8217;123 and withdrew this utility model from the infringement proceedings. A hearing on infringement with respect to EP&#8217;755 and DE&#8217;130 that was scheduled to occur in the D&#252;sseldorf Regional Court on September 10, 2024 was rescheduled for July 2025. On July 24, 2024, the EPO Opposition Division issued a preliminary opinion noting that it believes EP&#8217;755 is likely invalid, and set an oral hearing for May 2025.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nullity Proceedings &#8211; EP&#8217;122</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that EP&#8217;122 is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#8217;122 nullity action in support of the validity of EP&#8217;122. The preliminary opinion did not address any infringement of EP&#8217;122. The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#8217;122. On April 30, 2024, the Federal Patent Court issued a judgment containing its written reasons for nullifying EP&#8217;122. On May 7, 2024, CureVac appealed the judgment, which is currently pending.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation Proceedings &#8211; DE&#8217;961, DE&#8216;974, and DE&#8217;575</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;974 is likely to be cancelled. On January 23, 2024, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;961 is likely to be cancelled. On March 7, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, the German Patent and Trademark Office issued a preliminary opinion that DE&#8217;575 is likely to be cancelled. On June 6, 2024, CureVac submitted a written statement to the German Patent and Trademark Office waiving DE&#8217;575. On June 12, 2024, we withdrew our request for cancellation of DE&#8217;575. On June 25 and 26, 2024, the German Patent and Trademark Office heard oral arguments regarding DE&#8217;961 and DE&#8217;974, and at the conclusion of the hearing on June 26, 2024, confirmed that both DE&#8217;961 and DE&#8217;974 were cancelled.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation Proceedings&#8211; DE&#8217;123 and DE&#8217;130</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we filed cancellation actions seeking the cancellation of German Utility Models DE&#8217;123 and DE&#8217;130 in the German Patent and Trademark Office. On June 6, 2024, CureVac submitted a written statement to the German Patent and Trademark Office waiving DE&#8217;123. On June 12, 2024, we withdrew our request for cancellation of DE&#8217;123. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. Patent Nos. 11,135,312&#59; 11,149,278&#59; and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070&#59; 11,286,492&#59; 11,345,920&#59; 11,471,525&#59; 11,576,966&#59; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910. In June 2024, CureVac voluntarily dismissed with prejudice its claims of infringement with respect to the &#8216;493, &#8216;525, and &#8216;966 patents. Currently, a three-week trial is scheduled to begin in early March 2025. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against EP&#8217;122 and EP&#8217;668  in the Business and Property Courts of England and Wales, in the UK High Court of Justice, or the UK High Court. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#8217;122 and EP&#8217;668 patents in the Business and Property Courts of England and Wales. On December 18, 2023, we and Pfizer amended our pleadings to add a claim for revocation and declarations of invalidity and non-infringement with respect to EP&#8217;755. The UK High Court held a trial on EP&#8217;668 and EP&#8217;755 between July 10, 2024 and July 24, 2024. On October 8, 2024, the UK High Court released a judgment finding both EP&#8217;668 and EP&#8217;755 invalid. The UK High Court is expected to hold a hearing before the end of the fourth quarter of 2024, during which hearing CureVac may apply for the right to appeal the judgment as to EP&#8217;668 and EP&#8217;755. On October 25, 2024, CureVac agreed to a final and unappealable revocation of the UK designation of EP&#8217;122 and to discontinue its counterclaim for infringement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna Proceedings</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement of two European patents, 3590949B1, or EP&#8217;949, and 3718565B1, or EP&#8217;565. On November 7, 2023, the Opposition Division of the EPO revoked EP&#8217;565 after a one-day oral hearing, and on December 7, 2023, it issued its written decision revoking EP&#8217;565. On December 8, 2023, the Opposition Division issued a preliminary opinion noting that it believes EP&#8217;949 is likely invalid. As a result of those developments in the EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025. On February 7, 2024, Moderna appealed the Opposition Division&#8217;s revocation decision on EP&#8217;565, and the appeal is currently pending. On May 16, 2024, the Opposition Division decided that EP&#8217;949  is valid, in amended form, and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued its written decision regarding the same on July 8, 2024. BioNTech appealed this decision, and the appeal is currently pending.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit asserting </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, and Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales, in the UK High Court. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of EP&#8217;949 and EP&#8217;565.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK High Court held a trial between April 22, 2024, and May 21, 2024. On July 2, 2024, the UK High Court released two judgments. The first judgment concerns the validity of EP&#8217;949 and EP&#8217;565. In this first judgment, the UK High Court found that EP&#8217;565 is invalid and therefore not infringed, while EP&#8217;949 is valid and infringed. The second judgment concerns whether Moderna&#8217;s October 2020 commitment not to &#8220;enforce &#91;its&#93; COVID-19 related patents against those making vaccines intended to combat the pandemic,&#8221; or the Patent Pledge, amounted to a consent under UK law to carry out any acts that would otherwise amount to patent infringement. With respect to this judgment, the UK High Court found that Moderna&#8217;s Patent Pledge amounted to consent to carry out activities that might otherwise infringe its patents prior to March 2022, but not after March 2022. A hearing before the UK High Court is scheduled for September 25, 2024, where the parties are expected to apply for the right to appeal. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK High Court held a hearing on September 25, 2024, during which the Court granted Pfizer and BioNTech permission to appeal its judgment regarding the validity of EP&#8217;949, and denied Moderna permission to appeal its judgment regarding validity of EP&#8217;565. No party sought permission to appeal the UK High Court&#8217;s judgment on the patent pledge.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. District Court Litigation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit in the U.S. District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of U.S. Patent Nos. 10,898,574&#59; 10,702,600 and 10,933,127 and seeking monetary relief. On April 12, 2024, the U.S. District Court for the District of Massachusetts stayed the litigation pending resolution of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent Nos. 10,702,600 and 10,933,127.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inter Partes Review</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board, or the PTAB. On March 6, 2024, the PTAB issued decisions instituting </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings on all challenged claims of U.S. Patent Nos. 10,702,600 and 10,933,127. An oral hearing on the merits is scheduled to occur in December 2024. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8216;949 and EP&#8217;565. The District Court of the Hague held a hearing on October 6, 2023, on infringement and validity with respect to EP&#8217;949. On December 6, 2023, the Court found EP&#8217;949 to be invalid. On March 5, 2024, Moderna appealed this decision, and the appeal is pending. The EP&#8217;565 case has been stayed pending the outcome of Moderna&#8217;s appeal of the Opposition Division&#8217;s revocation of EP&#8217;565.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the High Court of Ireland. On </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 26, 2024, the High Court of Ireland stayed the lawsuit pending the final determination of the EPO opposition proceedings for EP&#8217;949 and EP&#8217;565 (in each case including any appeals). </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of EP&#8217;949 and EP&#8217;565 in the Brussels Dutch-speaking Enterprise Court. On May 29, 2024, the parties filed a joint request to stay the proceedings, which was entered by the Enterprise Court.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arbutus and Genevant Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus&#58; U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief. This proceeding is currently pending.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GlaxoSmithKline Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, or GSK, filed a lawsuit against Pfizer and us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Delaware alleging that the cationic lipid used in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes U.S. Patent Nos. 11,638,693&#59; 11,638,694&#59; 11,666,534&#59; 11,766,401&#59; and 11,786,467&#59; and seeking monetary relief. On August 14, 2024, GSK filed an amended complaint to assert infringement of three additional patents, U.S. Patent Nos. 11,759,422&#59; 11,655,475&#59; and 11,851,660. This proceeding is currently pending.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">adewig Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we and certain of our officers and directors were named as defendants in a securities class action complaint captioned Ladewig v. BioNTech SE filed in the U.S. District Court for the Central District of California brought on behalf of a putative class of investors who purchased our securities from March 30, 2022 through October 13, 2023. Plaintiffs allege that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, by stating that we were &#8220;well positioned&#8221; to remain a &#8220;market leader&#8221; in vaccines for the prevention of COVID-19 and by purportedly overstating demand for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Plaintiffs further allege that we failed to adapt our inventory to reflect the emergence of new COVID variants. On July 15, 2024, the case was transferred to the U.S. District Court for the Southern District of New York. We believe the allegations to be without merit and intend to vigorously defend our Company in this lawsuit. This proceeding is currently pending.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">University of Pennsylvania Proceedings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2024, the Trustees of the University of Pennsylvania, or UPenn, filed suit against us and our former subsidiary BioNTech RNA Pharmaceuticals GmbH in the U.S. District Court for the Eastern District of Pennsylvania. The suit, captioned The Trustees of the University of Pennsylvania v. BioNTech SE, et al., alleges that we failed to comply with certain royalty obligations allegedly owed to UPenn under a patent sublicense agreement that permits us to use UPenn&#8217;s mRNA technology in our COVID-19 vaccine, Comirnaty. UPenn asserts claims for breach of contract and unjust enrichment. The parties have jointly stipulated that we shall have until December 16, 2024 to respond to the complaint. This proceeding is currently pending.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_632"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_645"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our strong financial, scientific and operational accomplishments, we believe we have the resources to diligently allocate our current capital to drive a multi-platform strategy and deliver a fully integrated global biotechnology company. We focus our R&#38;D, on rapidly advancing our diversified clinical oncology pipeline with synergistic potential, developing next generation COVID-19 vaccines to maintain leadership and pandemic preparedness, as well as broadening the label of and access to the existing vaccine. We also plan to invest heavily to build out our global development organization, bringing in talent with clinical and regulatory expertise needed to accelerate our pipeline development. We are also diversifying our therapeutic area footprint, which will enable us to fully leverage the potential of all technology platforms across autoimmune diseases, inflammatory diseases, cardiovascular disease, neurodegenerative diseases, and regenerative medicines. In addition, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing. To support our future trajectory, growing the organization and expanding our team is of utmost importance. We are on the way to develop our global footprint in key regions including Europe, the United States, Asia and Africa. Additionally, investing in manufacturing capabilities for key technologies and deploying our pandemic response capabilities remain priorities for us. As a science and innovation driven company, we will continue to focus investments on R&#38;D and scaling the business for commercial readiness in oncology in multiple countries by the end of 2025. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we had cash and cash equivalents of &#8364;9,624.6&#160;million, current </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security investments of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;7,078.0&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and non-current security investments of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;1,137.2&#160;million, accumulating to &#8364;17,839.8&#160;million in cash, cash equivalents and security investments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and financial securities are invested in accordance with our asset management and investment policy, primarily with a focus on liquidity and capital preservation, and consist primarily of cash in bank accounts and on hand as well as long- and short-term financial investments.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_652"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_2282"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for each period presented&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.254%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended <br>September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine months ended <br>September 30, </font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions &#8364;)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #becd32;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #005a64;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from &#47; (used in)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #005a64;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(638.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">811.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">671.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,520.5</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(142.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,232.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,687.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,259.4)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(311.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(765.7)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash outflow before change in cash and cash equivalents resulting from exchange rate differences and other valuation effects</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(788.9)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(732.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2,055.5)</font></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #005a64;border-top:0.25pt solid #7facb1;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(504.6)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from the sale of products and services rendered. Our cash flows from operating activities are significantly influenced by cash we generated as settlement payments of our gross profit as well as our use of cash for operating expenses and working capital to support the business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended September&#160;30, 2024, was &#8364;638.9 million. Cash payments for our operating business exceeded the cash received from our revenue streams, resulting in a decrease in cash of &#8364;638.3 million. Additionally, we received positive cash contributions from grants of &#8364;60.7 million and from returns on our financial investments of &#8364;73.1 million. Operating cash flow was additionally impacted by cash payments of &#8364;134.4 million for exercised share based payment programs, especially the programs in which the Management Board members participate.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in operating activities for the three months ended September&#160;30, 2023, was &#8364;811.2 million, comprising a profit before tax of &#8364;227.4 million, negative non-cash adjustments of &#8364;110.3 million, and a net positive change in assets and liabilities of &#8364;639.4 million and income taxes received of &#8364;10.2 million. Non-cash items primarily included net foreign exchange differences as well as fair value adjustments of derivatives without cash effect. The net positive change in assets and liabilities was primarily due to a decrease in trade and other receivables related to our COVID-19 collaboration with Pfizer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in operating activities for the nine months ended September&#160;30, 2024, was &#8364;671.0 million. Cash received from our revenue streams exceeded the cash payments for our operating business, resulting in an increase in cash of &#8364;556.3 million. Additionally, we received positive cash contribution from grants of &#8364;102.7 million and from returns like interests or sales resulting from our financial investments of &#8364;353.3 million. On the other hand, we paid income taxes of &#8364;190.8&#160;million and the operating cash flow was impacted by cash payments of &#8364;143.6 million for exercised share based payment programs, especially the programs in which the Management Board members participate. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operating activities for the nine months ended September 30, 2023, was &#8364;4,520.5 million, comprising a profit before tax of &#8364;522.9 million, negative non-cash adjustments of &#8364;490.1 million, a net positive change in assets and liabilities of &#8364;6,378.6 million and income taxes paid of &#8364;1,292.4 million. Non-cash items primarily included net foreign exchange differences as well as non-cash fair value adjustments of derivatives. The net positive change in assets and liabilities was primarily due to a decrease in trade and other receivables related to our COVID-19 collaboration with Pfizer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended September&#160;30, 2024, was &#8364;142.1 million. The amount includes &#8364;59.4 million mainly spent on security investments. The capital expenditures supporting our operating activities amounted to &#8364;79.1 million, whereof the majority was related to investments in building our laboratory and office facilities in Germany as well as our facilities in Singapore. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended September 30, 2023, was &#8364;1,232.2 million, of which &#8364;382.6 million related to in-licensing arrangements, collaborations or M&#38;A transactions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2024, was &#8364;2,687.9&#160;million. The amount includes &#8364;2,327.2&#160;million mainly spent on security investments. The capital expenditures supporting our operating activities amounted to &#8364;236.3&#160;million, whereof the majority was related to investments in building our laboratory and office facilities in Germany as well as our facilities in Singapore and Rwanda. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September 30, 2023, was &#8364;4,259.4 million. Thereof, the amount caused by or driven from in-licensing arrangements, collaborations or M&#38;A transactions amounted to &#8364;620.4 million.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended September&#160;30, 2024, was &#8364;7.9 million, mainly related to our lease payments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, net cash used in financing activities was &#8364;311.0 million, primarily resulting from our share repurchase program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the nine months ended September&#160;30, 2024, was &#8364;38.6 million, mainly related to our lease payments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, net cash used in financing activities was &#8364;765.7 million, primarily resulting from our share repurchase program.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_658"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operation and Funding Requirements</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue or expand our research or development of our programs in preclinical development&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue or expand the scope of our clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or increase our manufacturing capacity or capability&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional suppliers&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including new and expanded sites globally&#894; </font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain skilled personnel&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals and reimbursement for our product candidates&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify and validate additional product candidates&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire other companies&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone or other payments under any in-license agreements&#894;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license and research and development agreements with universities and other third parties, as well as patent assignment agreements, under which we have obtained rights to patents, patent applications and know-how. We enter into contracts in the normal course of business with contract research organizations, or CROs, for clinical trials and clinical and commercial supply manufacturing, and with vendors for preclinical research studies and for other services and products for operating purposes. We work together with contract manufacturing organizations, or CMOs, who manufacture our product candidates and products, and enter into lease agreements to lease laboratory, GMP manufacturing, storage and office spaces. Purchase obligations under our agreements, to the extent that they are quantifiable and not cancellable, have been considered when defining our guidance for future cash commitments. Most of the committed cash outflow within one year is related to lease payments amounting to &#8364;45.1&#160;million and commitments under purchase agreements and contractual obligations amounting to &#8364;230.4&#160;million. Further, we have lease payment obligations with an amount of &#8364;230.5&#160;million and commitments under purchase agreements and contractual obligations of &#8364;1,725.3&#160;million for the years 2025 and beyond.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to all of the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of research and our other platform activities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical development plans we establish for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates that we develop or may in-license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any ADS repurchases we make.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_549755815136"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Factors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any such risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and&#47;or prospects.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1255"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reported commercial revenue is partially based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods, which may impact our reported financial results.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus and, even if we are successful, a market for vaccines against these variants may not develop.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials and delay or prevent regulatory approval or market acceptance of any of our product candidates. Since commercialization, we have received, and expect to continue to receive, product liability claims related to our COVID-19 vaccine.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies, or that negatively affect our results of operations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our shares could decline.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA drug development has substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approved product and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our efforts to obtain, maintain, protect, defend and&#47;or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1267"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our COVID-19 Vaccine and the Commercialization of our Pipeline</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our COVID-19 vaccine, we had not sold or marketed any products in our pipeline. As a result, a majority of our total revenues to date are attributable to sales of our COVID-19 vaccine. However, we have experienced and we expect to continue to experience increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine, now that the virus has entered an endemic stage and as a growing proportion of the population becomes vaccinated. We expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. Such revenues will depend on numerous factors, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which a COVID-19 vaccine, including any booster shot, continues to be necessary as COVID-19 becomes an endemic virus&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from other COVID-19 vaccines, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully and timely develop effective vaccines targeting new variants and mutations of COVID-19&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive full regulatory approvals where we currently have emergency use authorizations or equivalents&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to expand our geographic customer base&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our pricing and reimbursement negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments, including the transition towards ordinary-course insurance coverage in the public and private sectors&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of countries and jurisdictions to store and distribute doses of our COVID-19 vaccine to end users at cold temperatures&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety profile of our COVID-19 vaccine, including if previously unknown undesirable effects or increased incidence or severity of known undesirable effects are identified with our COVID-19 vaccine&#59; </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property litigation involving our COVID-19 vaccine and COVID-19 vaccines in general&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing and distribution capabilities for our COVID-19 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot accurately predict the revenues our COVID-19 vaccine will generate in future periods or for how long our COVID-19 vaccine will continue to generate material revenues, and we cannot ensure it will maintain its competitive position. Uncertainty in the demand for our COVID-19 vaccine and difficulties in targeting appropriate supply of our COVID-19 vaccines have in the past resulted, and may in the future result, in significant inventory write-downs and cancellations of contract manufacturing orders. Our business and financial condition could be materially affected by lowered COVID-19 vaccine revenues resulting from any of the above factors, or by production and supply chain difficulties. In addition, if our revenues or market share of, or other financial metrics relating to, our COVID-19 vaccine do not meet the expectations of investors or securities analysts, the market price of the ADSs representing our ordinary shares may decline.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our reported commercial revenue is based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods, which may impact our reported financial results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported commercial revenue is based on preliminary estimates from Pfizer and other assumptions and judgments that we have made, which may be subject to significant uncertainties. Our commercial revenue includes preliminary estimates in part due to a difference in Pfizer&#8217;s financial quarter for subsidiaries outside the United States, which consequently creates an additional time lag between the recognition of revenues and the receipt of payment. Although our revenue recognition policy is based on facts and circumstances known to us and various other assumptions that we believe to be reasonable under the circumstances, our actual results may deviate from such reported revenue.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on Pfizer to determine and provide estimates of the costs and profits to be shared with us in the countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for our COVID-19 vaccine, which we refer to as the Pfizer Agreement. Because the information supplied by Pfizer is preliminary and subject to change, the commercial revenue we report based on such information is also subject to finalization. This is particularly true for vaccine sales outside of the United States, where Pfizer has a different reporting cycle than ours. As a result, we may not have the complete sales and costs results outside of the United States for months not covered by the reporting period, but we are nonetheless required to report estimated figures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has historically provided us with profit figures for our COVID-19 vaccine sales in the United States using standard U.S. transfer prices and manufacturing and shipping cost variances (as far as those have been identified) that could be subject to adjustment (e.g., due to changes in manufacturing costs or the price of our COVID-19 vaccine). Pfizer has also provided estimated profits for COVID-19 vaccine sales outside of the United States that were preliminary in nature for the last month of a quarter, as Pfizer&#8217;s subsidiaries outside of the United States have a different reporting cycle than ours. These estimated figures have changed, and in the future such estimated figures are likely to change, as we receive final data from Pfizer for the applicable period in accordance with the reporting cycle of Pfizer&#8217;s ex-U.S. subsidiaries and as actual costs become known. Further, to the extent that Pfizer does not provide such preliminary information in the future, our provisional sales figures for territories outside of the United States will be subject to an even greater level of estimate and judgment. Any changes to the preliminary data we report herein may have an impact on our reported revenues and expenses, profitability or financial position.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, and even if we are successful, a market for vaccines against these variants may not develop and our ability to continue to generate income from sales of our COVID-19 vaccine is uncertain.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 disease itself is unpredictable and each variant comes with varying levels of transmissibility and severity. Consequently, the burden of the disease may wane or dissipate such that our and other COVID-19 vaccines may be considered less essential from individual and public health perspectives.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine was initially developed based upon the genetic sequence of the original SARS-CoV-2 virus that was first detected. The SARS-CoV-2 virus continues to evolve, and new strains of the virus or those that are already in circulation may prove more transmissible or cause more severe forms of COVID-19 </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease than the predominant strains observed to date. Our vaccine may not be as effective in protecting against existing and future variant strains of the SARS-CoV-2 virus as it is against the original virus or currently known strains of the SARS-CoV-2 virus. While we continue to monitor emerging SARS-CoV-2 strains, undertake investigations into the immunogenicity of our COVID-19 vaccine against new variants as they emerge and develop modified versions of our COVID-19 vaccine against new variants, these efforts may be unsuccessful, and failure to timely and successfully adapt our vaccine to variants of the SARS-CoV-2 virus could lead to significant reputational harm and adversely affect our financial results. It is also possible that we may expend significant resources adapting our COVID-19 vaccine to protect against certain variants of the SARS-CoV-2 virus, but that a market for adapted vaccines does not develop for one or more variants or that demand does not align with our projections or cost expenditures. Moreover, even if we are successful in developing an adapted vaccine and there is a market for the new vaccine, new variants continue to emerge and any adapted vaccine may not be as effective in protecting against such future variant strains.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we discover safety issues with our products, including our COVID-19 vaccine, that were not known at the time of approval, commercialization efforts for our products could be negatively affected, approved products could lose their approval or sales could be suspended, we could be subject to product liability claims and our business and reputation could be materially harmed. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information. Billions of doses of our COVID-19 vaccine have been delivered worldwide, and our COVID-19 vaccine is being more widely used by patients as an authorized product than it was used in clinical trials. As a result, undesirable effects and other problems may be observed that were not seen or anticipated, or were not as prevalent or severe, during clinical trials. We cannot provide assurance that newly discovered or developed safety issues will not arise, and we have received, and expect to continue to receive, product liability claims relating to our COVID-19 vaccine. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in clinical trials or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Safety events that arise outside of a clinical trial setting are difficult to monitor, and given the widespread use of our COVID-19 vaccine, we have experienced difficulty tracking potential treatment-related adverse events on a global basis. Any safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause the price of the ADSs representing our ordinary shares to decline or experience periods of volatility. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unexpected safety issues, including any that we have not yet observed in our clinical trials for our COVID-19 vaccine or in real world data, could lead to significant reputational damage for us and our product development platforms going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to comply with continuing regulatory requirements by us or our collaboration partners could adversely impact regulatory approvals for our products, result in product recalls or suspensions, and&#47;or subject us to fines and&#47;or other types of liabilities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to comply with applicable continuing regulatory requirements, including good industry practices, such as good manufacturing practices, or GMP, we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific drugs, product recalls and seizures, operating restrictions and&#47;or criminal prosecutions. We and the manufacturers we engage to make our products and the manufacturing facilities in which our products are made are subject to periodic review and inspection by the U.S. FDA and other regulatory authorities. If problems are identified during a review or inspection, we or our collaborators may be the subject of adverse regulatory action, including the issuance of untitled or warning letters, which could result in our inability to use the facility to make our product or a determination that inventories are not safe for commercial sale. Any of these factors could adversely affect our business prospects and our financial position could be materially harmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable to our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, and&#47;or delayed payments from government authorities could limit our ability to market those products and decrease our ability to generate revenue.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford certain treatments, including our COVID-19 vaccine and other product candidates we may develop and sell. In addition, because our mRNA product candidates represent an entirely new therapeutic modality, we cannot accurately estimate how future products we may develop and sell would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our products. Additionally, even if pricing terms with governmental authorities are agreed upon, there may be delayed or denied payments. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement for newly approved products in particular in the United States, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &#38; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. The Inflation Reduction Act, or IRA, enacted in August 2022 allows HHS to negotiate the price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D. The IRA&#8217;s negotiation program will apply to high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics), among other negotiation selection criteria. The negotiated prices, which will become effective in 2026 for the first round of selected drugs, will be capped at a statutorily-determined ceiling price. The IRA also penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, once the out-of-pocket maximum has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the IRA may be subject to various penalties, including civil monetary penalties. These IRA provisions have begun to take effect progressively starting in 2023, although the drug negotiation provisions of the IRA are currently the subject of legal challenges. The effects of the IRA on our business and the healthcare industry in general are not yet known. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importing from other countries and bulk purchasing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government policies, including relating to manufacturing or export controls, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact the manufacturing and sales of our COVID-19 vaccine and other product candidates we may develop, if approved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a heightened risk that vaccines could be subject to export controls, adverse emergency actions or supply requirements by governmental and other authorities. In the past, the European Union and other regions have imposed, or threatened to impose, export controls that would limit or block the delivery of COVID-19 vaccines manufactured in or outside their territories in instances where manufacturers have been delayed or have not fully satisfied their delivery obligations to such governments, which could have prohibited us from delivering our COVID-19 vaccine to other jurisdictions. Vaccines are also at risk of being subject to adverse emergency actions taken by governmental entities in certain countries, including intellectual property expropriation, compulsory licenses, strict price controls or other actions, such as the requirement that specific quantities of vaccine doses be set aside for designated purposes or geographic areas. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, public sentiment regarding commercialization of vaccines, the safety and efficacy of our COVID-19 vaccine, other COVID-19 vaccines and treatments, and other public perceptions and misinformation relating to COVID-19, mRNA technology, and our and other COVID-19 vaccines may limit our ability to generate income from sales of our COVID-19 vaccine and other product candidates we may develop and sell, and cause reputational damage. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of vaccine manufacturers, academic institutions and other organizations currently have programs to develop COVID-19 vaccine candidates, including vaccines developed by Moderna, Inc. and Novavax, Inc. Our competitors pursuing vaccine candidates may have greater financial, product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and may have the resources to invest heavily to accelerate discovery and development of their vaccine candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to continue successful commercialization of our COVID-19 vaccine may fail if competitors develop and commercialize COVID-19 vaccines that are safer, more effective, produce longer immunity against COVID-19, require fewer administrations, have fewer or less severe undesirable effects, have broader market acceptance, are more convenient to administer or distribute or are less expensive than any vaccine candidate that we have developed or we may develop.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine to obtain permanent regulatory approval in jurisdictions where it has been authorized for emergency use or granted conditional marketing approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine has been granted full U.S. FDA approval for individuals 12 years and older, emergency or limited use authorization in a number of jurisdictions and in the United States for individuals six months to 12 years of age and approval for use in certain other jurisdictions. Our COVID-19 vaccine has not yet received full approval by regulatory authorities in certain jurisdictions where it has been authorized for emergency or temporary use. We and Pfizer intend to continue to observe our COVID-19 vaccine, including vaccine candidates that we may develop for other variants of COVID-19, in global clinical trials. It is possible that subsequent data from these clinical trials may not be as favorable as data we submitted to regulatory authorities to support our applications for emergency use authorization or marketing or conditional marketing approval or that concerns about the safety of our COVID-19 vaccine will arise from the widespread use of our COVID-19 vaccine outside of clinical trials. Our COVID-19 vaccine may not receive approval outside of the emergency use setting in the jurisdictions where it is not currently approved, which could adversely affect our business prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is, and other product candidates we develop could be, sensitive to temperature, storage and handling conditions. In particular, while we have improved the required shipping and storage conditions of our COVID-19 vaccine, it must be shipped and stored at cold temperatures. Loss in supply of our COVID-19 vaccine and our product candidates could occur if the product or product intermediates are not stored or handled properly. Shelf life for our product candidates may vary by product, and it is possible that supply of our COVID-19 vaccine or our product candidates could be lost due to expiration prior to use. This has in the past led, and could in the future lead, to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or for commercial purposes. Such distribution challenges may make our COVID-19 vaccine a less attractive product than other COVID-19 vaccines that do not require as cold storage, and our COVID-19 vaccine may become increasingly less competitive as additional other vaccines become authorized for emergency use. If we, our partners and customers are unable to adequately manage these issues, we may be exposed to product liability claims and the market opportunity for our COVID-19 vaccine may be reduced, each of which could adversely affect our business prospects and materially harm our financial condition.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are developing other product candidates and services in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals and manufacturing, marketing and selling drug products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates that are based on previously tested or accepted technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">products that have been approved or are in late stages of development&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborative arrangements in our target markets with leading companies and research institutions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face intense competition from products that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop products in the future. We also expect to face competition from new products that enter the market. There are a number of products currently under development, which may become commercially available in the future, for the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of conditions for which we are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively than any products we develop.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate competing with the largest pharmaceutical companies in the world, many of which are currently conducting research in the fields of infectious diseases, immuno-oncology, rare genetic diseases and cancer immunotherapies. Some of these companies have greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully-integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies or shared tumor antigen and neoantigen therapeutics, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we successfully develop other product candidates, and obtain approval for them, we will face competition based on many different factors, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and effectiveness of our products relative to alternative therapies, if any&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and scope of regulatory approvals for these products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability and cost of manufacturing, marketing and sales capabilities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price of any approved immunotherapy&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement coverage&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property position.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our acquisition of InstaDeep Ltd., we also face competition in the rapidly growing and developing artificial intelligence industry. Our competitors may develop or commercialize products and services with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical, biotechnology or technology companies, providing them with an advantage over us. Our competitors therefore may be more successful in commercializing their products and services than we are, which could adversely affect our competitive position and business. Competitive products and services may make any products and services we develop obsolete or non-competitive before we can recover the expenses of developing and commercializing such products, if approved, and services.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The market opportunities for some of our product candidates may be small due to the rarity of the disease, or limited to those patients who are ineligible for or have failed prior treatments. As the target patient populations for some of our programs are small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA often approves new cancer therapies initially only for use by patients with relapsed or refractory advanced cancer. We expect to seek approval initially for some of our product candidates in this context. Subsequently, for those products that prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first-line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. We are also developing product candidates for the treatment of rare diseases.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our products, if </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved, because the potential target populations may be small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate sufficient product sales revenue.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only relatively recently developed our sales, distribution or marketing capabilities in Germany and T&#252;rkiye, and, other than for our COVID-19 vaccine, we have not historically designed our preclinical studies and clinical trials with specific commercialization or marketing considerations in mind. In addition, with respect to our COVID-19 vaccine, we rely heavily on the sales, distribution, and marketing capabilities of our partners, except in Germany and T&#252;rkiye. To successfully commercialize any other products that may result from our development programs, several of which are undergoing pivotal clinical trials, we will need to continue developing sales and marketing capabilities in the United States, Europe and other regions, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our current and future collaborators do not commit sufficient resources to further commercialize our COVID-19 vaccine and our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product sales revenue to sustain our business. We compete with many companies that currently have extensive and well-funded marketing and sales operations. Without continuing to grow our internal team or obtaining the support of third parties to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to achieve or maintain profitability in future periods depends in part on our and our collaborators&#8217; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve or maintain profitability in future periods will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our collaborators pursue&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing medical practices and customs affecting acceptance in the marketplace&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import or export licensing requirements&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental controls, trade restrictions or changes in tariffs&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer accounts receivable collection times&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer lead times for shipping&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">language barriers&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exchange rate fluctuations&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of epidemics, pandemics and other public health developments, such as COVID-19, on employees and the global economy&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement, pricing and insurance regimes&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation of contractual provisions governed by local laws in the event of a contract dispute.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have prior experience in all of these areas, and the experience we do have in some of these areas is limited. Our collaborators may have limited experience in these areas as well. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the requisite approvals, the commercial success of our products will depend in part on the medical community, patients, and third-party or governmental payors accepting immunotherapies in general, and our products in particular, as medically useful, cost-effective and safe.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical, social and legal concerns about research involving mRNA could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, we may not generate significant product sales revenue and may not be able to achieve or maintain profitability in future periods. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential efficacy and potential advantages over alternative treatments&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products, if approved, at competitive prices&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any undesirable effects, including any limitations or warnings contained in a product&#8217;s approved labeling&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any undesirable effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of transportation, storage and administration&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products, if approved, together with other medications&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies, such as mRNA vaccines and therapies, and of physicians to prescribe these therapies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity concerning our products or competing products and treatments&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for our products that are approved for marketing, we and&#47;or our collaborator are subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with current GMP and current good clinical practices, or GCP, for any clinical trials that we or a collaborator conduct post-approval. In addition, there is always the risk that we or a collaborator or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with our product candidates identified post-approval could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid in the United States, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because certain of our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time- consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our product candidates in any particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The advancement of healthcare reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the IRA was enacted, which sets forth meaningful changes to drug product reimbursement by Medicare. The IRA is anticipated to have significant effects on the pharmaceutical industry and may reduce the prices we can charge and reimbursement we can receive for our products in the United States, among other effects. Any reduction in reimbursement from Medicare resulting from the IRA or other legislative or policy changes or from other government programs may result in a similar reduction in payments from private payers. On August 16, 2024, the Centers for Medicare &#38; Medicaid Services, or CMS, announced the results of a first round of discounted prices effectively set by CMS under the IRA, applicable to ten products of other manufacturers&#59; those discounted prices, set to take effect for calendar year 2026, were as high as 79% from 2023 list prices.  Additional products will be discounted in future years. We cannot be sure whether additional legislative changes will be enacted, or the effect of forthcoming guidance implementing the IRA, or what the impact of such changes on our products and product candidates may be.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize any products for which we obtain marketing approval.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products and product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as our products may no longer be commercially viable based on their expected net present value&#894; we may have invested significant resources in product candidates that cannot be commercially developed&#894; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations may no longer be deemed commercially viable to pursue based on our collaborators&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from our approved products and from product candidates that we may successfully develop and for which we may obtain regulatory approval, and may affect our overall financial condition and ability to develop product candidates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug marketing and reimbursement regulations in the European Union and elsewhere may materially affect our ability to market and receive coverage for our products in the member states of the European Union and elsewhere.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is currently approved in the United States, the European Union, and other jurisdictions, and we intend to seek approval to market other product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our products or product candidates in a particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of our products or product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our collaborators and the potential profitability of any of our product candidates in those countries would be negatively affected.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1276"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term sustainable profitability is difficult to achieve and maintain over time and is highly dependent on various factors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to generate revenue and achieve and maintain long-term sustainable profitability depends on our ability, alone or with collaborators, to successfully complete the development of, and obtain </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the regulatory approvals necessary to commercialize, our product candidates. Although we generate revenue from sales of our COVID-19 vaccine and additional limited revenue from other transactions, we expect that future revenues from sales of our COVID-19 vaccine will continue to decrease as demand for vaccination wanes. The amount of long-term revenue from such sales, including the sales of our COVID-19 vaccine, is uncertain at this time. Our ability to generate future revenues from pharmaceutical product sales and sales of our other products and services depends heavily on our success in&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research and preclinical and clinical development of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining U.S. and non-U.S. marketing approvals for product candidates for which we complete clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining market access and favorable pricing terms in the United States, the European Union, and other key geographies&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furthering the development of our own manufacturing capabilities and manufacturing relationships with third parties in order to provide adequate (in amount and quality) products and services to support clinical development and the market demand for our approved products and product candidates, if approved&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of our approved products and product candidates as a treatment option&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing products for which we obtain marketing approval and reimbursement, either through collaborations or, if launched independently, by establishing a sales force, marketing and distribution infrastructure&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments, in particular, declining demand for any of our approved products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing additional internal systems and infrastructure&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our expenses&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have incurred significant costs associated with the commercialization of our COVID-19 vaccine. Our expenses could increase beyond our expectations if we are required by the FDA, the EMA, or other regulatory agencies to perform clinical and other trials or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Accordingly, such costs could adversely affect our future ability to achieve and maintain profitability.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our ordinary shares could decline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this report&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and timing of orders for our COVID-19 vaccine&#59;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of adverse events during our clinical trials or post marketing authorization&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and manufacture our product candidates and commercialize and manufacture our COVID-19 vaccine at commercial scale&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth and spending&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute our corporate objectives&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of research programs, clinical trials, or other product development or approval processes conducted by us and our collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our collaborators to develop and successfully commercialize products developed from our suite of therapeutic classes&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our relationships, and any associated exclusivity terms, with collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contractual or other obligations to provide resources to fund our product candidates, and to provide resources to our collaborators or to the collaborations themselves, including take-or-pay or similar obligations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we repurchase outstanding ADSs under any share repurchase plans we may enter into in the future&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the international aspects of our business outside Germany, including the conduct of clinical trials in multiple locations and potential commercialization in such locations&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to minimize and manage product recalls or inventory losses caused by unforeseen events, cold chain interruption, testing difficulties or decreased demand, and our ability to write down certain inventory&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to report our financial results accurately and in a timely manner&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on, and the need to attract and retain, key management and other personnel&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, protect, maintain, defend and enforce our intellectual property rights&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know-how or technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our collaborators&#8217; ability to defend against claims of infringement of the intellectual property rights of third parties&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional capital that may be necessary to expand our business&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborators&#8217; ability to obtain and devote additional capital that may be necessary to develop and commercialize products under our collaboration agreements, including our COVID-19 vaccine&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to minimize and manage product liability claims arising from the use of our COVID-19 vaccine and our product candidates and other future products, if approved&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions such as power outages, strikes, acts of terrorism or natural disasters&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to use our net operating loss carryforwards to offset future taxable income&#59;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of counterparty defaults within our asset management portfolio&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased or unpredictable pricing for the commodities we rely on, including as a result of inflation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the factors listed above may be affected by the changing impact of COVID-19 on the global community and the global economy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the various factors mentioned above, and others, the results of any of our periods should not be relied upon as indications of our future operating performance. Our operating results may fluctuate significantly from one reporting period to the next, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause the price of the ADSs to decline. While as a general matter we intend to periodically report on the status of our product candidate pipeline, including articulating anticipated next steps in the form of development plans or potential data readouts, we may not always be able to provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosures of any milestones related to any of our programs that are managed by our collaborators. Any disclosure by a collaborator of data that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on the price of the ADSs or our overall valuation. The price of the ADSs may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have incurred significant losses in the past and we may incur significant losses in the future. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the first full year of commercialization of our COVID-19 vaccine, and for the three and nine months ended September&#160;30, 2024, we incurred significant losses and negative cash flows from operations due to our significant research and development expenses and our investment in our manufacturing capabilities, and funded our operations primarily from private placements or issuances of ordinary shares (including in the form of ADSs) in connection with our public offerings, generation of proceeds under our collaboration agreements, secured bank loans and issuance of a convertible note.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and we expect to continue to experience, increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine. We expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. We plan to continue to invest heavily in research and development as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing. Even for those products for which we have obtained or may obtain regulatory approval or emergency use authorization, our future revenues will depend upon the size of any markets in which such products have received approval or authorization to market, our ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If achieved, profitability is difficult to maintain over time and is highly dependent on various factors. Our future financial results will depend, in part, on the rate of our future expenditures, the extent to which we experience long-term success of our commercial products and our ability to obtain funding through revenue from commercial sales, equity or debt financings, sales of assets, collaborations or grants. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue or expand our research or development of our programs in preclinical development&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue or expand the scope of our clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or increase our manufacturing capacity or capability&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional suppliers&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including new and expanded sites globally&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain skilled personnel&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals and reimbursement for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify and validate additional product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire other companies&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone or other payments under any in-license agreements&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The amount of, and our ability to use, net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty. In addition, pending and future tax audits within our Group, disputes with tax authorities and changes in tax law or fiscal regulations could lead to additional tax liabilities. We are subject to routine tax audits by the respective local tax authorities. Any additional tax liability could have an adverse effect on our business, financial conditions, results of operations or prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, we have unused German tax loss carryforwards for corporate taxes for German group entities with pre tax group losses, though we have not recognized deferred tax assets related to such loss carryforwards for IFRS reporting purposes as of September&#160;30, 2024. Deferred tax assets are recognized for unused tax losses only to the extent that it is probable that taxable profit will be available against which the losses can be utilized. In general, net operating loss, or NOL, carryforwards in Germany do not expire. Furthermore, under current German tax laws, certain substantial changes in the Company&#8217;s ownership and business may further limit the amount of NOL carryforwards that can be used annually to offset future taxable income.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the German tax group we incurred tax losses up to and including December 31, 2020. Even though we recognized deferred tax assets on a majority of German tax loss carry forwards in 2020 which were fully utilized in 2021, they are, however, subject to review and possible adjustment by the German tax authorities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have U.S. federal and state NOL carryforwards due to our subsidiaries in the United States, which may be subject to limitations on use after an ownership change. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to utilize a material portion of our historic or current NOLs or credits in either Germany (resulting from our German tax group or non-tax group entities in Germany) or the United States until these have been finally assessed by the tax authorities or when the limitation period has passed. In addition, the rules regarding the timing of revenue and expense recognition for tax purposes in connection with various transactions are complex and uncertain in many respects, and, if challenged, our recognition may be subject to a revised assessment. In the event any such challenge is sustained, our NOLs could be materially reduced or we could be determined to be a material cash taxpayer for one or more years, which could have an adverse effect on our business, financial conditions, results of operations or prospects. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our ability to use our NOLs or credits is conditioned upon our attaining profitability and generating taxable income. Taxable income exceeding NOLs will be subject to taxation resulting tax liabilities. As described above, we incurred significant net losses in every year since our inception other than 2018, 2021, 2022 and 2023 and anticipate that in the future, we may incur significant losses for some of the group entities. Our ability to utilize our NOL or credit carryforwards in the United States and for some other group entities is uncertain.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Under German tax laws, we are obligated to withhold a percentage of wage tax and social security contributions on personnel expenses if contract services providers are considered to be our internal employees and remit those withholdings to German tax authorities and social security institutions. Late payments may subject us to penalties and fees. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German tax and social security laws, we are obligated to withhold a percentage of payments we make to third parties in consideration of the services provided, in case these are considered employment payments, and remit those withholdings to German tax authorities and social security institutions. After a significant volume of service providers were engaged to assist with research, development, manufacturing and supply of our COVID-19 vaccine, we discovered after internal review that we and certain of our subsidiaries did not withhold, report and remit certain German wage taxes and social security contributions in connection with certain contract service providers engaged in a manner comparable to internal employees, which we notified tax authorities about. If we do not properly and timely make required payments in the future, we could be subjected to fees, administrative offenses or other proceedings or penalties. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not possible to seek the refund of these wage taxes or social security contributions from either the German tax authorities or social security institutions after filing returns. In Germany, employers are considered secondarily liable for wage taxes. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, value added taxes on invoices received by contract services providers who are considered internal employees are considered non-deductible and must be repaid to the German tax authorities. It is possible to reclaim the VAT repaid to the German tax authorities from the service provider. There is a possibility that the relevant input VAT claims against the contract service providers may, in some instances, not be enforceable as a result of a contract service provider no longer existing, the lapse of time or any other facts preventing the enforcement of such claims.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, marketing and distribution arrangements, other collaborations and licensing arrangements, or a combination of these approaches. We may require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to the high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of research and our other platform activities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical development plans we establish for our product candidates&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any other strategic transactions, including relating to any acquisitions, into which we enter&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates that we develop or may in-license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our products or product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs, including the development of modular production and clinical facilities in various markets via our BioNTainer network&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity securities, revenue from collaborations, and revenue from sales of our COVID-19 vaccine. While we are currently generating product sales and royalty revenue to finance our operations, we cannot be certain that we will continue to generate sufficient revenue from product sales and royalties to finance our operations. If we were to seek financing from outside sources, that additional funding may not be available on favorable terms, or at all. Should our revenues from product sales sufficiently decrease in the future, we expect to finance our future cash needs through a combination of product sales, public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing or distribution arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all, including as a result of the impact that the shift of COVID-19 towards an endemic phase and other global events, such as political upheavals and economic downturns, may have on the capital markets.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of the ADSs representing our ordinary shares to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our shareholders&#8217; rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ordinary shares or ADSs, share ownership interests will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to security interests in our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements, sales of assets, collaborations, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would be desirable or relinquish our rights to product candidates or intellectual property that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates, or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations, cause the price of the ADSs to decline, and negatively impact our ability to fund operations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may encounter difficulties in developing and expanding our company and managing such development and expansion, which could disrupt our operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. In addition, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an evolving biotechnology company, we are actively pursuing drug classes, platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing products for, and fully understanding the regulatory and manufacturing pathways to, all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of certain operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure and&#47;or give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to effectively implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our COVID-19 vaccine and our product candidates, if approved, will depend in part on our ability to effectively manage the current and future development of our company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm the business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. The U.S. federal securities laws, including the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and the Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations result in substantial legal and financial compliance costs and have made some activities time-consuming and costly. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section 404, we document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have needed to continue to dedicate internal resources, have engaged outside consultants, and have adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting. We will continue to implement steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC thereunder. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with international financial reporting standards. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected by the company&#8217;s internal controls on a timely basis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering, we identified a material weakness in our internal control which has been fully remediated, but there can be no guarantee that we will not identify additional material weaknesses in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully remediate any future material weaknesses or successfully supervise and rely on outside advisors with expertise in these matters to assist us in the preparation of our financial statements, our financial statements could contain material misstatements discovered in the future that could cause us to fail to meet our future reporting obligations and cause the price of the ADSs to decline.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have various international trade obligations, including customs value calculation, customs tariff number classification and other related securities requirements. Late payments to customs authorities may subject us to penalties and fees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our supply chain, production and distribution network across the globe creates an increasing level of complexity in customs and foreign trade processes. The requirements for internal control systems are increasing and must be developed simultaneously. The risk management system for customs and foreign trade, which we are continuously improving, determines which stakeholders, goods, and means of transport should be examined and to what extent. These risks include the potential for non-compliance with customs value calculation, customs tariff number classification, trade restrictions, security regulations as well as the potential failure to facilitate international trade. We have in the past discovered that certain of our and our subsidiaries&#8217; customs value calculations were not applied correctly, following which we notified the customs authorities of potential late payments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and will likely continue to be, subject to various audits that arise from time to time, including customs and potential future foreign trade audits. If we do not properly address our international trade and customs requirements, we could be subjected to penalties and fees. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;foreign private issuer,&#8221; as defined in the rules and regulations of the SEC, and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we file an Annual Report on Form 20-F within four months of the close of each financial year ending December 31 and reports on Form 6-K relating to certain material events promptly after we publicly announce these events. Additionally, we rely on a provision in Nasdaq&#8217;s Listed Company Manual that allows us to follow German company law and European law applicable to European stock corporations in general, the German Stock Corporation Act (Aktiengesetz), the Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE), or the SE Regulation, and the German Act on the Implementation of Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE) (Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157&#47;2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE)) (SE-Ausf&#252;hrungsgesetz-SEAG), in particular with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are exempt from regulations of Nasdaq that require a listed U.S. company to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have a majority of the board of directors consist of independent directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require non-management directors to meet on a regular basis without management present&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adopt a code of conduct and promptly disclose any waivers of the code for directors or executive officers that should address certain specified items&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have an independent compensation committee&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have an independent nominating committee&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">solicit proxies and provide proxy statements for all shareholder meetings&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review related party transactions&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek shareholder approval for the implementation of certain equity compensation plans and issuances of ordinary shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are permitted to follow home country practice in lieu of the above requirements. We therefore continue to follow German corporate governance practices in lieu of the corporate governance requirements of Nasdaq in certain respects. In particular, we follow German corporate governance practices in connection with the distribution of annual and interim reports to shareholders, the application of our code of conduct to our employees and the Supervisory Board, executive remuneration disclosure, proxy solicitation in connection with shareholders&#8217; meetings, and obtaining shareholder approval in connection with the establishment of, or material amendment to, certain equity-based compensation plans.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to U.S. companies listed on Nasdaq. As we are a foreign private issuer, however, our audit committee is not subject to additional requirements of Nasdaq applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as a foreign private issuer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks related to catastrophic global events including natural disasters, political crises, or public health epidemics and pandemics and other public health developments, that could adversely affect our operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of catastrophic global events, including natural disasters such as an earthquake, fire, hurricane, tornado, flood or significant power outage&#59; public health crises such as the COVID-19 pandemic&#59; political crises, such as terrorist attacks, war and other political instability, including the ongoing geopolitical conflicts in the Middle East and in Ukraine, and resulting sanctions imposed by the United States and other countries and retaliatory actions taken by Russia in response to such sanctions&#59; or other catastrophic events.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ongoing conflict between Russia and Ukraine and the conflicts in the Middle East, and resulting sanctions and other economic actions, have contributed to volatility in the crude oil and natural gas supply chains. Prolonged or expanded conflict between Russia and Ukraine and in the Middle East, and political responses to global actions, could further destabilize oil and gas supply and demand patterns, increase energy volatility and have severe adverse effects on regional and global supply chains and economies and our business. Our commercial production of our COVID-19 vaccine is currently run on natural gas, although we believe our production could be powered by alternative fuel sources if needed. Additionally, we continue to evaluate the impacts that energy shortages may have on our partners, suppliers and service providers. Were any of these parties to experience significant impacts from this or any other energy shortage, our business could be materially harmed. We cannot predict with certainty the impact increased volatility in energy prices would have on our or their operations, including on the manufacturing of our COVID-19 vaccine and the manufacturing and testing of our product candidates. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have generated revenues from sales of our COVID-19 vaccine, there remains uncertainty regarding other potential effects of COVID-19 on our business. For example, if a new variant of COVID-19 emerges for which existing vaccines, including our COVID-19 vaccine, are ineffective, infections may become even more widespread, negatively impact our ability to enroll patients in clinical studies and complete clinical trials on the timelines we currently anticipate, or result in an economic downturn that could affect demand for our products and services or our ability to raise capital, which could have a material adverse effect on our business, operating results and financial condition. Our suppliers, licensors or collaborators could also be disrupted by conditions related to COVID-19 or other pandemics and epidemics, possibly resulting in disruption to our supply chain, clinical trials, partnerships or operations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We currently maintain insurance coverage for losses relating to property damage, business interruption, transportation, product liability, cyber matters, clinical trials, and several other areas of coverage.&#160;We are dedicating resources to exploring additional avenues for more adequate coverage as our business evolves. However, the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, operating as a public company has made it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Supervisory Board, our Management Board, or our board committees.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, or SVB, a bank which we previously used to support operations in the United States, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a statement by the U.S. Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day following the date of closure and we received such access on March 13, 2023, and neither the amount in question nor any delays in access were material to our operations, uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have caused declines in the trading value of previously issued government securities with interest rates below current market interest rates.  There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in a timely fashion or at all.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain our cash and cash equivalents in multiple financial institutions worldwide, our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1285"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platforms. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and we may not be able to obtain approvals for the commercialization of product candidates we may develop. Any product candidates we may develop and the activities associated with their development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our product candidates, we and our collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective, including in the target populations. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a new drug application, or NDA, to the FDA, a Marketing Authorization Application, or MAA, to the EMA, and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. Although our COVID-19 vaccine has received emergency use authorization and&#47;or regulatory approvals in certain countries, it is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and may need to rely on third-party CROs, regulatory consultants or collaborators to assist us in this process. We expect to submit initial BLAs&#47;MAAs for our mRNA-based product candidates in the United States, the European Union and in other countries globally. In some of these jurisdictions, mRNA-based medicinal products may be classified in different ways and may be subject to specific requirements. Securing regulatory approval requires the submission of extensive quality, preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Benefit and risk are regularly assessed, and any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals in the United States, the European Union and elsewhere is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies and standards of care during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA, EMA and comparable regulatory authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional preclinical, clinical or other trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays or non-approval may result if an FDA panel of experts, referred to as an Advisory Committee, or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies also may approve a product candidate for fewer or more limited indications or patient populations than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA and other regulatory agencies review the Quality or Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, MAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential mRNA product candidate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining, or if we fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues will be materially impaired. Additionally, even if we are successful in obtaining marketing approval for product candidates, because our preclinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA drug development carries substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, other than our and Moderna, Inc.&#8217;s COVID-19 vaccines, no mRNA immunotherapies have been approved or received emergency use authorization or conditional marketing authorization to date by the FDA or the EMA. Successful discovery and development of mRNA-based (and other) immunotherapies by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic or clinical holds, or fail to reach the market for many reasons, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery efforts aimed at identifying potential immunotherapies may not be successful&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonclinical or preclinical study results may show product candidates to be less effective than desired or have harmful or problematic side effects&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may show the product candidates to be less effective than expected, including a failure to meet one or more endpoints or have unacceptable side effects or toxicities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or distribution failures or insufficient supply of GMP materials for clinical trials or higher than expected cost could delay or set back clinical trials, or make our product candidates commercially unattractive&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our improvements in the manufacturing processes may not be sufficient to satisfy the clinical or commercial demand of our product candidates or regulatory requirements for clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes that we make to optimize our manufacturing, testing or formulating of GMP materials could impact the safety, tolerability and efficacy of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement issues or other factors could delay clinical trials or make any immunotherapy uneconomical or noncompetitive with other therapies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to timely advance our programs or receive the necessary regulatory approvals, or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, BLA, MAA or the equivalent application, discussions with the FDA or the EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proprietary rights, products and technologies of our competitors may prevent our immunotherapies from being commercialized.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For administrative purposes, mRNA products are classified together with gene therapy products by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and may cause certain side effects, mRNA is highly unlikely to localize to the nucleus, be reverse transcribed or integrated into the genome. Side effects observed in other gene therapies, however, could negatively impact the perception of immunotherapies despite the differences in mechanism. In addition, the regulatory pathway in the United States and many other jurisdictions for approval is uncertain. Our COVID-19 vaccine is not currently classified as a gene therapy. The regulatory pathway for an individualized therapy, such as our iNeST mRNA-based immunotherapy where each patient receives a different combination of mRNAs, remains undetermined. The number and design of the clinical and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for advanced medicinal therapy products or therapies that are not individualized or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and submit an application for marketing approval by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates may not work as intended, may cause undesirable effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most biological products, use of our product candidates could be associated with undesirable effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have impaired organ function, compromised immune and other systems and may be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or comparable regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable side effects arise in the development of our product candidates, we, the FDA, competent authorities of EU member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA or comparable regulatory authorities could also order us to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monitoring the safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our ongoing and planned clinical trials, we have contracted, and are expected to continue to contract, with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA, the EMA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. The centers using our products, if and when approved, could also have difficulty managing any adverse effects of our products, or use medicines that do not adequately control such undesirable effects or that have a detrimental impact on the efficacy of the treatment. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we successfully advance our product candidates into and through clinical trials, such trials will likely only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effects and safety consequences of taking our product candidates over a multi-year period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval and we or others later identify undesirable effects caused by such products, a number of potentially significant negative consequences could result, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall a product or change the way such product is administered to patients&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates or our immunotherapy approach generally prove to be unsafe, our technology platforms and pipeline could be affected, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our pipeline is in preclinical development and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for product candidates, we must complete extensive preclinical studies, including IND-enabling Good Laboratory Practice toxicology testing, that support our planned Investigational New Drug applications, or INDs, in the United States or similar applications in other jurisdictions. We must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing. CMC activities for a new category of medicines such as mRNA therapies require extensive manufacturing processes and analytical development, which are uncertain and lengthy. For instance, batch failures have occurred as we scale up our manufacturing and may occur in the future. In addition, we have had in the past, and may in the future have, difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our preclinical or clinical product candidates. If we are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of preclinical or clinical trials of such product candidates. For example, we cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept the results of our preclinical testing or our proposed clinical programs or if the outcome of our preclinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and complex and can take many years to complete. Its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates. We and our collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our collaborators conduct that could delay or prevent us or our collaborators from successfully developing our product candidates, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, other regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have optimized in the past and may in the future optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to additional studies (including bridging and bioequivalence studies) or potentially significant changes in our clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in an effort to optimize product features, we have made in the past and may continue to make changes to our product candidates after we commence clinical trials of a medicine which may require us to repeat earlier stages of clinical testing or delay later-stage testing of the medicine&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in trial design between early-stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable effects or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us or our investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate or any other of our product candidates for which a clinical trial may be ongoing&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of trial participants required for clinical trials of any product candidates may be larger than we anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may be slower than we anticipate due to perceived adverse effects, limited patient populations, competitive trials, risks related to COVID-19 or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">despite robust sponsor oversight, our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may elect to impose a clinical hold, or we, our investigators, IRBs or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to infectious disease vaccine trials in particular, we have to wait for particular level of infection in the placebo arm in order to assess protection provided by vaccine, and we cannot control the rate of exposure or infection which can make timing uncertain&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or efficacy concerns regarding our product candidates may result from any concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the DSMB. We may in the future be delayed in gaining clearance from the FDA or other regulators to initiate clinical trials through, among other things, the imposition of a clinical hold in order to address comments from such regulators on our clinical trial design or other elements of our clinical trials. A suspension or termination may be imposed due to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols&#894; inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold&#894; unforeseen safety issues or adverse side effects&#894; failure to demonstrate a benefit, or adequate benefit-risk ratio, from using a product candidate&#894; failure to establish or achieve clinically meaningful trial endpoints&#894; changes in governmental regulations or administrative actions&#894; or lack of adequate funding to continue the clinical trial. Many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. We must also complete extensive work on CMC activities that require extensive manufacturing processes and analytical development, which are uncertain and lengthy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA and regulatory authorities in other jurisdictions have limited experience with commercial development of several of our technologies. The FDA may require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be certain.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA and other regulatory authorities have indicated that, prior to commencing later stage clinical trials for our mRNA-based product candidates, we will need to scale up and further refine assays to measure and predict the potency of a given dose of these product candidates. Any delay in the scaling and refining of assays that are acceptable to the FDA or other regulatory authorities could delay the start of future clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data for our clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant additional preclinical or nonclinical testing and studies or clinical trial delays for our product candidates also could allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in the development of our product candidates may harm our business, financial condition and prospects significantly. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on June 28, 2024, the Supreme Court overturned the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> doctrine in the combined cases of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relentless Inc. v. Department of Commerce</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> doctrine gave deference to regulatory agencies in litigation against the FDA and other agencies. As a result, more plaintiffs may bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, which could delay the FDA&#8217;s review of our marketing applications.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we or our collaborators encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on enrollment of participants in our clinical trials for our product candidates. In the past, our collaborators have found, and we or our collaborators may in the future find, it difficult to enroll trial participants in our clinical studies, which could delay or prevent clinical studies of our product candidates. Identifying and qualifying trial participants to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends on the speed at which we can recruit trial participants to participate in testing our product candidates. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. If trial participants are unwilling to participate in our studies because of negative publicity from adverse events in our trials or other trials of similar products, or those related to specific a therapeutic area, or for other reasons, including competitive clinical studies for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product, or termination of the clinical studies altogether.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient and subject enrollment is affected by factors including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexity and design of the study protocol&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the study in question&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical study sites for prospective trial participants&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of competing therapies and clinical trials, including between our own clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to monitor trial participants adequately during and after treatment&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to recruit clinical trial investigators with the appropriate competencies and experience&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and trial participants&#8217; perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain participant informed consent&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">major changes in the approval status of competitor investigational products during the clinical trial period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impacts related to the spread of COVID-19&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that trial participants enrolled in clinical trials will not complete a clinical trial.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of trial participants available to us because some trial participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our product candidates represent a therapeutic novelty in contrast to more traditional methods for disease treatment and prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other investigational therapies rather than enroll trial participants in any future clinical trial involving more novel product candidates. Additionally, if new product candidates, such as gene editing therapies, show encouraging results, potential trial participants and their doctors may be inclined to enroll trial participants in clinical trials using those product candidates. If such new product candidates show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our clinical trials. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, certain conditions for which we plan to evaluate our current product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing patients may prove costly. Each of the foregoing risks may continue to be affected by the spread of seasonal viral infections, including COVID-19, as well as the potential for any new pandemic caused by an as-yet-unknown agent.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We, our collaborators, and other third parties on whom we rely conduct various activities, including research, clinical trials, manufacturing and, where approved, marketing, in jurisdictions across the globe. Such activities are subject to a variety of risks which could materially and adversely affect our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities increasingly span different jurisdictions. For example, clinical trials of our product candidates are currently being conducted in several countries, and we plan to commercialize our product candidates, if approved, globally. Accordingly, we are subject to additional risks related to operating in multiple countries, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in such countries&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in Germany and shipping the product candidate to the patient abroad&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import and export requirements and restrictions&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on transfers of information, including certain technologies and personal data&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular economies and markets&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">taxes, including withholding of payroll taxes&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing operations outside of Germany&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in other jurisdictions&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as Germany and the United States&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or public health epidemics or pandemics.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our global operations, we and our collaborators rely on relationships with entities based in various jurisdictions, including for clinical research and manufacturing activities and other regional operational needs. Such relationships may involve the use of our or others&#8217; intellectual property. We expect to continue to rely on such entities, which include locally-based CMOs and CROs, in the future. For example, we and our collaborators rely on WuXi Biologics Co., Ltd. and its affiliates for outsourcing activities related to manufacturing and the supply chain, research and development, certain IP, and commercialization readiness for certain of our product candidates. Such entities are subject to evolving</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">local regulatory requirements, and may also be subject to U.S. and EU legislation, including the proposed U.S. BIOSECURE Act, sanctions, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trade restrictions, and&#47;or other regulations. Such requirements could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material, or have an adverse affect on our ability to secure significant commitments from governments to purchase our potential therapies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 virus continues to impact our operations, including our clinical trial operations, as it becomes endemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including new outbreaks, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In the future, similar events could affect our ability to manufacture and commercialize our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we and our partners have conducted and are expecting in the future to conduct clinical trials for our product candidates at clinical sites located outside of the United States. Although the FDA may accept data from clinical trials outside the United States that are not conducted under an IND, acceptance of this data in support of a marketing application or IND requires the clinical trial to have been conducted in accordance with GCPs, and that the FDA is able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from non-U.S. clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of non-U.S. data alone unless those data are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid without the need for an onsite inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an onsite inspection or other appropriate means. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States in support of a marketing application. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of a product candidate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations and our collaborations with our collaborators may materially adversely affect our ability to attain or maintain profitable operations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim top-line and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically extensive information, and our securityholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by our securityholders or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our planned clinical trials or those of our collaborators may be less efficacious or may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our product candidates are being developed or are intended to be co-administered with other developmental therapies or approved medicines. For example, autogene cevumeran (BNT122&#47;RO7198457) is being developed to be co-administered with checkpoint inhibitors. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other regulatory authorities, ethics committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts focus on the clinical trials and potential approval of our existing product candidates, a key element of our strategy is to discover, develop and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug and target discovery efforts, exploring potential collaborations for the development of new products, and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to develop and commercialize such products successfully for many reasons, including the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the research methodology used may not be successful in identifying potential product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified senior management and scientific personnel.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry, as well as a current global shortage of these highly qualified individuals. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing and commercialization objectives. We are also aware of physical threats made against certain of these people. In response to these threats, we have deployed personal protection for such employees and increased our security generally. We currently do not have &#8220;key person&#8221; insurance on any of our employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will be critical to our success as well. Competition for skilled personnel, including in mRNA research, clinical development, clinical operations, regulatory affairs, therapeutic area management, manufacturing, and AI, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, and the failure to succeed in preclinical studies or clinical trials or in applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of services of certain executives, key employees, consultants or advisors may impede the progress of </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have an adverse effect on the results of our operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and consultants, despite our robust efforts to prevent such misconduct through sponsor oversight. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, to provide accurate information to the FDA, the EMA and other regulatory authorities, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment-related disputes, including employee litigation and unfavorable publicity, could negatively affect our future business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may be subject to claims by our employees or regulatory authorities with respect to employment and workplace matters, including lawsuits or proceedings against us regarding injury, creating a hostile workplace, discrimination, wage and hour disputes, sexual harassment or other employment issues. In recent years, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment- related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit versions of our COVID-19 vaccine, or, if approved, our other product candidates, could have a negative impact on our financial performance or reputation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have in the past and may continue to illegally distribute and sell counterfeit versions of COVID-19 vaccines. Counterfeit products are frequently unsafe or ineffective, and may even be life-threatening. Counterfeit medicines may contain harmful substances or the wrong dosage. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reports of adverse reactions to counterfeit products, increased levels of counterfeiting, or unsafe vaccines could materially affect public confidence in our COVID-19 vaccine or other product candidates. It is possible that adverse events caused by unsafe counterfeit vaccines will mistakenly be attributed to our COVID-19 vaccine, or, if approved, our other product candidates. In addition, thefts of inventory at warehouses, plants or while in-transit, which are subsequently improperly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation, and our business. Public loss of confidence in the integrity of our COVID-19 vaccine or, if approved, our other product candidates, as a result of counterfeiting or theft could have a material adverse effect on our business, results of operations, and financial condition.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach of running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the EU General Data Protection Regulation, or the GDPR, relevant law of an EU member state, HIPAA, and other relevant state and federal privacy laws in the United States or in other jurisdictions. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failures, accidents or security breaches to date, in December 2020, we were informed by the EMA that the agency was subject to a cyberattack and that some documents relating to our regulatory submission for our COVID-19 vaccine candidate, which was stored on an EMA server, had been unlawfully accessed. None of our systems were breached in connection with this incident and we are unaware that any study participants were identified through the data being accessed. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have put systems and procedures in place to minimize the likelihood of such incidents reoccurring&#894; however, we cannot guarantee that third parties will not be able to gain unauthorized access to or otherwise breach our systems in the future. Any such unauthorized access or breach could adversely affect our business, results of operations and financial condition.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and an even greater risk related to any commercialized products, such as our COVID-19 vaccine. We have received product liability claims against our COVID-19 vaccine, and expect to receive additional product liability claims in the future. If we cannot successfully defend ourselves against claims that our products and&#47;or our product candidates have caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product or product candidate that we may develop&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients, healthy volunteers or their children&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant time and costs to defend the related litigation&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products or product candidates that we may develop&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry clinical trial insurance and product liability insurance, which we believe to be sufficient in light of our current clinical programs and commercial operations&#894; however, the amount of coverage we have obtained may not be adequate and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our products become subject to a product recall it could harm our reputation, business and financial results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, some governmental bodies outside the United States have the authority to require the recall of any product or product candidate in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recalls of any of our products or, if approved, our product candidates, would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are investing in AI technology systems, including through our acquisition of InstaDeep, and such systems are complex and rapidly changing. We face significant competition from other companies with respect to our AI and machine learning services, along with an evolving regulatory landscape. The introduction of AI into the development and manufacturing of our product candidates, or the provision of services relating to AI technologies and applications, may result in new or enhanced governmental or regulatory scrutiny, litigation, intellectual property risks, confidentiality or security risks, ethical concerns or other complications that could harm our business, reputation or financial condition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty around AI may require additional investment in the development and maintenance of proprietary datasets and development of appropriate protections and safeguards for handling the use of customer data with AI technologies, which may be costly and could impact our expenses. In addition, AI may create content that appears correct but is inaccurate or flawed, and if created by third parties, may be mistakenly attributed to us. Our customers or others may rely on or use this flawed content to their detriment, which may expose us to brand or reputational harm, competitive harm or legal liability. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance, or ESG, matters, including related social expectations and concerns, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the price of ADSs representing our ordinary shares to decline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are rapid and ongoing developments and changing expectations relating to ESG matters and factors such as the impact of our operations on the environment, access to our COVID-19 vaccine, corporate governance, our practices relating to product stewardship, management of business ethics, human rights diligence in our own operations and our supply chain, and human resource development, which may result in increased regulatory, social or other scrutiny on us. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we must address climate risks due to our own contribution to climate change (inside-out perspective), risks due to physical effects of climate change as well as transition risks (outside-in perspective), and interactions between both perspectives. To this end, we have set ourselves near-term scienced-based emissions reduction targets for our own operations (scope 1, 2) and for our supply chain (supplier engagement target for scope 3), validated by the SBTi in early February 2024.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are addressing increasingly complex regulatory requirements with respect to human rights risks, including German legislation (for example, the Act on Corporate Due Diligence Obligations for the Prevention of Human Rights Violations in Supply Chains (&#8220;Lieferkettensorgfaltspflichtengesetz &#8211; LkSG&#8221;)), potential legislative planning by the European Union and local or regional regulations. We are expected by </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation to identify, prevent, mitigate and ideally end the extent of any potential adverse impacts or violations throughout our own operations and value chain.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we are faced with increasing ESG related transparency and reporting obligations. These requirements arise, for example, from the EU CSRD regulation and the ESRS sustainability standards, from specific human right reporting regulations (e.g. section 10 of the German LkSG), any potential SEC rules that could require registrants to provide additional climate-related disclosures in future periods, and other possible obligations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we fail to meet our climate protection targets or if we are unable to adequately recognize and respond to such developments and governmental, societal, investor and NGO expectations relating to such ESG matters, we may have to pay substantial fines, forego corporate opportunities, become subject to additional scrutiny, incur unexpected costs or experience damage to our reputation or our various brands. If any of these events were to occur, there may be a material adverse effect on our business, financial condition, cash flows and results of operations, and the price of ADSs representing our ordinary shares may decline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have observed that in addition to the importance of their financial performance, companies are increasingly being judged by their performance on ESG matters. A variety of organizations measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. We may fail to comply with standards or best practices put forth by such organizations or by governmental or regulatory bodies. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. In light of investors&#8217; increased focus on ESG matters, there can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to our proper role. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, the price of ADSs representing our ordinary shares, financial condition, or results of operations, including the sustainability of our business over time.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1294"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Manufacturing of our COVID-19 Vaccine, our Product Candidates and Future Pipeline</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our COVID-19 vaccine and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes for our COVID-19 vaccine and our product candidates are novel and complex. Due to the novel nature of this technology and the recency of our experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons, including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This has resulted in the past, and may in the future result, in our having to resupply batches for preclinical, clinical, or commercial activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our products or product candidates could materially delay our or our collaborators&#8217; ability to continue the clinical trial for that product candidate or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical, clinical or commercial supply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2021 we received product quality complaints related to our COVID-19 vaccine in Hong Kong. A thorough investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient container closure process, or crimping, at one specific contract manufacturing organization when such containers were later shipped at ultra-cold conditions created by shipping on dry ice. The investigation did not identify any safety issues related to the product quality complaints. We and our COVID-19 vaccine collaboration partner in Hong Kong, Fosun Pharma, subsequently supplied replacement COVID-19 vaccine vials, but we cannot assure you that we will not experience similar product quality complaints in the future. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rate of innovation is high, which has resulted in, and will continue to cause a high degree of, technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of, new manufacturing infrastructure or may adversely affect third-party relationships.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process to generate mRNA medicines is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply. Additionally, for individualized therapies, we may encounter issues with our ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to the manufacturing process may impact, in turn, specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of lots and this could lead to a substantial delay in our clinical trials or an inability to supply sufficient commercial quantities of drug product. Our mRNA product candidates may prove to have a stability profile that leads to an unfavorable shelf life. This poses risk in supply requirements, wasted stock and higher cost of goods.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the number of different programs, we may in the future have cross contamination of products inside of our factories, CROs, external CMOs, suppliers or in the clinic that affect the integrity of our products. Additionally, for some programs the manufacturing scale is extremely small compared to the standard volumes of supply, such that we run the risk of contaminating the process each time we reopen a container to use remaining supplies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates from IND-enabling studies through commercial launch, including shelf life stability and solubility properties of drug product and drug substance. Due to continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as six- or 12- month stability testing. That may require resupplying clinical or commercial material, or making additional GMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our COVID-19 vaccine and our product candidates. Further, now and in the future, one or more of our programs may have a single source of supply for raw materials and excipients. Some of our suppliers are located in countries different from our manufacturing sites. Export restrictions could lead to unplanned interruptions in manufacturing, thus impacting supply of both clinical and commercial material. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA products and product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA products or product candidates until the manufacturing or testing process is rectified.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and product intermediates are extremely temperature sensitive, and we may learn that any or all of our products are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our products or product candidates and result in delays or interruptions to clinical or commercial </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions. As we transport intermediate products with holding times in refrigeration (TIR) and allowed times out of refrigeration (TOR) across long distances and crossing borders, traffic issues and customs delays could lead to the loss of batches which would need to be replaced.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our product candidates are uniquely manufactured for each patient and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of the third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide such product candidates for clinical trials or, if approved, products for patients could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We custom design and manufacture certain product candidates that are unique and tailored specifically for each patient. Manufacturing unique lots of these product candidates is susceptible to product loss or failure due to issues with&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics associated with the collection of a patient&#8217;s tumor, blood or other tissue sample&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shipping such samples to a facility for genetic sequencing&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation sequencing of the tumor mRNA&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biopsy of a sufficient quantity of cancerous tissue to allow for proper sequencing and identification of tumor-specific mutations&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of appropriate tumor-specific mutations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effective design of the patient-specific mRNA that encodes for the required neoantigens&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">batch-specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control testing failures&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected failures of batches placed on stability&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely manufacture and release of the patient-specific batch&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shipment issues encountered during transport of the batch to the site of patient care&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to define a consistent safety profile at a given dose when each participant receives a unique treatment&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on single source suppliers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to evolve our own custom manufacturing equipment. This equipment may not function as designed, which may lead to deviations in the drug product being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, we may not be able to supply this expanded need reliably without significant investments due to the custom nature of the equipment and single-use assemblies. In addition, there will be considerable time to scale up our facilities or build new facilities before we can begin to meet any commercial demand if one or </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more of our individualized product candidates are approved. This expansion or addition of new facilities could also lead to product comparability issues, which can further delay introduction of new capacity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those of our product candidates that are manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, the sequenced data derived from such tissue sample, the results of such patient&#8217;s genomic analysis and the custom manufactured product for such patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in product mix-up, adverse patient outcomes, loss of product, or regulatory action, including withdrawal of any approved products from the market. Further, as our product candidates are developed through early-stage clinical studies to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery processes will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our inability to manufacture sufficient or appropriate quantities of our COVID-19 vaccine or any of our product candidates, or our failure to comply with applicable regulatory requirements, could materially and adversely affect our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing is a vital component of our individualized immunotherapy approach, and we have invested significantly in our manufacturing facilities, including the acquisition of a manufacturing site in Marburg, Germany, the construction of a novel modular manufacturing facility that we refer to as a &#8220;BioNTainer,&#8221; and the construction of a facility to support manufacturing of our Individualized Vaccines Against Cancer candidates. All internal manufacturing is performed under GMP guidelines. We also rely on a network of CMOs for the manufacture of our COVID-19 vaccine. We do not rely on any external CMOs for the manufacture of our individualized product candidates and at this time, and we have limited redundancy among our facilities. Due to the individualized nature of our product candidates, we do not maintain product reserves. If any of our or our external CMOs&#8217; manufacturing facilities, including our BioNTainer units, experience difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our clinical development programs may be delayed or suspended until we or our external CMOs can resume operations. We may also be required to incur significant expenditures to resolve such difficulties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner also have experienced, and continue to face the risk of, inventory write-downs or redundant production capacities with respect to our COVID-19 vaccine. Planned new formulations of our COVID-19 vaccine, including versions that could protect against new variants of COVID-19, have resulted or may result in significant research and development expense that was not or may not be recouped. In addition, we have experienced in the past, and may experience in the future, redundant production capacities under our agreements with CMOs due to planned new formulations, adaptations of our COVID-19 vaccine and increased internal manufacturing capacities. Significant inventory write-downs or redundant manufacturing expenses would negatively impact our results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are subject to various regulatory requirements and may be subject to announced or unannounced inspections by the FDA or other regulatory authorities at any time during the development or commercialization phase. If we or our external CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or comparable regulatory authorities in other jurisdictions, we may not be able to rely on our or our external CMOs&#8217; manufacturing facilities for the manufacture of our product candidates. If the FDA, the EMA or another comparable regulatory authority finds our or our external CMOs&#8217; facilities inadequate for the manufacture of our COVID-19 vaccine or our product candidates or otherwise deficient, including as a result of a site inspection, such facilities may be the subject of adverse regulatory action, including the issuance of untitled or warning letters. If such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly delay or otherwise impact our ability to develop, obtain regulatory approval for or market our COVID-19 vaccine or our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may experience manufacturing difficulties due to resource constraints, labor disputes or unstable political environments. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials, or to provide approved products for the treatment of patients, would be jeopardized.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designs of our facilities are based on current standards for biotechnology facilities. They have been reviewed and approved by local authorities and have also received GMP manufacturing licenses. We have designed our facilities to incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. We have attempted to achieve a high level of digitization for clinical and commercial manufacturing facilities relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to a delay in supply or shutdown of our facilities. Any disruption in our manufacturing capabilities could cause delays in our production capacity for our drug substances or drug products, impose additional costs, or require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our development and commercial capacity, we may continue to establish additional manufacturing capabilities in different jurisdictions, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete the construction in an efficient manner, recruit required personnel, and&#47;or generally manage our growth effectively, the development and production of our products or product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our COVID-19 vaccine and certain of our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and suppliers may not be able to deliver raw materials to our specifications. In addition, some such suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under GMP by biopharmaceutical firms. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we have experienced and we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms or at all, which could have a material adverse impact on our business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to significant regulatory oversight with respect to manufacturing our products and product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and costs of our products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of immunotherapies for clinical trials or commercial sale is subject to extensive regulation. GMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in our products and product candidates. Poor control of the GMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in loss of potential product </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales revenue, cost overruns and delays to clinical timelines for our clinical programs, which could be extensive. Such production process issues include but are not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">critical deviations in the manufacturing process&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility and equipment failures&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contamination of the product due to an ineffective quality control strategy&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility contamination as assessed by the facility and utility environmental monitoring program&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective process, equipment or analytical change management, resulting in failed lot release criteria&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective product stability&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failed lot release or facility and utility quality control testing&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failed or defective components or consumables.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must supply all necessary documentation in support of a BLA or other marketing authorization application on a timely basis and must adhere to the FDA&#8217;s, the EMA&#8217;s and other countries&#8217; GMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with GMPs and manufacturing controls as described in the filing. If either we or one of our third-party manufacturing sites fail to provide sufficient quality assurance or control, approval to continue delivery of our commercial product or to commercialize our product candidates may not be granted. Inspections by regulatory authorities may be announced or unannounced and may occur at any time during the development or commercialization phase. The inspections may be product-specific or facility-specific for broader GMP inspections, or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may result in adverse regulatory action, including the issuance of untitled or warning letters, which could influence our ability, or the ability of our third-party manufacturers or suppliers, to fulfill supply obligations, impacting or delaying supply or delaying programs. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including, but not limited to, clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our collaborators) and our overall business operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for any product is subject to the FDA&#8217;s, the EMA&#8217;s and other regulatory authorities&#8217; approval processes, and we may need to contract with manufacturers whom we believe can meet applicable regulatory authority requirements on an ongoing basis. If we or our third-party manufacturers are unable to reliably manufacture to specifications acceptable to the FDA, the EMA or other regulatory authorities, we or our collaborators may not obtain or maintain the approvals we or they need to release and deliver such products. Even if we or our collaborators obtain regulatory approval for any of our immunotherapies, there is no assurance that either we or our CMOs will be able to manufacture our product candidates to specifications acceptable to the FDA, the EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foregoing could have an adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not have direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our CMOs are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our CMOs&#8217; facilities, and could result in the sanctions and other adverse outcomes described above. Our potential future dependence upon others for the manufacture of our products, product candidates and raw materials may adversely affect our future operating results and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the EMA and other regulatory authorities may require us to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other regulatory authorities may require that we do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our CMOs have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our own facilities or those of our third-party manufacturers could cause us and our collaborators to delay clinical trials, product launches or product supply, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we train and qualify all personnel around the appropriate handling of our products and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1303"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Reliance on Third Parties</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, collaborators, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. Furthermore, we currently rely, and expect to continue to rely, on third parties to conduct certain research and preclinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs are required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of preclinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We are also responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the regulatory authorities of the EU member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot be sure that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of GMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have designed, and in the future intend to design the clinical trials for certain of our product candidates, our collaborators will design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials results in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have staffing difficulties&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to comply with contractual obligations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience regulatory compliance issues&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undergo changes in priorities or become financially distressed&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">form relationships with other entities, some of which may be our competitors&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make human errors&#894; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to cyberattacks.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past, certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing collaborations, or any future collaboration arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop and commercialize our products and product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations under which our collaborators have provided, and may in the future provide, funding and other resources for developing and commercializing our products and product candidates. We expect to enter into additional collaborations to access additional funding, capabilities and&#47;or expertise in the future. Our existing collaborations, and any future collaborations we enter into, may pose a number of risks, including the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform or prioritize their obligations as expected&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical trials conducted as part of such collaborations may not be successful&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates and products that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the collaborators&#8217; focus or available funding (for example, we are aware that there have been allegations that Fosun International Ltd., an affiliate of our collaboration partner Fosun Pharma, is facing liquidity risks), or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates developed in collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in Germany or the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful development and commercialization of programs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty or other contingent payments, or otherwise yield the expected benefits under the collaborations. As a result, our development of product candidates and commercialization efforts could be delayed and we may need additional resources to develop and commercialize our product candidates. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this report apply to the activities of our collaborators.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether or not we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current or future collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Pfizer for certain targets, and under the terms of our respective collaboration agreements with them, we will be restricted from granting rights to other parties to use our mRNA technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in the future contain non-competition provisions that could limit our ability to enter into collaborations with future collaborators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to licenses that give us rights to third-party intellectual property, including patents and patent applications, that are necessary or useful for our business. In particular, we have obtained licenses from Acuitas Therapeutics, CellScript LLC and its affiliate, mRNA RiboTherapeutics, Inc., to patent rights claiming certain uses of modified RNA, as well as licenses from certain other parties for intellectual property useful in pharmaceutical formulations. We may enter into additional licenses to third-party intellectual property in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute the patent applications we license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">including amounts to be paid pursuant to certain program milestones being achieved or to royalty obligations, including the triggering of royalty obligations and amounts to be paid pursuant thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, our co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We and our collaborators rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect to continue using our own clinical manufacturing facilities where available, we also rely on outside vendors to manufacture supplies and process our product candidates. We only manufacture our COVID-19 vaccine on a commercial scale and may not be able to achieve commercial-scale manufacturing and processing for our other product candidates, if approved, and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for our product candidates, if approved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may not be able to develop commercially viable products other than our COVID-19 vaccine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on a limited number of CMOs exposes us to the following risks&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory authority questions, if any&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMOs may not be able to execute our manufacturing procedures appropriately&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future CMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over CMOs&#8217; compliance with these regulations and standards&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not own, or may have to share, the intellectual property rights to any improvements made in the manufacturing process for our products&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs could breach or terminate their agreement with us&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, the approval, if any, of our COVID-19 vaccine or product candidates by the FDA or regulatory authorities in other jurisdictions or the commercialization of our COVID-19 vaccine or product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our COVID-19 or our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our collaborators currently rely on CMOs located outside of the United States to manufacture their clinical materials, and we expect to rely on CMOs located outside of the United States in the future. Such ex-U.S. CMOs may be subject to or affected by U.S. legislation, executive orders, regulations, or investigations, including but not limited to the proposed BIOSECURE Act, the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, sanctions, trade restrictions and other U.S. and other regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material, delay or impact clinical trials, have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies and adversely affect our financial condition and business prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on single source suppliers for some of the components and materials used in, and the processes required to develop, our COVID-19 vaccine and our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our COVID-19 vaccine and our product candidates. We cannot ensure that these suppliers or service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our COVID-19 vaccine and our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our COVID-19 vaccine and our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our COVID-19 vaccine and product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the FDA&#8217;s approval of our product candidates, we will also require FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single source suppliers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these suppliers, service providers and manufacturers subjects us to a number of risks that could harm our reputation, business and financial condition, including, among other things&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays to the development timelines for our product candidates&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers&#894; and</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1312"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our efforts to obtain, maintain, protect, defend and&#47;or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our COVID-19 vaccine and for our product candidates, proprietary technologies and their uses, as well as our ability to operate, develop, manufacture and commercialize our COVID-19 vaccine or one or more of our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, including any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and&#47;or licensing patent applications in the European Union, the United States and elsewhere related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties&#8217; activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in other jurisdictions, including Europe, nor can we be certain that any claim in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our COVID-19 vaccine or our product candidates, or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that issued patents will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to apply for patents on certain aspects of our current or future products or product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even claims of issued patents may later be found invalid or unenforceable, or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our intellectual property and proprietary technology, competitors may be able to use our products, product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or collaborators will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our products or product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patenting process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims of issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#894;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other parties may have designed around our patent claims or developed technologies that may be related or competitive to our COVID-19 vaccine or to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent filings, either by claiming the same or overlapping methods, products, reagents, tools or devices or by claiming subject matter that could dominate one or more of our patent claims&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any successful opposition to claims of any patents owned by or in-licensed to us could deprive us of rights necessary for the development and exploitation of our COVID-19 vaccine or our product candidates and other technologies, or the successful commercialization of any product candidates and other technologies that we may develop&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">because patent applications in the United States and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s)&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a court or other patent proceeding, such as an inter partes review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and&#47;or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns&#59; existing legislation (for example, in the United States, the Public Readiness and Emergency Preparedness Act, etc.) may be interpreted, and new legislation may be passed, to permit third-party use of patented technologies relating to a public health concern, with little or no compensation to the patent holder(s)&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing competitors a better opportunity to create, develop and market competing product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the U.S. Congress and in other jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as U.S. or EU laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, if </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of these parties were to breach such agreements and improperly disclose such output before a patent application is filed, this could jeopardize our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring. Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and&#47;or term of patent protection of our products and product candidates and&#47; or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and&#47;or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or our product(s) or product candidates, or which effectively prevent others from commercializing competitive technologies and products. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor&#8217;s or potential competitor&#8217;s product or service, and in some cases we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, patents or other intellectual property rights that we may be able to secure for our COVID-19 vaccine or our other COVID-19 vaccine candidates could be restricted or preempted if governments determine that they will not enforce, or will require compulsory licensing of, technologies useful to address the spread of COVID-19.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management, technical personnel, and other employees even if the eventual outcome is favorable to us.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product(s), our product candidates and other technologies&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications or those of our licensors may issue as patents&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to successfully commercialize our products on a substantial scale, if approved, before the relevant patents that we own or license expire&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, our co-owners or our licensors were the first to file patent applications for these inventions&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not develop similar or alternative products or technologies that do not infringe the patents we own or license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the claims of patents we own or license will be found to ultimately be valid and enforceable&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third party may not challenge the claims of patents we own or license and, if challenged, a court would hold that such patent claims are valid, enforceable and infringed&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may develop or in-license additional proprietary technologies that are patentable&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have an adverse effect on our ability to issue patents, or otherwise on our business&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors do not conduct research, development, testing or commercialization activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies, product(s) or product candidates that are separately patentable&#894; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our, or our collaborators&#8217;, development and commercialization activities, including our manufacturing processes, or products will not infringe patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other companies or organizations may challenge our intellectual property rights or the intellectual property rights of our partners or may assert intellectual property rights that prevent us or our partners from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We practice in new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and&#47;or claim certain technologies, including products, reagents, formulations, tools and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, testing, manufacture and commercialization of therapeutic modalities and our </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery technologies, including LNPs. If we, our co-owners or our licensors are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our products, product candidates and other technology and any other products, product candidates and technology that we may develop, our business, financial condition, results of operations and prospects could be materially harmed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the scientific fields mature, our known competitors and other third parties, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents, and they have filed and will continue to file patent applications claiming inventions in the fields in the United States and elsewhere. This may limit, interfere with or eliminate our and our partners&#8217; ability to make, use, sell, import or otherwise exploit our COVID-19 vaccine or our product candidates or other technologies. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our co-owners, our partners or our licensors may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. In the United States, the Leahy-Smith America Invents Act, or the America Invents Act, includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. We expect that our competitors and other third parties will institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we face ongoing COVID-19 vaccine-related patent litigation. Alnylam Pharmaceuticals Inc. has brought litigation against us and Pfizer regarding U.S. Patent Nos. 11,245,933&#59; 11,382,979&#59; 11,633,479&#59; 11,633,480&#59; 11,612,657&#59; and 11,590,229, the latter five of which are continuations of the &#8216;933 Patent. In addition, CureVac SE has brought litigation against us in Germany regarding three European patents, 1857122B1 (&#8220;EP&#8217;122&#8221;), 3708668B1 (EP&#8217;668), and 4023755B1 (&#8220;EP&#8217;755&#8221;) and three German utility models, DE202015009961, DE202015009974, and DE202021004130, or the CureVac IP. BioNTech filed a nullity action in the Federal Patent Court of Germany seeking a declaration that EP&#8217;122 is invalid, initiated cancellation actions against the CureVac IP in the German Patent and Trademark Office, and filed opposition proceedings in the EPO seeking the revocation of EP&#8217;668 and EP&#8217;755. In the United States, CureVac asserts seven U.S. patents against us and Pfizer&#58; U.S. Patent Nos. 11,135,312&#59; 11,149,278&#59; 10,760,070&#59; 11,286,492&#59; 11,345,920&#59; 11,596,686, and 11,667,910. BioNTech and Pfizer also initiated proceedings seeking the revocation of EP&#8217;122, EP&#8217;668, and EP&#8217;755 in the Business and Property Courts of England and Wales. ModernaTX, Inc., or Moderna, has brought litigation against us and Pfizer regarding European patents 3590949B1 (&#8220;EP&#8217;949&#8221;) and 3718565B1 (&#8220;EP&#8217;565&#8221;) in Germany, England and Wales, the Netherlands, Ireland, and Belgium, and regarding U.S. Patent Nos. 10,898,574, 10,702,600, and 10,933,127 in the United States. BioNTech and Pfizer also initiated proceedings seeking the revocation of EP&#8217;949 and EP&#8217;565 in the Business and Property Courts of England and Wales and have filed opposition proceedings in the EPO seeking the revocation of EP&#8217;949 and EP&#8217;565. BioNTech and Pfizer have filed petitions for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review before the Patent Trial and Appeal Board in the U.S. with respect to U.S. Patent Nos. 10,702,600 and 10,933,127. Arbutus Biopharma Corp. and Genevant Sciences GmbH have brought litigation against us and Pfizer in the United States regarding U.S. Patent Nos. 9,504,651&#59; 8,492,359&#59; 11,141,378&#59; 11,298,320&#59; and 11,318,098. Promosome initiated litigation against us and Pfizer in the United States regarding U.S. Patent No. 8,853,179&#59; it has since been dismissed with prejudice. GlaxoSmithKline has brought litigation against us and Pfizer in the United States regarding U.S. Patent Nos. 11,638,693&#59; 11,638,694&#59; 11,666,534&#59; 11,766,401&#59;  11,786,467&#59; 11,759,422&#59; 11,655,475&#59; and 11,851,660. We cannot guarantee that we will not become subject to additional COVID-19 vaccine patent infringement lawsuits in the future. In addition, should Pfizer not prevail in any of the ongoing COVID-19 vaccine patent infringement lawsuits to which it is a party, Pfizer may seek to require us to indemnify Pfizer for losses suffered therefrom as well as any losses from future COVID-19 vaccine patent infringement lawsuits in which it does not prevail. We believe we have strong defenses against each of these claims and intend to vigorously defend ourselves in each proceeding, but we can make no assurances regarding the ultimate outcome of any of these matters.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will continue to be subject to similar proceedings or priority disputes, including oppositions, in Europe or other jurisdictions relating to patents and patent applications in our portfolio.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our co-owners, our partners or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management, technical personnel and other employees and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many issued and pending patent filings that claim aspects of technologies that we may need for our mRNA products or product candidates, or other product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for immunotherapies we wish to develop. In addition, as evidenced by the lawsuits brought against Moderna, Pfizer and us, there may be additional issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for the development, manufacturing, testing and commercialization of our COVID-19 vaccine or of our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms, if we fail to invalidate relevant patents, or if a court or other governing body determines that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may be unable to perform research and development or other activities or market products covered by such patents, and we may need to cease the development, manufacture, testing and commercialization of one or more of the product candidates we may develop. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, and test product components and manufacturing processes for our development pipeline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to certain intellectual property through our owned and in-licensed patents and other intellectual property rights relating to identification, development and testing of our product candidates or other technologies. As our activities may involve additional product candidates or services that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with academic institutions and&#47;or utilize services of CROs and CMOs in certain aspects of our research or development under written agreements with these parties. These agreements may not ensure protection of intellectual property rights in developed technology, or may fail to provide us with sufficient control of or access to such intellectual property rights. For example, agreements with these academic institutions typically provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies. CROs and&#47;or CMOs may control certain technologies that were utilized in and&#47;or developed through work on our behalf, and may not pursue protection of such technologies, or may provide us with only non-exclusive rights in such technologies, so that relevant technologies may be shared with other parties including our competitors. In any relationship with a third party, there is a risk of disagreement over intellectual property rights (including inventorship or ownership of, rights to protect and&#47;or enforce, and&#47;or rights to use) in utilized or developed technologies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development and commercialization of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The lifespans of our patents may not be sufficient to effectively protect our products or product candidates, technologies and business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most other jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The USPTO can also require, in certain circumstances, that the expiration date of a subject patent be shortened by the filing of a terminal disclaimer over one or more patents that may expire sooner than the subject patent. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. For example, we did not extend any patent for our COVID-19 vaccine. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to comply, or are viewed to have failed to comply, with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors or other third parties, we could lose license rights that are important to our business or suffer monetary losses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are heavily reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product(s) or product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop, test, or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in any or all of our licenses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from, or that arises through collaboration with, such third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution (including preparation and filing) of our in-licensed intellectual property or of intellectual property developed through collaboration, is controlled solely by the licensor or collaborator. We may also require the agreement and&#47;or cooperation of our licensors and collaborators to protect, enforce, utilize, or defend any in-licensed patent rights, and such agreement and&#47;or cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our collaborators. If we and our licensors or collaborators disagree over IP protection strategies for relevant technologies, disputes may arise, and we could lose access to or control over protection of technologies important to our business. If so, we may not be able to adequately protect our product(s) or product candidates, including not being able to prevent a competitor or other third party from developing the same product(s) or product candidates for the same or a different use. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may disagree from time to time with licensors or collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under our agreements. For example, we have been in discussions with the University of Pennsylvania, or UPenn, and the National Institutes of Health, or NIH, concerning royalties and other related amounts allegedly owed on sales of our COVID-19 vaccine since commercialization. UPenn has subsequently filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania in connection with this dispute. Substantial uncertainty exists as to the ultimate resolution of our discussions with NIH and the ongoing dispute with UPenn. Any ultimate cash outflow from these ongoing negotiations may be greater or less than we currently expect and we cannot currently predict what our ultimate level of future collaboration with NIH or UPenn will be, nor can we predict the timing, amount or structure of any potential resolution of these matters.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to have failed to satisfy obligations or materially breached any of our agreements, such as licenses to third-party intellectual or any disagreements between us and our licensors, a licensor could potentially have the right or reason to terminate the license, to exercise the option of a non-exclusive license, which would allow our competitors to have access to the same intellectual property and technology licensed to us. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, including royalty payments, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which event we would not be able to develop, market and commercialize product(s) or product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop, test and commercialize the product(s) or product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are rightfully terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours, and our licensors may be able to seek additional judicial remedies. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Failure to prevail with respect to any contractual disagreements could result in a material adverse effect on our competitive position, business, financial conditions, results of operations or prospects, particularly if discussions result in legal or other dispute resolution proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors fail to adequately protect this intellectual property, our ability to develop, test, market and commercialize our product(s) or product candidates could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop, test, market and commercialize the affected product(s) or product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Some of our in-licensed intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights and certain reporting requirements, and compliance with such regulations may limit our exclusive rights and our ability to contract with manufacturers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain intellectual property rights that have been in-licensed, including patent applications and patents that we in-license from the University of Pennsylvania, the Louisiana State University, the Broad Institute, the NIH, Genevant, and Cellscript, have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. The U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S. government rights may include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions covered by that Act for any governmental purpose. In addition, the U.S. government may have the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations (also collectively referred to as &#8220;march-in rights&#8221;). The U.S. government may also have the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any products embodying any such inventions or produced through the use of any such inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. We may not be able to obtain a waiver of this preference for U.S. industry, and this preference may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or in-licensed future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. If we or our licensors are unable to secure an exemption to these manufacturing requirements, if we comply with them, or if we are unable to comply with them, we may experience a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our current proprietary position for certain products and product candidates depends upon our owned or in-licensed patent filings covering components, manufacturing-related methods, formulations and&#47;or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have pursued or obtained patent protection covering components of certain product candidates and tests, manufacturing-related methods, formulations and&#47;or methods of use, we have not yet obtained patent protection for all components of certain product candidates and tests, manufacturing-related methods, formulations and&#47;or methods of use. For instance, we do not currently have any claims in our owned or in-licensed issued U.S. patents that cover the overall construct used in our iNeST product candidates. We also cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter, tests, manufacturing-related methods, formulations and&#47;or methods of use of our current or future product candidates. Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, testing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or abroad. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property rights of third parties could adversely affect our ability to commercialize our product(s) and product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop, test or market our product(s) and product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products and product candidates are still in early stages of development, testing or commercialization, and one or more features of the products or product candidates, or related technologies such as their manufacture, formulation, testing or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize. Furthermore, even if all aspects of our product(s) or product candidates, or of other technology, were known, it is possible that third-party intellectual property, which may or may not currently be public, could develop in a manner (for example, through issuance of additional patents) that could impede our ability to make or use relevant products or product candidates, or other technology. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will impede or preclude our ability to commercialize products. Furthermore, while U.S. patent laws provide a &#8220;safe harbor&#8221; to our clinical product candidates under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when an NDA or BLA is submitted. Accordingly, after such submission (including for certain formulations of our COVID-19 vaccine), the 271(e)(1) safe harbor may no longer provide the same level of protection from third party patent infringement claims for that product. We may become exposed to lawsuits from third parties who consider our COVID-19 vaccine to infringe their patents. More generally, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we might want to submit an NDA or BLA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or more third parties may have issued patent claims that cover such products or critical features of their production, testing or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture, testing or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop, test or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly, licenses could not be available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, with respect to our products, product candidates and related technologies that may play a role in addressing a pandemic or other public health emergency, it is unclear whether governments around the world will protect vaccine manufacturers for liability from infringement of third party intellectual property, at least during the period of such public health emergency. Thus, it is possible that third parties may assert intellectual property rights against us relating to our COVID-19 vaccine, and that we will not be successful in arguing that commercialization of our COVID-19 vaccine is exempted from infringement and&#47;or liability for infringement (for example, under 35 U.S.C. &#167; 271(e)(1), discussed above, or under the Public Readiness and Emergency Preparedness Act, or the PREP Act, etc.). Furthermore, even if such commercialization was deemed protected from infringement during the period of the pandemic crisis, now that various global and U.S. agencies have declared an end to the global COVID-19 public health emergency, any such exemption may be terminated so that continuing commercialization could expose us to liability, and might even be precluded if third party(ies) who hold relevant intellectual property rights are able to secure injunction(s) or are unwilling to license to us on commercially feasible terms.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platform or product(s) and product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18 months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platform or product candidates over time, and we might not be aware that such amendment had been made.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be involved in lawsuits or other legal proceedings to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property, each of which could be expensive, time consuming and unsuccessful.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-U.S. patent offices.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties. We have a number of opposition proceedings ongoing at the EPO against third-party patents related to mRNA technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products, product candidates and services may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a patent infringement proceeding, our owned or in-licensed patents may be challenged and a court may decide that a patent we own or in-license is not valid, is unenforceable and&#47;or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforce a patent directed at one of our product(s) and&#47;or product candidates, the defendant could counterclaim that our patent is invalid and&#47;or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and&#47;or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement or written description. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and&#47;or unenforceability, we could lose at least part, and perhaps all, of the patent protection on a product and&#47;or product candidate. Such a loss of patent protection would have a material adverse impact on our competitive position, business, financial conditions, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, testing, methods of manufacture or methods for treatment related to the use, development, testing, manufacture or commercialization of our COVID-19 vaccine or product candidates. For example, BioNTech SE and certain of our wholly owned subsidiaries are defendants in litigations initiated by CureVac SE, Alnylam Pharmaceuticals, Inc., ModernaTX, Inc., Arbutus Biopharma Corp., Genevant Sciences GmbH, and GlaxoSmithKline Biologicals SA regarding </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See &#8220;Legal Proceedings.&#8221; As patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product(s) and&#47;or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the testing or manufacturing processes of any of our product(s) and&#47;or product candidates, any molecules formed during the testing and manufacturing processes or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop, test and commercialize such product and&#47;or product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for testing or manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop, test and commercialize the applicable product and&#47;or product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non-exclusive.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds we need to continue our clinical trials and research programs, to license necessary technology from third parties or to enter into development or manufacturing collaborations that would help us bring our product(s) and&#47;or product candidates to market.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our management, technical personnel and other employees from their normal responsibilities. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of our competitors may be able to sustain the costs of such proceedings more effectively than we can because of their greater resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product(s) and&#47;or product candidates, which could limit our ability to generate revenues or achieve or maintain profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties for licenses to such third parties&#8217; intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, the price of the ADSs representing our ordinary shares could decline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies&#894; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology companies, our success is heavily dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that have affected the way patent applications are prosecuted and also affect patent litigation. Such legislation and its implementation could increase the uncertainties and costs </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, decisions by courts and governmental bodies in the United States and other jurisdictions may affect the value of patent applications, issued patents or other intellectual property that we own or in-license. For example, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and other administrative agencies, and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for some of our technology, product(s) and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery development, testing, manufacturing and commercialization processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite our best efforts, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Any of these parties who may have access to our trade secrets, know-how and other proprietary technology may breach such agreements or orders. For example, a former employee of our COVID-19 vaccine collaborator, Pfizer, has reportedly misappropriated trade secrets on our COVID-19 vaccine. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. In addition, we cannot be certain that our proprietary technical information and related confidential documents that we have shared with our collaborators and&#47;or have submitted to governmental agencies including regulatory agencies for evaluation and supervision of pharmaceutical products will be kept confidential. For example, certain documents relating to our COVID-19 vaccine were unlawfully accessed after a cyberattack on the EMA in December 2020. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, financial condition and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, including alleged trade secrets of their former employers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual&#8217;s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management, technical personnel and other employees. Claims that we or our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may be subject to claims that current or former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, collaborators and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. In addition, certain such agreements, even if successfully executed may distribute ownership or control of intellectual property rights between or among parties, for example based on subject matter, relationship to other intellectual property, and&#47;or one or more aspects of development of the intellectual property&#59; after the agreements are in place disputes may arise over such distribution principles or over proper treatment of particular developed intellectual property in accordance with them. Disagreements may be difficult or impossible to resolve, may be expensive to address, and may result in our failing to secure or maintain ownership in or control of intellectual property necessary or important to our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants, independent contractors, collaborators or other third parties who are involved in developing and commercializing our product(s) and&#47;or product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, operating results and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management, technical personnel and other employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the laws of some other countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the U.S. laws. A majority of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees are subject to the provisions of the German Act on Employees&#8217; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act that may be costly to defend and take up our management&#8217;s, technical personnel&#8217;s and other employees&#8217; time and efforts whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who assign patents to us may be deemed to be insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases, where employees&#8217; rights have not been assigned to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business, results of operations and financial condition could be adversely affected.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product(s) and&#47;or product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States, particularly those in Asia, including China, can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Germany and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States to the same extent as within the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product(s) and&#47;or product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions, particularly outside of Europe and the United States. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property or development, testing, marketing and commercialization of competing products in violation of our owned or in-licensed intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. In particular, the validity, enforceability and scope of protection of intellectual property in China, where we derive net sales and maintain collaboration partnerships including licensing, are still evolving and historically, have not protected and may not protect in the future, intellectual property rights to the same extent as laws developed in Europe, including Germany, and the United States. Consequently, the time required to enforce our intellectual property rights in the legal regime of China may be lengthy and delay our recovery.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours or collaborators may fail to use our trade names or trademarks appropriately or at all, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse or failure to use of our trademarks and trade names by our licensees may </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jeopardize our rights in or diminish the goodwill associated with our trademarks, and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make COVID-19 vaccines or therapies, and&#47;or individualized cancer immunotherapies that are similar to our COVID-19 vaccine and&#47;or any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, our co-owners or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, our co-owners or our licensors or future collaborators might not have been the first to file patent applications covering certain of our or their inventions&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims of issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business&#894; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1330"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administration of some of our product candidates may require the use of immuno-assays and bioinformatic tools in which patients are screened for optimal target antigens of our product candidates. If safe and effective use of a biologic product depends on an in vitro diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several years, simultaneously with approval of the biologic product. Similarly, in the European Union, an in vitro companion diagnostic may be placed on the market only if it </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conforms to certain &#8220;essential requirements&#8221; and bears the Conformit&#233; Europ&#233;ene Mark, or CE Mark. The conformity assessment process to obtain the CE Mark can be lengthy and we may fail to demonstrate such conformity. Further, the applicable regulatory framework for in vitro diagnostics in the EU changed in May 2022 when a new EU regulation with stricter regulatory requirements for in vitro diagnostics became applicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our individualized immunotherapy candidates, the FDA and comparable regulatory authorities outside of the United States may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require PMA supplemental approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing companion diagnostics and plan to rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our individualized therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our individualized therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we may address in the future. For instance, we and our collaborators are applying our technology to develop therapeutics in indications such as certain rare diseases, including some for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain rare diseases may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other jurisdictions may make similar findings with respect to these endpoints.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The FDA, the EMA or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the results of our clinical trials are sufficiently compelling, we or our collaborators intend to discuss with the FDA and regulatory authorities in other countries the submission of a BLA or respective applications in other countries for our product candidates. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA for any of our product candidates. The FDA, the EMA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, the EMA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, the EMA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, the EMA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA or comparable regulatory authorities to support the submission of a BLA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, the EMA or comparable regulatory authorities will inspect our manufacturing facilities and may not approve our facilities or our manufacturing processes and controls&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of the member states of the European Union or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we expect, and even if we are able to, one or more of these regulatory authorities may not permit us to proceed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of filing on our product candidates is dependent on further preclinical, clinical and manufacturing success. We cannot be sure that submission of an IND or IND amendment with the FDA, a clinical trial application with the regulatory authorities of the EU member states or similar application with other comparable regulatory authorities will result in the FDA, the regulatory authorities of the EU member states or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may seek Orphan Drug Designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug Designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes filing for Orphan Drug Designation where available for our product candidates. Under the U.S. Orphan Drug Act, the FDA may grant Orphan Drug Designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union with respect to drugs or biologics designated as orphan medicinal products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not protect the product effectively from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union with respect to drugs or biologics designated as orphan medicinal products. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may seek Breakthrough Therapy or Fast Track designation for one or more of our product candidates, but we may not receive such designations. Even if we do, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a Breakthrough Therapy Designation in the United States for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek Fast Track Designation in the United States for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot be sure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We expect some of the product candidates we develop will be regulated as biologics in the United States and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been few approvals of gene therapy products in the United States and other jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, be reverse transcribed or integrated into the genome. Consequently, we expect that our products or product candidates will have a different potential side effect profile from gene therapies because they lack risks associated with altering cell DNA irreversibly. Further, we may avail ourselves of ways of mitigating side effects in developing our products and product candidates to address safety concerns that are not available to other products or product candidates classified as gene therapies, such as lowering the dose of our products or product candidates during repeat dosing or stopping treatment to potentially ameliorate undesirable side effects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a gene therapy medicinal product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us. Notwithstanding the differences between our mRNA product candidates and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the European Union and potentially other counties could adversely impact our ability to develop our product candidates, and could negatively impact our platform and our business. For instance, a potential future clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly could apply to our mRNA product candidates irrespective of the mechanistic differences between gene therapies and mRNA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapy products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our approved mRNA products or investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative effect on our business by lengthening the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory requirements to which our product candidates will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394&#47;2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As the regulatory landscape for our CAR-T-cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product sales revenue to maintain our business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to market our products or product candidates in any other jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union and other jurisdictions&#8217; regulatory approval processes involve all of the risks associated with the FDA approval. If we fail to comply with regulatory requirements in certain markets or to obtain and maintain required approvals, or if regulatory approvals in certain markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions may have submission requirements for drug clinical trial and marketing applications that require us or our partners to submit substantial detailed materials related to non-clinical and clinical development and manufacturing and quality control to drug regulators or testing laboratories. This can include executed batch records for the production of biological products or other records or documents that set forth detailed information about the manufacturing process. If these records are disclosed, lost, or diverted to third parties or competitors during the application preparation process, this could negatively affect our ability to protect our intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners in different countries are subject to local regulatory requirements on the manufacturing and distribution of drugs and the implementation of clinical and non-clinical research. These include but are not limited to good manufacturing, distribution, laboratory, and clinical practice rules. If these companies do not comply with applicable standards, they could become the subjects of investigations and enforcement, including orders to cease the activities pending remediation that is acceptable to the government. Such an order or other similar enforcement could interfere with our clinical development activities both in that jurisdiction and others, if it impacts supply or the quality and transfer of data.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A third-party investigational product candidate used in combination with our product candidates may be unable to obtain regulatory approval, which may delay commercialization of our product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing several of our product candidates to be used in combination with our and third-party product candidates. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing products, we would continue to be subject to the risks that the FDA, the EMA or comparable regulatory authorities in other jurisdictions could revoke approval of the product used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing products. If the products or product candidates we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. We also plan to evaluate current and future product candidates in combination with one or more product candidates that have not yet been approved for marketing by the FDA, the EMA or comparable regulatory authorities in other jurisdictions. We will not be able to market any product candidate we develop in combination with an unapproved product candidate if that unapproved product candidate does not ultimately obtain marketing approval. In addition, unapproved product candidates face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA, EMA or comparable regulatory authority approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA, the EMA or comparable regulatory authorities in other jurisdictions do not approve these other product candidates or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the products or product candidates we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any product candidate we develop.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information, and the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar requirements apply to holders of (conditional) approvals in other countries. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In other countries, advertising and promotional material may be subject to similar rules.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue a warning letter asserting that we are in violation of the law&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval or revoke a license&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical studies&#894; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve a pending BLA (or comparable approval) or supplements to a BLA (or comparable approval) submitted by us&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize product&#894; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to allow us to enter into supply contracts, including government contracts.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our products or product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences following any potential marketing approval. Products or product candidates we may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our products or product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates, if approved, may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following regulatory approval of a product candidate, the FDA or other regulatory authority could require us to adopt a REMS or a risk management plan to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw approvals or revoke licenses of such product&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way a product is administered or conduct additional clinical trials&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients and their children&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the successful approval of a product candidate, we will continue to face significant regulatory oversight of its manufacturing and distribution. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and adherence to commitments made in the BLA or comparable approval. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to additional healthcare regulation and enforcement by the U.S. federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business. Our operations may be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act&#59;</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. state law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents, as well as non-U.S. companies that are registered with the SEC, from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Similar statutes, healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union member states and other jurisdictions, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as &#8220;trade laws,&#8221; prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other collaborators from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and&#47;or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or collaborators, even if we do not explicitly authorize or have prior knowledge of such activities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as &#8220;data processing&#8221;, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and&#47;or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal data in the European Union had previously been governed by the provisions of the EU Data Protection Directive, which EU member states were required to implement. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that targets goods or services to residents in the European Union or that &#8220;monitors&#8221; their behavior in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of patients residing in the European Union. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we are located in the European Union, we are subject to the GDPR. Additionally, as the GDPR applies extraterritorially, we are also subject to the GDPR even where our data processing activities occur outside of the European Union if such activities involve the personal data of individuals located in the European Union and the above-mentioned applicable law triggers apply. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. In particular, in China, where some of our clinical data are originated, the cybersecurity, data privacy, data protection, or other data-related laws and regulations, including the Human Genetic Resources Regulation (which now only regulates transfer human genetic data generated in clinical research to foreign or foreign controlled parties), are relatively new and evolving, and their interpretation and application may be uncertain. In the United States, we may be subject to restrictions and requirements under the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, signed on February 28, 2024. Practices regarding the collection, use, storage, transmission and security of personal information by companies have also been subject to increasing regulatory focus. As such, we cannot assure you that we will be compliant with such new regulations in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition, and results of operations. In addition, the uncertainties regarding further interpretation and implementation of these laws and regulations may adversely affect the secure storage of documented work as well as the cross-border transfer of important data and personal information originated from our clinical trial activities, which are critical to the development of our pipelines.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR and other international data protection regulations, especially with regard to clinical trial activities. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated, as enforcement practices vary from country to country. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the EU member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which can result in monetary penalties of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, as well as regulatory penalties. In many jurisdictions, there are legal requirements to provide notice of breaches to affected individuals and&#47;or regulators in certain circumstances. Such a notice could harm our reputation and our ability to compete. Regulators may also have the discretion to impose penalties without attempting to resolve violations through informal means. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1321"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of the ADSs</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical companies such as BioNTech SE that are developing potential therapeutics and vaccines to combat COVID-19, as well as conducting mRNA-based research in oncology and infectious disease more generally, have experienced significant volatility in the price of their securities upon publication of preclinical and clinical data as well as news about their development programs and commercialization activities. For example, during 2023, the closing sales price of the ADSs representing our ordinary shares on the Nasdaq Global Select Market ranged from $88.00 to $156.28, with significant volatility occurring, for example, shortly after announcements by us or others related to regulatory matters, to our COVID-19 vaccine, to other COVID-19 vaccines, to development and commercialization pipelines in oncology and infectious disease, and to our transactions with third parties. Additionally, we have observed the trading price of the ADSs respond significantly to news and statements by us, government agencies, other vaccine developers, financial analysts or others relating to our business as well as to other COVID-19 vaccines and COVID-19 therapeutics and the spread of COVID-19 generally, even in cases in which we believe the news does not affect our business or vaccine specifically. Given the attention being paid to COVID-19 worldwide and the public scrutiny of COVID-19 development and commercialization announcements, and given that our COVID-19 vaccine is currently among the primary vaccines being used worldwide, any news regarding </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, supply and distribution of our COVID-19 vaccine or unanticipated side effects of our COVID-19 vaccine, whether or not accurate, will attract significant attention and scrutiny and, as a result, the price of the ADSs representing our ordinary shares likely will continue to be volatile. In addition, volatility in the overall market and in the market price of a particular company&#8217;s securities can result in securities litigation, including shareholder class action lawsuits. Any securities litigation can result in substantial costs and a diversion of our management&#8217;s attention and resources.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions, joint ventures and collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numerous risks, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the assumption of additional indebtedness or contingent liabilities&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships&#894;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals&#894; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. For example, in July 2023, we acquired InstaDeep, a leading global technology company in the field of AI and machine learning, for upfront consideration of cash and BioNTech shares, and potential future milestone payments. Although we believe that AI and machine learning technology has the potential to accelerate the development of therapeutic programs and further optimize manufacturing and supply chain processes, it is possible that our use of the acquired technology will not achieve the desired results, and that we will not be able to retain and grow InstaDeep&#8217;s business around the world. If demand for the services developed by InstaDeep does not continue, or if we are unable to improve our AI and machine learning technology in a timely, effective and competitive manner, we may not be able realize the expected outcomes from the InstaDeep acquisition. There is no guarantee that we will realize any anticipated benefits of this or future acquisitions, or that the diversification of our business through acquired technology or products will be successful. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Articles of Association designate specific courts in the United States as the exclusive forum for certain U.S. litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association provide that the United States District Court for the Southern District of New York shall be the competent court of jurisdiction for the resolution of any litigation on the grounds of or in connection with U.S. federal or state capital market laws. In the absence of these provisions, under the </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Act of 1933, as amended, or the Securities Act, U.S. federal and state courts have been found to have concurrent jurisdiction over suits brought to enforce duties or liabilities created by the Securities Act. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The choice of forum provision contained in our Articles of Association may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our executive officers, directors, or other employees, or impose additional litigation costs on shareholders in pursuing any such claims, particularly if the shareholders do not reside in or near the state of New York, which may discourage such lawsuits. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other U.S. or German courts will enforce our choice of forum provision. The enforceability of similar choice of forum provisions in other companies&#8217; governing documents has been challenged in recent legal proceedings, and it is possible that a court in the relevant jurisdictions with respect to us could find the choice of forum provision contained our Articles of Association to be inapplicable or unenforceable. If the relevant court were to find the choice of forum provision contained in our articles of association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition and operating results. The choice of forum provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering a U.S.-based action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of the ADSs may not be able to participate in any future preemptive subscription rights issues or elect to receive dividends in shares, which may cause additional dilution to their holdings.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, the existing shareholders of a company generally have a preemptive right in proportion to the amount of shares they hold in connection with any issuance of ordinary shares, convertible bonds, bonds with warrants, profit participation rights and participating bonds. However, our shareholders in a shareholders&#8217; meeting may vote, by a majority representing at least three-quarters of the share capital represented at the meeting, to waive this preemptive right provided that, from the company&#8217;s perspective, there exists good and objective cause for such waiver.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement provides that the depositary need not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our future rights offerings and may experience dilution in their holdings. For example, ADS holders were unable to participate in our summer 2020 rights offering. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The amount and frequency of our dividends and ADS repurchases may fluctuate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, timing and execution of any ADS repurchase program we conduct in the future and the amount and timing of any dividends we pay may fluctuate based on our priorities for the use of cash for other purposes, and any ADS repurchases would be subject to the parameters contained in the applicable repurchase plan. These purposes may include operational spending, capital spending, acquisitions and repayment of debt. Additionally, we may choose to repurchase ADSs so that such ADSs may be used to settle outstanding and future equity awards granted to our employees. Changes in cash flows, tax laws and the price of the ADSs could also impact any ADS repurchase program. Additionally, we may enter into a Rule 10b5-1 trading plan governing the repurchases, and if we do, we would have no discretion over the particular purchases made and would only be able to set minimum price floors and maximum ADS count ceilings.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, five percent shareholders, and their affiliates beneficially own a majority of our ordinary shares (including ordinary shares represented by ADSs) as of December 31, 2023, and will have the ability to influence us through their ownership positions. For example, these shareholders, acting </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that shareholders may believe are in their best interest. Such insiders may also act in concert to waive rights to participate in rights offerings, as was done in our summer 2020 rights offering, which would have the effect of permitting the ADSs or shares underlying such waived rights to be offered to the public in an underwritten offering without contravening German law pricing requirements.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed registration statements on Form S-8 under the Securities Act to register all ordinary shares issued or issuable under our equity plans. Such Form S-8 registration statements have become, and any other registration statements on Form S-8 we file in the future will become, effective upon filing, upon which shares registered under such registration statements become available for sale in the open market.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain sales of ADSs or our ordinary shares that we have made have included, and we may in the future make sales including, holding period restrictions or registration rights. Sales of ADSs or our ordinary shares as restrictions end or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult to sell the ADSs on favorable terms.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are a &#8220;passive foreign investment company&#8221; for U.S. federal income tax purposes, there may be adverse U.S. federal income tax consequences to U.S. investors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our income and assets, we believe that we should be treated as a PFIC for the preceding taxable year. However, the determination of our PFIC status is made annually based on the factual tests described below. Consequently, while we may be a PFIC in future years, we cannot estimate with certainty at this stage whether or not we are likely to be treated as a PFIC in the current taxable year or any future taxable years. Generally, if, for any taxable year, at least 75 percent of our gross income is &#8220;passive income&#8221; or at least 50 percent of our gross assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period) are assets that produce or are held for the production of passive income, we will be characterized as a PFIC for U.S. federal income tax purposes. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. However, rents and royalties received from unrelated parties in connection with the active conduct of a trade or business should not be considered passive income for purposes of the PFIC test. For example, if we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. Holder (as defined in &#8220;Taxation &#8212;Material United States federal income tax considerations&#8221; in our Annual Report on Form 20-F as of and for the year ended December 31, 2023) holds ordinary shares or ADSs, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us and any gain recognized on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse consequences of PFIC status can be mitigated if a U.S. Holder makes a &#8220;mark to market&#8221; election or a &#8220;Qualified Electing Fund&#8221; (QEF) election. We have made available to U.S. Holders the information necessary to make and maintain a QEF election for the year ended December 31, 2023. See &#8220;Taxation &#8212;Material United States federal income tax considerations &#8212;Passive foreign investment company considerations&#8221; in our Annual Report on Form 20-F as of and for the year ended December 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition and value of our assets from time to time. Each U.S. Holder is strongly urged to consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1142"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclaimer</font></div><div id="i58ee89399d9d45f4ac20dcae213591ea_553"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning&#58; our expected revenues and net profit&#47;(loss) related to sales of our COVID-19 vaccine, referred to as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> where approved for use under full or conditional marketing authorization, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners&#59; the rate and degree of market acceptance of our COVID-19 vaccine and, if approved, our investigational medicines&#59; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages&#59; the initiation, timing, progress, results, and cost of our research and development programs, including our current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations&#59; our expectations regarding potential future commercialization in oncology, including goals regarding timing and indications&#59; the targeted timing and number of potentially registrational trials, and the registrational potential of any trial we may initiate&#59; discussions with regulatory agencies&#59; our expectations with respect to intellectual property&#59; the impact of our collaboration and licensing agreements&#59; the development, nature and feasibility of sustainable vaccine production and supply solutions&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the deployment of AI across our preclinical and clinical operations&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our expectations with respect to legal claims and proceedings. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this quarterly report are based on our current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#8217;s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">projected data release timelines, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this report, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data&#59; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation&#59; our pricing and coverage negotiations regarding our COVID-19 vaccines with governmental authorities, private health insurers and other third-party payors&#59; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine&#59; competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response&#59; the timing of and our ability to obtain and maintain regulatory approval for our product candidates&#59; the ability of our COVID-19 vaccine to prevent COVID-19 caused by emerging virus variants&#59; our and our counterparties&#8217; ability to manage and source necessary energy resources&#59; our ability to identify research opportunities and discover and develop investigational medicines&#59; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines&#59; the impact of COVID-19 on our development programs, supply chain, collaborators and financial performance&#59; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us&#59; our ability and that of our collaborators to commercialize and market our COVID-19 vaccine and, if approved, our product candidates&#59; our ability to manage our development and related expenses&#59; regulatory developments in the United States and other countries&#59; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine production levels, and our product candidates&#59; risks relating to the global financial system and markets&#59; and other factors not known to us at this time. You should review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in this quarterly report for the three and nine months ended September&#160;30, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#8217;s website at https&#58;&#47;&#47;www.sec.gov&#47;. These forward-looking statements speak only as of the date hereof. </font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this quarterly report in the event of new information, future developments or otherwise.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</font></div></div></div><div id="i58ee89399d9d45f4ac20dcae213591ea_1526"></div><hr style="page-break-after:always"><div style="min-height:64.63pt;width:100%"><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><font style="color:#3c9673;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quarterly Report of BioNTech SE for the three and nine months ended September&#160;30, 2024</font></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_673" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">Unaudited Interim Condensed Consolidated Financial Statements</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%"><a href="#i58ee89399d9d45f4ac20dcae213591ea_1131" style="color:#005a64;font-family:'Arial',sans-serif;font-size:7.2pt;font-weight:700;line-height:120%;text-decoration:none">Operating and Financial Review and Prospects</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #becd32;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#005a64;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report contains references to our trademarks and to trademarks belong to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark portfolio includes, but is not limited to, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> BioNTainer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> FixVac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> RiboCytokine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including logo versions of some of these trademarks. Brand names appearing in italics throughout this report are trademarks owned by BioNTech. All other trademarks are the property of their respective owners.</font></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a992biontechsearticlesofas.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i201559b556894374a83b2ae706862898_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:162%">Exhibit 99.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%;text-decoration:underline">Convenience Translation. The German version is authoritative</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt;padding-right:5.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:20.10pt">ARTICLES OF ASSOCIATION OF BIONTECH SE</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:28.34pt">General Provisions</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#167; 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Company Name, Registered Office and Financial Year</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The name of the Company is &#8220;BioNTech SE&#8221;.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company has its registered office in Mainz, Germany.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The financial year is the calendar year.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#167; 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Purpose of Enterprise</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The purpose of the Company is the research and development, manufacture and marketing of immunological and RNA-based drugs and test methods for the diagnosis, prevention and treatment of cancer, infectious diseases and other serious diseases.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company may undertake all transactions and actions that are expedient for serving the Company&#8217;s purpose. It is also authorized to establish and acquire other companies and to invest in other companies, as well as to manage such companies or to limit itself to the administration of the investment.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#167; 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Announcements</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">All of the Company&#8217;s announcements shall be made exclusively in the German Federal Gazette (Bundesanzeiger).</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:23.68pt">Share Capital and Shares</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 4&#160;&#160;&#160;&#160;Amount and Division of Share Capital&#59; Deviating Profit Participation</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company&#8217;s share capital totals EUR&#160;248,552,200 and is divided into 248,552,200 no-par value shares.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Any right of the shareholders to request that share certificates be issued is excluded, to the extent permitted by law or unless certification is required under applicable stock exchange rules where the shares or rights or certificates representing them are admitted for trading. Global certificates for shares may be issued. Form and content of these certificates shall be determined by the Management Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The shares are registered shares.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">In the event of a capital increase, the profit participation of new shares may be determined in deviation from section 60(2) sentence 3 German Stock Corporation Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">AktG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">).</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board is authorized, with the approval of the Supervisory Board, to increase the Company's share capital on one or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">more occasions on or before June 21, 2026 by up to a total of EUR 122,657,313 by issuing up to 122,657,313 new no-par value registered shares in return for cash contributions or contributions in kind (Authorized Capital 2021). Shareholders are in principle to be granted subscription rights. In this con-text, the shares may also be underwritten by one or more credit institution(s) or one or more company(ies) operating in accordance with Sec. 53 para. 1 sentence 1 or section 53b para. 1 sentence 1 or para. 7 of the German Banking Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Kreditwesengesetz - KWG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) with the obligation to offer them for subscription to the Company&#8217;s shareholders (so-called indirect subscription right). The Management Board is authorized, with the approval of the Supervisory Board, to exclude shareholders' subscription rights for one or more capital increases under the Authorized Capital</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">to exclude fractional amounts from the subscription right&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">in the case of a capital increase against cash contributions, if the issue price of the new shares is not significantly lower than the stock market price of the Company&#8217;s shares already listed at the time the issue price is finally fixed. However, this authorization shall only apply subject to the provision that the shares issued with exclusion of subscription rights pursuant to Sec. 186 para. 3 sentence 4 AktG may not exceed a total of 10% of the capital stock either at the time this authorization takes effect or - if this amount is lower - at the time this authorization is exercised. Shares issued or sold in direct or corresponding application of Sec. 186 para. 3 sentence 4 AktG during the term of this authorization until the time of its utilization shall be counted towards this limit of 10% of the share capital. Shares used to service bonds with conversion or option rights or conversion obligations shall be counted towards the 10% limit if these bonds were is-sued during the authorization period under exclusion of share-holders' subscription rights in accordance with Sec. 186 para. 3 sentence 4 AktG. Treasury shares which may have been sold by the Company during the term of this authorization under exclusion of subscription rights pursuant to or in accordance with Sec. 186 para. 3 Sentence 4 AktG shall be counted towards the 10% limit&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">in the event of a capital increase against contributions in kind, in particular in order to be able to offer the new shares to third parties in connection with the acquisition of companies, parts of companies or interests in companies, or license or intellectual property rights&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">to grant holders of conversion or option rights under bonds issued by the Company or its subordinated German or foreign group companies a subscription right to new shares as they would be entitled to after exercising their conversion or option rights or after fulfillment of an agreed conversion obligation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">to implement a so-called scrip dividend, whereby shareholders are offered the option of contributing their dividend entitlement (in whole or in part) to the Company as a contribution in kind in return for the granting of new shares&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">if shares are to be issued to a member of the Company&#8217;s Management Board or to a person who is in an employment relationship with the Company or one of its affiliated companies&#59; restrictions relating to the shares issued may be agreed, and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">to satisfy an option agreed with underwriters in connection with an issue of shares in the Company (or American Depositary Shares representing them) to purchase additional shares or American Depositary Shares (so-called Greenshoe option).</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The total number of new shares issued from the Authorized Capital under the authorizations pursuant to sentence 4 letter a) to c) above, excluding subscription rights, may not exceed 20% of the share capital stock, either at the time this authorization takes effect or - if this value is lower - at the time it is exercised. The aforementioned 20% limit shall include (i) those shares which are used to service conversion or option rights or conversion or option obligations or subscription rights of the issuer, (ii) treasury shares which were sold during the term of this authorization until its exercise under exclusion of subscription rights (with the exception of treasury shares sold in accordance with letter b) paragraphs (v), (vi) or (vii) of the resolution on agenda item 8 of the Annual General Meeting on August 19, 2019).</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The new shares shall participate in profits from the beginning of the first financial year for which the annual financial statements have not yet been submitted to the Annual General Meeting at the time of registration of the implementation of the capital increase.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Management Board is authorized to determine further details of the capital increase and its implementation with the approval of the Supervisory Board. The Supervisory Board is authorized to amend the wording of Art. 4 par. 5 of the Articles of Association in accordance with the respective utilization of Authorized Capital 2021 and, if Authorized Capital 2021 is not or not fully utilized by June 21, 2026, to delete Art. 4 para. 5 of the Articles of Association after the expiry of the authorization.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The share capital is conditionally increased by up to EUR 4,943,452 by issuing up to 4,943,452 new no-par value ordinary registered shares with a pro rata amount of the share capital of EUR 1.00 per share (Conditional Capital ESOP 2017&#47;2019). The Conditional Capital ESOP 2017&#47;2019 serves exclusively to grant rights to the holders of stock options, which were granted in accordance with the authorization by the Annual General Meeting on August 18, 2017 under agenda item 5 para. a), also in its version by the resolution of the Annual General </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Meeting on August 19, 2019 under agenda item 6 para. a) as well as in its version by the resolution of the Annual General Meeting of June 26, 2020 on agenda item 5 and its version by the resolutions of the Annual General Meeting of June 22, 2021 on agenda items 6 and 7 para. A) and its version by the resolution of the Annual General Meeting of May 17, 2024 on agenda item 12 (together the &#8220;Authorization 2017&#47;2019&#8221;), have been issued by the Company. The shares will be issued at the exercise price determined in accordance with the Authorization 2017&#47;2019 in the version applicable at the time it is exercised. The conditional capital increase will only be carried out to the extent that the holders of the stock options issued by the Company on the basis of the Authorization 2017&#47;2019 exercise their subscription rights and the Company does not fulfil the stock options by delivering treasury shares or by making a cash payment. The new shares shall participate in profits from the beginning of the previous financial year if they are created by exercising subscription rights until the beginning of the Annual General Meeting of the Company, otherwise from the beginning of the financial year in which they are created by exercising stock options.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The share capital is conditionally increased by up to EUR 24,855,220.00 by issuing up to 24,855,220 new no-par value registered shares (Conditional Capital WSV 2024). The conditional capital increase will only be carried out to the extent that the holders or creditors of bonds with warrants and&#47;or convertible bonds with option or conversion rights or option or conversion obligations issued by the Company or a company in which the Company directly or indirectly holds a majority interest until May 16, 2024 on the basis of the authorization resolution of the Annual General Meeting of May 17, 2024 exercise their option or conversion rights or fulfil their obligation to exercise the option or conversion, or, if the Company exercises an option to grant no-par value shares in the Company in whole or in part instead of payment of the cash amount due and provided that no cash settlement is granted or shares from authorized capital or treasury shares or shares of another listed company or other forms of fulfilment are used to service them. The new shares will be issued at the option or conversion price to be determined in accordance with the aforementioned authorization resolution. The new shares issued shall participate in profits from the beginning of the financial year in which they are created&#59; to the extent permitted by law, the Management Board may, with the approval of the Supervisory Board, determine the profit participation of new shares in deviation from this and also in deviation from Sec. 60(2) AktG for a financial year that has already expired. The Management Board is authorized, with the approval of the Supervisory Board, to determine the further details of the implementation of the conditional capital increase.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The share capital is conditionally increased by up to EUR 1,300,000 by issuing up to 1,300,000 new no-par value ordinary registered shares with a pro rata amount of the share capital of EUR 1.00 per share (Conditional Capital ESOP 2021). The Conditional Capital ESOP 2021 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">serves exclusively to grant rights to the holders of stock options issued by the Company in accordance with the authorization by the Annual General Meeting on June 22, 2021 under agenda item 7 para. d), also as amended by the resolution of the Annual General Meeting on May 17, 2024 under agenda items 12 and 13 (the &#8220;Authorization 2021&#8221;). The shares will be issued at the exercise price determined in accordance with the Authorization 2021 in the version applicable at the time it is exercised. The conditional capital increase will only be carried out to the extent that the holders of the stock options issued by the Company on the basis of the Authorization 2021 exercise their subscription rights and the Company does not fulfill the stock options by delivering treasury shares or by making a cash payment. The new shares shall participate in profits from the beginning of the previous financial year if they are created by exercising subscription rights until the beginning of the Company&#8217;s Annual General Meeting, otherwise from the beginning of the financial year in which they are created by exercising stock options.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The share capital is conditionally increased by up to EUR 6,213,805 by issuing up to 6,213,805 new no-par value ordinary registered shares with a pro rata amount of the share capital of EUR 1.00 per share (Conditional Capital ESOP 2024). The Conditional Capital ESOP 2024 serves exclusively to grant rights to the holders of stock options issued by the Company in accordance with the authorization by the Annual General Meeting on 17 May 2024 under agenda item 13 para. f) (the &#8220;Authorization 2024&#8221;). The shares will be issued at the exercise price determined in accordance with Authorization 2024 in the version applicable at the time it is exercised. The conditional capital increase will only be carried out to the extent that the holders of the stock options issued by the Company on the basis of Authorization 2024 exercise their subscription rights and the Company does not fulfil the stock options by paying cash or by delivering treasury shares in another listed company or other forms of fulfilment. If the new shares are created by exercising subscription rights before the start of the Company&#8217;s Annual General Meeting, they will participate in profits from the start of the previous financial year, otherwise from the start of the financial year in which they are created by exercising stock options. The Management Board is authorized, with the approval of the Supervisory Board, to determine the further details of the issue and the further conditions of the stock options&#59; in deviation from this, the Supervisory Board shall also decide in this respect for the members of the Company&#8217;s Management Board.&#8221;</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:16.02pt">To the extent that the above paragraphs provide for authorized or conditional capital, the Supervisory Board is authorized to amend the wording of the Articles of Association after expiry of the period for utilization of the authorized capital and in accordance with the extent of capital increases carried out on the basis thereof.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:19.02pt">The Executive Bodies of the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 5&#160;&#160;&#160;&#160;Two-Tier System</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company has a two-tier management and supervisory system consisting of a management body (Management Board) and a supervisory body (Supervisory Board).</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company&#8217;s executive bodies are the Management Board, the Supervisory Board and the General Meeting.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:19.68pt">Management Board</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 6&#160;&#160;&#160;&#160;Composition</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board shall consist of at least two persons. The members of the Management Board are appointed for a maximum term of five years. Reappointments are permitted.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The number of members of the Management Board is otherwise determined by the Supervisory Board. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The appointment of deputy members of the Management Board is permissible.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 7&#160;&#160;&#160;&#160;Management, Representation</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The members of the Management Board shall conduct the business of the Company in accordance with the law, the Articles of Association and the rules of procedure issued by the Supervisory Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company shall be represented by two members of the Management Board or by one member of the Management Board jointly with one holder of a general commercial power of representation (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Prokurist</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">). If only one member of the Management Board is appointed, the Company will be represented by this individual alone. The Supervisory Board may grant one, several or all members of the Management Board sole power of representation. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board may, by resolution, authorize members of the Management Board in general or in individual cases to conclude legal transactions simultaneously for the Company and as representatives of a company affiliated with the Company within the meaning of section&#160;15 AktG as well as in individual cases simultaneously for the Company and as representatives of a third party.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board may appoint a spokesman or a chairperson of the Management Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Furthermore, the Supervisory Board shall issue rules of procedure for the Management Board and shall determine in particular which types of business may only be transacted with its consent.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 8&#160;&#160;&#160;&#160;Passing of Resolutions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board is quorate if all members of the Management Board are invited and at least half of its members participate in the adoption of the resolution, unless otherwise required by mandatory law. Members of the Management Board may cast their vote in writing, by telephone, by telefax or by means of electronic media.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The resolutions of the Management Board are passed by a majority of the votes cast, unless otherwise required by mandatory law. Abstentions shall not to be taken into account. In the event of a tie the chairperson shall have a casting vote, if such person has been appointed. This does not apply to a spokesman of the Management Board who may have been appointed.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:24.34pt">Supervisory Board</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 9&#160;&#160;&#160;&#160;Composition, Term of Office and Remuneration</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board shall comprise of six members.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Unless the General Meeting resolves on a shorter period when electing individual Supervisory Board members to be elected by it or for the full Supervisory Board, the Supervisory Board members shall be elected for a period ending no later than the end of the General Meeting which resolves on the discharge for the fourth financial year after the election. The fiscal year in which the term of office begins is not included in this calculation. Re-election is possible.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The successor to a member who leaves the Supervisory Board before the end of his or her term of office shall only be elected for the remainder of the term of office of the member who has left the Supervisory Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">When electing Supervisory Board members, the General Meeting may for the same period elect a substitute member for several or all Supervisory Board members or as many substitute members as Supervisory Board members and determine the order in which they shall replace the Supervisory Board members who leave the Supervisory Board during their term of office for the remaining term of office.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Each member of the Supervisory Board may resign from office by submitting a written declaration to the Management Board. A period of one month must be observed.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">In addition to the reimbursement of their expenses, the members of the Supervisory Board shall receive compensation of EUR 120,000.00 for each full financial year&#59; the Chairman shall receive three times this amount and the Deputy Chairman 1.5 times this amount. The Chairman of the Audit Committee receives additional compensation of EUR 50,000.00 for each full financial year. The respective Chairman of another committee receives additional compensation of EUR 30,000.00 for each full financial year. An ordinary committee member receives </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">additional compensation of EUR 10,000.00 per committee for each full financial year&#59; the compensation paid for chairing a committee also covers membership of this committee. The basic compensation and any compensation for committee activities are due for payment within the last month before the end of the financial year for which the compensation is paid. Members of the Supervisory Board who only belong to the Supervisory Board for part of the financial year or who chair or deputy chair the Supervisory Board or the Audit Committee or another committee receive the respective compensation pro rata temporis. The same applies if this regulation or this regulation in a specific version is only in force for part of the financial year. If the reimbursement of expenses or compensation is subject to VAT, the VAT must be paid in addition. In its own interest, the Company maintains appropriate financial loss liability insurance for its executive bodies and managers, which also covers the members of the Supervisory Board at the Company&#8217;s expense.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 10&#160;&#160;&#160;&#160;Chairperson and deputy</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board shall elect a chairperson and a deputy chairperson from among its members for the duration of its term of office. In these elections the oldest member of the Supervisory Board in terms of age is the chairperson. The deputy shall have the rights of the chairperson if the latter is prevented from attending or delegates his or her representation to him or her.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">If the chairperson or his&#47;her deputy departs prematurely from their office, then the Supervisory Board shall immediately hold a new election to cover the remaining term of office.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 11&#160;&#160;&#160;&#160;Convening and passing resolutions</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">As far as possible, the Supervisory Board shall be convened in each calendar quarter. It must be convened twice every calendar half-year.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The meetings of the Supervisory Board shall be convened by the chairperson verbally, by telephone, in writing, by fax or by email, stating the agenda.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board is quorate if at least three members participate in the adoption of the resolution. A member also participates in the adoption of a resolution if he or she abstains from voting.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Resolutions require a majority of the votes cast by the members of the Supervisory Board not taking into account any abstentions. In the case of a tie, the votes of the chairperson of the Supervisory Board or, if he does not participate in the passing of the resolution, the vote of the spokesman of the Supervisory Board shall be the casting vote. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Resolutions of the Supervisory Board are in principle passed at meetings with personal attendance of the members of the Supervisory Board. Absent members of the Supervisory Board may submit their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">written vote through another member of the Supervisory Board. Unless the chairperson of the Supervisory Board states otherwise in the invitation due to special circumstances of the individual case, it is permissible for Supervisory Board members to participate and cast their vote in a face-to-face meeting by telephone. The Supervisory Board may also vote without convening a meeting by doing so in writing, by telephone, fax, video conference or email, or in a combined resolution. The chairperson shall decide on the form in which resolutions are to be passed. The Rules of Procedure for the Supervisory Board may stipulate that resolutions are to be postponed in individual cases to be specified in more detail.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Minutes shall be taken of the meetings of the Supervisory Board and signed by the chairperson of the meeting. If resolutions are passed outside meetings, the minutes must be signed by the chairperson of the Supervisory Board and forwarded to all members without delay.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The chairperson is authorized to on behalf of the Supervisory Board make the declarations required to implement the resolutions and to receive the declarations addressed to the Supervisory Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board is empowered to resolve upon changes and amendments to the Articles of Association as long as such changes only affect the wording.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 12&#160;&#160;&#160;&#160;Rules of Procedure</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">The Supervisory Board may issue Rules of Procedure for itself within the framework of the statutory provisions and the provisions of these Articles of Association.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 13&#160;&#160;&#160;&#160;Committees</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">The Supervisory Board may form committees and may refer items for resolution to these committees within the scope of what is permitted by law.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:19.68pt">General Meeting </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 14&#160;&#160;&#160;&#160;Venue and convocation</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The General Meeting shall take place within the first six months of the expiry of the fiscal year at the registered office of the Company or in a German city with at least 500,000 inhabitants.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The General Meeting shall be convened by the Management Board or by the Supervisory Board.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Extraordinary General Meetings shall be convened when the best interests of the Company so require.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The General Meeting may also be summed via mail (also via simple letter) or via e-mail. The postal and electronic addresses registered in the share register are authoritative.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 15&#160;&#160;&#160;&#160;Chairing the General Meeting, Right to Participate, Participation of Supervisory Board Members</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The General Meeting shall be chaired by the chairperson of the Supervisory Board or, in his&#47;her absence, by his&#47;her deputy or, in his&#47;her absence, by  another person determined by the Supervisory Board. If no such determination has been made, the chairperson of the meeting shall be elected by the General Meeting. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Shareholders registered in the share register are entitled to participate and exercise their voting rights in the General Meeting if they are registered with the Company in good time. The registration to attend the General Meeting must be in German or English and must be received by the Company at least six days prior to the meeting, unless a shorter period, expressed in days, is provided for in the invitation to the General Meeting, at the address and in the form (written form, text form or another (electronic) form further specified by the Company) as stipulated in such invitation. The day of the General Meeting and the day of receipt shall not be counted.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The chairperson of the meeting shall determine the order of items on the agenda as well as the type and form of voting. The chairperson is authorized to limit the question and speaking rights of the shareholders, as appropriate and to the extent permitted by law. In particular, he&#47;she is authorized, at the beginning or during the course of the General Meeting, to set a reasonable time limit for the entire General Meeting, for discussion of particular items on the agenda or for any particular speech or question. Furthermore, the chairperson of the General Meeting may prematurely close the list of requests to speak and close the debate, as far as this is necessary for the proper execution of the General Meeting.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The chairperson of the General Meeting may permit the video and audio transmission of the General Meeting in whole or in part, including a transmission via the Internet.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 16&#160;&#160;&#160;&#160;Procedure, Minutes</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Each share carries one vote. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Voting rights may be exercised by representatives. The power of attorney must be granted in text form by other means. The details shall be determined by the Company. They will be announced with the invitation to the General Meeting.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board is authorized to provide for shareholders to vote without attendance in the General Meeting in written form or by way of electronic communication (postal vote) as well as participate in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the General Meeting and exercise all or some of their rights in whole or in part by means of electronic communication without physical participation and without being represented by a proxy (online participation). The Management Board determines the details of the postal vote as well as the scope and procedure of online participation in the invitation to the General Meeting. </font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Members of the Supervisory Board shall be permitted, in consultation with the Chairman of the Supervisory Board, to participate in the Annual General Meeting by means of video and audio transmission in cases where their physical presence at the location of the Annual General Meeting would not be possible or would only be possible at considerable expense due to legal restrictions, their residence abroad, their necessary residence at another location in Germany or due to an unreasonable duration of travel, or if the Annual General Meeting is held as a virtual Annual General Meeting</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board is authorized to provide for the Annual General Meeting to be held without the physical presence of the shareholders or their proxies at the location of the Annual General Meeting (virtual Annual General Meeting). The authorization shall apply to the holding of virtual shareholders&#8217; meetings for a period of three years after entry of this provision of the Articles of Association in the commercial register of the Company.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Minutes shall be kept of the proceedings and shall be signed by the chairperson of the Supervisory Board unless a notarial record is required by law.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 17&#160;&#160;&#160;&#160;Resolution</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Unless a larger majority is required by law or these Articles of Association, resolutions of the General Meeting shall be adopted by a simple majority of the votes cast. To the extent that statutory provisions also require a majority of the share capital present at the time the resolution is adopted, a simple majority of the share capital present shall suffice, unless a larger majority is required by law. In the event of an undecided vote, an agenda item shall be deemed rejected.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">However, unless a larger majority is required by law, resolutions to amend the Articles of Association require a majority of at least two-thirds of the votes cast and of the share capital represented, if at least half of the share capital is not represented.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Should no majority be obtained in the first ballot in elections, the candidates with the two highest numbers of votes reached shall be put on a shortlist. If the election results in a tie between these two candidates, the decision shall be made by lot.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:15.02pt">Annual Financial Statements, Appropriation of Profits </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 18&#160;&#160;&#160;&#160;Annual Financial Statements, Management Report</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board shall prepare the Annual Financial Statements and any Management Report as well as the Consolidated Financial Statements and any Group Management Report for the past financial year within the statutory period.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Management Board shall submit the Annual Financial Statements and any Management Report as well as the Consolidated Financial Statements and any Group Management Report to the Supervisory Board immediately after they have been prepared, together with its proposal to the General Meeting for the appropriation of net profit.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Supervisory Board shall examine the Annual Financial Statements, any Management Report of the Management Board, the Consolidated Financial Statements and any Group Management Report and the proposal for the appropriation of net profits, and shall report the results of its examination in writing to the General Meeting. It must forward its report to the Management Board within one month of receipt of the documents. Should the Supervisory Board approve the Annual Financial Statements after examination, they shall be adopted unless the Management Board and Supervisory Board decide to leave the adoption of the Annual Financial Statements to the General Meeting.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 19&#160;&#160;&#160;&#160;Retained Earnings</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Should the Management Board and the Supervisory Board adopt the Annual Financial Statements, they may transfer amounts of up to half of the net profit for the year to retained earnings. In addition, they are authorized to transfer amounts to retained earnings of up to a further quarter of the net profit for the year, as long as the retained earnings do not exceed half of the share capital or insofar as they would not exceed half of the share capital after the transfer.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">When calculating the portion of the net profit to be transferred to retained earnings in accordance with paragraph (1), allocations to the statutory reserve and accumulated losses carried forward shall be taken into account in advance.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The General Meeting shall resolve on the appropriation of profits retained resulting from the adopted Annual Financial Statements. It may allocate further portions of the profits retained to retained earnings, carry these profits forward to a new account &#8211; also by way of distribution in kind - or distribute them among the shareholders.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:10.36pt">Legal Disputes</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 20&#160;&#160;&#160;&#160;Jurisdiction of the US Federal Courts</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">In the case of litigation on the grounds of or in connection with federal or state capital market laws of the United States of America, only the United States District Court for the Southern District of New York or, in the case of it being replaced by any other first-instance Federal Court of the United States of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">America having judiciary over the borough of Manhattan, such court, shall be the competent court of jurisdiction, in each case insofar as this may be determined by these Articles of Association. This shall not affect any exclusive international jurisdiction under German or European law of the court located at the Company&#8217;s registered office.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:19.68pt">Expenses</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#167; 21&#160;&#160;&#160;&#160;Formation expenses</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The formation costs of the Company shall be borne by FORATIS AG.</font></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:71.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Company shall bear the expenses of the formation of BioNTech SE by conversion of BioNTech AG into a European company (SE) in the amount of up to EUR 100,000.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:203%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>a230530_ihub-labxshootingx.jpg
<TEXT>
begin 644 a230530_ihub-labxshootingx.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
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M=.5!)0E8^CG;<IIG<=9<;D'(/ 7%N&!A!PHKK26*($1$X!&HHR+VUCRA(U,
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M]<XW4/[<\5TE]Y\]T'Z#GAK,=9P\]7"Y71IZ/HQ^BG676S;% T%J/4,BU&_
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M]2-IB*:44U#8KQ(2FEH68BQ]D=IUK0D]E-THOIR6K:T#Y&X]A:LRC,C0-(F
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M.S2S%?.["=Z8V-\H\C+OR3XR<<715WZM]?UQ^F/?M[)>7_A,/F3^'?C'J_\
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M*IBB->W9(11!H@BP? A"=65*LN=N \Y9YU<WHNEU-MF?@;Y?0GYC\WY@_/\
MR2?$[-:^DYM6>O\ .1+LXVMV(U@JGWG-UQ>-[/0/&[%Z>LU2^S;77R#I=*_?
M=O*G]9OKT:]/U,[,=>:JN8+(T[U[$==IUURN^%E6*['"[M.&U@G[)=>2@1@9
M=BP)(:!'8 ++JC?/N98X.H(OH@:NH=R6SBL][;3;$IH#6VNA("TT48TYYA.3
M@3=C4$@&4L'':'J3>IJQLD%I+9U3.R,ITY+!OHD^J)&4F'-Z-7_//HU%_/\
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ME'#/H>9SAV>58^'=U)Q^G[=^S\'ZR>U\3*-%$E!Z-)U#TA@P[M%1M%1!M4D
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M#\<?#6ET))]7OLKZ+V9YT^U(>)LBM'/@._@1?K<D1V*GUT']58WG\BSOS;Z
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MX$@!N,S=)Q;)O5%9JRE7#;I2>F,Z5@6V4GE%E7*%TQ/72/I0=!F3^IC#HJ"
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M4VWZ3Y3:7HOF]E]3RLKV\=T9,LV1JQ"P: [37:W1\S<,S-X# (>$:1'X L-
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M "P(AJ&D= ^J<7JE%HD I=?7*O:RE=U%%7YZFNSQI)1R,D3Y"019ZP((727
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M@7-YW'7RWR_%'XW^6^>WB.'XU_J?ZO[;W\_W9^U^R_*A[_ZWX1\SI?HG_/\
M^FN_O*=KSXV]#LWG5]E\/&-P=2F^=]"*4=>G/J/Y_P#S5??_ ,M\]=WATOTL
M76?G>SR=W.7T/Y?T_H]\A^I]->$[U4^GQ>LGDM<PUU>2GLN)Q/\ 0_$/:X^Q
MORSU_C-]1\SUMXCU7MCY5=F_H?X^!]/Q8K&*&C&X:( 1B6YIG>,R[[E="V2V
MF3NN.H,0&@6M<DOQ5R'F)FJ\U,&[T_MR1,*]6J *Z(4L9$/Q5HLE>W <T26
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M;-=PEZ7RU,]+AN@]#_/>E(<_K Z;[)Y'6@.[#!>QYX=Z/@V*]'N13UO2KO\
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M'NF%.VP>-V.TZ.E=G3QL[*))[3QE^>T\A^:&>#P<AQ!Z08!S;ZZ1FM=9E?\
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M>8H;K<&!R4;NK_3G\*^Q_H4]#Y%8CQ=EWUKS;^@L>GHKJ\ASMR<(>3]EU?\
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MLMONN8/TO[*NY-%.[39-M6\T2;4Z N:XA,"%DUL+8C52\2YG>4+"Z#X]&F8
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M%>F9XKWE],GW8A_KO/03K\B$LAMN88)4'D@%4X]GL15>Q6Z!8+2U69%II0X
M(1<(@$$SN&HAX $ !!LT&*TI+0Y V$DMA)[J9FZYS<2N60MKFB$KD2N9<,)7
M=3?=>?=* B4B,W1&NOG;91T=S[7);!K<!57@'2X"/V3L"HM_-NAET(I/))*]
MAZJ3(-V.D$0= H#@-P6!$&@(,=I*#'A%;E#9T-BJMR'.TZ78CR8=IRWQI9;$
M,<Y#& Y#D;V29W""-@A]1;(6Y<J$:Z%0LZS19%8LG!]23<BJNY0, >48+?C'
MBEI8=JTXK9:V4 E+B3G7<5<F'6?4GTS?F+U<2O,'!LN^Z_MW3L&F_GOP/G?(
M?\R?&O,[X?\ &X'RO(61\VFQZ1KMA <\"?%W0SL><K[TO@X[T\XW5L4BBF31
M+N9Z.R>?]#L'J[K4X_=N&GL2VK02YDY#Y"[H;W_J/9/^D7U[MS[7[]7?H^LE
M)(ZSU0U3HS574LLC6,))%I(B\AL&\&1I*OU#E(D $4,C+H6D2 ?:'(2'60IF
MR=MY8U;MGVSDVD9&[3L$60\4$E@=*=M+;)0# *#-+ALZJ-LS3"NPC"D*#=/0
M/*BKL=,W<ZYS.H!!#F$R>?458_F_I/%47Z5,^2]'Y&?F?[7R_P">Z-YUY_33
M52_])QO*KR?1[ W9;P^M\;K'T'&CG![7FUX_Z#U+N\[U+W^)T#ZOS>V^@;.B
M+<OI#N5T)EU.<[G%+#T3^W,\NS*W9*X;#]OFDNKSKBVY9Y7*H?+>AJ#S_9D=
M9(=.7'9YP;U/G(GU>9#"H0";2B:8@B$H6JTV95:A(OKIR&MZ&20$(H$)17U#
M@J<,%%@CU=T<A0.A!2.XVU.&3;33)U.4SIDUJE%JDNBIV)M(F4T8E&60GU/1
MJZ,S;50@-M80JI793<F:]U5?!+^>8A8'E7N BR5MY]!^J_ 02_(HW+*-6R,,
M>H(C7$X!P"H*!H# -1K"3! (C:1ZRAB5*EL;=?)3RY<2R'S P<VDX%&1"#=P
M" (C*258!#XOH>Z,A%535GCLQUQ"LL"5M=#Z*K+LJTFBWF,Q4Y/"TD$IVS2N
M9*%KF:KR3XDP2\F_,XI/T+NFM?F2='SFB.?\FZAT^FOS1Z>6RVH49_-#Y-\!
M\7?AWSI;Y;Q.HOC?KH+Z'!6W8\W)/'^G1Y<8QU.!#>YXF+]? PT:G-5,QXGL
M9IC]7,>AZ"0=/7(+]\CIME&2UQ37T#Z+T'Z!OWI^ENY/JWO0_0N^DYY&4M6L
MXI%Z),&J'U55A9F=U1C@"(CFMND/V5Q>OD$@8A4B?3.=[30Y"%J:,YOMLNR%
M<\G*Z:K,E9<M.+2V2KB6:*3JET)VZM:(Q0#G7]79 YY.>IE_9+1<LPD$%)$7
ME)9V>]J^*3!VPHAT,O#>M%*U1)2>]LJP\ST_+?\ /7V:O?/7PSEZ?3GT''O3
MI1Y"\CNC^*N3>^R=9^RY,GHV0GE=23Z<MU^L\O-?3</;17]?64UXS4HPC@]B
M/<#JS;I89OU^:7Z&..J<"RW"K:T-F=PI6!7)3/J,]+G4/X[TT0\WV+/ZO*K'
MS/?DOT[P@?O\2+[< 9)NFBUH-'-#2+^+,I+K4)V8\@C8"YJ/LA];@<"ODZ_3
MA"A$Z;(K7JB8F+11$R)7-HHN*^FR;4RD9!W<BLZI.)RQM-35DE08)=G9>A=%
M-S1E:79JQNIF4&9KUP>S"ZA/9PDJOU=Q.N9ZMZA$]&0-*FP*-N86* Z$^&[!
MR"X;A\&@8! -0P#0,@RM46FHJ\@IQYK=$<:: : H%;@P@J[5CZJQ9'P5HU6B
M9J2NF^#].%CE([OE5"13>-L54#,#K&KHOX6.1<J3Y5<%10)X7%W;@=3"X$YQ
MX9>/RU;TO(7)K^/P"?Y'@2^&VXJIN;Y+#O J8="?B/[9TO\ F[[YYSKXW6OI
M.=7/I,&.?98'SWTL=YF:$]7QL*[OC(CVO/,=%QWGZ;6\C]5LG3[.4=SJ/MMS
M7?G;Z,Q"V=Z^Q]/^C;]L?I7L;Z)[BL^E/+4RC.=EM@UDF6LM"9*ILY*D--5>
M/-%(1&1'M,G8G%RKF0)8?#(4RCHVADF-9IK85C)5]9.42AV'F?TY.4I)&1Q;
M8]+-65E;5EE4W6,K@ AH("1)P&6'C"^?9W/31P$@L%'RLJ&9=M5;\"*;T'HU
ML^Q2M;2-Y$8YFOSO^'?:(;@Q\C>/]AZ9]+B])[LG(WFNX8JS=#^JY-_>WXC.
MG664A&'9%NOFO[Z5\\F'0PR&^LM96.IE$\>QACOENS//MF(Y,0KD+HNC.:Q2
M;*6)"JP3?!WNQO)0B7!Z5'^']4QHMJ[A=*9?0?($O3^=CW5Y@L@/# 9$A%?-
M[R%D:A#PW&BP0E&Y$'B5ZRO(V0"F^$J$2KMAH100X<D"Y;%T3HIOC31<=BF#
M(E9&(.$;$L!N00DE9$D2G*9)S[HP=$38IK"RE-.0O!%C1"7CT0:BV\F24Y!&
MPS3HW".79HU9GFE6PG5:Z#8'0$@4!V&P)A\" L#T#(]A*!@40M(G.(4HH-T
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M&X)@B#H2@XI,BUJ8J-*3PQ-P=BB3B$!&"4;:16]#HEWQH2I"*2LN#12'C9+
M%A&0(U.ZK(IRA-%;4#JFU%W5E>X\27 /=DH&.).,Y2KM6J.G7YX\^/@?Q>3$
MM'Q6N=OX4&9/E$FR<0WT.9*>AP9%OY9[!VNE/P?^^)M^;OMD0T<B';^<[M)A
MQ]-<\+ SX]<3\_BC^/F1KH<,+OXQ7'V9?N[\P]MTI#UNEMHK$[Z]/7;/>_\
M;WZ*]"/J7MZPZ,HM+*@QRIRQ:[*5DZKD<E9,HN9UW'5H)4L#)<U::H''(K0W
M0U;5!;% T2('H( )@[>K&-RC3.?M$+6J<]O=R9YL[)&$3FD56R!V8879*6UJ
MV:];<<2=&Q%,I8N58J/FEKU>J?-S,0:AS%?9R/HM[VSY3M#)HRQP"B:%&U:"
MCF6ZA_GOL:'\/ZM7CZSGB^^_TE4^=Z\HZ^+N?ZCXXW*(O4[F]!PHIL=W^V\C
M:W1Y<GLK:3!=C;(P"$(LT.9LQ *6-PS0%P= J/<$DOAKBVB1/-.IN#U6./0Q
M17W2YP+;CB^ZD3*AJZ]1;L^3V%N/8/@HP%0:!'Q0,*T)UKFOK&$Z_%%QQ@4?
M'&A#:9V9:^L-577FO-TWHKN$)W&1Y2=RK5J=9ZH\D65@%$D!,"PR<HV9&79^
M+J4MIR\A=7/VGR9SF-[ *WG5>N;5R3KPUG*OH:NWH#'T_G$5;GCUE$HJUGZK
MG .PTD/XCX' ;A@-@0!$-@U#(:!\ L&H1NY5G/'5)6 E5JTU ?!N:).DH*/G
M1V.4 W$LY3FZ(UDT:&NLE&VL57)HNZK'*5.&D N=7B[K?CL=-):,;J&GFFK#
M)"WZ11-M? >*CP9X?B8M/X[7?5_ :F7YLYP4EM7/M'N<'KG+]HF5?L8-\O[M
MQ?CW].2;P?L8+AP$^-;!USH!Q>4WY<1G)2'(BQP5!UE3Z(;]3:2]%,QV-&G6
M<5]'G]"OUI]M]@_T1]4>[-@6R+25+1T:I.AR1;YV%@ETOJ)JG,ZMABJQX$$L
MKY?T4#:*GU9MH4(G* 1@9&\0XI<?L5O5,=8H?8H%-AM$.WLLT9S7;DT(R2$D
MUJKZW%'Y3LNES]:XPZHH920T7$8BIQ>:NB_U@Y];%I%'DOOV]/0QWY1&6UO(
M91NWD6(;FN-P3C=+E[XM]0?<;96?"Z','+[5QU5@\._I7V/G^]??>2 Y]\VZ
M_*BO5S3SVWE.KN_Q3\U'V1UBZ"8$:8HP0JZ36;,HD$$YBFP\6O=M0%1:@B-<
M'8#:U76#5!<6A7'>&NR5OOHBFS(%8SGF<-81M)*!F+V# <RB5&W%'F0A%:QM
MK+/?6<7  AX1N)&XD98RJ=P6G:&R/6VO)T];&ZD3Z&B11T/)4E)VNR,!LKX5
MV8H+76Z01 B$JN71679U+DV<6];%:&.$O08CJJ&ZBYLUG.6C+0NJJXJK.IN?
MT=+,R<XCG$U#9(:+7@;,78O$(@L"P;A@- 0# +#^$@#0- (A&V0N]4Q+#4DL
M[5"F>"ZFY+%B='A6(;!#7FN:5C0K7DY99))IVI01Q804Z<KG+64(Q2JF<V:;
M)KG+K(O)N1+94U&2F"&\BB@X#PY?*OC?/PUOSMW/\M5?T_S)6F'R+DIZCZUW
MI!D_88&%//$?G7+O'\HP^<_1>FOS_P#9>@OB_P!9:^<Z<+X64+R:V-%;N-_U
ML1DLL?GC;=',MTY%^UJC?L,O3?Z6^H>O'Z=^N6GUN@FQO(;2&3RLBC /ULEZ
MLLISL:FPX$D"40V&86/:RJ+CGRS#IG2=Z M58)R2V @ &!<U+87*O+0O%!-4
M>L<LV$YDXQD:4D6L<IUQ9EPXVY7J*JR%/($=3L-T1YE",X9MEZG84Q0@SQ\Z
M>ST0Q8K0I;T-T:AJQ(!\+Q/(Z=5_/_65OX7U#'M\[C/P'NVO&U7Y*BT>SBZ?
M[7.GG3R%]62"]G-:GO?'W3Z7@V;(9!%[D4@Y94/JHMIMFQU$52"V*)WJ S0Y
MP>3LMW-.8P;@;L-PU# :@*SJK:;H;S= M2)VYZ.Z>6/V9_IU/ 4JM^(;"RS>
M-BL+N.[,F0T;&)1D((%=J=<Y[X'&4*' ZR#TRC8MV7!8=M:(=8]''TO,NB#L
M2.Z6#*@\!X!,(M9'@KI\^D%3JD]8<9/*K.S,FQO.5>6Y9O4%(7MYPD5.RFK^
M<UDD7*U*+Y&6MY8V(&%L/4V%HMG:;-.JF70Z#8' ) B& R'P- P" +@1".A#
MID!NQ5$Z*QE",Q&4@D@]6JAJOC: SSZLN"-@(I>WSE\[%G >$- H#L=HQLD]
M<HW6*LG2)JPM>I KRZOYBJPQT*6(<28JH;7R;@MY;FKR_-=7QWRS/Y[5C9\P
M])K/TAU@_O=>9^'RMH^,>;-WQVB.']*>SCT;XOT':GY^^SW;\ ^O%?G/I%<.
MXKITN;9":<T?AEC5W/2Z"V]'.V?U%Z3UL_6?V6[^OUF]XV!)B,TT!B0'O'ER
MET=L]'/8W2BL<A)5.6FJ25S?5NI[U5$\\>D1=55<\S.+P3=QFS:L^A_7J!2'
MQ"Q9.UZY9 H$F5QY:HV50&S+)866@M0X<#>(>X%P2"+ARO,HJ]^B_/&L&W%Y
MI]._O##1)ZC ;,U0V!JQM&V,^8]!2?Q_Z&_]CYFK\.^F?"^PLW&[%V5]3]?F
M%))MI8BVNQ?HOCK=]CYD@U(;!I(E429YQ>QI1&(HLU6FJ//^VBG-U96N6T+)
MS26GFG+Z8$HV3"%AU,K$?@X'L&@A>9UE1=45&@\HPKJX>?\ TV)$KGO,G9?,
MW.49KA]%8)8;\_98L#T::@)9$XD$""JR!9KH-&==)0+/9'R+IEGV';NRCKC=
MGOJ1:D78L;IPM)H" + 2!V MPXYZ&7DG3D%P6X$F=#47=DX^C1.[+,<M0V3G
MU=S=E>3K@5M=D52=LL"O:A+"S05-A_/::3:"87HC2R($T;#V$L"(:A@$@%@V
M!Z,@)0(L$? 1.,$NQU/.H JVS(.#-%2YK':IB;<_<Y9&L/<%+)316O@B3K M
M+@3"8*=EYK!UH)J)&B7#,WJ3.9\F/)4"9JI5-7U5/['<-T6L>93>?SG,W'^3
M5M1\]GW0MB2XG/U?SSSVV?EGSRXGJH_+KJZZWT\Q"..P/)W7?\?]QT=\1^S7
MUXGZ;9?"]$1X?2;\O0A4;[;#?WS1Z<_NGZUTGZ3T.+@9*(R5;9FLQL X0]YM
M2N5K9-B1M.0NR1PF5;F=5L^CHF-#>@$D-45OI.7-66F(XQ-:UA(PIS2MO+")
M2J8S74U-SAM01Y$K-+M7Q1UQ@QV&MTJ)1=TUZ9M6I(#8(@'(-A%;H=X9)MXN
M+Q7(>^SLGFP23T:U!NC1B:!Y.J/F/NB>71MZGB5[YWLM>#UY_FT7!MQD,FB/
M4V3CU?GIIZCB2/T/+>:(R"1-D2:(]3;Q4;L*VLA2NS/6.X<NZ?9K+2YL"\9
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M.1P'X; J"8) W!$>!$04 . \)4!$&XQ(HJ*N-&%22BY&IW7SBEO3"5P%[&Y
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M:"-9"[YV5D98FK*]W&2:2@_@P FF37.@UT)+<R$F*"<!*H)P*K-6</:7WCU
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M"5V0Q51EVRM0FA26D&+IE)DF4WJG9$++KHVC9UA(UMP9D&$H\K:LW.XIQ-=
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M&ML<)2"J!>%Q.G4[#X>XMF*H>ABI4;;*O '.D.91+!8"4.F$P< FFS$V8V!
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MNP$I4K$5A+!@I^4,"5#(? K?)6Q[AL"@?!@$PU# 8#<% R/(O@^#X>!8'J+
M5'91PO9EM3#KR[(M=A$MB0T$102&X:1!FA$,,T1JQ5&&T!? Y3R(>RSKDK*'
M.]U3EU6K"\/$!!+J[99"3UR=*2R?P_DC!48F K8A'&-J* )L;I;,)QLWE7LF
MV:TC:DXJ 54CL&]J> :@&",7*!SK&N+4!X,P9 U#0%0/A)P<A&P,S+[SV7A1
MT524(>?P-R9?$W)T.5)X@I2)LFQ3]%+L_JUIY\TG$>),'\=,FCI*J7<=6K42
M8VPF(,0; 5N2FN,>OL05(V$!J'$)OJ+!ZNB\LZVBNY*--E5=%\/4@\4UAITM
MM<@[@ NRQVW(PE4]4YA'7-,VPU&>H#)1B6O!$K<8X4VA.Y(V2M3BL=/U%Y:N
MQ="M+V#(,9#:^MNX@G@W)1YPY]5G#-NP7&!R-,!SPJI(:I2;=3=;+JHKE90Y
MK:['2D&)ZWKH:[!7-[X[JVQ7/7)*W8KT6I=CGVZNYHPHN4O/+*^:W?;61V;1
MJEK'4G%$*Q+)==A7YY,[SD9_4NC5)<MZ5U9+QTPD0*@6! -TS:MD86$%DQV"
M,/23ITX# ?,5$_=1HI($% ^#86XMBC"66;#WF?3:L4K)J6/9&[-P^# :@F&P
M*@H"@]Q9#X,A@> 32Q!<KZ<?'=U!RNVZ<&IG(B=^<&X(C5$^ RM#Q7,W2P*&
MS2 :!D,@B/=)PQ4!H36Y2:2Y^MI>-RU B _KG8-&B4K8Y#<,@U$S(,I9#ET8
M?;4S S"3%L.Z]4."3M6*.IPI_$FP)"= =JD2@;(&LCH1::CMJ"N(B#0BFEL&
M;&0(!\#L#@.*EBUI :GGZ/S:[3IZ2+I@!G\%:*_'JG=4%F4@0<V*0Z'Z-SYW
M8-]0\(7$B8/<FN3Y]-:4S]A[YI @ ] P!0,0PW9>^ NZ(YU"HC"+>4V_53C3
M(A*-F.5MY.G(Y22F.T$U;M0VLJQET!&BD#;A%VT9@26K5,J-TDC-5,6XQC5D
MA=V!LU-Z[+#C+97:PU&\MY.JU5-0-Q[@@-B1VT4(RJ%/(S=3,./87?G[KZ7)
M^3.;(R>*GMIWU73UA?DLN59MD1+*ZE*'Q$XM.LO#9"_9T47=HXLJH)Z.?(YP
M?8]TUAI[-V+J7+"H[CSG<N+&7)G?44K^@90G\:H9"?-D6Z*I]9&6CS7L"U6P
MZ^B\$6EJSS24R3B[F'8#,"D;#1*0!;*N2KNIKFU.U8NVN"H+DW! JQRQ:-F&
ME&E&9%L/<%@V#<2X+C78I)JS:TA63^# 9#<%P7!P"H;AL&X;!]%?1-XKAC=@
MHR=89QN7-IM''J!R<7OS#95M@T FK3-&A1 ^ZH?/.D& T'@6H? X3>"8,*6*
M>M4IHJ7 [ #*4[S72N.QV3W!L P@(EE;**\E,+T,=>!S.,\I1B0'#4>X.0=@
MD \$4%ZPY!Y ..&3C$),#6FLWK$0B,%%I+.PNDQFT@P"H,H.6Q@VMD1$(MY_
M8F'O32&I<C$7A\E(5^:]=D?IA(81Q&1JV%U=?ER*V5CX+E*[]'!DYA8OG+#9
M[/:KTF-$,!B&@R!0V8K<V5G;9 +(1Z5:54G674)6R&SP-V7?EZ1V&E*[,YFC
MU=YBK2F@?HH#WY0]F(=*M4@?CHE.?:?A8^=@DJC&G-$K\+-U26-\BK1&.B39
M=YRC2ZA:ZKL^L6''+BB)L#=IT\V^B@0Z!QF:-<-5ZOS<5[.6L.8JR<CO^5'I
M"^+TU961E:'GIB+T@) (I8RML3*7C<HS*'F9NU<G^E\7)/K?P(]LP'_G'V6R
MOG7TSTHSZ.\UF#VRYDLEE7WE3"YE.;D5%.OY1XN=#&$)R$FDU8] /7..VY.A
M%GL#3-Y(<2#KL>P2L6;)$PL8E8L=O,N?)1E$=Q[)8#8,!E#])RA**;)JH4:5
M9N"HU6*,7$NQ8%I2<,73=1'3%'%<:LIK">%CMCER<1%D.)M=M>L4BE4U&N+.
MKSXH(<%PQLF^71(<NB.R(_H@)EE:H<,*4;"-34 9.#&R"5B3=.X:Q>U,UKI/
MG) HT%/+U6]U7T4+3DE-L_JUNRY,;(09YP3SI ^ LB7WIP F2D*<IJ;9$08"
MM3=CV(YBV]8.O-:B21/@BX0T(H$:D#XP;$]Q8&T#4SY4$IMI)MYMK3%&(]ND
M\M;R>0B0[.P]TFM"I4PEEY.CFX.SSH[.R+C547'[H,>YSGMCOCB:WZG) -2.
MB-]/75.NI,EWPVPF(" C=T M:U5DJMIN;7,/*47GGQ1=I1O@Y&!:,5NX]LYH
MZC*W+K;484Y/GWOZ]0^=(79SA5^(:\SL#U6B3U:SD9NBUBXQ>_!%]%'S"E=9
MF-LJS]"2X]Q*G2\4UH&J$&:C6FDK(C;,R0%BM>6<-HSL'0,%P6:_S8/94V/+
M>&=2156QM\79GH/A#?H>+FG/]S??)^R=^5^UN:0/ ))8''('"U,_*'1EJKWG
MS>-_JO\ G@T]M\-N[\N?TQM/XE^B/0'E]OT NPR>;)62NRBR:JQ82<AJRLW'
MB(H5KC-).36,A5I81VQRS#T!'-9&B:[9$D^MF]J9>(1:G([%CL&,X5QXHV/,
M7NCX/A_):MJ-;#4%JGLE\S='P_A?#R&!?,W#Y&6?(W'L+<?Q'X/F]D;#W:^B
MMP4;W1N)9&XW-Q7N_.)!=.WU83BY9DTO*+8W(BNFL2\R@$Z-K^H=(38R0TT2
M;SAM%9JEB LQ^&\XC;\Q^V#.VJ. YKLLK)K*QM;6R$ $EG %#)I9,PT?1)IA
MED7M3H)? .U.*!"&"6.9I[5)%(9((1:;40",(C+(P %""-6EF]D*H4:16<2W
M4T9064\J<EEGGSC+[9+V9K\A?U3F[&Q+X@S,]4+-Q#&KGZLT%1]#C6B$=Z^*
M10+=Y6]F#\)!)=J[CNZC9Q-F,CU$R8*M4%>>&Q1.N]Z3Z&VQ=W.*3H=U:H]5
MLJNS ;@[9Y_55E-C?G>B-PN)T[?HRCFKG!-7.;.MVF>KU2FG623=@DX1?3D
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M 511UB@*@;#B?-'@?-%XV\F.BM9-ZG*[%+Y5FV;A@(M$%5O>+D]\7C-!IB;
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M!*YG356]%.BY8I0M-VSLO;)'GK?&DY8AX!0"1+<KT=#8KJITOFBS"X1N$,L
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M0-%WFOUMO<?+J[KS4=VZ9=8JQO.(*2U' %76,LE(<W1%V]8/2MZ26(F@]1?
M6M#TT7!8,A%6FZ:HY*)X& BX5U2X'&S06Q!MGT3#1-E!"X(92J[K>ET?@< Y
M!\,ZET5H716NJW'?,5*&W5US9#9DU'8N6[0-P< X3(B7!FQ)-%K4)1'HH U
MX*Q /!N#4& #@ M #)1Y&(.-B V"- ,   P& "P:)#:8"%6Q6E5FT!/'*/8.
MB%QMS$>.+ZZM\XDDBDPC,)(?23^R!16/Q/0?C>66/9#H3X;NZIU.EU-;V5IS
MDFQ,$P1$A7F1@8#Y/Z2Q,^B*VO)HPUBFK8MV1F*WBDV;H38W0U!F#.YLP9UP
MM/LS"Q(](CQ!MGB0MC(862:-A%-V+,QG&P6X,KHOZ6G$;+=N2U *\9!USL&5
MCKM;!=<Y8\$/CMJ+F>M9<WJB*[PW0PYT\DU9E> L)S*H@)W#5J-5&LJDI4_
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ML*34$ 5 C(.3D8M8FM0]!1!6YH-MIK(/ S,:10Y,%,(0"X;R/I -PKL=>9Y
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MT.;"1B5@_@.P/_S!0HFPE[K]/?H*0V8B]'Z?'M_\!7M5[]7?M]$:]N@M<D$
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M0H1J*  J]>E&@A-&,4J>)5;?0?0$$>G62_CWI"2>CW\>J"Y,=*/&I/X] *0
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M9+D+OV\FY&<@/S++]I\'(EDR^,3/)LN&->'7 ^$7IWID)/LVI4(J077Z#_\
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MQT3H:,@KS6O):\EI9DM[J5[J4.X^BXJXIG I/%0917NFO>KW11-R)+ S"[2
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M$VH$&I#VOT#$4)>Q=0/=KS4ASY,':@26IG'B>YZQFQ+K:O*S,RE:4%B(P*8
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MW-\)C6*UJQ'/E 34+D#Z/4CJ;VI"31O8J5J])_'H[>-7NW3Q6K"U,ENGA^X
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M_M^GTZD@!IS;)S4QUR]RD*/G29)GR+F255,TL;DH6-K5[?D/!09 ME\:E?W
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M2F0/B8$F14&H9:BP)@7QWLNXGPAJ-Q%G 2QD\@VL^N?/Y'EO3;9V.1MW%?[
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M-;D(5B8,@[4K5:WT2=V/I3/7D17DQH2$!GI22#Z$D];VH,U>;"E<&CT]:M1
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MF+5CR>05;UB"H:B!!065_P",K!:D<U).JT,Q6;;Y_C4 NP5%3'C\:5?(^YX
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MQ$BA1:BB $Q(7\I%8Z;*SU<?'GQ'MOD+8?&?Q]J^"Z% $IE_=+&WN*/%4_C
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M&HJPH]JOTM5JM5J4>19 IM1B-B"4F06\FK]U#N*MT'0=Q2J6I8_W.BBK6Z$
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M5/\ BC%D8!@!8.WB$8FF6XL;C]M+<MTD4F@64'N;&D_A1%99LEZ90P5%%2
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M;U?H"15R:D'>2])8,9":C-UE';_" 254**7M3%2";#S##I>BXKR%>=>5'O\
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M-.;X/%L?>\NWW(<SA&5,F(<R:?3:C'&-(LJ,TZ0-&^(0,;%R-AFXF+$()1!
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M_MI/,9Y/=,U2+[<&S!6?&[Y"_1Y#I(PZ+W4@BB;!?Y?4IL6\2$/8'NP+5:K
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M M+Q_)9L $,*!!^@>G61@QIV(-(Q)F)"DV-_KD_B'8!"6/0&X]3?H[6-2BK
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MUILO):AFY:G[[(-'(=@RAB+1T&<U_P EE:Q4H:-KV!H #I8$2!YT8?N[T_\
M)OXR=QE"QRT-R@)="*=1::,"F6]>!H+9E)/0D@$>(9;5*@J2(M7M%:BR BQ2
M--)KLB!L3638>"8YHI5Y5JH]SJ)(U19\="DN+*K\)VN)B:=LS(9H)IC6'DR"
M7&D)K293%0I\55VIRH 9BLSMX(X<E78B*2O9>C"PI%*T:D]:L*  J-C>0=SY
M H.W^1+ 4/5QV:S+T3^3C]E=^H-NL<LD+E(LQ0MC$I%1_P 54V534/8Q"U(O
MC1-NC  L5OTM0%Z"&ZK>E"^/D"#7,-"-QK<K)EPLJ>4?:XFSPA+R+8+B)%O/
M?BRSDOB<0RFR,7#1-/C;C,&QS8/XN M26\E'D44"F  D<BH_X+W#"QZ2#I:I
M#=B+B&/S9+(L-_"2=PFJ(->\0F"X9X/,H/\ ^I+H,;[8["2T3+YUC9+Q%7$B
M[ 7P]BWE%+%YC&B#R-8ODX<,D6)BAUA4Q38:B,;:%\J55/N<:S%,L<P*I,#2
M.*$_DHD:R2!J$G;S-C<]'8K0:ZGT7MTRI@*:4W_P2_RI'\NGB;5&14K "G;]
ME=J8AB:3^*_RBL%![5!C2Y,@ETN'1Y!GQ4_)-[*) TK71:+DU<U8?6CF,M-&
MU!8;7AK_ (S1*WNE>=&5J,KBA(YKR8BYJU V(N1;Z!<'(C 'I3'O(;+)Z9*U
MDQAE:.U$$5*A)F6P=?(F.P/H*,=J,=-&;.@5EQI)J;"6%'QBQR(S RYY@.JY
M)A9 Q,A2-;L@'?<X\,.>3/ES66OZ_,RDPL>6#,QXO.DB"C"B8-BR]^-CSF50
MQDD"I&?>$\B(".TPAC&) L=>TH(C6O:2G2*S1*::,"O;%^D9L[7#?YE_C:]1
MF\C$@U(+/2"U?IZ?X 6!B>/,<Q2(R6NI I 2#+%C!^2X<5?[;)2<KQV,&XUN
M6TLMJ,]Z]\BO?>_OFA.:&234>1W^X%'(HS@5),I',>-XLTV;#^S*UR^#8\^<
M%TB1.^$_VW&M:^M.[V#35WLC@--_%W4,CAF9K4TBK1:-BI"EG-/(2?>%HW\J
M8!@(A3)8&)::, 1H8Z)8T"RP2 ^>K)\#,U:R4>YG3DA8DQ\:*/RK:S&5U!BC
M1PSXDI-9_?'V9M2I<8<2)D8>(N14^-)CS&/M*I,WW/O4(_*A%X5KLE<;98T@
MDH?R@=67U'Z*++2, >A1Z0,#0!)V.6V)$9I&?R+5Y/\ 6>U26O49L]+_ !;U
M4E:+%J-J8W/Z5:C4; 4A!)MX1DL(8FE+2R3JCJE$T0;_ .)0".X/J Q%$DT&
M("N;F0T'N?,W5O+H6!Z?K4;6HBWTE>TL?@65@6)NY[3HI$JDU+$%5EL645+&
MQHQ$@H2#$142>3"(!)+!6#-0QT0>:>+0EA/CVK8+<3']ZLRG"WF7KCJ.21;&
MB_FN'I_O9=9I^*ZH;K?Z_"P-<!F;-("C1X5PL/C2LR5Q>.^ EDIO-S9<>+%Q
MDE6156I,:$.+@476BP )N2;434BW 4@VB-11]G6X\#X?Y4%EJ,68W/27N*3^
M-'U_P6N,3++J,>93)EX<-2[3)<'R=E2BHHHPJQ!PL\SH90"917OJ*^Y4 YL0
MI<R!J7)CL)PU>[1E--(QK((EBY#AQXNV>%#69$D65B:I7$L@ FR1$N1-[T]>
M5FD9O$DW5P#)(07D9Z23Q4.OE+D7!?ND@\H2#49)%(A(,)--VIFL(U\EG8^#
M]VU7=&N&P9/!]7#)EY3HA;-V*ZZ/#ADGK(B9V$8C.*S#*RWO!LAYM$23@(7&
M*#&V['_'!E*IDQTGB]E8A#&0N3 $=E?SU64LD.)^YI4:-H)4E7L /2OT0@_0
M%)I5 K:2^>6>P24BK?7V-.;F@;&]"0!2;D^M.Q'6]NA].Q6,W5"2L*@EY3,2
M3:H/W5-$+$$'Z.WT* 5!\21<4>_0,MCZU>AZ^2BB[$1CZ I-=^I:W0U-84RW
MJ6,J7]94-I% :2.X=&%.H\)DO10&B&%>WY5$EJM4D:D11B\P\FC4AD9;RPET
MVV/-XRXF6&>)DIXV\8<IH)./[E,S&68HJ9J7W#*Z)$$.)D8LP5+TL0J* VU<
M'V^ ZLM1KX1PVR) !'KIDO+*;OT;^5'T_2]7L"28Z5R&0W5OX_Y1(HKW!4=K
M4?5E)CL;H.QH@D^+?2 6H]C2GM):\D\\PM04M2BPHD426KP:OW(9,][/)(YN
M:LQ%6JY%>347D:A[E"25:^YF4<XQ(+/@1V5%A+S5)DQH<[8.[!"&)-&/NZ@)
M*A!J606\NWD*,EJEF'B<@LR2^ Q)2:5U2DD\S&W9K 2D>+O:L<@QY+?L:2U:
M=RTC0@R=XIL7:0XR-M\@Q(QFE@7VUGD\*:5"8RHR\J)Q66UYA:L%TB$(=FS,
M>.3"4,7@D>,XAQ,D08Y!V<($&6SQOQW.26/#-T9P:,4D-1,KBF;QI#^Z,D-<
MT#>E7RKTZ;.4#8--7EY5[K] +D( 9!VZ$6^A&Z=NK$ =#Z?HP\3<VCJ(]Y$8
MCO2BYJ-BKD^2RQAO\*FS2"D/8^O4FYH'Q+']W2,=J!!Z#Z&4DW85>X<?N/F3
M,":<"I#976Y<6J9 2X 9U(9D#4R6H16"?R_5SY&-2*CQ&E;58V/[<V#AR)-K
M0#D:V'R^PQ++BXCUD:;2Y4>U^-\!PZ;+B^PUVZCSXV<!9IPSF2X=@M:K>OCI
MA219J:;6R2Y'M!DDA0G,*+%JB/%DCR,61$*O?R[=''>F]*)L%8>78@587$A4
M%C[?^=18?I0-J\0"#^WI:B!15;>V*92O0?N5E\:3NOB*<6/;K^XBE_E3*#0[
MDH0*OV+@CZ%?Q!<FCWK?XPSM1G.RMD2LA.2A$LSR#(L:)H5X]BG[9UL9++3N
MPIC<T[^%23@4KW*.WFDXC6+)]UHS=8Y HDE#&4]VE!:*8 2SDJ\HMJ<Q,>27
M(C:%%EG33ZG'CK>[2)Y,6,1)[P%9$H*HTC+@PF27+[KDBV2T=JPPLF-$_M8,
M[J\$N,J2&(PR1HS2ZK9)D29MCA9%_N-/((9L'%0P_8K;[5E6'$,9]D6DB_:J
M%2+BE8W12U(1;]'86Y'$4SA*I,5Z\!TC'>G'[>PZ$$TXL>H8BF:Y#&[/?Z#W
M%&]$V,0N883(Y(=^U*%-,MC6++WFB\:E%F^JQ-#U(!'=2P\NMJ"D]1<GIY&K
MDTGKT0]^K>C,%#$$RQW,O<S"U3&I*=;%U\A,+4_9F%,MZ*6(6Q9@:%KIVK'=
M"^-DF)XITD7TK'02,F/I\E]QKLG$CPME@[% 3;8Z/6[N+9\ _J(8\UY4$C>2
M/XI,XL"0=!-GSYV)DY,<)V&8]>+LV0":P04D53X/&6KVC7LFI(R 5\@013#I
M(>U*>U!V%*?W ?\ %_F07:OTKN*!)^H*37C8L :86I" 2H-"RM1 8,+'I:BH
M-,OC2O84XKSN*)N.B*03Z_1$YB/(M:<7)DA-Y4\3/(14C^56+/X-2H2)% 61
M>^1&0&2]-'8R'P,DA>B""/4L /,N<)0HBD[!B"LEV?O1(%%A1F8@2>50LU]9
MEE8\,J:R\T8L&&S&2Z*AF[!C(8T_;@X+)%-<5G.ON$!FQE$:V']++,T>$"';
M,A9Z3(*-+[C5K,_[W'S]<990?M<_19 R\)"/$T4!/B316PD46J,=_P!+BO*O
M*MEBQ9T#X\N-/C'O[2=$("^Y1\C]$@/T_K]3C]QH FH%)D 2)/3H&(IE\C2-
MXM$WO)/&5?ZK@A+7IE-(1;]:/HIL?&]7[@E:L#7BU'H"1086\UI2+GJ1<2JO
M6;]JS=C(26D)\B+J1:ID%Y%O3*PJU>M/)XTTG:-R2'!J)R",CQ3!S_&;L1Y2
M@MB2,\._RX,F&+3;#+VY?5991XS&P Y'@KK]^(S>_::]E+,_QYQV/6X;2%ZP
MU+/X]I;^>)&?=QX 8SBBYQ!;[*IX&6IHA3C]K>E2>M#M1[#*V>) T6=$P7)#
M+[E&0"@RD_XX_P"5.U@A)'6]*%(-J+@5Y,X4>(JU,ES3+Y'IZ41T'\:(#"UB
MI)!4&OUZ@7+L1]1[CE<?_!DY 0Y66*:<R4X-(ANBWIHR"ZDU(*FC\EDB-W1J
MFB\J^W*%X^YC[B)FJ* )408&,V4DM1'1U8N59C%QS=Y58_!^1L(.![(4^I&M
M=,R?R@E>0P1%%,[ 1>3KCXUSBX;,3$%K*4"MN/;EP9+J'$8@0OBHB%B?"LSQ
MGCEB/BGNO"LKH,3/3-@SL4QR<)G,F!%W'Z='/[7_ (UY*JOD=SD,#]R#7O&F
MF4UEXL.9'%BRQ/[0Z7[(IN1V*$=6%PR@'_%(>]01M)2Q18Y[6Z@D%UMTQ9+'
M. -6('T@A5!L5/D"+A19G4=!8@ FC^Q2Q/\ A7R\EO;JP#CH\8D6?N78J";F
MBAM(IIT%2GLU,P%2R^=!@:1+U<60FPR6LT[-6EV?WL4Y("931E%AD6&%\5L<
MOD8VRU^-! J$GED29&U>(*"+-*.W#.)3;C.C2-*C1XY(D$87N"HO@@')A( L
MA=RA!]NLNUI@*GIOXT_\NG+N20Z#7Y/RGDY^7K?D>6(Z#E.%LHVRHE&\YCC8
M%:?Y+Q<[88>2N5#_ (E-EIFNR$?7XJ* [?0*MT'>B+CP ![%&NG0BX4>(M4@
M%F%J0>71%8%_Y4%)^GD<!DP\V-UER5(/:E4FH8NZQ6)%BRA@\+&I4O4F/<"
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MD\>5C%#8 JY ]UK AAD0%JE0QMWODHQ5RRT'(:1[U&/WDW"=V6",TF.BA6=
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M40JSOYXN1:N13QKC^X14\@7(\FK3[1<E"XF!!894#2#,B9,F=S&^JSURX]I
M,G">RMIF9H-20=?]$KL%R>XF! E%Q(I!86(J,&T)[XK%6]RK 5;Z2"1UE_E4
M@)I?Y=0+F) B^/D H6@*87'T,E$$=8?YY0O1%B!<^!HBQ^A3<5(*O^SH!<N
M#T"EB!''7E(]%.RK8,02;=%;RHAA2D,.Q!NIE42(01436)4$[:"RSQE210]%
M8J3(6$V,LH>)HG(\ZGA\214@[Q?^1RU*;$2^(3*%&5?'(R#XRS,0'-X'-F9E
M7BW%&W[)$$C L!V'6]. PF9@83^Q)05\VHFP\Z\Z\CT=NK,J+R;F6+@Q\G^0
M,+.S=QL$R<C+E\J_M6P'TWR&D2P_)&+Y#F>)DG7;F"=M;L65L/D>=&,3F&4@
MAYP5K$YM&]8W)L28PY,&0.B_R<$'_P#A)\C2BP )H'M0]:%#T^A38L02O\B:
M<D=6)"]14I\ER[%&-@P\858 *?(#QNS>75!:@.] $U(0S9.#%F"3C>(X_P!5
MUI.+JL'"I(2!(GM1UL(_<QXU(63"&3'FQ,&R(Q1@45[=JXQQEMB\&-# GM!C
MXD 1=@"H,GC0D!#MY5*WB.2;T:^'WV**[F&1BM8F/"$QR'R=>P5FD*OYA4FE
M"UCSGR7-1I.0K&,.3'C\<]O'81$N,.>;'FP-@1(EI$9O(38HD;.P9/'6SMC3
M++YKO]2RYV!"^&O%\EY,+I^M2BZR@$31=Y4-V2]/#>A':D0BH0"V,HM8?X''
M?HZAJ86-!?$UZ4*C_BK%:!:R$D#M14,)$"#H&(*L&IAY"W1/Y27:!_Y+V:BI
M'TJQO3*"$[%@ >BJK!K@A*\R*4J"7)H,PHR4"+O8&E;Q*&X\+%65RU[>IEB)
M$9[HQ!F@CG3.Q/8DE7P*V-7I>U ]\O%7)C=7C+HK++C^VTT3"BK*8\JY6=&H
M2JU-.%+Y)O)*S%_Y5 I(XOPZ7)I(HXQT4]/7IZ=)^Q4^)0_M;TZN2*\S:_05
MS?D,6EUW+_D"'9;#*VN+-39"N,W)#Q[3,ECK%(F;-R,[7#C_ "AY%T/)76M/
MR.%ZUVWC=X,X$#*%/D=XMOF8SZ?GDD3Z;EV#FQ1Y$4HO>BJV+%NB"Y^BW>DI
MCVZ"] @]5]5]10Z/_%?X]NA]!^YI#Y.W<2]P@N*?^/1!Y$#O0!J0A5_4  2$
M5ZU&H9@BU/)[DE9+!88T+R/$(UV> //*P[%X&6N/:5MIGQ1)"A!% D4&N.DH
M'20VK)R%2/:Y7]AGQQ!W;%"110_<%IDQ8M.Q?)B<QT7N9O)8)1X45(K&\%DS
M<K[K)@\9*R LJX>,ZET1A A6L#,;%:*2/+IXG6GC66LO6H*QI6096.N3%(I+
M<6E"U^A4CHW\2+AA<.MZDA!J2$V:,W,5>U42"^,O:PH7 ^IA<?KTD0D6(H]!
M;HG95[+2A0/(4#>F4,K#]W1& JXHJ#12P4V(-X'!OWO3"]%"/H'8_K;LMQ))
MZ]%O<N%H /3@ = ;=!ZOXWZ*Y6E=2&4/08T5M7<AHO$T"",W'$T>5 8V*^-1
MJS$1$T8V6E(*Y.'%DK)&\+>RDXEQ? S8]21^!\V4QRWC,@)H@V=[OKM;F[/(
MXQPC%UB>)L :(M1%Z46Z =.].#?)3Q,8,K1G]K6IB1TO4E_+JS6'S?GRM!E0
M9DS9RMCSG)O4[,8MF@*Y#OCR-E^ZOW(P<C2;_P"X&NW\@76\DG\M=R>0'$WX
M>EV"2B2>C*36%N,O ;C_ ,@2JNFY3@9\:S>:=%%A]-J%Q1/;H>U**%KGL5-C
M85(2K^G0@$(;K7ZN22B$$W]U!Y2'OU?^- $TJVKTH>I/B"WD2; OV O2=FB%
MJDF\(J8A1L)&E7!3Q5U\JVN.A&1C$M+A-?C6+'C871%\B693[C"C(U/(!3R]
MS(;<MW!B$;(6@D5*ER9<QI]CC8,<DY<:J,)(X\CZ!G9Z^W0F3&*UL)#[<BRE
M\B:2#%P,-\C)Q./Q*FUAE@F@ULT<,@0-#-+BOB[:&9/%)5-3P*7QE;V\O& F
MT5A,I!6ZD$*58_MIU\69#3+317HX]Z;&[&$WAB[Q)7MBH[V^ME(^AE\J$;&O
M9[>W:E4*0"M=JL3TN:20B@2U. ?H5[4#?HW<PF\<G\;VH>G1E+ (;=$]+FF!
M!<=[4%%=Q78&B2?H%6-$7%CU\C2-( 95:E>]6-BJLI%B'*B0W.RQ68RPL&AQ
M[E8KT<)&$FL:GPIXQD8BS+/@Y&*/#WDFQV6LO'\7>#NL; &/]P'>0.[:'@69
ML&U^MP\%!Z]";]%]?HD%9@%8;^U.PNO<5[@IG!%R*MY#I)-'%6?O\/'C^6N1
M8^?DY$B0Q[#,.1DXZ@)EY)-9?DYV>(I7&DD5LC'$BQ32:J32;3[J+ RC&,+=
MA*Q-VJG!WA+XFYCDI<U'"?P\C?7;[,UK\9^0(B<#=X6<H-PI)'?Z!8CZQZGU
MJ]ZF'[R]PC%N@_E5KTRD&,$E2"T5@IH,U[BG[K2+0]*%[S$FNRD.:O<CU!%+
M>I7N:<73(2TD  3$C21\K'CR*EUI\LW7R1+H@#C6-^XJ/L7%FJ64I32%A+(5
M&QSFAQ=]DG*S-<LDZS-[59^QBQ N5YG&/F-;#9?;\C[9!56)"*4S\AR),H1!
M0 )L;SK%QUPSKLJ7(AVLN!KHIN21S1)C[*>9H<C%B2;Q;$VD\50;"*<*"Q'9
ML@*R8A;'FQY@T(((5K!_XTXN&7Q,@'CXBB!1 -%%+11WJ+MT]?\ (744!8-?
MQ\C<L!T L(Z=/(GMT4E2"&%K'JK>-*WE3BL4W,G\:3NM6H4;FF3Q%(0#37(8
M$*"12@WD_P  H.;AF%* 1X T(^Z$@F-37CXT+BF7QID#B@MZD4/&<=+1XRW6
M!J*^VRAS0 HQ*U-B0FLCC^'D"?B^2%RN+9AJ;C^Q5DXQN)C%PS>SUA?'^1;7
M\8TN$A1@]7KR->75>K4I[2>F7_!;*T#W#^K@#I^T @&F]<_818:\GYZ,8\VY
MIMIXM3MCMZY3MEGR\2TN1-+'BB.-V9XR5W4B0#"4Y$T>#(5R=7YA'R-?'JL[
M(]K$V"WCV#%<79S1MA[B45B[@5A;59:BFC=3Z>[)"-'S:?6R<7Y]B9X@RX,A
M 0"'#&]>2DAB&M?Z;=+$LW\J![36*>%PJD$/5N_5"/ , !^R,^I%Q:U.>P%R
ME[=%/B6(\F2]%2M"]U'DQ07+6 JW3)4A[%$AFSUHS9[4[9),C1ET6*.HR2*D
M4&F(L9XQ63G0 OGLU2YF21R/-R%C@]V5L0KBXF9N/^9IWEEQ2Q;61L]8LGM(
MC$T0#2*T8SLBU9+%A+[L-8LF1(^%KCDM'IX/)2N/C[740[1=?IX,839"XL&P
M?89;8^+E 2M[,>/G^R^'GLB)DQN#[<BK$P;73&*.&4/'WM3+:K$TT?D2MC(M
M,UNEJ5;5'ZVH. /K<_1+:Z-XDL30-B[!JC[NMO"D8&GMXE?$T"0>Y^H,16-:
M\J_O-KH01U"WIE# "[6\6Z,U^@8B@/)F'C_C5A:]?J&\A5[4#:@;&2,VC%Z:
M,@-& T<+2,JA?K5A8J#2@K08FF[ T11%PA/1_3JO4^J]J8DC(_C*P#XYN+VH
M@&F%CTR'*K\P_(Z\?DP/D%=G-OMIKLC7Y+Q?=/,7>")HTV64HR,;($2Y.;&M
M;>*7,72Z@"H-0OBW'_)<[CPJ752XLBJ\8PF*)%/Y"#+<-CY@4Z_;R)+KMR&:
M':1R4TWDLTQK WN3J<GA'R4N36NRX\S&]P41Y *P(("D7KQJ]$=+ =!3^M T
M!=4_C(:4$BAZ4:D-HE4.\S7%7H=@>Y7L1UO^VQOZ5(.RBZKW J5B3UR5I1YL
MB'Q\5%.+-XCI'8*TJ+4N3'XRY4D@./(P^TCNV-';+QXHH^1;-\W.QUQ\*/-V
MKYM3Q>\%B"UK(6>73Q%)%QR!XE2T\<3R[#SIF#&9;'$U'W!BTV!CB!D6B;4?
M=D$F'DK6#BE,>3$@(:"%:VLBI!F2^>!_6R311XDRQ1SO&D.2)#%,]HY.\$[-
M2Y4RT,UP#FDB*7SH$.'5;O& #&10C! 1C2H  *[]$))^HFYZO>_T(0&1C2KY
M4RE:NQKQ8T002I%$6HVMT%J,9%>)J D-.+2U'ZU;HGJPL5'[W];WH_OIK7Z+
M?RD]?K_3H* L*!M0L:*VZ VKM8H067R'MVER $;_  *6(-=N@H#M3]Z1O(,+
MCJ/7H>A-ZRG"QNWDV.Q*(&MY,"YNW3-O[/SG!DYG*!_9XN9KH]YL7?'GC7'Q
MC)*$"L,,M)]A'X38R,LFI]]]?J2&Q\.H\1?'(UR.-EHHS0T\(+X)B(QO;I18
MQ W,A58-@\1Q.0>*P<CM46R$ZICOD/\ 'W -A)DZW'&-#4; @J30!O0[T18W
M%_U!)Z&FL10H-:@0M.02A-S2>E7J?M4%B25->;"F/E3FP]*5)/$*15A0442.
MGZ-W*CL%44@LA)9NL][!;2("$H@$-&+5<"G4O28CM2Q+%TL!4R=_D?E::['Q
MY0J9>:T\F$[9$F0B5@:;$A$ &7DX\443'(CL9%=<S,#S^\HK&/NU'C@!%$8,
MOE4# /&8?&.WB50D/&HFD1%S]G' N9OA.=-C2-'C:_[B23#B>/9:^3%:-)H9
M8IA9&\#AS+>#P96BB%0P?N15!  IP#1'C4H_<!:BQKUH$@^ZW2/U^G].K?QH
M]J/6]1LQ"N;JUA[E=J4 T8[UX@O:QD%CT4D@7%( #E"TK @Q@7ZKV+^GC9G-
MRH+400+=02"23_D5[!3<4*)O5KU:O0>5Z\>S1-+)D.?NE)(H4J$U[:TU@R@&
MB%6O/M1O8$>/2]J#!J(O2MY4+4>G>O(T2:DOXQG]U@1E$,@K'/[ !XR6OY+<
M=QZ5DCR3YEX]DQ[5L>[K9ZR,"$MLHX,=ECB2O:\&G'MDW PO!U@BB:DB KPM
M17MD8Z/61C(K3X0<'$96R BR0B21&B<"<O&4V#QG%V=<.Q<_<Y?"/C!,6L'7
M18L21M3+:@2"C7Z^8HM&:\HQ0)8]'-@3^WK*+-0)!J] WI 6F=O.1?V8[=G(
M4T 6/MA3Y,*)9NM_H+>)4@+^DY\(OHF/?Q EZL;+Z5^YB  !Z,;MTYIR['T>
M+L,N?89,SDG*BE0<;U__ -3&+Y$^3LECFU2F%$\Y68F,;#.7'QWR":9F+:M6
MLA +^F<2JX4KL(&50F5'9\R(#*V$BUD;262ICG9\VNTD. ^# Y.M@50$4G/P
MUEBSL81K)>T>0WCCS'W,+*[H0P':E:P\VH$@NP-$!@R^)[].WT>OTD^1Z$7I
MOXVH_0B A?2D-UK]+T"30%RRF[J2.B&QH?RRS<RU&.U?KT?T/8&UPRJ.QJ3K
M8_XF%C5Z!L47QJW2]J%S] )%1LJS3JC9'B1U5R.A -!0"_9D%S1ZFCZ(K"CZ
M FBT@H2GJ33N5/FY*)X@FP<WI2*A<>U[M22 *^4%J"1GI7%I'!KE7%L;D$'+
M/BU]<,K#]M\N/PAS)&GR<<@4,,/67'[<;1+Y8P-\<D"(W /=V J1KT[^+(SB
ME@5UR-,L8_KV\6QV6LK'_;GPY;-\?<"VO)-E\:_&.MXIKX,9(U6)5HT0"&7Q
MJY%*]Z8>5$6HJ#5@.K.!T6WM]902M#L?,&F'=!81_MKUJ?\ : CO06('N0%"
MC_ _\K>2PH',T@EE^C]KSDEFZR$!>]>+&O#P!?RHJR].3<EQ])C[G-R]KD.I
MDJ''24XVN;,GSYE@PWRY2FI@!SL.!I)?VQ)L\Q<=6>3(R(\/(GK!T1 @UZH(
M\%5K^N+'8Z2>98]9F8U1$A?)*F@DE>'4R3(NAQTH:J.(+K)7DAP4@K'3P2$=
M\J55$\;3B16CD#>V]VCK79R2C&FNJ ,/I\ 2R)8]C>KGJI_;U) 'IUO:C( 7
M8,>@I1<CT L;7I+@*I/5?3M2L+%13IVZ(22_9I'\XF':/UIQ^T&XKP%G?OT2
M_BPN""#7<C_*AN+]+4K$%3?Z1:F537@*(4'RM1=J [NU DL%"T*-7Z GSKTH
M.+'O7?I[CBA*U"127()]*5V!<]I#XT^65DQLCR'NLQR<A0A_<8\GPH9-Z^YJ
M6:,US=!G19.+QV2;Y#Q\3$AAPCD2+B$LV!]KB;!@!9F: =X/(M$:+4S"LK)]
MNA.)1C0@KC@!C$I$F+</@>5'5H:XK\=9W*=CP'X\U7%]?# #2Q!:((ZL/('L
M02*C<-1 /5_X^9-,02JACZ+U(NM>)LO\E'B";"552*.-7DE?W)" :].H'2W[
M;T3;K^A6[!0#$#Y_0>U20"+Z?6G\2#(HHL6J/^3V";W<0ZS$VV1G[S+RE(CC
M@$C1:=G/L18L>9D^_.V,9AQWCQA1IDQU^^FG63"+MC+A8AUF&<D1X0%+A=TQ
M!=<=5IE4#9^/MQ8T[F'6NS0ZQ$H0(%]E14L2LT4(N2%JZBCE 5X39,K8D?L[
M/7$,X(:3Q_K,3,E3*P9PP@E%@+K]#$^9[U:K&W5&L?):["F8WKTH,#3, &<L
M/I15\0AL!8 ,05-+<#HO2Q/3M4L?CT!(I6N"+Q4H/E3_ ,4_BY('D2K#Q7HM
MK5)_+_/>U*X-#O7KT'U,UF\ENW\NGD>B EC7I7>N_P!!!("'P/J5N5\J (^H
MDFLES>53]["+-W:C $'O0LJIC&FP8'K[-$,T*A/FWG.RQG3DF\1QG[#,;!Q!
M$,3&2MWDI#%.WFPFM-!,M\5[O'(+&2PRLH1#,R[UA,2(Y& BG\BLW<5&A>N*
M<+SN49?$.(XNEPX(2X50H(IKBB+BOU=1:@Q6D>],MNCV\>B6\?H4'R_7R8T@
M8&D7S;(93-!X 4%[$6)Z"Y*BU&Y!O7KT/T0IY+;Z$'DTMF<W)^B0F]!;T5LF
M?FIC1;78S[W8YV;C:V.=CD# PSCI/E+$FWSW<Z[!5EU>MB62%1XS0!V..Z)+
MB3N<#CTT\V+J1"JX2BE@B%!$%2*UF@9A)A>38^ J@8Z+7M+30WIXI &A=J2*
M048)F'V4Q,6N52(42CZ;  KL8?98%VQQ 4DT43I'$2&4CQ^@HI/BHZV^CM7D
M;=":4_OD-V[?2$O42]/ $!+5V-6MU'16*D]S5O(.OBWMA@"4(:\5#H>X3^+
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M2)G\1U^8N]^,-=G)RCXIV.(<_CNVP!)A!ERL=XZG6[>%Z&,E)BD4<6])C*#
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M%=JL:-.U>OTP94\0LI''YM1%F;+2Y_'IHVT_,X8M1R7 SX>*Z/.@RL++UTY
M-6=:7Q90;-W\F4D_4 20 !1(%'U_Q),5H2QM1]>EQ]9:P))KN*[UXF@.A-$W
MZ>/U-Z.;+L93+L),-66+&D0X,ILC7JYJ[5Y.*\I*,CU',]?=2]9?2-#(\:+8
M=NEC0C%F515J-JD/;Z(R+=%[?2"12DEBJFB@(*E:87#1D%6(,)N']:<5@#&D
M+X&HE.3@RPS0867E"2-XG/:@XJXL6%@2*!O3>@H@CHX_=7:K6 [5Y-1-_KMW
M]N@*[VWT9?7?)^1]KS!\Z<MI<7*R<7"T$F0J<8UT(FURA_MY!.[Q1G-U<V.8
M)O?@\58;3QFB$#RY$,,N+C)G1Y-#(\#KMFNFY%S6+'R=9I86EA^ OB3%?CGR
MK\5X@P.70XF",F$NNOC.-E_&V<<_A\?\:8V4"Y4>(J0]OID:U7/0K<Y$0<2Q
MF-V4D,MJ%J)M4;6J(U#>PO8CN.U>1JY-&AT4D&G_ (U;O0-0O8R?N/14)H"P
MZ*A8%#2BR]'-S& 30KTH"]>%=Q0>F%,K?7#(5+,&&@Y-)J(]QQ3&DU^RES(>
M/H6B;:<DV.\Q[4MJ9?W&1?$'MT[#Z/T467T#/WM05C7@0+$$ FO%J\6H@@V(
M'T*Y!5P:[TQ(H4/3Z&/=1<^%%: MU\CTMV^MB )#9=?*<O;I$H80JX3&$;1^
MH<5Y*:\A185Y %22;CJ;&HQ9 H4#N:!M18D"YIE8 J+2", &X158%%-)C!J7
M7(Q&L%'7$%L.-28H(Z/V]><5*8E"MCRT5\&C*EK 4/*\B*]26!D3QJ&0AF/D
M:(-M%BPY;Q:S19N1-%@/DYFXD@?-V$&=B0KLHL[/^^^W38\UQWQ=QM9!"S2J
MT9B'N)7N1T70T744W[E].@ )(L?H N2"#T50U"]NFS3S@^>>&9/_ +#P^"9:
MKI]%#KM9("JR1H#LE/L+&L^N$+,&A.5I]7E0LI 83D"I8(T?4I#L%VF+-K<W
M[N45E%5C^-,B?;\=XAJCEY7%=:NIX]LL--A@?(.JR\;D<^(Q>#!\6^"LULK@
MT?\ &F'D%0WZ2>OTNI--)XE'#="@>LN!31B%WB(!'B78 (Y-8X)$2]K5WJQH
MBO2A8T!WZ?H6+ U:F\A2EA2NMSZ'M2 !?HC/;KZ5ZU'T !HBU VKR--1%NKK
MX]+$T$)H(M%%-%2M8OM32\F?%?;":98M/!@<RX]A\7V4F]R=+Q?DK9F#FZZ?
M6ZK.V\K*8J>Q)6Q'H:?^- 7(CHD*/,VN6(C[!0H^BU6JU,MZ$8-&-@2K=02I
M$UAYJP*FE!!)- @]"W1?6C] %Z\?J) JXHM1-ZS&*XV@Q@9 ":46%_K]*\CU
M N1VKW&Z7(H=^ER _D058=+5XJ:9+#Q=@4EKPF! E "L:\5KP[&55HDL4[-C
M2PD--KU,=B3X >*NLT-$4PJ-K@*332(M8.ZR]:LDTLIL*M0!)>,7\F M1520
M H^A$4UXBWB#3&QH"Y*M1!ZH+EU-R+$BX1?$=<A;K\[\64\E&KBQ*DB]LY!
M#2,S.%EROZ\8,6'X^]C_ +,:2%H,Z7(RE$DF7"4S%8:;+32\BYOJ=>\>?A1N
M,/3-.W#-3+AX/P?QD[[G"@!2*_('0M@<HEBLXL3^-F9)-QE/3H/3]34@^HBX
M=O%[VI3:AZS#RI4!++8SA;'UQQY-  !'8$,M%J/E?Q%>->T: [MZCL1W$BVH
MK8J?$O:X<FA(+P$M04$*EZ]LU[9KP:@":0'RZ_I4?I>@UA<GZ+ CPO1[5ZT4
M4T  .EP*9@0.QX?/H]CD\FX[-QF=&96?E6UEP8B\,FLY&G)JS\S'XIA7,K*
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M?B?N?I0J*$C"ED%7^@@$%".G>D4DLP 0!J4 *P1B8#1A(I4-K"B5ZWKR-,S
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M]P]#XBBZ4.]6Z8[@4>EJ\31[4*,E'N>@)!5PU'T:RK_A07(%&F8J"Q8]8QT
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MU!M1-HZL:\&-".E 6E -"-*M 0RXI'C'8,JA9!3SL!]PUDD6FD6TK>56I4N
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M"+$DT/3JH(=S8=(Q6(.X=E&3E,SMD&[-Y+1^@='%F9E!%V88]J!!J]^L1%Y
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M\"KY%,Y\V0."/>"5]P+C(!KW>QR ##/Y!&(/T,I8^)H>GTWZ7 KRHL!5Q18
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MHE^X<%HC^T W8?LH$BO,T'!IE4  FI!VJ3^6N0M+FI[=2'NO\>@)!=@PJ%;
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M  0:_7R->9H,#1(OY5Y U?J'8!3<$?NKS\22+'N.A \.MJ/2X%,]Q49L]Z)
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M:,3^*B:E$AHHC48H4H/"@#(P"VKRC!'B:98S0$9<(GA[*5:PIHE8B*,5[<=
M !CXJCRR PQFEC1>@ %7Z6[T*BE5%ED5^GZ43U[4+?2#8R2>X8W]LLWDR)Y
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MDUB/I((^F_1017I7ZQJS,55J?P#?Y?TZ'Z$1GHP&S1NM?I])](A9#ZJ;B?\
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MJ)U1I6#/#&Q-,BM21^#U+(K*@O4'\/TOTQ_XJ/&HHBX]J(!;!B*63Q!!Z"0
M,68A11(H>IM;T#>2T8R68!3Z'M=?!6=@6%,[%$G=!]W&A@D\B^0@C"PY<>1C
M8OC)"X'2W1%$C(MC'&"&C)$V.PKTK(0/#SC&&OVV+DB2!KTX+#8H[,Y8 Q,)
M,3%ED.'J_P#CXUP^::3 UD6-!\@1"&#%R/,XDBN-UBC+U_QSHDUV"H*FE]$8
M5*;D TS!5:<D$EC1KO\ 1^GZ4D@10UG47J7]JJ#>$$M<5)VDD_E>X>0,%J$6
M1P&5XC&$#((^S0NJ"_D"36MA"UCE,2.63W&ED+E6"TL;2.\9L,6<TF(YK[<+
M31$TR@4RKX^#7&OM6-@Q7AQEQ^C$ %E4-FQ1TCR3,)(XZ.VC1GS8I"CBIL=Y
M537E0J01$YJQL9VF>*/Q7$Q6R'@B2..)2[29$"#[I9&,AD5&4J9X8JCD]RLH
M*5CC\%V;H\>$XL\HC&PD$SY-P=>/(XTHBDP\A&1V7+QME#YM+&2,J,(]S0L1
M1[]$%D;J&[B1U"2*_P!2]C$+LL9<,C .H%-Z6H@&C%>E103'<E&%=NDXNG18
MFOV!MT_3I>ID/F#4H_;T'JQ_=Z_43:O6N_3M]-ND;>+G(-$W/7T^J-O)*OT<
M1DJI:3P\8HV(/>UZM>L?&G!,<=?M5;F@UJN30]2>] 4?2]ZM5ZO8FQ!9Q7FQ
M))/175I'5@$\2\@1C^@1C0C:W[S2MXGR(+R^2L ZOCN"18T:QQ=E!M"A"^VU
M2Q@B>+Q9D\EYOQX9\:196NRU*.'+&LK%209N&8ZQM/D94FHX3DFM1Q&#'37X
M,6+'(AO\F(QTVL\D36LOAI=8VTSM5AKCP/<2'U'H#XL[=VG-V9GKT_Q=NA-1
MWJ4EG5"Y  %3JH)7RHJPHPD"$>2>-PP() ((/D@L+$E;^.-C')EQL96DR+,&
M("N.RPAB<>RJHIYBBWO3.HII5HPO.5P_"H_:4,5N,R6&GV<MFRIBWNS%7G<L
ML_@AS9G)9B8R&7%$#!\[%@6;<J*EV.3,"S$PQNZA? XS>Y6*WA4NUQX!-O'F
MI<IY#ALTA:98E.2K5%XF2,)? _\ LY;JBR;B18<_7Y'G)F,$5I;C)3_BUSE3
MYGQU&0!+"RQGD<8!D0/6VA]F2@;=':P/>H?0^A8"FOT!-);R!##UZBD]8S^Z
M(CQM>I% :O#IZ5WZ'TZ./)73P)4A86+)TM]!IE\P0:!N)%"@TTJH3<D&U>1K
M].IZ7Z]^EJM0JQ)CB:[0FO0]>]$=OH@/_':OTH@$^M%00H5*(! Q5-0XQC)^
MC]/HL?(^@:]%B:'H6[AXP"5D!C '@H+CQ,88!R76NY%>36O>D*HQ]LUVMT*J
MQR,:.GC9!6*.\:$G'C#!XB@D6QRE[>-JSL5<F+E''6@E*F"FRX_':[K'U\/&
ML7$WDV#QL8T6/@1Q!$5* HU\@XYFU4."5;2IE;'.T6EQ\)0 E3*0[@^0%NDS
M$="0*:1:]WMYM1=C2NRUZ?7"GFZ=J'=X39A1]2 :D"JSGO\ K$H\JD_G0-V%
M0C]R+>M>/&7"LL#D@E0RMCD!202TDA'8=ZD$E)BS2D0QK7A:AAS2%=<D=/[:
M([O)0B9*<68,109O-A<>@':K^(.2;,[L8\5W")[8 !"Y8 \O(KFQP*=JQ+SM
M+)&"!C)=8\V+&CDS3DM@(68'MCN6DQP\$QD?W.0(?O,%A'69D"2*$^<><HAC
MQX6!'I@.$RH5_9-BKD)L8)-9F[N/RQ;="Q"@,Y\&N@*J37Z 5;I>U0DE>EN@
M)%*:1F),QLS!CZUVZ>E#UH]AUL#2*4$8L@^D_1+XAV%U_22_GU7UZMZ?X+TI
MM08,)F\4^DBXZ $GQ/DJJH^F5P*#AFA@D>O9\ UB?K[4&[CT_4WH=JM7:NS$
MK2?M;W;5<AO<>N["Q%'TK]+5^@<@>;6Z6N K5DP*T4L9C.& RHE8T0\)4LC_
M ,,BQ5OY5E86/EKM.!0SOG\#V&._(/C;>SQ_&>JFP\U$8J8Y*$;W1&23L:YD
M;8.MP-MR'/XUQC%TN-%&$%%?.!@?*O!B9HV->+"BMZ]JO:6O:->T*]M:_2A:
MAU-8XLK>GH4<!NY'Z&G;R9OYFH?Y'L#W(H?R/K#ZQ 5A*+X$9.%+&64*::)S
M7]:Z!<%O!M>]VUN0*&(598V(DQ& ]F, A43)E>UJ:0*SR(RE34:*R")!4HC0
ME[TKAZE/[T1F./BJKS92(/>]M3D>1]X49":!(H7(B )]U8%.5)-46/+*V/CQ
MQQQ2+&?N?*M>Y+32$F*3QEY"RY./AEO'(:RX2M,FZ;W,K&6T*KVC/C)A2>]'
MC^2KR;5C+PYXGFU$B7Z#L;CH3:OUD<@J2%JXM<$0D%0;BCU! />Y)/T#Z']>
MWT7JWT$&Y[?06"AG+O)V7UHJ#7?K>U=B*N*_7Z?3Z5D=026^N_1.SUZ?5!$T
MC#$7RC*!6_D#VMU]/I[6!OT(HFQ9E0"92UY/</\ *QH42+"U7H@^7<&Q-"]&
MQKO7?K^D4B*4@BR8VBDA?-@F]W' #Q6!A?\ ;*XJ077(L5(L3WHT>U,B-63K
M@HBU,29,:^*4:'I;MF8JSC!U./B"&-8Q7Z)_">,4L3,/MVKV2:..*^U9J&,"
M?M.Q@*'V'K[:O9 #XZDO 15RM>1KRO485W7M7Z&D%1R$5:I[79E [T)EN+BB
MK 58TJ$M#&#04"HA6&.\1*Q0X\<N.VM@<Q8?MF#%$E# )IM0AK(UDPC.H()P
M#$9<4D2P1(LTHM*3)3!F @D=O8$=$FA,H$DS"O-W%(PI$\V#1XYDR'D)?Q![
MTQ5:'@U"P9BI#$FL<D.N*V0T.) B(L:!\Z*!!FR2MKQ).L/B@DN95_<N8%>"
M&+P,F,98]%@-Y9N.'SR53&(/B5(&@=98Y(E!GA\SM,0Z],F,+)(GCT/3N:]!
MXJQ(M4EP1<E&"D%AT]Q!0935QTO0<5YJ:#*37N)]+_0]PH/:KGJK T54TPM3
M,J S1BFEA=2Z*'FC8>Y"*,\ +-&Q\EKR6KJ:# 46%>2T&O18BO-:%B/-:\E-
M>2WNM6-$J*\UH?N!L*"7HQ@+=:[&C^T%UH,IKR44KJ&&3#3Y"U]R@I<B%B'C
M->24I5VBA]NNU!B!TN1]/;K^JBW1C>F8 &(O2PHAD9KKY "]>2@T";$_M[E1
MVJ]=[^G7O7Z]%+!%D8H6'B($8BX:&0H7<M3$FI3=+ TT8M:]=Z;O43@#P*NT
M5Z((K]1T]MKJA6@+#I"Y(F6Z1QF010"AK0X.L>CK7%?UKU_5.6&JD4#5LHDP
M&"O 13Q,*>.I(@:92IJ ?NE)6./^!0%5(6O);^X11?O:BA-+ HI%-^P"6+6H
M>D(L@"$B10=81(8H6*8$:M#C*JGVD(@\12LI"FYF_<)XFO+'[=-8&50QFB?R
M:$DA "T?_'+>SFRCN&4D@6JU1BQ>?VZ\V\O=>B2QKO9%51785%CRS&'$$-%T
MC5\N=C[\C F]01/(T$HQX_>*+]Q[\(8C'<]F6ZQHT=:^00X[J),C)B\$["II
M/"/49?VN5CO&\84"N28'W>MR%%V'BTG=?7J1V_2UQ(EP 15_W1H*\>_C7[A1
MN:(- $4SR&E=TJ.7R+7)O7;Z&].A^I;>75U%,.U.ODKH%:PJPI@JJ5)ID\1T
M(L?7I:K5;I;IVHVJPH"Y]MC7M-7M-11A5J\6KP8T18]KA?(F*U$6KS%6*T5)
MI"%K]I7"A$+B1VDB5AT[_1VKUH"_4#H"#1M1 H 7->O17=B:]:(M2QEJ )+*
MP/ZMT/7R:W5"11D:_D!0+I0,>2BDJ;L:D:PE;N[^%>ZUKTJEJ\%) L)3X97D
M TH'B +^E+W86Z6J_125*37+(&J'(G@.NVV+D20ZL31MJ+4=4@K^K I=1V;5
M/;(US*<G7 5D8S)4J&\HJ:WN5C_Q9?-15ZL*"BO%*\11DC6ON%N,A2P935Z[
M]+VI)/$+*I)>.M;*8I\>$-' C1HD7BJ^0"2> 2=;^XU-,5J5U%9">:R+)=EN
M7%J9HQ4S&I)V#2]C)$ #%V*D5W-*AM<D$-1ZVZ*[DJKEX,=5I9%C+93$.]@9
MA:$GQC<,T$\0CCF\:R)V,6KS%0^1\9.P:58UC;S"N/!7!ES.Y9^^6Q]GW7C;
MC>W B28.V5%YQ["+QFD[M)(;_213R>-7[**)J(F_U=Z]*CD+U8?2P)KT^GTZ
M@V(<DW-7-2=V-./ UD5?Z+ @Q@T$45;L8U- 6IHU:A& 2BFO;4&K"WBM$7'M
M+TMUL" BCI;IX(:]I:"J**J:"@5XK7:BH-(@+I%+(&B"#ZNW3M5J_0"U>E?J
M!1(%*.XO>BJL;DFQ->@%Z[FB#25;Q)H&_7M]%KTY!HCOT!(9V61B[&I'*@M:
MC;H#:E<J ]S4RDNZW8V-!48L/$H%MT].GKT'\PP/0JM^"\@]S*_J?W?TBECI
M !_2^(FU#*N9K&6LW#"UL<4%,B$)4R%1..D=XU>560@6#JU6('OFO>-,Q:NU
M$"O$4 *CD%@ #YUY-32**^X  GO6#-XY&&1X1IYA3^TL%KS)(9A09?%3Y4K7
M:7LTJ 5-$0)(RJRQJ&DNPE'D)8WN\1:O9:[QLBBYJ3^%,ZE:].JQW5%44*23
MPK[F.ONR:,C%D?RI9$5XY5-8TGD;]ILD.=:UY%8 Y4J(BR!CA3=FR?V![39<
MI,LLMFGF#QR,%&FG:*;"R9(I7F^YBY;&<*6;.*T<\T<][?V,@/\ 9O0SW-'8
MN*&U>CGL2,MC2Y<E1YBV3(#'[B.A,C4)$(,BBO<%"137N(:]X>4,BAO*B]%C
M0((Z/]!!\O+Q7J#:O.C(*)Z-:U3'R*@4.WT_K_\ "[]3T]?J@_\ -&_C&S>3
M>IZ6O5K5;H*  HV%>@OWO8 @A?XMZ@6!)H$GI;M8+7B;=J]*'<]P6L2+5V'0
MBWT 4O<*JM&X\#&(VIC'8"H9(U#E4J20 LQ9J/IT%('=YX#Y+_+Q%7\:_<3'
MW3M] ZQ2!!0K33-C;O#U#30)I% _HPM?TJ>61HE";/5>)VFN\3L<?OL8@'G1
M;3_Q6WE+(K+TO2M8R*GC]'CW[TM[B1?%YC?W'H]^A%83E9<%_*. ?M4J0QN?
MT%6O2@A?$7))*1(2ZV,\(*31@!_YNE./VNI9:E'[!4C"S/<!2Q6)J:-AT5"0
MWK0D[,[$DW-C<JJJ"14$;/15&K'G$ EV,DJ0M=<&5XYVD-LR=Y&P_%9H@5R#
M<!KAI"2<CM*YN96(;7RA'5H_:T>QCBKF^@.PT<Z2$^W>O;:I8G9O8FH1R"FC
M8'VV-"%[Q0$4L;BAZ FQ85Y"E<B@3?WFKW6HR2$&5_*++96^Z-&]>H[B@3<&
M]/TO:K@U>U2]TC9F'Z=!1HB]$4Y%C>WD6^F_^($&A_\ $-0@^[;]EZ-+8] 0
M*\A1]:8D &]&@*L;D4J@!K^*@6[&@+U:NX"!K "X<"O(BF;RH410)%,K*>X%
M$BC8BQH=SX]I4L0Y4NWD:]:MV%2EBDM=NE^W7$0Q0I=9F5A.?=%!'(L0?WJ/
M%P/H/1;>2S7*L&'DT=?&>QCY%PO[2&PP\>OM(K9.*EMKC15NX$!VT=GV@!.1
M;QF \/I_0GR/7];U^OT6ZQ/X/QS).7AP >"I36+4@O2P]G7PJ$>1E0D"]UA\
MFGP PR,=/*7"B#-A]Y<=/+)A5 \BI3Y#,"YID++[1%( !<43:CXL.YH** %$
MFK&DC4J;*'8$_P!7D+"N=I\9O[^,/G<JSX3_ +YG"H>:9$LF#R752U&\&5C/
M&KTP]J3'D$V1[';(B,<B &LE?WE/WRQJSQQ^#8LLAQL9S')JI8\K#^0>'IKY
M62Q(\2ZV/:_0* ?6D4 4OIV'6PJUQXK7BM#TD'9>S>[+TOWZ!K4XZ3&T<4BH
M&6],MQY"-@01],P'B0&#KXCV02"2W@:",:\&)]N459EKSKRKR[]J92H"W'C1
M-?Q'F*\Q3,QH&04'[ DUZT217F*!+44E%>0KS%>8HM>BC&E 4LW>\E!WI59Q
MC7?+N"U$&WZ5:CU[6_?;UH@V (%'R%*7)M5[$7JQLH>U?IX)>U7%?MI0E,4%
M,S/7Z7JUZ/J>] ^)8 Q@^)F"!OI%B)%8CVW%'M]"*7:X=D;_ .S-VF:X4$BD
M=O$42:'I7KTO78].UH6LW:OQFW[/JS(E>H]*RK^UMVLV]>];8_NVE9+7J;_Q
M]3U'<^PU !08XS30IXLI7HOI[(*^A^@'OPO+ $3M7< 4JEBJ>- @CL*12Q52
MQ**0$"LJ^29L$9:>,QM,;M/_ .3,< S?SCQ"]+C*E2+XO)<(!>B#37"QDN>A
M(%?JA*M'A9+K)-J\8+MLR)CB9>4QPR*D547D^!E/+)CYD.WAXSQ[8XO&<S.7
M>8.3E8.=-C1P9.S;_DUK%Y3&0VPB:.H8"Y?&LTR-&T_=H"I.N"S88QW@;2Y,
MJG-P\3:Z;D>EEUVQ..PHP-:3&D%>TX/LM0A%+'W\0*6 L$@!I<=17L)7VT5#
M%44<92/M$!^W6C M30V4IY'[5:/<>@ZDD])4+K[#790]*OC3FSQDL?ID!*$$
M$BX\2#X(:]"JEEH.&KL:,26]C]K(RGO5KDQ.M$"X-FC6,K,B*.U 7HP)9XF6
M@K%_MUHXZ$?;**:!A31N*L*[=.U6%[BU^G:H2WGB>RIO^ZN]B0?IO7K0JY%!
MN@KM3W()L:  Z6%"]$WH+Y-=2;]BUJO>KV$:D4T2,RJ%J/5Y,BXG%\_-K+XA
MDXF-(A0H]ZL"5C\)&MT[T+7)!+&Q<V97#5*#2BB; =ZB)0K:,)_YI?\ R2$V
M*,SQJ5"GO>E[+U-?KX.2008E+4:^ ]@^%S]7N/,W\WMDL/;V["MTPK:"[;2L
MCUR#87^CTI59Z06'T-&KEH12HUZR.PKO]'&LT8V=$WDL1J,BBMJC0%A&4 4>
M*B@+ &FC->B9"EGFQB1+!WR4(>?%DDD^P04T?MTQ-I&D([T#?IV-/'Y$DJ/9
ME:1M?)4FRTL,3;C*E#J\YP];*T>%H 0W'696T(%)PK+RWVG MWB/L>#Y=C\>
M2SS:?A&7A)K<'7:V1LM?+-F9Y]'9\C(@/AM81)C:R)),?*P4C67 C>#*0QRX
M@_=KC&%,_MG5,%R-+F.PYKK/W20$,Z&.C U+"ST,9Z^UIH M&):=2M*H4?I8
M=/7H!7>QIQ8!+RV:O<DJ.7L#])HB]!Y*\WJY-1>H^H^@L0R^0N03"C$*% -Z
M"J*) H$="+CVHZ150W%%%8F!*C41B179UA8T8%I)K4T@=$C<OT[5<=#""PCC
M%&.,U[,=&&(4T" 5WI%#%D*+CA/#Q- &K"P6]$$= ": M1]1U_4&]$V![#];
M7)<*!W'1F45Y7H$@@*Q,=*A(D'[_ !!I8P!'B>1U^G8QZW0*%QHX<,2X\<T?
M*=8^OV0[$.PHN"I7O] K(4I47\I3W6CZ2-9((O;@G \;E2TK-5Z#K1D( E+A
M UNI(%7O4**P556I.Z0J5%?%4WV_R(CA6'<=[SG]NW-SNB;;3UVE[Y-3_P J
M'T0JH7_ *E \.MJM6*_ADZ+(^YU\(6R 6!N(U!84H#$(!21I:UF"FWMDJ\2^
M4\809"GRFA!,J&G4@3,0Z8[N#A,0VN8@84"F3'\3#J=A-&T6IQ@=QAPU/O=O
M+'L=M@8BYW-_.3BW(I-@_'M7/ML[C_"F=<'ANN@9>+ZDJ_#<!JV?!,=1G:IE
M@WFMS-5E9$V4SPD(6F($3>2Y'_FU#%<[VP8,R/\ ^KAN/8GQQ- F']O!LD'W
M<'_&-?*KR3PQ^Y%.$RM)D><_*(A-B9<1C=E5J/@E(P:O3I*>].GD:_2-?(^U
M7MI0  * EHAXVH]P@NUAT_1#=!Z6MU-2R>(_3H"04?RJ_P!%ZM8/'YTZ&,NO
M@2;UWKN!>_0&O(5Y=0"6-@:/0>M.GFJ+XK>O*BQKN:/2_8'HSHM32*1&/=8P
M)0@-)&%+FXQ4*1@&OUH=@U ]Q;HP[V[#OT!L;W%Q1[BW0T#5Q0-+&2(X$(*@
M4B@A5-F-@R,SQ1*U8T8-8.H$V1K,$122N5B8NT>&48?(>E9(7C)/Z@W(\; 7
M/45E*;(WB6/D0!9JCMY12,[2,61K6IW\>GE*QB1@4)*]&:U>I L818#I^M?&
MG_\ OX[T&*FUQ/<5M16[516UOY;0]\@]I_Y43U-0_P#C^NW2;O&K,I[DCO0]
M*!L>'2,<2*] 6",+1DAJ51425WM>HE(4J"" 1)&KB2!B9H6%30D4V#+)4>K(
MHX 6GQ9*ECQ8UGWFAQZ;EFP4961E[!FDQL==AR?#Q5VO/,K-ER]E/EOQ[BFP
MW"\-X6^=-P_AF!HL'$G"I#C9@2&*8"!2:R,7R&SUF/G0<ST[S:/(B"2$=PI8
MP$".8AI->?!X>\62H>'7P/#D0]HYL7WSRK'DQ]T#8ZH B0+>)@9]4?;FW4:O
MA;-?_L5,!X>E0MV\EJ7QM<&CTCB+%@/I8VCN*%+_ #[U:HP&D4>*U?K(W@E#
MTZ@E:C-P#=NEJ]>D_>I3WJ]-)Y+7@?$@BB"*OUC_ )LBL3$P)O7>@:\C7?I?
MH*C7R+H%'T&)#7M1TJJI/_DZ#U@-^A[]+FYL:L35S1-J'<'T;UZ*:N17?I^A
M4FB+"W:%#7@:LM!$8%0 2RTQ#5CP"0QX1(UFNC6M?JI8&Q(B7R,5C/%"T(QV
M\DWFL@VNMW6O&%,X4-Z5:Y7L3W/0>LS!ZD6W61_%$E8R0MX418M:OU;LU!2Q
MC]RA=4+O5V(%#L;4DBA ZM7:N]"OB##;-^0%]"#9?3('[-MV&[-VVM_+;&U3
M?QG_ )5Z]341O'_A(\@" *C*^4KW-#N>#F^-#Z_HC69;,5-FC/B1>TE@EP*6
M1E5I"P2WG(H!(!$N*I#X*.?L8TK?<CTFEK,Y_F3KF;S>YRE0Q'I-EP8ZY7(6
M<[;"Y:^/L]E)'6+CY^YFXYP&#'DUO&X,.N&:R785.@BCPL./%AP((W79QQ0G
M&EM,R C:XWLQ\MC5]9G1WDF"QT6<LA(2L7Q$.!^[#>)S&D"IG>0CPD/N0<DQ
M<7*Q9,&6(ZV\4R0>2"+VLS 'CE[ _P#T]H"9*(J6WN=+4/4FNUSWIOI873H$
M/G8T2.D3@CJ>U2@M%^H].GKT0?M -Z]#T-34P# QL"(W->TU,H7IZT#]'I0D
M !EHLQ_PKVKUIHU%%U*?0/4]0"3 +*I##UZ1AU4=Z[@6-"@31/>K U^OJOHH
M[#]#&+I$P6/%1XL<X$E3010*,>6=DUT01\&-%9(57'T<V4J<>(:'20@P86.H
MP,)85@B#U#B)$LL!;(D@3PBOX+:W.]9'%F9,3)(EB@ 3Z.XJW<J2\K!C5[U*
MI98HF0I5[TR]KD5>O%05E1J]*%SU*M2>MP&JUZ3]HH^GX\X7O\HCCN B"@I-
M3*WAMX[#=#]NU!(VPJ<$+/\ Q N6C*5^E"H75?\ ',@4_HLC*"Q8]J7^7!OV
MXL;E6\B"91YP,I0.%(E5:64E3(:\A0:]>9%+(MYL_"AK(WV/#'B;S(S2<C(D
MK8XZXN+L]J<]V#LIL!E;/&QAL>0S!-QO=GE#7[OD6EFTGRO$,?8KM.?UH.-0
M8KZ_48FCAUVLFV67QO#CUV%E2*0NQ>*'(Y!R?&J+>Y\]8.SEBGU^S&6-J%76
M\ZS?M-+LY?\ FDE]RGD(,4:KC@W&IB$PUMQ@Q?NC$)-*UQB./9WQDDQ1,WM8
MN*)GB# 9T)7-Q(X[[=OML39,S,;U[L8H_P K&B+=!Z=(K^#?2#8=J-[1M^WR
M'05$A44.C>@ *]O+Z(T 'URJ2M&KTTBBF8L:[V^CUZ?KU",:*L!]$5C5NWFQ
MZ>M"-B&4J/H47*HH,1[  "CZ6(-?I]()H_R/KTNUP5)CLU/',\T\H$F-G9$*
M8$D.;C/(BQIB[+-.MX[@XU'$15:/R5,!&,.IE(Q<"*-(TC15MXV6FB9@L1B1
M+^7+-6,S$Y%B+#L#?RZ 7KN";$ +X^V4#I:O2AZ'N ;5&?W=J8>0\%L!>C*H
M*>/C:]7"UY5ZE184M[U$55E7I>P_&J",P>(-+ 30@8UD1'V]NA)W<=AMQ9MN
M/W3_ ,<CQ\0;&K5WK]*C)\?\+('#W4@7)4J5'DT4"(VIU0UV,GH9I&$@8/#,
M5H2,M">-$?9Q@-L937ON0NPD\6.WR:?791K[(%?^&.H2%C O7+53/P\W49>
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M=!J]AS7FVXED'+LJFT6VR$U^AQ,)-+Q_.WLV%JL?5X>+HS.^!I3BC#QRBQ@
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M%RC))/FLL\*,Y6")*F4M%9;1!"?)Z5B*CL65/*L@^V>0Y?\ 78^/K=QMY,+
MP,..;;P8:\@Y-LTDY!DX^3+'#'$/3IQ?B>;R67$T<.#BP:TAH,14$6,H(:DE
M"',G$^%X6&%(89\*3S&[GCQ]=QS*,0ESP!N\DS-D2AC[MA[A)F(+!2M:B,_8
MZ($XYC4G"*QC87^QRFEOK4]W7/&)1-BF$S2M;WU;(DF\CL;L<V10WI5ZO23
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M .3S;K&W>AUF-Y!Z_0.D0%(!<5$+MXK><WISV;N#Z4Y\5![?3%V3IVZO_/H
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M2AWJUA-W5A<"CV+BS, PKO0C8AE\5 N44#Z;=>QID4A4\:\5OXB[L2H-J$H
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MFDF'W.+R#$9CE8H,<D3QDK,2%F-$SFA]Q7_,*\IC5YJO+7E+7E.*_P#LU_\
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M%7!J521[B5^EJ_3TK]*]/K]*1@K ]O46("L35C5Z)\VJ1@S5*WC1-RDA44I
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M?\9B$4*OX@R%ZV6,)\')A53)$@0J Q%-_+HWHP(Z "Y*@=Z]*EE"4&)H$'_
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M,C!AE$VO>!F8+3*SK!Y(V2!.DB%'(\">]#I%Z>M*;"@;'R:O,D2-:I&\S?\
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M6CZ_0C^*PR=YT4IWIA1C04(T:I<8.9\6MC@"2/><#U^W>?XXU.#.>/18BYL
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MCV$L<<4,>Q5FCK"G:H9O<4^A_P %[4IN/I_2K4:]37:F4,)8O;*]E0=_H/\
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MRI)(K$GJQ[]0* [45L5[A_2A2_RI&5EF4%.D9)3Z/T]?K[_5^OT^E-"PKP)
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M0U<&@2<BLB[3=K7Z![$,#19E:X-2&XKN:'16Z1!68_NIXQ(/8KV*,+T4=0P
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MR$DT^,ZNE3(1U%-;R4^-.7!BDN RFIHER(C&T+RJQ6IP?&8$U,/(FFL:4#R
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MC):#BQG,7!'(7XY<B;X[E(S/CJ>-<[B1QZR-,*S=6;;?3A5FB(:)6#1J5./
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MJQ\%G.LTK,VHXZ)#A<79Z@XF?%N)7K9\6!/)]"D0S]4OCM-=X-N,5&3/QO\
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M@1]@*.#'38*VS-2K5)AI$(O^2A@/++!KCXC7H <!"&UZ77!,38LDD1!##O\
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MY1$#Q4K)&M1J[*B!!1HTSJI$[5[S4)S8Y#49K(9GL22::Y^NYZJ#U/:B2?\
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M:]KL8J$8%.M$7%3*%;I!V9^R^;5Y-UDE\&:3RH,5H*S5[=!5%>: ^5Q<WD)
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MB>2_;M4RA6PB%;+7S?V2 P"J2HKDFU,$/(.8O@M!\QZQI-'\FZ_-R-+L5R9
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M3 CH,:6\>OE:HM85J/&11< &10?=IY9 /=DHNY^I8[@(@K]6M;R[N P920%
M+_RE)H@$$%1,2(^5O_\ 3Y?&LE:/ B+<?PX?=XA&%9/X W'0U-_Y+WAB=09\
M"'(&9QC'D;_4X5.OT\&'2_M Z"DZ]J-^DA[GI,2*@_EAG_D<7!]#<GQZ#U
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MHUG!N+^(=[NS%J%*2"DRL.EZC:QZ?KU-*;BBS!E-QZ$.'4,& HSJIO00D!"
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M )'4L5 % $E$"*54U87D)\.W5KT"&14;VW_A1'0=J0@FA:C:]"US:_I1/>4
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MA45X0BG\+5WN*L/&E=UK[F6HY&=C785V-=JN.B_R0=HHNT<96E0 6%F-R[A
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M$T9G6,)FF\AA!KQL&B"K'$E2P_L,8!R8XS#(KK.T8)2$BL*(,,6.XC,2R&0
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MK7('?TJU 7*B]?J%[]Z"6(+66AX@DL*F95&9-XG89A4_?D'$SE)UF7Y-KW!
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MD* Q!\3>A<T+7'>E/8'MV 7T<CQNMZ-[]@21;Q:U@:]*2QI;"O,V%B%! 3U
MO2VH'O'VKL17B31%P"+WO7?HHH6%"EO2#NJTEA2V6@O=104&K&F4V90#( 3*
MMS*G:87+K:FM>04XM3@4X%,+!A8L!;Q[@!2!W%Z\238V6X"@A@#<>JBZ@ 4
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MJ4/=00,EB!FR7&426B8V=@PV+=MXQ%;L,9,F7QE,_8SD'[KQ$^2"7D1J$MS
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M76'QCKP!\8ZVP^-=<"/C;6D?^M]:M#XYUY ^/-< /C[6V' -=2\"UHH<$UX
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MFP6"'!L3A?N&L(']>4!UBJW]:GF^N/BVNBI=9"RG5PU_70^(U4!9]9"@761
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MWY$YQA;_ (3^4B;[2?+OQ%JI/[;X)Y/@Y.O^0]/_ %.UP=BA&/DHYPXS,<3
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M2-9R DI)1[DG]LMZD[U(US,UJD8%I&!IW[&0*!*Q%_%0P!4EBGCY!B"!>E!
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MJPUE\M2S>6NF4IBS7.(GFJX9#'!<"7#<TVM=SFG58,.UYUPO528_S-PW8O\
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M]Z#7]U&*&Z0T-RA:/= &/=QFH-NGE'M481[95&;L :SLL,7E\GB))C+ 9?\
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MSE2J0R-)[V,M";$ D5HS'("%LU([(!)Y5Y@M[@!]RY#A2)%N9>S3* TUZ;)
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M_&O\F^._-FGY-+E8V,O.,3C^XXW@8^'NM5*!&(PP#DU[MR7D!5PX#]_.RY3
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M+&ZM)":3'6HUN_MNU)&]HX/"L=$#X<=A%&526)R"LCI+$XCF+EO+M+D*%GS
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ML<9C6PP_)=K@ MEX+,-'"/'2XZ>.FQ!XZ_%%\#%(K$Q@*P<:PQ(04@QPP7"
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M@S_H%_)+GD/!/_T_/XJ\1&;_ -4G_7KJ\ ?]<_\ UJ5O_P#J2_ZQ><5SW_\
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M?P %K4%I%-PA!RE'AG1VK*C[S0@B2-JC%82=\!/V.ADUVUA2-I8XP<N0%_=
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MA/C08D&\WO&\^1HY%5Y7C]R**'!T.JPOCC@',^19F+\"S:;'_#I_@O\ &O\
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MDUBGWM7?QQ?&L=5LX;QS$)3(\20O<'P$LA(RU-9Y\X]J2IV+?LV:UOWBOO6
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M23Y.2[^);% 3(EC*U'#>'XFV_$>%\6ES,O938,\F!D\5P-7J]/P#C67O<O\
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ML%\>1V6/?0JM<C5;<QCM7(Y3;92DU%D^,F/FD-B9+ Q9C.D&0Q$4_C0GEO\
M<N&3.9",\"EVI0XN;=L;.D>HLIB8LG]K9#>"Y#TN2WMQY+77+]ML++(?7YL:
M2X6?"0,^%3/LL:*9,I4J?80>]GRQ9,O(<N3$X[\A<E3AV/S?<[K(>,ZA=8O)
M1#N-O/AY$L2SB3.\%FASM/.)\GR/W*0U%;PD<F**)V' ]2JSQ8$4.'Q_13#'
MX_QB',R=3KUQL.'7^.//%9I6CCAS8,:7$R-9#$,?(=AI-GF-F?!/YN?(WX^9
M7&_S ^%OR,CS.2Z^9=1D:B?$^0N&9&[TVO\ D/<<3P-OE\Z^0\KBGPGM8<OC
M$4&!.O"M5R?!W/QYON/G79<,#?'?QK\A?(#_ !SSS_KVXWO?RN^3_A3+V7YV
M_C[L,S!V?'_D+BF@X/\ )^%#FMAZ+F^G^.9-[N-_SWEAXUQ;D/RHOQMR?\BN
M=9_,<S@.YW7"M5\@<&P/S<_'^.19I]><=9_Q(^$<;*^$,K\=<<9&'\ X.MA_
M_'_&*Y7P%C(<CXA7&!X'- _PCO\ ^]^/9FM.LP5?E68&+@>2/OL-2T.Q65#K
M-XT#R9T4RV#2XWMXD R&VR2:]X&RT\1A9:JVM2;/?CFG]I,5519\Y,=-_P D
M8'3;"2:;\R> MON$!7I%F>DQLJOL\Z[XF;7LYH;QR8WC7*6A]V:09@-LRD^\
M+1G-+0MFLT<F3:.7)\4FR1333TV1,:.1,!]UDTN9D IF9%#-G-+GS4<R?S?.
MF-/G37DV$U?>REHI!J^/\JV_G#S7),V7)KERGP^+Q&+3<*:=<GXYD;$W'"DP
M(N+POK8M=R-U"QPY8EP0HV4!ACAR1D".(M'/A/6Q@9$\I*,#2&$&-XD>>&3&
M#)!!4T8!8$$!%6:=XS/*S.D8=M0AAC$L?MY<SBMZR9&9NYB).=9G]CG_ ""=
M9KM?\CY8,^WR\G:<OGA>27Y'Y6-?H9N<OB8'$])FX0;XS'*]YNLW-X]/\:?'
M[ZS>YL(U0_';:86@^./Q Y$FRW]QE\WY/%CY\OP!@9'#M[EZ33Y.5C_'>9H>
M/YV+D8.^TVG;4["'7C5Y/%#)"F&V5]G]WJ\X[')FP9Y,YL99MBDPRYV"XV^Q
M$/\ ;0W_ +6(U%M825V\-IM['&DW)8#65OX16/R''</R+'9AN8T,^Z@,7^P8
M%>P2S8_;*B\:R8U%2KXTT?FRM0]9K@9 L)B6$K63.4WF8@(2LBIY/(@)FCN-
MK"U;U$KD"&1N4!53EZR$<MLS;5U#),%>&8NT.0]H<AV$.1>HLDDK.\=.UZ$H
M(]\U#.A7'R'5<:=@89R*ARA*HF)J*9T$<Z"99KLN1)Y03,&PY98ZQ,]$:#+,
M$:SQ9!8HR#QFK8*<F;F.0_\ JOY7[>?_ &?"V.SV=<;FCGVF#P[-YA/QS_IV
M_P"S?Y$B^+O_ -,+_P!C/,8_RB_'_C_X\_*[!T*3DF!2Y3RC:*9HUT\+RS<%
MPY(7UW&VG;6:EW&FU;+&V)!@Q9DLX$,;.F4Z>67+-*<D!WD!!DV2XM0*^45T
M,.4OQ[^0'RGP*3XU^=N*\MUFAY/D0;#*W' ,N)<;&Y">/Y!V2ZF-VV7'XY=1
M!A94V2^V^*_@[XAPOS+_ #%Y!\Z;3<PZGB>A^8>%Y'+_ )"YUQ?79WXX?/G/
M,W?8&)P/D43?&\W,8N=\7^:=#QC'^1/R5/&.%<P^:MMM.:_D3\8<!^+N7;_\
M?>*[OX_^$]QRK\1_E_\ +KXKPOA3\JIAD)C?B=P \#_'O^KA(;2PF6;3'!$F
M!#DP[#4*];/1H:^!-E+K\TEY<\MY+\HK;'X)./O]4P;$RL-)TV6FIL7.@.FQ
MI93N90L.CS&CR<G"CGQI]5)+6KXE++)I./C'&*BQTV2D,?(=XT29.<<IM#C(
MD')N/Q<K^/\ ?:+9:/<0XJUCZX,%UH93K0RC5@@:EF8Z:8@:F5*.M<4FO>A@
M2>2X,@I,"0"/ E BPV4)BRT<5Q1QFLV&YIL.X^R(*XEZ7$[C$L/MB:?&J3%%
MGQ"IQL55R>6[+[-=\=MLILSA6?DS:_@)CERM=QSB^'\F?E;_ %*_'GS#\Q;K
M'VVPS-TTN1'@P1;:4R:/E&5@'6\FU6R&9JH-C#C\=3'J37B$SKXG+Q[K)CK9
M(O!_M![F.+RSHH>-7*S,0S,Q.0?:$T0=7A6-8C&*U[^#/*"<[*2*&61".:[/
M'Q\')VR89YK-ESX_R7M8VR.#<?A3D@W97C?)N6-R+;RZQ]RG&MP<3(^',#:\
M;X;R#;@?*.QX7'J_EK?\9BR=MPV=<#'_  ;VTR<TPYIM7\I<TSUXWA?%6Q:/
M;[[,P\7/UT*Y&%\F<137;K2B%L;(2/:G6(<7DIFS<EF@GQ!D_<,VVUF;CRPX
M^WEAS==L/&?&DQ\J.'+93!EFDQ,D,F/DD9$&2XS,7(6/.7*4X\6P+XV+E>3X
M^37*9<N/%_I<NAC]G@ K+A/CEQ 5D*14E_(7%!JR'8)E$T[D5D,'&89+S(UR
MO>"P#I^S)A 3:^)3>H+;]#&_),>N8QWBY0S [9B*,K>]BY MCS,:QI++$Y23
M&F+JCDT/)T$OA3,U0(#'!:^*TA$+A71C9'$BJ[3$3L8_?62,2*:5GBEBRO&A
MLW@5-QE9YQ<WW!EYNR;&CQ)4'VDZ9O*YQ!B?EAER8'*'5\&?_J:_Z</E;_L]
MY5^-7X3_ (P_AGQ*778*YFRER8:_)6#=?_D)L,&2*189E"DPQ!8V<8DKGAVJ
M?)RN(:HP2\3T8AAU&L:*>*/'UD:JL.7/+#-4OE+'%%)*^>YEFEAACE>%WEDC
MC>6*+VQ@9.+[6EUNFW$6=Q38X+<&_(;EG%I>#<O^,/D?%^-OCK38FLS\3AVI
MCX_/L]^F-PO;9^3E<0C_  ]^*/DGXHYQ\S\H^7/Q%Q=QIBG*."9N5C)@O\E<
MTS=/\._(6JRLC6CF_+,C:?'_ "_\6O@7CN'M\_.YE\D<KVFYV?X[<*^&]C^0
M'Y.<^POE3Y(YC^:N%^1OQ#^;W'."_%/P=^?F[P^0?E=QO"DY-S;1ZF'00IXW
M!2Q5&&RQDQGS(48Y^(#6ES)..\C7(62AD&WR@S?9\'D"[32.&P\9Q)#.JN9<
M16.-&(UV\1>/%9H9>/3IF8V)J(F.%KL=:QV@B$F9 J[C:F)-ALWE?3QM-/C'
MVH-/S8P[GEOQA\8_,F@X=^./P;P;7?-/X/<8Y,O..'\R^-=]#F"<Z_",XQ=1
M&1!HT=3Q>-JR.)K:?C[Q :7RH:I5":PJ4P+%,  '$M3P^(,8IU44Q\2TB@B=
M"5D0U&4M="285$C1"I7A8@0FLE!R+6Y.))B/L\DQOS7YWVVOGUW ?DWG.=I/
MA_6:HRXF'J$VFS<)EY\JF%79\*"3*:# $<VLW>ZPQKN58^4Y]F89V L@R,5P
M9,58S+ ZMC*ZMC0R,98*A[#*F?R0GRRY%"(5F9\<M1BC0H\:4V:Z8^UV5L:3
M+DD@^3-[%F3;G8:?68GR/RF1M1M<2;.E$1>;E&RE?78&"\<8Y3#!L/C+BF0T
MG,?D31ZGCGQOQW6\J^8?G.:/3\^WF=B9/QE\-;N+.P_QCU>9P_YIV\<[\@YG
M)B;_ ('PKDT_&<_DFQBRHOAGD<F;K?D_5)_:Y>FQL32<(,&XXWL#$N[:#RPU
M]YA+B1LL$<V'BSIE,,G&>6";#<200FWLL5CQV\OL@RSXQ2L^<1HQ:22'Q1\0
MAP,:.0<Q&&<KRR:,(J6("LQ*S8O(Y40#3(0&8*3* 9W).2]2R=YF6V4P E=:
M NR$BC;V\A#(FW3SK>J0W(8R*Y,B.>9HZGEP4ONYHU)F9IL,RUB2>;XID!A<
ME8C(HC1G94%S&;18D]0XRJ<;&*+!C%*BC"D*Q/@Y95D*J%-!9?./NP1W2";_
M (L3+_\ O8<[R5BS.!$I<03>)P7B)^1MMKH]7^1$^HSN8_\ 5!_U'?+_ /V:
M_(O ?C+X[^&OCC)QP,C*C5'R<=IG_P#U#OXR;3\?O^Q3[C/E>48^++BQ220O
MC(QU^"H/"\&5=A\=ZI#L.,XT/LZP?:Y,TWLF7+GG@@FCQVR),@+'Y1J[C$GV
M>5_Q:_.AV,?GD2+#,K+ILYL=]!N,-W@WT,J<B4;"+.?(P)N(?EO\U\8POCO\
MKOD2*/XL_/36\GX>WSIRGF'*N6\9YC\I[+X_X3QSC;R3\7FU7Y9?#6NVV%L\
M]!PGF&]?D6)R?C:1TW"XML^3\$: /ON'Z7CG#]CK</@_QS@_ &)I>$\NQM5N
M>:_D3\$;#\=,G-XQSGFV]_(CE^H^0OGSX%X7C_)'Y.ZC=L\8W4*B/=1O4>UC
M>FRXY(IO<PY\N2.LY0:^/MRNUX]C]T^35_\ I<.:VVTCLL&(S+D2I>A #03Q
MK;9 1(O*232;"3"EPN01^$?(8Z_V*/QR^0O4VTDR9<X*DFIF ,64?M\#9/D<
MR^,LN3.XT8I%/N2H/D#@G"?DK1?,OXA<F^+#JM8RKB87@,=(XUXA\$?)7+L;
M<_CQ\F:R/?Z'9Z.?[.._]="0V"BU]G#9H4%2(EY%!J0**FE5!-E1AI<M+_=K
M9<WNN>"#FB[98*SYG=LMB?O2#B[>?'E3D&JSQM<3@^TQM3QCXXX[+D21;K3\
MCV>GR,+D.9HU@R\O%S6_J(9%Q=- J8NM@]Y,"(SX^"$(A@0XFV;%R4=<D9L0
M6/+C]J1D=F3'=9((VOXBV6Q2I)"9)F\ \@807#$!TRD!D>8BILRU;K.!CW&P
M&MTV_9-6G(=S'LMGS/._L\O^O&+ &_J=CR?4Y>MR^89>5KZT&*^.F<TO!==\
MG[=Y-U^$_P 6XTG,OD%\?:[SG>5L>/:;X8R<(\Q^+.6XW(OR$WLLSXO+]K!_
M4<UWLO'LG+Y%A;75_"/+,R7%^4D62#<<>BR]A\8<<5=3LL1ER\#REQ(WBKP0
M1DQQZ]BD;M#C2)E8L48Q8(Z^TB"^S"AM"B;*3&D3.A@<R:Z(&/$8-KL% ,J)
MABY'%DG/^GP4T8J51;,05F)=LL UE^DK,*>6RSMY)DR#PGG[-+:/-R&I\@,1
M,&J"7R>,@*[^4>U ,?(%)&^!DKDD2R1<X1K\S0HN^\BY#>YA1,!BJ0<6.RX\
M,@K'Q)&DAP)"D6%,:XUPWDW-MU\1_P#2)_V)_+&'Q'_]-E^0.4,'_P#30N$Q
M/_TU?!XL7_\ YL]VN5S3_P#3E?DEJ</Y2_ZE/^P3XAE@_P"OW\\,E.0?AA^7
M7$(L_29^CS1+A2)!)'*F2\$8PCB1'%:+WH[O-]Y!C96HT?(>6K!\*?D!GB7\
M7/RQW.'^"/\ T*_)GY%_.?$-;PWXYXJN<)A(#;9(S2R$Y,'_ '+_ /7[E?G[
M^(NU>5I<;'$U10S!L>!O'1XA9^+I^_A2(D?&V63&VK-%JLJ=Y)#G/-+'(Q@F
M9\JMDR6R%*196.LD6+ N,8YB[XL?BWW?MOC;G[?)UNUFG:;*]U.02XJ8_'=-
MDYD'$^=[;E1U7R;J.(ZJ;\^_B7CTOPG^<D7(-'/^0>YR=CPS\@)9,G8<LP][
MK?D[CL"?(_$-9!J.*;_BDFSR\GC#XC9^![4NUX1!R#6S[0[39?/?--M\=\'_
M .OSX8X#J-3^,W$]W^5?SYRKE>ZC^5>/XD?W'_6)Q37<O^?H^6>Q W,K5A\S
M\I=?R RG"V7DNUV*PSOF%EED\Z^/=J=/N8R%/R'C//@Z'.QL'=<6=<O!(]J9
M((Y%;$ $V.;9NK:8P:PH1BNM*\T87-F ^]F!&5)-40[YA60822J\FP*X'#7;
M)WWPSE1_;.+4RW&T*10<,V'OS_+/XIZW85QGXUYUR_?_ !7^.W%/CZ*5/=&?
M%)#D08IVN)\C_BOQ7DL/-.'\J^/]O+F=FS@!+G,&EV$GC)FLU2Y#LF9DR^.5
MLY%J?=V*<@\C'NW8Q;!W'WTY#YDZ)D;.<$[&=R,Z8DYV4U?V62HEW<JLG(ZT
M?-,C5;#?8&FY1K.2G5ZK8/E<918^2\919N;\=QSC\YXT73Y#XY$8_ES@(R^5
M_DS\/<9S>.<BXUR;5\8G]W'R5#IEQQ%O;4LL#.+D#(D,1RIP:EC),WNM3X]F
M!NKR%E\;F8ADR,L0C/R9,B?E>W?9;+Y;Y3)EOFS32+!JO[&N::['PX=CDRYF
MZY=EA>*8.,VQQ_QYX'C9G-?EN;+TO+.*Z@_*.;^+7"#QGB/.])L<K(^2-!D?
M^O/Q_P W'R.8_BV(W^1F+_T7/'./O?DS@_\ [ ^/^+9+R<?X)O./XGRUL,B+
M8\3X;DX^YP)M>G%-1EZ]Y<W79Y?9_=0?<19L+SY>8ZT<\.!G1M6=L?*3$RT-
M)D^0DRU59=J6;+SXP)I?,NZFH%+RX$0\,V(B*"./(A^V6GIP:RQ<Y84C,/C6
M4U9#FC*PJ>4D9N1=ILGN<Q0N9E QMFF\600<68LR7$;/<;.P7>A"-^I0\A52
MO.5'AS:3P??9"7ERD][!S U8N3'6#DF>L)?*OQ^_$?\ )7\ELCX?_P"@S\]^
M?YWP9_\ IUOQBX4_Q%\'_CS^,^B_O,-F7;X_@\_)LVCQ]L@2\1T)1N)RQF%O
MD74&'Y"PILO#DS91RG@/!N<XY^#_ (+>/FW_ %Z_@WS]>,_]>/X)<:AV/X0?
MAAL(^3?]5?\ U\\H9_\ IU_Z^//XM_Z_?PM^%UU>CU.J@R,F#$63E?&HCR#0
MS[G"Y#QKF.DK#S/..//8+L<N2952$!HIX)?_ -1=_P!7TWQ!\E8L(A3'+1F&
M)6.DR$BR./2O$W"<SSFXYE0^UD/#+A2Y+S1K.%DBF*.<B1&R<YFJ8M)A931P
MK(%#Q1S(<G)$CP9)8P9+*<'8#&9MH,M7XW+G9,4,''=7\E\?V>+R;G.NY#R9
M<C0YF#D?C_\ (N?\6?(&NV63,-!R#*^ZXK\C!8=]P#C')<%N.ZK+B?X]U9@W
M'"<!8SP?&]R'DO*>1?)/S9^2,7R;\O\ Q%^-OSK^3<_Y=ZO6+E<PV/"_QD^&
M?RBV9X_CG@.PT?"?^C'X!.]']+.\1T,Y6'1Y,,VGQ"!"74;V.4UCJTJPZ\V=
M&QY-+GIL-;R' &;KMQQ61.4<*@?$UK2),N([20+[E>-PT()$,:AV@%2^+ H;
MR2!#CSLTD9($^48YM;F1/7(,E8=/PHMCS_&FT.!LQ(CHQ ')LOVH>"YY_P!C
M!(H *?$6N5.VP_?3"C A[*>8</XWSW1_.OP%R[X?F?9,JML7E:-G<10O=L:6
MV7A/X[;7S,,S6YCL-)FJ<?$R4;!P\AUCUTEI-;+;*ULPIL3(!3"G(?!F!RL2
M95S,3)]Q\#,+X>/DQGB.R$F+\F\-R-EN,GAG+9]US'XD^0M;@_'7#-OR?8;+
MXX?0<AY!\>Z>3CWY-Z/9_&/R1S#99WY!<X_&[XX_]8<4X3D2/G9&.(AE$++%
MC$R+C#QF3VAG2,P"W10&HA5DEC5I&3Q&3$5B8**>+R.<DF0-G&<3#Y;NGQ<7
M;PS[?8\Q@,>PXIQO#R=A\Q2>$T&J>3;<HPY<"'8K#CYD#R?'<7Y$\KR^=K^+
MWQ^<78?'>RP>);CE'QQA[:'FW'H<33\ QVC^5/QOQ3_N^CQCG<5^=L]]'B</
MYFNBV/)?C?3;WC?S1)R'A/*OB#GV-\B<&^/M#AZ/9[K#EW#PXD2R:7=)E[['
MV4>1B3;/[:3<^#KCYNLRXFG,>-L\U89<#9IY_P!G&PDRC()9"%RB;Q)YF;""
MKAXH][%B4#,F5ZUTJ)/[:5(0#*>V9=QG>++F@A<L]YV ,LI49.2H3/R0&ER>
MT^:!6;FAF?,;RQ\@^6/,08@&1W[9KFMZ4(WY K>L"GR O@_/\B1FY)E O-LB
MLG"=1R?G7)?P]_\ TSOY(_)6O^+?^BG_ *M> XW"_P#JL_ZXOCW8Z9-5I=,T
M6QRC_4Z\MCX.#C%C>B7!#M3?OHR^VTBVI&5AO='@<@PM-P/DNEF&QY^D<C<Z
ME:6;=J/#8-28N<3)KA,(>+:'V3Q7C<F0>.:2,G2<>]S'T^KQSE+[U;[0G*Q7
M]S"S(G5A/AR,6A]FMEM/<@^1^-\=^0.%_P#9O_UZ<P_Z\/GCW)7K$D4MC#QG
MTDRPY/$-FBGCFW;R?-]\K*OMR9,5X7*/+DB.1LKRFRV8IF1O=9C'&<X1N)U1
MH\LM4NYPM:D7(Y-GEZKD.%!%QO9)N\?7\,Q-[C_*GXQ\GT<O(^)Y,;\PX,Q@
MQ?B[:;'9\("Z7BG'I8)3L>;<;XED_'?R/-R7C7'\2;(BR-8HQTT0EQ>1Z.."
M/\I-J.-ZOX1^)I?EGG/SS\G<*_$SX]U/Q!IOQ&T?RC\DZO%X)SO)DS_C?YR_
M$'E?RM\'_B;^)?'OQ[QF^,X)G'QC$3D_&:JL?!'B#<6E2LOBYEB7CWV[+KAX
M;#"85P+8.(#$,B#;\/EGW.KUSXN''&%K6L%D]N]/&5J:5(AF;  19)<>X34O
MID-^[&+!EDM!ERH!@[$0MR+)]S2Z#Q5^(9H5^,YXSM/)(H7E609$XOD>SO0X
M8L2I]PFG<6205BDI1%NF1!CYF-^1OX?SZA,:-JPL0R5AZ_RHZX"N-?$G->?/
MI?P4W.4H_ ;X\8;7_K]QO;YY^)_R9\?087&; <;51_KBU)QE"&XJAH<66FXJ
M!69Q9?&3B2EQQ(&CQ $87%S">.<6QMOR^#A.+B_(')^(8TN'P/@L.AWWRCP^
M/.T^'^2WQSD\,_)3Y @^6-Y^)OP]I^-Z[0,\DO <PR;C-8-%DNJOC2*TDLK1
MG,R52I9H9:EFA%39+ S9:F1\N):20R/*0Z/@+XR0?\<N.(X^53+'7()ES,S'
MTB8\LF(=IS+C?'XH='\QZ+V]CAZ:%\KG&M;[7@^B2%L+*;:[_P".HI-CL?@+
MXPU? M!+/'O.1:2+#VFV_(C20:/<_'VJP,?=_C3JVDV/!L81Z7\U<[)U6/\
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MC1"U7,#QSQR1Y>>J+L-E([*[2F!+T$($A/A(HDK&14>4WQ<UA)'C,?/=2_\
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MB^2C'=A6(UCC']LC,]9C,8]Y("W(W59.1/Y)\@D.OR(UFTW!>:_+'/O^I_\
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M^2PP\')@.;GQXD<^P><ICY,]1\?SIC'Q2<4O'/:;_L%^&,#C7->7P8$VYSM
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M[&?3[G4Y(DA5O*KFB0*+"F;OWHKVRAXC%G)9F#I"Y-%0:9PE"0*(T+30X\;
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MXVT^#B/B8^#- (=9EQLV(%D27'-O=*%,T$QY(-.RN).U0.RGYAT<>XT?Q3E
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MFW_LY87BR4V4?S)\?QY,>/$\$G$<Z3'?&QL>9/\ ]0'^'6/E8.OF1J2:-&=
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M1<MU6="LF-(=AS*%&W^9CQPUE^$KY(2$'*@5<O:)&KR1%M5$<FHQ! OE#5P
MK'Q9KUD-89?IEGMEM89A 7)%2GM, :<&[E?%V[LRV,C$M95U=ON.(Z;W7PL#
M+UC<6Y!+Y:/8K,D2K,,_3)D"'6MB9.HR7AJ&831S1W$R 5)$I$^(%J)P#\JX
MI$?$Y6?&1FME+8Q. <B5O;W4LT$VGV,9K R_<CQY;ULX;IEQ$MJY;#72!7=8
MLS'V&6)$PT$-1S@B%0]21FO T@9B+ NA:F695?'$I&-CJ)3/#2YV1&LNZD>#
MF^-,D6O^6]S@H_,I-K)R*7&SILK93<KP.7<8S-3/J<W[3(UFT*Q_)?QQQ?YJ
M^,_GCXPYA^-WS=E[AB9,G*GF_'S_ *BO^P7\EM!QW_\ 34_F1ML3*_\ TW'Y
MRXT<_P#^GY_[+-2VK_Z+_P#M$BF^%_\ IB_[&!E_)?\ U8?)W"=AM_@7\IN*
MR3<9YEA/A<!^0>6OPW\+/R!Y1)\6_P#5W\A[.;XI_ +\?_C[5\W^/MIP7=XA
M!?5.%9-@8A_:>2[%7:=,CW6UY[J"LN8S5DRBZ2>4/.E1HOGG7QM/^/.PCPG^
M*<V'/U6KPA&!D&-(\ZSXNR K#V8OC;!77;\EAQ%V^XR,Q_DB#:G7?FUO?D'$
MY%\(Z7*Q=3SCGZZ?#^(]9-M,C2\>]G%VVJ6./FL<4"<GS(UDGW,"O@<C]H\<
MYS[*<<YF)5UG)(S6'RCM@<I[ZKD[5K>1^5:O?>9Q-BLBP2*U21QN),-8SC9,
ML#X\KS45RZ;%R+^#0LF7_P >TQM)E\03/BCDBF:484V3>**,C#P)9ZUF =5@
M99\I-Y(ATF,Y9) 6AV6)YGXQR_ZKFW%]JD9Y'R+#3$>4R2Z@KDX>ZFF58-9-
MF38^+BZS%V>;_8<UY!E2S'[X;_FFI7_AQ%\GU$(2.-CXY,A2+E^Q>7(S87>M
M;C6BY3@OM\_B^M76:?$S+2+."VPRRF-N\NP^0]Z,'7?"W%&YIS?:Y=S-D,6Y
MSB&7'^=N,OFXG&?@_:?+7RJO_5[^+7.VT?\ U3_@U@Z7YI_Z3/QIYAB<C_Z=
M_P I>(9'_51^)ORE\!2XF7AS+B;O&BDQ^284:9&[P#63R+7Q+M-_K367R.[9
M6WW4HYQL=M!!F9.3RG>XFI.OT7,>.YORASK7\6QM+B<DGQ]7(N=L.6[+G?!)
M]QOOC"5X<OY_V*:3X^V<.]YIF_'7QWJ]6WM0PXN+)DZA,GG&5I]?\/?'G)N3
M[#-_'G.Y)S/5_&V/H=-SW\9='\@X_%/@K X[A[7)7C>)S?3\NYBW&N,Y6*5Q
MMJ)]5NL?7G7<IDP(X=QB9D.5]GF8^9I6K9\?GV+Y''H<&3/_ .)=W!GS3Y?&
M3/M.3<.EV&?O.!Y1GSN+A(MKQW(C6;02M))QIF9.&S320Z(XRX_'G(_HI:N?
M$,#3/99W%93D5E-8Y94C,< 9+5,4%32]F?L\UZGD5BTZW]\LRS%FU<I2?A&>
M%;28^)L8)N+Y>(>/Y<\+:O-+)',KC*QHW,+>U6KS0*/C(,B.P:ZGW1XSQI(?
ME"(G4\'R5DP$L$RQ=?= +,)$V6-[D>3G+AY'',R:1(\@W:5I8<F,>Y![N-/K
M-:N*F1--E,P\J#^V(9':L>P0KYT\5Z2.U>%J2Y#(!4EJ6ZB0(U28H83:Z/QR
M=9!DXW..'-I\K$VCI'I-#+N,KD>NUV=+LL2#<0<OXAM=%/H]R2B;B25/_P!2
M1\"8.E^2_@GX)^7OR=^5_P#KU_Z8_P ?OPD$\D>2L<RHZ3EC&P*S3XF''L=T
MV;!L=5B;+(UO$L76#0;K/V6U^/-Y/'E<HTAQP'BRL72<E2%>3<3TGR-H.1\7
MVO"M]CR )DYYB,>Q+5)E$T/!I,(CR#WESG K+GL8\D+#S25F@^?II<<_"&^0
M97PGN2^GXYE^Y'L(![6=MOM3#R4NVGV;RELUH\7G_P L8.FS^._(.)LAN=SI
MYM=^0>DXWG2;K<:[B^'M>0OL]W\,\FQ=?C:KY%UL6-O_ )$U#P_(/,X)4Y?R
M@N<WE$GN)S@1R:;G3"N.\_=&T'.Q*FLY6LHU>_<C6;U@VJY"P&GY1<:CDBEM
M?OHW$6UBDK[@-4LHJ/8S8K\;Q=CR MP,IB[?$;6Y"D.94;9YF[PE5-;A)D.-
M \B:;C^6QP,$XM;/8A,5\EY)<@>_K<2 +4D4I7*B[["7^GY= [B/)F=BSR%M
M#D!7G3R9X,E3LLC(+\=Q8\OY'YAOAJM/\>XDBPX495-7CR29.NQ_%/X#=9H@
MQ]E_]J;+QS[>%Y!M!A1YNXQ8V@Q,(E<J*8&3:9-ZY)EE5^9MSX:O\?N.KQWX
M[V,S,\DC7Y+'[D7S;JE3!^"^,PXD'&M?[$$,L<=323Y#P:N)1#A/(8,.&!6R
M,6-GV&&@R<]LFI-1DSU!Q["%-QX+'LM5CX<'S=N\_E&WX_Q+1_'^IY+M\KD^
M'\;_ !*NNU?*]%'KLW#WNCY1\B_$L^$FWY;'D>Y\>Z5\OE'Y6P9&?PCAG$,/
M1(V#!DIE0'!P]+QV?,Q^"_"FFW*0Y>EXUJY^79(Q=OR#D^T?9XO.A/P#&WIU
M&9A8K"?684@WFMRL/6[;:*O#>1ZB7,TV?BY<FDX'S?;RSX.^@S5@VF3CNF=!
MDQR+@.^9J-3D)M.+83J_%VBGR.*ZQ<3D7'EDDV?#,>&3<<1]QY.'NPDX=$BO
MQAI6BXRB&'C,:U_KCU?LI-,UA.3;)8D9O9<Q@%S)$K)EO61,*FF-ILAC3Y0M
M-E"S97[AE%0DW?"R2)>)[OV#Q#ED:GCW)=?.C?TI$?(,6%L+?P2*FS2402+)
M6-)[3X4_N),GFF3YAFGO0EKY#ABFX]\<9(EU6.?,; _M'B'64(CR-(F_A2%^
M+9CO7OA4PI!*F=@OYQX\.OK%1I1.@1+7+J0(O(MCJ1&GE<^=E6@I6@MP?&S>
M(JY-"(4Z^%3.29I&*\EU2[->6Z'*U.PT>\D@ADRGSY<G%7<XN^UNTUD?(=<=
M/LL/9A(_^]OB&)SC_K8_Z)?Q!TGP#^),>9[D/W*K29T2F#+C9=AR3#P(\[DL
MF3+F\SGDEXG,9WW7,,GG>9QG7)B86)MVU7/V\<[7ZN-8LM9\K2Y''^5>WF<Z
MX9B_)VDS]=L-'L,U9),?%C=@L;^S ?VX3$O%*2V?-^W)9F,(R)&Y5@220_/.
MFE<?&,<NMS_@C9?_ -(XMLE$>7O8UBW;C,K#DR(I>-N63>9!QM#^2GS5M=9\
ME\)_)HZ_!Y5^:20UR7YJW_+'Y9RILEX)YGR=1R"?609ORMN<?(ROF'>,-C\A
M968-[R<,F=MA>;9R>Y@[Z:$\?YID)7%>;,LW&.6I*--O8VAUVUN-=N_;K7\B
M*G4\M\*UO,PPUO+5887(!,,;*::N,\-R]U+Q#B.)J<:?#QWQ^><.;+CCP)L2
M>"%(8<W'542:&$ZC8D/AR2SQ0Q3SS<GV"1Y"R^;8P66L<>SD6-LF%C'RS6-D
MXG%,Q=GHYHQ:8UIG2&?/(HY&:BYG_+D_%>6^U@^9]P_V'!](\6/B8#5H]:(T
MQL<1C(E5%Y+SKC,$DW+]9-1WZ2B7>Y4)X)I<O*K)!"J#'DXP,=;/(L.69;A?
MD#$S>7?(,V-AZK!R6\VEC)K:J9,?YQQD3CGP% L>GT^)(\"8$=+AA3!BGRGQ
MIDJ2+)(@U&?G28/#9YZP^+ZG#K^BU\T;:C#J7BJ25^6'R7K>(ZSB>!_7P\EY
M!+M=KP7AJYS_ #QS?CGP=\>?)OY,?(?R1LOQPXH_$N)?CMH^5<FY=K.%S['$
M^'^/8^IQ/D=SS'D^+AZ[2GBV5'O1C<?3";CW 1++B[)%Q<Z%-I6-@:F.''UV
M/*LO%\5G&CCC&;Q"XV.ST?'X.8_* RIOBW0;(ZS,UR[W8Y.DP,C'Y3QO-XY/
M@+GZ^7 W?W30A\9\Y'RY,V'(2*?*VDC<OGS\?&DS]T^0^3L'I\5I%SM,9!GZ
M.1V/'C7]":31 B+1^#?TBUY=@U.RVR&_;D,;YA-9K^)S9?WYDOD<K)N9<L6G
MRP3)E@F7+/B,H4F5(#%D%6@G%:K8RP5I^3SPC7\\V$0Q/D3:25)SS*ECU?R1
MNH3QKY3Q9*U_+L/*3%W8<ZC9J0D@<;#'+)(GML'#GF\<K\?^)<AI]7BR7CV#
ML(SX^Y&X:%9@)=YAB2'CC,F9+DWAT&/(T.UR8-+#AYYRY8I45<D^Y'&JJI\7
MJ, &.1R$\C3$FD\J6]6IV-F1F8>-*OD74%98KC( 492+(G*M&,V'>X,^AR]5
MF^Y4V^=,? R,K;;KFG!M=F196NR-!E?]GW'WY/\ ]<7X_:7$XG\%8N[22',W
M90Y>[R\:7+YM_P ,FSGE.;F3M-J\/#P!O=UE;S%X?')L-KB(8GW1/^U\:S&S
M-+LU,.9R;!&TU^.R*_"MI]U!SGXRU/R'KMIPW;Z+88&D<+_4L%3&=8XY'AJ'
M#>.')UMPVE\G@XZH;DNG[?./'+Q\/X\8LKX+)ATFDWGA'E[C_C.]#38&1CY%
M:'($!VLXRM5^;/Q3L\3E^U_M8&CR\J('?L@A,^VV"1F'8-E"#78V>9)9_;,>
MW]V)\W)R$$N2S$S!@CGRP,Z: \9W#K+Q_DKQCC'.?;73\O25,3DEQC<D11A<
ML(;6<U*5IN:,3Q';96RD^.OCK*RJT''L76PC+2,0RECG:],R+EG#K/-@SQ.<
M7W0O"VS3!P7D.*=9Q[E=;'.P^-XF2TTDD+@M$;-F^46VQ;FI$\EW$"G#^*-A
M]SHI M-'=L<^U*"9L;(CQ,;#^4-TVBX+P?6QZ+C6PFFY9\]<3U'ACX.F:1XX
M,/709FYSLM,G3P3UL8L;$CFB>1\;'9CK..XV5)CX<&'B3-Y&=2N0TMH=M(%'
M(G:=_A+CYWWR/FR%JE \F2LY/*#\K.0X'$?BO\/]-_M_!\?!2&,HWE#BEC%C
MJH]MG Q&F;$PQ"(I%5<F65F2(HJRI#%\]_.VL^,>-9G(-ES3;\QY;-L9?B'X
MIS<+"^'. (V#_P!COR_B\Y^3OC#\<6Y7A_%_XL<6X+B\*X;##,NFA@/RQSO4
M_%? <?Y R=EJ=9HMWO\ )^/^,YOL:?0XF ,EEOO9(T723LZ8#Q1#7[?!%-N\
M +L]\L8VG+,K(.Y;E7*MCQOXRU7":R=TF/K>+N)*PL#']WE'&H]KB<FXP-/Q
MTX\6YU>LV3SQ+$)ZSXD(V4$T1W.$1)F:U4*8-R8U,AUZ@9VFC<R:E%9M5'>+
M5+2:T5_5"B>UZ=["=NV2;'.< 9TA6MC,"<W)"'+R_&LC-'CD;(>3['PJ?8L:
M^]4"/,%8^27..6O@F3RP&-L!UMB%?%18B26!\/*AS$U^\VFHDXYS-"./\G@F
M71[!<J)HA(NSPW!LL5<DB$^E^*#+"^O9BF81[4SB.7'D:2*20Q9.9&)(M?%[
M>7B>$V3AJFJP]SBOM"L;X,F'E!EC8,K]G]P QI4!*TW[:C-P+TGJM@) &,GB
MI5[E''3)2XV4RHLFP*ME01RR<OXE]_CYF+F<=G39P9T>D6'5Q3S296PY%QS4
M\CQ_R*^%=AS?X5^+].T'Q?+%/K8O[&21HYY[3:Z)L?\ K9'0)',BZA<5]UGR
MYTGQUK%PL7$S"V5NO^':?&V2)\'>Q,K\8F&=A;#4#'R.'[*3 V.JRI(ZY=\?
M:?F^NWO <_CV;/IX_8DPXT$>"[RXV(+#4)*D>ECO!J%\>3:8&/Y@XY#)I^._
M;XM?&7)8\;#U'*(C%M.6+'CR\[A^ZXOR[WVT>V@*P;W#5/F7XHT7R3K_ )E_
M#S8Z!.4:R+2YC'[K)U6K6*)'$FPY'M!BXT&0S229+,-BR^.>JDY"^)=01$A<
MP1D'5DQ'#R9HSJ=O/"NCY3D1-J>6&18>3R%,?E(4X7+&=_BS#W?,-G\$_"T.
MEPM?BX>LQY=L"<?(9VQ9*QWK8ZV/*AY/P_QESLD8DD&SR@^-R'9QC8<@VF1&
M^2P(D>2H[%XQVWD2KR+%8W$88;B%F@^+YY-=R<*2)(QX^%:[8G'38[2?+;Y&
M]O99. HCA^$M/_M6Z@R]=J FQW\PB&##(^3)DLZCPVWAXY;([:V!I#HL0&LD
M_P#)-X@Y(/FY_9NI?V\JRWP,'A'%X>&<.RE:G0DE.^>A3'_.[=[3;:3X*^,=
M1\1?&'M75,?]T./:G\PT&,L<<&*Y6'%]I6A=JBQ&C=XE%?*'R/@\)U'R)M^0
M_(.U^0^3XF*?QT^((-G+@\-_M&^:N:'@_P 9<-_&3%EWO&DXWQB30..09NJU
M$&BU&YV.IX)A\\Y)NOF[GG!_BC8F/A_P)!?6<<P=9')CQ0/+B29#;OBN9EQ:
MS2[;7UBN@ ?&8G!FR6P>*YN4B<#UT FP<#5P;+7[39YV=CI!+HXW$VEEDC!F
MA6#EWN;>#79N1JMI,T>!G0B3$FRIX<M9DAE;;82>63ACVY<$BL?! 9E)9\03
MU+@?N3!#DX*FAA +]HE!O*F>]2.+9$EAEMVS9K#.E!K9Y++6=D@C,RRQR\SR
MK,RE5I=B!3;!04SF][&R"S:Q'E&)KBU1831C7JS+CHZ5A3^W4$J4T22AXYL>
M36;6'+6;$ECKC7*LW63<(Y<N2^ORUR(<K'$R[;!"%1%-B\;UBZK>X!"I.;QY
M7[<C7>!K:@PS0R-DXS2F%N-ZJ"*%\Z3+GGD\%VO_ )-=.JB!F<3J/* 6*$N4
M5BJ LL:V*CNH-+3>)IU+$Q$&P558$RNS5LL:22LC35/ T$<"#)')>)ZC+AY3
MQ1./[+ SC)%CF)7>4D94;Y(YKPW(UV=$WL21XO'0+ZTF'%W,ROI(L@''QL#$
MWF<9#APG)R=-$,/4X;E\GFV(^-M/BO*);>X2NVKER=5G[C$BS(,J*3$RN!;5
M<O&U>?D:F/8XFBY9B<YX9L.+R/K\9F.#'YXN/^W!Q RQZ]17V*JO*\>-8/EQ
MDCT?)N9PZ>7XM^5_=P]/\MQ..4?+$$&H7YD.?G\#^3<''@U7R[A^W#\L8Q&3
M\PX\5?FG^86^QEYM)\EF7XUGWN7D9;'%UKY:8F-L-J^=GXV,8TE:-5S6%LP1
MJF2I!1":2-A6MUPG.!I9$K%UMXL;#_=B^:+B[2;&,.ZF*MO<E*^%^"<G^2][
M^.GX_:K@FIQLO$TT&7R@SMA;@R/K\I6.-)VQY;U%("-CK8\N+EO$E0Q8 BE,
M#QIER,K-8E%J..Q45RB!3OL98D"']F8K/'!E/I_D"!KK)_&4+Y2RW+I[*\(V
MV1SKY8YWNI])PSX@XJ.-<0ARDPH?.6L4,:C (S)([;:=2Y4/-I\4LVI@$4,\
MEJ:425D_^28JL>W?R'.\^. @>Y#DQFF!%+'=MX5C@^/L7=_+?S[A8ACC$++4
M4/D5A(7'P6)^U1652""\\D,-JG6&%>>\UP>+:CGV[Y%\H[KE.!N,W1?'_P 1
M\2@Y+\?_ !#/%1PX-5KN8<GP.6\@VN$V;'PKX:S]E/IN$ZCBD)S]EM:SOB&/
M>YG%=3\;_'K:*2+9EKQJL<K!M>N1)AZ81TV-A01<AR,-X=?@Y.4V#H?$Z_5K
M$'9(TSDDOM\DH<=LC,#\9GD?'U,M]3KWPH<F5]A(VIQ<K7<OXHRG6;"7%+R8
MXXC!M)WR9)87K.#R+E1]Y4-VD\0 ";6#*&(B6C'>E@\3[9H.*+DLT@432B^;
M* ,_(-;.=0VSR@S;') .=E7.7G@KG9H896T+.<X.</+>1]06G7C>(&;5:MG7
M"XR,B'*XQD:]D@>,IY XL_B<.0N&2Y$37T6V%28:S5I-[F:C+^/.9P;2%9AX
M9F/%EQYNO?'DB%N08)+5*UHMEV?3/^[;1M+/H\6%H)-1@02X>3-E2^PBAV#C
M;1E:PG;W-?* LA+20IW5O&HG8'U93<)8C]/+Q+DFK&S,:4*Q>!!7LNU'$,@G
MPO%-ABA*F+XE9V6<K%WN+DC9YFLD\,?.EAJ#-5FE(]C;Q%-EO^-:[<XYT+ZJ
M2"2&59X9F6#3N$Y/OX\J3)CGEKC&K?)SLGQ@BU +3\N9-NGQI:#)V*C(QI$$
MATS--A[K'45P;8'$R]1E+EXC84;5+YYN)SWB3\9S;/&^$4<:P T!82G_ (^8
MS )\TYWCKOG3;3:G8\-Y9/K3!\I&)>=?.69EX''.=;?";#^:^3PM@_D-R;&C
M_P#RHWT%9GY4\DRS\0?'VKY;L^<?$'%/Z?EG =-QW:;><L.294N/B<8XMFY<
MN7IY8#L-<RPYN&Y790A8LB!KI!Y'6ZTY#Z;4V?6ZI",/2*RC564X+1(()%&*
M&*?#GPSR#Y9Y#^-_XYZ/XTT.1G86DQ=GRB7,EP=A[M:]RPU>6R'!S0PQLA2(
M<@5#.&K8ZZ+*CY-QCVGGF:,["7SD2,BHHK*H K].:'V\_$E9C%Y%)4 3G,<\
M,FLG&1CLEP\48)8"ODGDBZ'C'P#J)M=P;GDF7N=UK,./%Q9I 'Q)@QQ2#2J5
M3;R>VN>Q=\5/*328O9 T.+GSK&L3&TQ)GRFLN\?V8OF#D+8W+\1B<;)%.H+X
MT09_G#F/^M\6^)N)0:'0I#:HH;F+&0/'&2T7=_Y32"T4*AJ;(>$;[?XV+B_(
M7*<WY,Y%RKY'XW\8:C;?(?.?EZ?X"^$T^/-#D[G[7'^<OF7-A'QA\99.NU7#
M_CS5+D:O78F/!FZO$EG&KRL.'8Z?-RH8.*_=YFEXCLXH,;BN96/Q.8TG&H\=
M<U)4J?39&4[Z-2^FXW(!@\=D6AI642:(FLK0/()^'+(,'B)QC)QIL@RZ/(Q
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M@I+L$!#"XH#L5M7[K&1Z\F(L15V6A(J4)1Y2(D@VJ!5DQTFK>X/NX6<K2-)
M[U%Q^&<Y>MP\6.*3_DVVM5DB+BI\.*43:+'ED*)B3<MWN1EB#5(D>;!'?B.
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MY\/!,!P:C92"5%<BP(\G'X#G#-XZ2"DY%LB4!?FS(DVV%J,:+5ZOXQP5Y/\
M)V0ZHCRECAAB-=%Y+)((UVK($R79YM=CLS:+'\%S&"KER>3H_FQ),V0UQR%@
M%^6]A+L_R&Q4(Q\D$TZW.?-'K=;R_F!^3OF;3X"8F+''<Q8]J \!C"]#R]T,
M4=E9@\ZQ1Y6='!#\L<VR.2Y^4<70:C)^,,SY(VWPW\2\1X#K\K::O#BW^X;D
MDW'>+ZG RDP(-,G&MEN-U%C>&;FZC0XW'X)FGVV1F:63%QN&<#:*7%U/@B8,
M*5(\,0R9#+61'&BY9\:AQY7DT:JL,31 &:)::>,4V3'<9"FEE\BBL3[2W]N%
MA)A8SUL-#CN=OH7@EY'B8^7FP:#WH=YQI'K6 Q8YB\WR$5A(F.*DR8*(-_;H
M)XT8[$(32H;>!I9E8&>PFG/CF9/;89H%;/8J5V.Q45M=I"&S]D"N=GLJ9V<C
MKFY; 9N:5*Y@=N/R^<G#\8FN)X*^.CUZD:36*RX> MDU"9%9/"DG;EOQW)/%
MG:S(U\L$C*8I"P1Q>,DUJ]G/KY(SC;&'XGY)+J-ESO1OFX?%><2Z>7G/+^.3
MG!G#F#PEBY%$^.=-D#SVFKDV$'+.0IIAQ_F<V/DZ7:C-BCMY,_[,YG8$>$NL
M<A;6:(WIE(*W4XYNH%Z4V/<5W-%33 F@RJ.P)[T%\FCA-F\%K=Q^:0Q,M94+
M/B;G7".62$"19/:BV GRF?#RD5-PT >.#,I,9PTN.N+%M-R\K1XXGER?"**-
M#F9.+B)KL-R6ET,1][;QA,W9<8=3HM[[B:+.BWNNUX?#S9X?=Q-SKECS.";J
M;69>HV,.= /):2<BMKCXV<O)>'_T>1IHH_N%PT-9&)'[/,<1"WSG@*TOY&VF
M^3(M=%,>;ZQ!M\#$$518_?'@#G%Q/,+HS)6OX1FQ9NCP%?,R^$%DSN$L%RN,
M&!]'PL,V?JH</$RL-O+(U(FARM&@&3QU778<-CE!XPD<N-I!C'"U!\<?7^)Q
M<4E)('K*B"IQSC>RYCOOQ4^!-)P/1)G8NCP=YN,G83.0*+E:AF93K-HT5:G=
M@C%V:R#%V!5M;LKC$R0U12?MC?MO=3'E0\KXZ^NG\BU1^5PI8*/%>=@_UN"6
MO#,8UCR+MLHQ)C?&<_LH3VF< ;";Q58#R/Y1Y-L(M;J?Q\TK8/!<B3QI;EL*
M)GDQ54#(?P7;3=BI+:'&5Y== L:9TI RF+.@9000V4UDY!)YEYO[[\E1VCG!
M)CC#R_DW\ECB7%_Q0X_)G00* N'BDJ,<BC#8+#9/:\#E1%BF,6.V85\J<Q?'
M@U6L>42<=BFFQH\/5+'OXHIN0<Z+Y'Q;(W-]AQ?B6JXWH<?@";*;(FR>5YVI
MU&EX7K-EN\S.R^*<=GBQ,#AN.!'BXV$N1G@&3-:QDD<L&(;%9@VL]PQ8,49Q
MY5CJ/)=B"33?N9,<$KC(*O&E?< !LRU)DU&Q>I5NFVC#5O,"-,V3&23%GT:9
M.-L=>V-(1&N-,WC+,6 L#7B0"O81DT(R:$5>!->!H3]A,P,\]ES<@^.RRS6V
MS'<[7/"G<;)@F=G'SR\U6&5F/63D/XY4@:H<A'/$W/O\'4>7#L5G;CNO_;IL
M(*F)A*1#BLBI!Y5)J%R$Y/\ %^#N(^3<6SN.9\?D&A?QJ%^Z^,@UN?-@S:O/
M223@^YAWVGYYP_-TVRY5N-SB<YT3-[6),(ZW^(9L;7,,?+P)(DTWR9 L.9#F
M>3?'.V:2#'9G3(R$6LA_=5H0'UE_!+$1@J?52A#8S$D=B#V)[#O0M3V![5VI
M^]+':FR/;HS%QD(93)KU$>SQVC3<832#9P-BRRY@LCP/4^7"M-!]XT6O2.C
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MKUGZGOLL9T?:K*BYD" + 7?X\$D4O!X._$(P!QQ$":?N->MABK8)&&$40-1
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M(_;6)BT<R%*::[8Y6)<78"2E87+TC%J]I*=#?P %[5+?QE5K^T[&/$ K'Q5
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MQN\N/30E:>.U/$U/";216(0BH&*5K'#G48)DK4:BYUFKL,;!"K'%X5&5%%P
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M1*#4MS4R&H&93A2DB]Z!(KL0;6,:$-":NM+<&(JJNWG66'(AQYF?#3Q4 "I
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MYX=OAE8NAWZY4//.+0[G QL275YVMF\EQ5_?_P!BO,/D3A7&L'E7_8=Q;B/
M?@CYTU&@^,OP*UFUU'Q1^*O*OA3EW&N*?.G'N7<US^6X^E_]D?,>IFX[\F<E
MV,6CW4N;K8)Y-G+CZ':%6T&V+1:+: _T>P"X3-BSXV0LA8XZ++E(0@G=D9@(
MHXW:.(Q/Z#,E J2>Y^Y--/<9,[&L^< 9FPLQV85^0NVPX=\O9>7I/D#;\FR#
MD[?DNR?DNQD::3?)]O-Q;D+ZS=X?)YN/\ZCYEK]U@9>VAXS\G\ YWHMWJL+9
M()TSHIT^7/C_ !.0Z3EAS..9' >;97]9Q_G\;-J=_A[/#_+#@6'\8?*7QN,I
MM1^,'$APGX9_*/XPPOE?XAP.+87Q7'C2"09FSD&7_P!;&]FV7QA(+$V!@8)7
M+^8Q:+'V7*7SM1K"F0O'8_+/62SK)%-%+V,;$,QO'-(8J;+O65(&&VB5QRK6
M*QY]KE R]A[.2NU1F7.%TS00^<BM-M50S;9;3;A+3[:(LVSCI=DKT=@GF=@D
M@R-I';,V*5M-E&!G[B)5U&W1VT.W4#5Y\4R9NP;$=-P0-?NFCF^%^70['709
M*RP2Y  ES *GS14N9=IIO*IW(J:>])*6(CJ!"6PU]N'EDK^,996BR61M?E%Z
MPH2ZXV,J5J]C+C-@[&#(1F2^#L&@;7;&.8>\"#E6+9IM)F=XMB5(E&9%\GP;
M_BVE_%O'Y/C?$TO%]-L=Q\^[7Y7_ .O7\N?E+\^/B+1_BWPO\JOSE_#&'XR^
M9_CCYIXK\Z_DA\1?CIJ-7+%O,37@1)K'+1Q/^[#DNV+':D<!9)1;(S%6L59\
MDG7(QC7#PAE\B2-=CR*26I=FY(V<@)V\H+[J85'NIEI>03 IR%[Q\E\&Q>6(
M*PN4X[C'WF/)4>=#("(I!G:?'RDW'!8Y*GXME8HEP&0S87:?"8B7$=:3'GE;
M5\;-30B%-NO_ !Y<YA;9;(E?WS/K=29*BQ8\:/*RHH1G[@R.TY=HX2U32B"O
M&>8PX3>6-C>(*=\/$=JP,5(8ACB;6_&_&'S!J\9\F*+7^=/JE GT,:NN"26U
M;$MJC8Z>CI14FC1Z_P!?AJ;TSDO6+J1MMIGYL8&=M&6LW:,:R=A*QFR\AZE#
M&>308N5-KM/H\-\.37HL,N);5[!<9]7RW9B+$Y>JR86[X[D#4Y_#KXFPXDZN
MG%YRL&L2GCA 7#?);5?'\^4=?J-1I8M_/C9>%\O_ !CR#996+\/_ #/'%G?'
M6RE@YS^/N1F0;$\OX#M?Q^^:X99=/GJ\>NS%R$Y[PO\ Y=3%+[NCX7O-F.6?
MBM\>?).5I>(\8XUC>\!2^;G)E$:X^3YT^@U$P@TFIQUA@A2K1T&B%%D-6:IB
M0N]S<Y8,3<Y,>4.2312:WW)HD:*,3[3%@63E6N0X6\PLIAD1DS9*A,W*M3Y0
MO]V !F)XYV80-CF&V?EFC.2=9D^_@_F-H&TWRSNQ,<C;Z&9=EG:Q4R.=1^U'
M.9L?3_WW]SE:[-R<63F$33<JXKS";7:GB7R["4TO,USH\/D,66GY0_%<F3HO
MAWD^\BGTVXG@?B'+<W&BYSFP<EV?X]<%R>=_)^KQ$UVLS8(LS$_,/XU?@GSM
M%CNM9T2QR?\ 5?R69E<=VN*R\@1Q<@V$VZWN<3%J>/SY,+\7N<I6O)BXSHV5
M 0$N#W\,X6,V<8Y/OSY;$J\?)EO!SM5*\MF&/L5VI#0[)KC8,@R=S'&)MLSG
M(W"QKF\BC!GW9#C> TV]4,N]%/OD R>3(#E\FA6/:\JB\=CR16EU'(HQ)H^3
MJPT&_##:[D-)'O$C.+M[M\+?($FJV?&N71YN'D[N]?V_F),QC1R*;)L)\BGD
M%X3^Z(77'C_>$\,7D4;320:QY#%IBE10K"<7,"I!L4<KL(PHWTL-:GE[2/@9
M$>1'!,\0Q]NU?=!Z#EP5:\4)+8<7BNYUT6PP?^P3C7Y2_$7$/P>_,W0?FCPG
M-UFMS<;#_ OX.X]\F\ET>EY'IORT_#[??@G@_B-\9?*G_9A\I8F)C\6U69(\
M6!@1!(D2,G"P9/.%"J]V'V[2$P8L(FVN-CC+Y(JC/Y3+;/Y=.M9G+\\5F\^V
M&/4WRR\+)\NQEL?Y6QY*@^2<.40\[P7$'*\":H]MB3TF0C5'D9 K'W>=!6#S
M&6,X7,XR(>58[U'O\66C)@90R>.8>74O"<=X\W@3*)>$Y!,7"_M(6AS(3/'.
MR[;$R6CY"\B21:^?*DTW")9$EUL&M3;[K'Q!G[N7-DCG9FC=;B984#_<21B-
M!&B"HQ>L;">2L#%L))8XJR<-X>#_ !5J4UVA3%CB9HPM6\0'C-%%-%008Q10
M5X ED%>"5/F77*RQ;A3?>[C9Q9,+94;DY&,26Q6>FUCRF?23SKC:'-BE;4NE
M)H=TU'2<AB'N;;';3<CSL<X&\DRCJR9$U\#DX>.16-&BC&#3/J^'Y.0(,33Z
M9-CR['B&9RK(F8[[(22/F^IPL6&#:\HK1<1XUK\/E7(=$QY_\::#DXY#\!?*
M?".3?"G,]GG:779BWUNNDW,.FX/Q_2M=4#S"GE#5%%>@H49D#LN(Y29)@ TX
M43[-8ZFWKBCNLLMKL_*DJ*<LLCJR[S'$B\KC?!SM AV&8LHQX-AR!HCE9^1.
M<G,11K][)!DZG='(@?8#PV6U50VR)=,Y2/N4\<O-4KM<]ZRLQV<R.QU>:()?
MSPX=#DY69IY()>0Z6%*Y'@!*Y_A_\6EPXLW!T_!MCI\C'UYDU>9H4FV&7IV?
M4:V;9ZA^'_)V9II-5R_%RXL_*UG)./[WCV)P;YFXKN-9L)<6.# P-3&^?D?]
M<?PP6R))#Y#M7_93\0S;+1XQ1VREDDR/^K*$MS9E\J=BHY?LCAZO#(!UFMBV
M<'V&/B1\2C\D@'EDXZCQEC62.:(I)$?V[):WS'&S4S :ER/./?#R'.L(M7.M
M'[F2VDE##7Y,5-CY"T^JS<IUX9O)AL?C_FL@V7$^7:\9^RS-=1Y0MSRJ)#)R
MD(N1S41MF<X\6S>;M6QYDC-D<BD)U/(,CSXYO3[G'=UYQ[#;N679MYZ[9OY\
M6V<J9/Q3\AF2L;)&PQGDDB>/+O39EJ?*:CD^=&[5$"3CH67#QV+2X]L?98R_
M<00QU[*,,F "I,DP5/O#&^-O&=DVADK%R#Y:#?RXE:[>X^4D,Z/6.3?'".OV
MP-0P+426'Z<^UL\.+\R?C1\M_+>D_$1OGW'X%B\2]Q6X+#(/R=_#G1_DGH.$
M_%/'OB#C&1EY6WW&YRS-O,<7I5*G7[C*A,.7#DQRY4$ EV$DABUNPS:CX@KT
M.(X(5^&:Z2FX#JFI^!:H+O?C#39L/,?A:.)MOQ3*U,JXJVA@96CCE BR,F$8
M.]RHCK>1R5A;[SK'V<4E1M')7MD"3896/1Y/EQ-J^89\T^NY#[./B\J@:H]Y
MAS!9L-Z(QI!+K\!R^JP6,VBULR\L^+\'9QX7QQEX.1M<C#T>'S+Y#QX3D;Z?
M92Q3BDRAY0Y@!ESED&)E*7BG<OBQ9$[Z[6%ZQ< ()WCQDA]S;['/AQMML-?C
M&*4HKLZ@+ES$4N=^_$E8T5%BA%,Z*6DBHO';W$J7*9JR<LV^/N1?U?,<>;B6
M_63XOX_GUE_"/[8/B/).3IO@>&2+6_!G'\>I?C3AN%'C_$G -V=/P;C^M?E'
M%]5%B\ZTN-#L)\01RZ##NVCA'MX^3'%6#DR9+<?X=GY]8L&DT,6SYNEMIR9V
MK,Y_IP^;S3.G&9R3*>7XMXA-MF1 :YME9^'HN.?#O(LZ32\)X]I$,.'X[7@W
M%MP-?\;X&OS(4AQ(WRC3Y=UDRR3B*TI9A&J->IG4)&+S>Z$7*V'B9\YW9"TC
MX^*BK'ML&%\;*CF5OW#8H;<VQQ+%P&5H,78;N66GG+UDS@5F9'D<60B303^.
M/E;'Q78YQ$GW]1;*DS"U9^;8;/9JX]\R,/)C&;-^1G$?]LXGN=,D,O(]?%[&
MYQADXN\T7WZ:GA>7DZG(YJ_'MAK1ILS$CTV% ^Z^;?C'2YFKY5P;>#8<=V.R
MS]=M=EBPXO,=IKM=SSXX^2_D[Y/^'/A7#X3B<OY#KXY?@WXPV/R)R_X\X7J?
MCKA_EY4'L.?<,UO/N*_/WX_<I^$^8QZW)\O^LCX@V/'>(2+XKE2"-.?9ZRO/
MD")=!&(]?F,:XOC>WCX \\E#8(UZS\<&H@+[,67F9 *3-<9+>&WE#CD4*,O)
M])!._P#0XZ!])A)4NHPV&%QC#\M7QF ,>.K#C\HXOCY$?RMPJ/'3>["369<_
M)C65R9H4SN42JN5RR<F7E4H<;269\;(F+Z,L&T891QO*D4;38!)\64L=6&<\
M?3VAI]SD:[(^+?D&':8T\*9D,X>"17+@AKHI#)&SUC8;L<3%"KB1 -DJ5AV0
M F]T*5REJ5P]9>%(1FX,D;1Q2J<=I0,+- .#F7K&SI8CJ^5.AUN\BE&#L$EJ
M"8.(;&D_B[6J=!,D?Q-Q>':XVDP,%8) @@F#5DM$$WJP3HVCAAR.*;#(W_/L
M951-9@Y6RFQ])CX<>;F(KXNLRLYL#0PPA,>.-;6/>F< RY(439_<Y!<YN%%E
M1\P^.\/9Q\J^/,G52""6 QD$>*W'B#C9BJ<38D'!VG;#V8M#L%(F83)EQD-Q
MG 6)=MOV$B\DRHCC<RRXVU/.6E.)NFF67:LJS[T+4?(+'&WL<M/]KDQ?+7"M
MWL<;?Z#?:O+QY"K#*M2SL:2;(<XF'+,,#4Y#/KM$YK!TMABZ_P!NIBD";?8F
M>7A&M>?-X[J\?%< (LT_MU-FE1L=DBQP;=),C$RTM]WV;*0KM=L( W+(KCE\
M+5_M,521L4S(W%2RRZ[8PY'W.+JN1Y^'+Q3E,&:JY>HC3#Y;@4-ZLR[#(.6F
MGV$FCWF6Z[+&!Q=GB_)/QE'MX-EH\S4[7182@8<DA/'>![78'1Z#4:.+<\V&
M*-Y\@8>''R#YRRIYM;H>7<HGRQIN-0?V>\Y1F?&OP?DQ28&MCP(5B45_P(1*
MI*O :#X]/*E-/:GG-FF!,LA-8>(^0T<28\<D@)C>]9D@\8QXU-*UIV<GP):!
M%A7>[QHUCS<B7+X]L']O'R5D3.C$B\AUAFJ'%CQ(Y^U2S!1ESEC*"U0 ^YAY
MJX>!L.2^<IV;2ELRR_V3 XVYK+V8*Y$[2N@=0A(I'L-[KUVVJ^>N(9W$>9[Q
M$GBRXSAYBZE99=#IIL2?YNXWJLGCO)]_\@;GE,G)/E/VHN-;3)Y!QCX,Y7MX
M>"<=^6\+7Z'CD\&-\I[V/$POC_C3X.)RC>0Z#5?"OXY\H^2M_P#BI^,VI^$]
M'Y^3AQ:,H6,BJ.:\+XCS/ B_!3X0;D/&M1K])KLCM6ZRO9CY'NO>V6+(^1/B
M1^U!.MY]*@AP-.I*QCLBD4JF17Q&CDW7[8N7HQQ/N6#-G,%SLGR&[<$;B-?+
M("J,MD->]&HPLF,5QG'2<Y&&2-]K"\?RQJP</Y?:/$VN9LBM9>VEK.W $9S9
M<AM!QPYCZ#@F!*-=\6:F4ZCX9U1EUWPUA)6%\5X4,>=\>P1/#Q4K)H>)1(NL
MT.'4^I"+Q?8YNAV7Q[RR':8.SUPD6.-HC#B>ZJZP@X^*J+% MXP!6,P#YKJ(
M=KE!999W%1RO4<AL+,,G7I*,C5&*CB@ EXVP,XJ<?+#J,BPP=W/C-I.71O6I
MW$<@P\A7#9/B),Y+C-0G&R$DI\=77[1KPQLE;/(]M-EGR-/%&<G#UO$8-%%-
M,T:<:WBZW&GV4NR&MTZ@X\<4*B0"A+V\Q32 5/D6K(R&8^+&BRK1R0!,4D3D
MFCQ<R'F7&(8)LA9,=ADLH>>P27Q.'F,K8>96'G$G'RB:BS/VJZY$YS'BQYE#
M5,4O),M\7,?'DXSR$RUL-B!%/N'=EV#U!MGC.-R62,XNXQLZ/DOQWH.2Q\L_
M'J3'DS?CC=:V:+BF8IP^*/?!XRRG!XX4.)J0BQ8P03YD6,N[WH-:Z(LW -9X
M8."@5)G"KF2$TS,!LD9SK<-<7)UY9%?)D]S-S#CK\G\^P>.Z_-_-K@D&?%^:
M? F;_P#-'A528?DN5A"VTUZ5P+.?-XSV:H,S,QI)>2;61(>2Y^-+\=<N7;02
M2(R<G#^7Q]M<Q<?,/V65DSM(OR%\>1\A@XU\=;=&T^HU&G7'VG?;[=Q'RW<2
M0196MV&_R^(?&F'@P<GY+A:6/C?Q?N^;9?#?CK4<>QH(DB1LA8A)F2$_<,Q^
MXD!B,LE>^D=>]>I,@V#F0S1]L?'EDFB6+&CFS06]X,$-ED)D:P (IHD:IHA'
M69G.PVWDRZO +2:UH81!L\9%?;8;C9RP2)/)=\A^^1D]Y)03/,",9R7Y!E20
MZQ)RY6;QKW[U(S&O(J6<LL0_< :5 :C3L(E:OR*^%L?G>CYCQ?=<3SLKCYSZ
MP.+;"./$T6:E?CY^%&K^24_-O_K.^&\/1<L_%;<Z^;E_PURG5U\/XJ3Z+0XM
MASOG>BX1KM&D7+]K\8?BQ\K<TU7QO^"G#,+(X;POBG"\&"4N(7[*W=90::?]
M@832>:)6OD'LYTRHG.^0)A8KY4N1)Q6)\S:RRC'ATYESL\M[6%JHS'"""JLI
M,4L*U++%X\ER/&N1NLFHF>QFR*G&1*-IK\IEW6IV)K;^[@UL-W$&S>2QI6)S
M3"23XXY+@YV-_P#7EQ]Q"H3YFAB&K^6(,C-V>=II:V&HFK/U$YK1\:+'C/'S
M&O&]+X)H=1#?4X,25K\>%C*8HVRHXA6%%B%H1C>.$V-&L>5A2*DL*/\ 'G*V
MU>5QO;Q;;#S-0 V,GB5@!HQ^!C9;B90(L@ELMF,&R7_E=1Y E"DEJCG6HI/)
M9(T<9.*165 XJ%F1L'*-ON+TKFT>;)"W'N6SXTFBY;#D(-NLB9N;(*_V.3';
M4<EBF;6Y2SH$C"94J1KO-@+/+YS:Q[+EXJS1\DP=ECC4\7VLT6!I'Q8Q'-&/
M=>YR@@^^\B)VII6-2*6IH6J19!4_N@R2SJ)L[)4Y.Q>5>71+*-Y 1.4[>+6!
MJ)_$XV0U\+,[P9BVAG?(.)%[*RY! RLNLO9,A;9O))KM-O-DVEXUE:U=CD,8
MFE;S$IHS&CE%:Q]O- =;RF1*@WF)F1[/4:G,K)XEK0W^N8<173PJ4PXHS*8X
MQG;>.([3=O*8(VR)M7 )LCCVN7#AQ1^W)4^.8DA8PLJ[<M6OSER9=>[LEG9M
MW.Q7YPX6.9:#E7_6=E9&YWO_ %S\QUM?_@A\AT\"BLK&K/P/.N"2?8[6?Q1Q
M+&M963XC!P<K;Y'#^/OI(HC))%-J3D&/80ZB7"V^%N</*RL7%&;O8ZFVK.XS
MR3BYUFS)W(VFHR]ME\3X+#AKR_?O'7"_C(3S:G3XN!'"OE4A""1O)A"STN)V
M9(HJES"2LC-2FX\"6C@[.MZ@C$29<[LUI+P*27LBQD$E0Q&,S5'AFV=A$Q-C
M^$^RUWO0[+<8^JAX]C;;DV3B\,P5BR>'XT0SHEP$D?MG9-EE<W9KU*X-8Q_=
MR4>>C@R/$1N6"@D^-+%<_;FACBO9"TL9)2/NJ6$D4<R?D-^/6)S+&Y!Q#_49
M]'LM-L,SBGQ9\?\ $\/5?,6GQU^6>5:?Y&X#N(MIQO;;C13[3&XI\?\ )]+G
M:#XY^2]Z,3_JP^1_ECE?X^_]:_Q9\1X^/J1Q77C&XYNBO"HW$VLVNJ:/([QS
M!J20K4DJNL3=[F1]7(OV_)M[!C)SOD"Y^9AXSSGX]TIBDV4HF;B.K\7[9&;C
M+9/.1:N:3'NO(>7X6D63FL&[3>;9$PI\N%GQEQW$,.,1EXN#X<I6%5YECN#R
M3(;%?9[LJ<S;Y!?X9W.4T>EV>>T.9D94R?+&KER]7\@<.6+,GX<H.;PEF&3P
M/]NLX@T67Q;B;NVNT#XYC27%76;5P<';@5D[EEDR-ZOCB<CQD?$WT<@'((O8
M7D^.E8F^DR9-)N?!_B_Y!$3:C-Q]KBY>&V+)#DA1+,MO>9C&2U0 WG :+9J!
M*Z'R_3T*%J24*JY(L61Q-BK()< U"'C,'DX"%1,_;&RRKZW=S8YU?,94.)N\
M?-3+PXLM/M<S!EXORD 0;:*:+:;!0NUSO=>+NVOELV*PD7&Q<-C%)C1C[B!J
M_P")ZGQXV6; D<IA"(,+%GI6!KQ1J^VC<MKXVIM1"U2:"!QE<6QWK=\!^YCY
M=\?96,<_49&#(T;4(_$J?&A-XG&S71M4TN0=>(88WS([S9JVFFGR6U?QMR#>
M/QKX?U^M$^/J-1%NN10S233ET>158Y%J]^Y,EJ\JCF*U!LYX3'R"<'_82Q?=
M*:?<"TNW8UG;DJNPV3S5XF1X8A!C\2Q#-FZ\=L;L'0.KXU9&(OALL $8>HC6
M?'P%2MLYPAS7Y<U.HW+_ "UQ++,G)?CW)CS).#;:3_2M!3QJ3+%WR,17J*'[
M/.R;2Q2R>%29*VX9EQX.5HI?[:/7:UO'=[#$UN/RKF1,^F^2MKJIL3Y0P=SC
M[#F&5K<_6[N#-19688DUIH-8<H87&\?'',>0QZV#A/$9)9<#"CQHX+2,D!5'
M@E8IA$ ^U$,C+<DLS@J;PHQJ.+LL-RH(!!\@+HV.69L2U(OA60Z!9-]K,8MS
M'$!7E[T.79!)YE&J<JYD$>3GF]7'678;C-X5B186)[RJ-AG1QX^RRON,C(E\
M1DR%C,P%$]I6[0.0=WC3S<?Q[F6".RA:CC[(@LL(I8;D8]>P*6(W$9HJU^3.
MT.)^5LNK@U4'YBX/!N39'YX[O>18GY>;D4WYN[S"'XZ?/FA^8.7?%W#^#Y6+
M@<*XG!!%K-5CG)S(L+$RY&63 SI(Q)&LH2 0U!R'98!3(T>R$FFRKI+)"TF9
M&P@@D1<O(7%BFY-]G'S/F 2)9)LN?0X)<IDXVKP]/'%L)\3PPX-!C^XZKXA$
M9BRQ8L?/?E." 9>[S,^739!5.2YTJ0C:PM)A9T0$&R51E;(F/>9,?AS//@5.
M<[*\V=ELTL_N2-\%XDA&IUH^WGP.WR%@@Z_Y.<1[1L@JF0#*V4T0BX[JY=CD
MZS32X<$F!MQ6PAY)!2YW*H6Q]ARR(;+D_*(%V/R)L\=,KYAC\])\V3P5#\X3
M9$>/S[-S)M%SZ-$U/-TR*UWR0<23X?\ G_ SVP=YK]]A98DQY,:<2J$[0"PA
M%$$Q[9![DB6H@BE4TH-K7J,,"G[0&%&,2!L'R,,'M"ZVSQX1MG-%+K]@)*Q\
MR]8FWFA.KY=XMC[+$S4>((V-R7+PA-R5LL29+2-AJS"!A&=9DAA')8/ELM#8
MR>4&>YJ/+8T<@&I,@&I90:\A0>U">P7*H9-?<"FS!7W -7CD&UT>%G1\Q^,X
MYQN^'Y.#)-KW4ZCA>\WTNB_'S/R%Q_QZU\8D^%3C@_$^TCH?%.R-:_X@+OI_
MCW3:E9\S3ZF/=\\CC7:<DR<VH)&>3(<B.1B65KT7LP>U>?8%S0N0$ID(/M5*
M51<[:1Q+-DRY-+&S##Q?(BV1D<'P <G$L!C6 !-B:G4LN7"CE(H8C%.D:_(^
M_&%K_P ^OR(W? ^39'Y^\]UV1P?_ +%^1;//_'R2'F?#O]4QZ:,6="M3J#62
M&%:C(^_TVP0AI8Y%?5&01_%O)<;"GW7.=7KL7EG-\O9SS)-,SXQ4^4L#8V[$
MD>CVHU>9K\[%SL9)%BFXSN,0Q<IYGB:W&XGI<W>YVLPEQ(GFK#<1UC9N$0^Q
MUL2Y6\PA4F\PB<O?Z]*AY%K&J/D&G-+R'2BL?<ZV4Q3X\@)C8",DB&RA6#Y1
MB@BV'(O*0ZK;9]-CZC $6XU\38F\P&:'*PIE084PS.-ZG.&\X+C0QX.F3$S-
M+A&*#VO!.4;= S.;9<AO,UC+Y,77Q$EZQD)K5Q)EZK-P9-?N-?@3RA=)E C4
MSI7V<J%8"*6,7$35[%"(T(&:H];--6]XOCMA?F?I\3%X;\L8O)1SR#+YKCTV
M_P";8PAY?R5Y/^MC>9V?\E?"N,PU\\,\>,VRW\^;C\BCS<J/'[%VC$<Y"1N)
M1FABT<EA#+)&HW:9"Q\?AER-CN)\?+V_(&$>UV2Q1[+>9/(MAI-?XCB6+CC*
MWVJVVNGXUL)L7(ARGRWTV-[:)"2-AM\35P_(/R5D3TTTL[XZ>*82EC\OSP:S
M1-R-%.#S>"(Q<ZQ/'(^0]/"G)/DG5&+F_/\ $E78/F["3*T,C,^H93\":=@-
M=K2D$FO;Q^0M87P/F'7!-Q-K>\N'*0FC>>/XZ^.Y\EM+\09$PQ_AV5*F^%%F
M$OP$\[K\!2*>1? \WM_(_P ";F&'Y6XWRGBLVDY'R6>72;;9UQR?:[&3@7QM
MLMH.-?$<J0M\6*L>?\9[""7XAYWR'12X.1C;O FQI,>7';R5!8QT3^S9+=I4
M-Y%N;B\;"X%R(^X0$&,FHP 4M:15J4D'(<LFU\EEUN:ZMBYP*KL!4>:6.OW&
M5BOJ^5B:D:+)1L,QF)6+848"R*16JG8/!)YI/7=6QF4F,@!B*E8@SS,@&=^Y
M,CS'F*,I%?<D5]V37OL2)V!2<TLUS-!'.N[X/B[,8WPWKFRM)Q#5ZN**+&A!
MEB439N(M2[/!2LKD.MA&?SO"QEV_R/+)6?RO+RJ?-DD>,NQQP;9,I"LQ8JUA
MY=$7N@L0*$@L9*RLU($V&XEF*B1RL J+&]QLF5<>/58Q\>)Q^QJL63MBR J&
ML"PLQ/CM9DC7?<UBUV4OR+C>/R]\F8D.J_+O"S?DGE^V_'38[!_BC\6MAD\Q
M^$>)_P"O<&]F&GC)J5+-D"YRD '$)V6?8:WR$VL9AKH&ABQ<3)5GQ,W*5M0R
MB75@+DXK*TV.S&/%5CCXB6T^UFU<T>>N0C;M,"+C.IR^2['3X<>%#[K5M<G(
MB@S^3\I7(BVN_9<W>\ACK(WN_E;&RMI*8<"26L?6Z\4,;3PA<O1QG5[GCK'#
MPL#,237[;%77[LI))O=1"N=R*;(D.NV><LF1K=/%N.92R-/N,N5I<UZ?<Y,9
MQ^3[.,8G+=JDFBY3+D46&5CK@1QYVM6%H^4\@Q<"";(DR)9'[93]Y2*=K4[@
MAS8XMZTLQBFY?A1IOM*84CQVQ2KQXC5DPXI$^-Y,N++1C$=&=%*3AC#(%I'6
M_)\NV'^96SMQ/Y,Q,*;F4&JQ)!M..X8CV>I5)/\ K8D$7R[\)2J=>(5;#WN;
MB80_%SFGS-R[1QX>_P  8>X>5$EQ,P%_MVGGC=<W/CQY\?>6#;.%UQ<QFEDV
MN-L(>=:'^NKGG+)-SF\;U@MB8J1+BY>1C9G$^3:WDF!E\!S-=G\>X>\:QKB8
M$6YYACP)S7G92(S9.=)CP>16.U:##,L_Y4;3^MU^;RB=!M^;YL*;[Y3Y!CR_
M^W>2/)KN0[G<+J]$<@?Z_'"C:">4KPV62OAKA;XL>!Q]A!D:8JGR#K/'"^6]
M$9MI#P789IQ?AW>93Z?X2W!R/CKXCEQ(-)PR/'BQ^'Q2(O",9CB\$@-?^O\
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M=PQ+>*,"D"V15 S85(S8;UEJ+9+!&EE51[A=]6@ABV3R;',X9J<75IE\LED
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M-\Q_BUF*>,_*VMS=OP';Z7D6WYEJX$Q=>'5Z3("QRRO+(@"KR[/5-?\ +_\
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M>%C> %C%':C( '-ZC2]"U@O8"I'*5-FE0\YO)F(HDRFIL@V\S(V##[:3S>Q
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M!Z( 0Z!J**M=J#5(U2FG6X\%JP%6H"I%)J=3?(D*B3)</!-(S8[$C'%ZBJU
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M\,B0>Y%(&I3<9$B+7(]BL6/\K?+HXI'Q_P#*/$V\V#\HY&>C;Q\QL7)!K S
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MV5K%[22JD21G)FU>'XK"HC59#1EM4N583; "I<YB?N6>HV+'4 O'M\4"77H
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MS,M"921,J8F:+M)Y&N(P^]GJ"7Q5/G$122$-+&LRYVN(K(PV4E/$HQ0P2BR
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M]V\=B@,V'&(X-C%([ZE&59P57]@(0A,*,A^%;K9:U?\ ?MY6)H;/@<>B>O\
M7%C.NT<),VGQ4;6:O"9==JL))%UF&!EX>%$SQX-84.+-F0ZB/VM@T6*1F8<L
M>Z:"-9=S'$6Y#CV;?8S,NXQ"<7:XQ?7Y^.R1Y$#!4QY%U?%8]HFVX3'B*W',
M5Q-Q2$UE<0_9L--+A.$%,D(5H<5CY8D='80I3[21C]U(Y+L:#V9*918 4H-
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MR^]DB9-Z\(UO)8R,39PRB?+4#_N#_*B3\8_Q$E^3-E(Z_)N=<_)^:5C^5-B
MOROL:C^7L]3\;?,6U_V3\;_D+(V>+\;;!\J+3#_@"BWC6<O_ #^(O&!?%'_"
MRBTBCQV+>(V.7(BYNRLT6V]RFV)-?W'C.-F9*DV)6GVI6LC<B&'_ &%_/_8B
MI'(#2\@O2\@4G^_#'!W(>71'W1J,-77 UP:H=2I5M,M'3J1+C+$<_( 64AFX
M7BKC8Y9I: $0@4J8S9)0!2@ +=::U2)VP@3#JG(*829$>RT1!R->8VDQ_ D%
M2&IX0:;'[O!:EALT*D"(6IY++E26#@NWB%&0+U(GDPQO(QXI%1XQ%0XI8X^
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MT,\4E9&.8JD+*<<?=0OA10M@F-ESI9"]F+"%A0B(J/'L8X*CQBS18JU'C=C
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MK98 0?<"TAL"UCY,Q0@@#O957*6%BF#C25#JL<CGNEQS'R72I&_VC&L#%*N
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M:);_ - HH:3M#I1>'3"T6FJ/4(*35J*36 -'JT"KK@M)KEI=>M1X( 7 %)A
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MY[-A2GQ1U(E;O,Y!?(-\[.$<6XS)-]R"*/VH)KVE%,MZF6X$5Z,%JD@4%L4
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MY99=+,'&-(#C",_<\36T^7@9^''K=NOE!,9!!D8/),"#BN1KX>60?<<1FPO
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M>(UJLV3Q.(NNBPXG&MUT2INLOQGDV^+@8O'VR7QM1"!C8485?90-D)Y4?W
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MJ'$L%QS9,6]#%6\>("L>,UDQS=<8BD@I<<"DQZ6!5I8:6 6]FA" 5A('LFC
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M4-"'0CM;NF@)%;Y]Z,8[LJBF2E.4_-+,DENQ\_DCZOTI>9-7J]<R:E^=U_\
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M@,KN#[_%7<^_P32\%4*4=(<YWKT_%:]KR2'*A[:77V]J3@9YGOR\%':WQ/4
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MN],5NPVH&<YP,(@9R(]W6WN?^00,7E3:SEVD/I'6Y%F6WNF,=4(@"@&F+?I
M% !R&/5&7]4;]F7=B'RXJ<%#P-S01[T57-&B8T3-5 # 2Y*J<*F:"[T4P3A1
M"*9LUI%T2M,0SYHQ9VS345:J@8=/JM6Y;Z)]B(/)$,(I]PO\EY1XJ@3Q3E4
MIB[! RHJ6PU.R.UZ6.N7O9#?]94G+DFB-,(Y!>485^")(IU7E1?-2TT#K5N
M.G   S=-_3\61UYV7^3W*TQZ(%JYHR$:*4C6,B'[\D&Y(@Y>[J8G< GP'P1W
M3:?F_P#<:?!2C$TDU.Q&&1^:GMJ>H,"2W=@/3[A\A#=]PCN92#(-8I^2<]BO
MA543*E\6Y($)\*<%.%_9.GX7&%$V/:F'!1.,+HG+AI[5G5<'5.-R:X/; DGN
MY>Q(&:$9?SZ*B,IDLFB+JN:UW^BY]R&5U=>:X3N$Q+]CK3M60C&K7I0\JY,A
M(W]\T)2+].2 '?\ 1.#\.%LW1$9&)Y^_->:N7('WYK6U6MDOLSN:Q/3D>SGG
M@1A2H7),%1,<'3F(?NNC*>W&4;FE7.?5?[.QMAKN+BKH1Z(L5U0(06DTMU9K
M^*/J)1\QS;/WLM$ SX-AI.=#V'YHQ.195++DF-%0J^#EE1,2KE7=53*R\R<6
M3X$Y%,RH"Z8CX)P$'"LJ( 75,D"<*(]499E5R3 ,W-<V1B]>7U6HFB,#0+3$
MU")F:IK!/(_!-$$^/P32! [T 20Z\I3$!DY 3A>5:8!:MT]GYJ@71:1= !?Y
M$\3[_5/$-ER7D%>9NF-D8BR<%/*J&G/"K!:3=:8UET4I3+ >]/Q0AH,FMR_
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MRE(4<FF=*?%..?P1)C46[$3EU1F!6-66]N0#',#M0F PF MC:<"4 01_TV5
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M .G-';U#:@2XC  $=L[E:A4\S7YIT%_\U^R[TOL&)C*,27!%0.CAZ]RV-_\
M\L])O;WI8R_S:=1D(LQ,@^1+TY*/_D/_ (QZR>SL3CKCN0W_ "1 %1*!(TR!
MH02I_L_H_6G]S]"'?>TD"$@*P$C2?;&B\M#<-?+Q[%.,32RU2[/?M4^4A\E#
M?@?T%I#H3[T4=L5,=8?L*AKR+>(6_&!9R*=J$'K$=Y5$\00CN'S1F :7#?,H
M_:+F-P;CM6R)B\ 7R!R4/6[!TZ;AZ5N.];4Y&HCE4=CYE/%55%FJ%75^.G V
M!;+!E3B)Q?&F#%4Q<8.:LJ>S=JIR.*N+L%;"P50J!.R=65ERPLJ@+]-Q?Z)H
MV(^/5.44""P3'+@JG"<HOF&7F95OGA9DX"T_W)H\DZ=,<Z)M+IH@ =5H:KCL
M1(H$ 2W>F8 <W!=",*\N7BB!0+40Y1,CT9#4' R7E7V]HN<Y<NQ/.8+=BAZ?
M9E'1+GS"D]RS]O1:SSMR47!HAS<_EW%-N!I7I;$%.%V!T$Z<I^2*93G#,:?&
MZ\IJ@>14I"H52M*(=,>[L4>%\"2J9)SAO;$HOK@?A6G5_@FS540F0Z((=B9/
MPO[&JI["4CR;PLB/>B?GBZK=T2G%U5-SPU<D",PF(0)LM1+E5MAJ.:U'!T"J
ME43*N7O:Z<0+#/) >IW(QY >:1[ *'Q43Z?9UVK/RCM,0]>WO1U[GVP7\NV!
M$$'F;^"M4?U&I\2C(E-E\5IA$D]56'Q48>H)VP<R*/UY+[D90W=J=,C$]_/X
MH[P]'&,@_GVB"3_Z3RZW1EZ;[OVMPO*'FC$U>HC(1YLP7^OM ;( %ZG3E$'(
M#Q.:E_K'7-F?(=BD9"Y40153D!E9;GH]VVY!P>H7VI&N752C#]$=L3/0NRV_
M0TT[DAW@>]5/8(K"1%<P#^"$XFX'R5U#>AD<T9QBTB*GFHEGD &7^Q ,P^/7
MZ+_5,FC?JYI14R3)BGYJV%4P*+\#)PNJJGP*,0K9>Y3+RT5$0> @X.:X,<*<
M07E*Y8.%9,,/-P4JO-1.^%5=75."F-2KIAAIS5:*Z<<## 1-16BH0F/CDM.H
ML.B<V3LPP>*H&15>N%2G& 8LM1LH1N[]RU&M+*-&;W[D=)<^]E5%T\UY.Y>8
M?1NJ!->B<E@FB'(IR3LR&NGOFO*X[U0.Z&S,Z76YL[(TD"A^JU@D9,]%#:)(
MD30@]C?)0WKF(TR[1GU1@F=ZW1(/E( (ZW!'4( FG--?KP/W+2]L BFYHLH>
MFVFU?JEWY=WU54#&A1F3=73,JV5%YCP40"\MN:<U1&Y1T<&.<9#X%2AR);Q3
M(O?"O- FV'<@_M:)\:<4H$7"W(P%+C%\UIQ:55R3Y*J9!C5 JZT@H"90>Z=.
M"ZJ7)7E36?I]5I ))H*7[.?<OO\ J&VHG.9$!\:H">[+?E&I&W B/892^@KD
MB?3;$-L9&7GEV@'-$^IW9RZ$Z0W8**6]ZW>C&, 2SAZ+[/['M>0']1KJ[&%E
M+T7KMD[?J-JM+&)L2C.9$7%/G1&.U)VJ"]>]5D22?=EY01E=".X2#V*.U,D@
MC/GFCZW]CF9[<S_EV"7CN W8$M&8R(4?6^G!&W,4<^:)_MDW]43]$#.<F:E4
M026[5YD3MV%*6<>^2'Q4R:BRGMQ#';\I[)&RVLI1W"*I]TC3ZG:GMCH6?^2V
M]@.)^GG(5N;L/P0]5MG227D!VU4/4"NW.$2#E&C^,D91I%OBZ$!S*!D:CW=:
MI5G(N'[4X'EF*CJH[0+ FHYU6H+JJ<#C"N+<^)JX6\5;@[57$G <%"G/ .2+
M8-DODG*JO*4Y.#R5E08N,*)Q; *B\W-DZ:ZLJ45:IQ@P"U8N,*X:0FBB ]+)
MV;#M3!,,!@&_)$DUKBY6H!5!\$(Q0D34!E5/0FJ ( "9ZIY29&CNM,-KOZ+]
M5?>ZJ0#V+S;@ Z_1/"O5J>Y5[=R86^?5$FXY9J6X2T;1%_,I2E)Y2%^3>]D1
M(W3:KY)X$B0+OG[E1AJ/*8MI-WZO1:AS^B=5Y(Q54^)&2+]<:9H%1>P!EWBJ
MEO',D\ DV&K).,N!@O*J)TZ%$'P!-FE\E.74_,X.$Y%4PP8KN0]LQ5$_&RU"
ME_@O' IRO,B G3'!TYPHG6LFR#(&4JK_ !^_XIGOR0.UMR+V-AXY(3]?ZF&W
MTB1N2ZTC9K,3=$>GV-S=.4MPZ(GII'S6G8,?31LVU$ _^\^;M8A'?]03N3.<
MB9$]7*,YE@*E?_B=Z(G4LXRY_BMST?["VQ&+^<E]5[64-W<W9TN92HQZ9]+H
M^HB?L>E>N[,,9BYTQ]WY(S_;HEZ:]V0\TSR#5;(<E"&W-HU:/]O5^9/X(&9,
MI2M[\E]Z<XQZ7NB3,)S(]R\H>/- Q/E)KGWH^AA)]OU(,N0C.(K3_DF>V!C
ML2%#8YU;\4Z&R30U*]5.']1H>L33WS7^U ^:$Q)N^O<O1_N'IY,TXE^DK^^2
MWO4;',2 [19"3_KB_80*CM=;>U$MN; TSCGS![&S14&R*W-B-XD^!*A$VK\
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M/JO42)G*PJP'(5^*J2F)3'#2Y1)JA^[3\QD/)3]+&O9VYH[^_+2]GYW4H;(
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MN50F.% ZH OZ/'@8YX4PH$QX20BCV)E1%,G"?$*BY+S%,53 8.4\:!>4X-)
M(*BKS3,AH1/#5,JIQC3-$'$'G\\:!TYSP8)@@!SQ<4[$T/C3P&:,WJ/=E'U&
MQ*6W.!>,HEC$\P<CU^BCO>H;[DC5@PD^;<SFM>DT^/8AN2BTJT]^B.V])D$=
M-1JO3^FF[1C1N>3_ ((@]O<I;0H0;&CH1VH$;CM=PHZ2"_S1E$EV&;HM<63[
MI9?JN:.M4C4/H?,@61], 3N#RD'P6MO*_>C$%GK=T9RJB M$^[\T.M^B!B[B
MQ4=N7^6'*3.!VH2B"'N!<'J$=O8B91OV96Y(QF&(Q=J<UYJIQF@38+22LL6!
M5\&*I3#M5?9/BQ3A56G.ZLJA5]^["_!9.K*RHK*RLJ^UW?VO>I'<:4#_ &[D
M;=Q%".=5*,KQ+%#:%S;N#H;FXY8M3)$[<A+59LNB,!FF 8=BTBI=:I @QZ74
M-K;#::-V9O@05]N99&<9 CM3BH7E'P7)EJW"S<T=GTGDB#67/LY+S%SSO\57
M!P;*N&DJR'3$O?ZJ@OT3,5JL/?P7E3E/+-/)#JG.:BAJ.:,W6XQHQ"V_1 ^6
M4HANKH[<#8ANX!;NUZ@/ID6'=3\D9B@V28GMZH;1'] '>/Q40V5>^Z!%A\%H
M-0PNJ9A%C5_@@38)N1R4=N= X8O[_FOM;GZMNA/]PR(Y*BHJ\3>R=6X*IC@R
M8<1"(7;@X3BZK@,.Y &Z?-/*ZK9#2A$)C@_-451@";8.KX!U="BIQU3!5S55
M$!#24Q.'9C1--%^Y4R54!@-)8,O-W(L7^01K0*EOKS*]-+8+2D3)QD 6%>O-
M?Z7[G,;.Z&$3:,AVV$NB$-0,!4YE;?JB-6T2*CI=^2VO6QJ',3]#TY(?ZVHG
MD*T1;9U2O^FOBGG"0?I3Q0VO4W!:N;Y#JB-LD@Y')">@<[H2)8BM+(SWY.!F
MUA^*V_MO'8V7:X[2>U?[6S$ TU$9YH3H8M[NG9BC +04"$Q/1",:E1<6O5"0
MH?FW/FM49"$NM0>P_0T1VI>7<RY$^^2.SO!I"BHB]T#*B %41S0B6*H 58*P
M3Z0JQHA+<%_#$@((#V-51!L $V> '-:2[JY7F*H75U4JZK(+]7R7ZDXDKCQ5
MQXA5D/$+]0\520*_4$SJI"R^"N%<+DKA9+)57-9)P0$/509Q27XJ&X::2#VJ
M4!8RR&9NM>Q(\R'NA]TL5J$G':M(1E*Z:5EKC8JJ?T76G>GW82TO9Z>"#@Q(
MN"F%$=N%_@Z\Q[D0,**F')40.+A.B<^28+M3+HF(N@.7NZ'<@J7*B"H;<+D^
MY4CD I;$* WZJ._N!X;8)+\\NQ"1I4E;D;.0?&ZW/L1:4BX87-SVDJ>SN!C"
M0'+.RT2Z*<34/1 BS>+*(-V/S3QN'/OS1$1Y(OWGWHM9R\5I=Q NAOQN!4%"
M3MT52G=75/875U=4*NF=,K\#<;!5P?FG1Z*N!3# =Z#*O8A'!PJIDXI9$G 1
M3Y#$XU3LC).$#UP<*RHFX&*HM/-?'@9-B\0'1!RP!**>[ISFM1S3W)4IRN0C
M*9J2WC^"C$6A$1 Y,@71A,_=VFL36/8;E^MLEMS$P"14 NQ&7:,U.4&)V],G
M'A]4PIR6@ENQJIW![E]S;8$<K%1VM^3 49:HR=J,@-J6DIIM,( QT \A\^B)
MVR".BTRLR^U-CJSYK5')"3.0Z$BB38)BM#*DA1"KQ0U%VL<U&.X0)"TN?*+_
M %4MO>CID+A43]F#!%PF%.'L.)P'LF(44W!&8R*$P!4 ^*LK!6"_2$6'P1>-
M.Q?H"_0/!4@/!?H'@OT#P7_;'@F^V%2 7Z .Y?I"_2W>K?$JWQ5OB56/Q*_3
M\2K'Q*M\4[*CCO5Y?^Y7EXJNKQ6J$CV&H0D:Q.:+UJ@06'O1:A=:H6S7E%;%
M%A9/R6F#LFW0]$[.%JB W8CJ(?-/$MT1>_;@<&"ICX8"62+\@FD'PU!.R8*B
MJA/"IL@!9#H H]BWO4SIH81?-3EN>6$,^:)B+E^Y0G']6\7D>PT'@FA0!?;F
M&$F;N1)#M5;I 8B8/1"<>U.;%446&2GMGJI;6V,K=ZI<A/\ TV9:!)A*W:#5
M..2 .:<,KBJR\2F++33XI@WQ3.$U/BJ$?%7C\5_2J"/Q5662J8^)34;O5#'X
MJXXVX.U43+L3JJ<HNB$Q9^::+H(!E3)/P<DR9-C0)Q@9##IP.<L'>BHG*<)@
MFP=.%3)$\@J8NB>,F]5I",0;#W"<K7.QNAM1NKLURG!3(1S9_FB23]N=ZLW7
M\5O?MNYN5W8M&3TTFH'=GFC^V^M-<CD8Y%T)C^F_7H>B$=L1 /6R!W/5",2*
MB-_Q480W#,2H)&E;,?Q49;MHT+6D.1Z(2($7RY(S=G-^:_R5_!:MN>DE:)R!
M>@;ZII 2^AZ(_:DV;(GU$]3V7VF8/3!R@0:IY%T8P+OX!#;E'28AR:-V(9BZ
M>OW,NY':W!ID.?S7ORP!0CF"WOT6DT/#*',%L244XQ+^P;@LBMH\@W@J495"
M<<%.%E3@I[  IK\),35PR,Y%S5:@FBA(61,:?51GS5JE.X\$89V*$MV3!&'I
MHCDZ)G+-.:HX.Z<XDO=.2%VH*J8)EI;DA@)1P;HAV8#M3%",,J*>[,L-L/[]
MJ$8?IN>_GV+_ $_2UC"YRD?P",MT-3YJ&VS"%/P4YQ'Z0W>?P=;>Y_:!WYH@
M\G\112E&-)?12TV3&QSR[$0<RC&&2WI2N[>*U0H311 /EC9?<B''R5"S,?#+
MM4=V)<2 (Z.*NM)N A@ RTD53 *H=63,K*BJ%963LG)"8U!5E;IP%L7/ 'PJ
MNA7)<W3G@\N:" *=%47F3#@=E4_54QLC\$Y3"^#G"BJF5. -B0<)1^:<\%3B
M]<6YI\RC+P1,BJV^:E$&WNR.Y(50R3FRTCQ^BOD@ AL^I\_IW+_W1?ETYJ.[
M QUD [<S4%[!Q\1S6YZ7U,#&<"01EVCF.RBH$^Y(AOBGB79JJ$Q5PAN&5.7-
M#TND2D_ZKD= B8%B[=427%,W57)-T1(T3Q-32A7^&$IRY1#_ "7^Q/9D#'(W
M(YL]0.B'WWC(UTFA'==E_P!SX+09@_!:JL[=$V04ID5+^ 0 % *=JUBX][IF
MT[\;'(CKS*.U,-*)K^6 [4V=TZ8E/R5EY@AU1B<CB>[V3IL'Q8)B%I_M-UUP
MH5DGNJ>PJ5<*A3>UJH>F@?TC4>TV]\D3S19="GDF%^?5?9WYZ)1#!W([D\1(
M@9C/N*TB+@YHB)(!1))73ZXE/9!4MA2RJG<H *ET65<:X,0RIXKS(1')=JTQ
M_DGN43'E5?ZVU:<AJ[!D>^J/H_3N-S<O+,"BV]N-S<K2+,,E"8!?<-#V+_6>
ML]R(ZL]?!1B.@^'N$Q-T"S'1+Q1AD:J.W(W0TVPGO"Q [BO,O*._\5IB<J]5
M&0R%5':)H"0A/-O%=,L*53FYO[.N#J^>(9.<>].>%DQLC$)BF";"A3FJZ)\R
M@,&*?%L&/L'5TQ3A/@R/':I1.05"Y*JBRK5%C7M3FJ\YLF%%= 11U()PB,D8
MQR3"Y3 T&)7Y)CDG3G-?9V)-MRO')NG(]0H^HC(N !6OBJ"@3R7V]K]0K^2^
MT00W2R.[41C4GD/GX+<])Z#:EO;T2VJ5(=6S/3XJ/J/5;,-[9!:6U$-(N:F+
M/4"PS4/5[&H1F 0)#3*)(=B.G6ZU:1,=!^".X'+4[.BCO[L1",RT003/J1'/
MHH[/[5ZCTO[?N0!_5MPW?43)%3*<H2C!S81K'.J^W^X_NA]1ZD%PXCH%Z,!J
M?L\%#U.X&EJ$7[7OS')^B.SMR/X=J,=0D+V8H;.X+Y'-\T);88"X1C"@/N5
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M KH.51'DFSHG5$PNJE,]UI&00BZ8YU?Z)@7-/!7JRCM"X1W=WWZJ1D?* 3W
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MG]ZXLF"J4(PB9'H"7\,SDM?JI0]-$F@W9:9'KIK(]6%$P]5_L&S;42 _64F
M3>DV8QI^J7GEVU8?!:]^1D3SMW<DSCQ52!WJOF7DB LO!-.((\$Q&GXA:H-(
M=$W\TVW.41T)6H3D_:43K)?FQ^=569[@/P3QW"O.0>X?@FD$THN^131B!V!6
MO[\E9=J94LJJF#2LM0K/;86=X!Z\R8V-Z,:5*+*BJBM*ZI^Y.<"0*G"M,*6^
M:J&P<!T'S3A43 .>B.H,FC1",<U#TG[C$3TBAY)_3Q !Y .M<2X^*W-MM6Y
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M+&S>^2^SNMN!^\-FO]Z.S ^HB#$STQ&YI-QJ:M+$NO\ \9MD;.X?)NQK /\
MTS%XF//.Z$XYU!%B.:;<JZW8;8:&Z-40+=H3F@3*B,;]@JO_ )+]P#;^^#I
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MHD>[H*R$6S3XL$05Y 3V([@%!>]D>?),(@I]RO1@P[%Y!7"B9DT03V#),($
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M#+S45$PPJ@U\*)L\75%J%UR*JJ<-,9 >[*JJ@RI@XP/4+_<V@6+O3K9T\X@
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M:1IRP<%EYC9.2RJBUT3 L$1J)7V]@:0:+40);L[F[=%6@!=:Y4=-R1B17)-
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MFB3LC51BP'RNHAF R05,&-O9U5,&"KP]$V#&O1?<VS3DJ)\ WLF%O8/P2D;
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M#QJF*?V9 [TR)PT3#&M3FB$53%D^#XMQU_@ZH[F_-M-Q0E3AZ(_:V7(ZR;Y
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MC\DX31[@RK1>9,.!_95P?%L:(CKA1-@$1ZB&HO1D-6T0O_P^H$V<!O%W4MJ
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M'I5!!$\L0#@PX2^#\L.Q>6J:0HF'%3$>DVO^YZJ6@'E#_P"X6Y-1#;VQY8@
M#LHK*WP5O@G(^"H'0F8M^&:LWX($Y(=1[-U0JI5<'"<T3BO)65<&JF5\'X@
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MD71?F40>2=,5>B94JG5;(N<Z8ZBAIODF&2+=%Y0Z &28D!5D$3M_I[560?\
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M.G7!LTX->BJ73A!PS\3A.?X-RG&+&Z^Y'XH$98T6LJP0NJ53:1\5^FOP0[L
M.2J"FMA<*X5*JX7E()3D,;<%2Z<554=%LK*P^"-E6(5 RHWP7ZAX*]>Q4(\%
M^KYII&W0*Y\%4E6/BF+D>"M^*_2O-(GP6DD^ 5RK_)6^*TC"F#F1;DZH5=5*
MH4SA5*NM0;ZJB\P(5$P*S\%4%5!'!8*RLJ!/I58J@5 K*RR"N%<?%9%/9\E0
MA.X7F#)Y%E0JI"N5YCX*AJJE>4IOJO,5Y:A47FH%0JX5ROU%7)5E;XJ@"L%8
M*H"LK.K!6^"L%^D)V50 JMX*WP7Z0@1$56G0 K!4^:_-6\5Y@ J,KA?DOR0B
M,7P?A!:G/AU! RRX7X6!HP#< ER5@JET!<#WNM2J61EUQ>(5BF*C["G">E,:
M8/N#L"><7>R<W77WHJHBSX,#9UVID <TZ<6'\.#SX "4!$.ZJ$00OS525<K-
M?FK)M(5@K!6^"U 53#&B8HZ'\W-9+S&O)&1S58@("(KSX/-9/$U[7PJK*W!4
M>UKPUQ9667!0("-TPNM/>@XLGD63ZG"H<'=CVIM5%^I5;N5_?M5_BOS3P<IB
M"K$*KE,'"S^"N?@A$FW:K%,Q5BJ15E0%5"L?@K%6*.D57F)5#95 *\P\$PY^
MX50ZL@7<A5#JC <DQ8KRAOBJA,&5_!?DGIX)I,ZHP^*OX+]2_45^KXIQ),9_
M%7'BKOWJKJI9?J7ZOFOU!._>+*Y53XIC+YKRDE?S3BJ?2OTE?H*>-O8&1R5!
MXK2S<8.VP1B<L7B7:ZIC7$ZP>Y4MB-5D1$ %,2>XT4>_@ +EE<)PA(^]$#T]
MH=5WX!GFG(I? &Z>_((N$1[W4@.:)'-55$6-,E4O=..7M<QV46L$FN#JG$.$
MZS5:A6R8%,50XT5:*ZNKJZNKJAQ9,#17^*%5=NQ?J*\Q=75,&\<+J_ W"P6:
M_+!CP73!U;@NJE4E\0AJ/R506^'BKE?J^*N/%7'P52%22H0KJX\5<>*JWBKA
M7^:O\U=.X3.F3.%DJ_573 'P3FG<51SW)W*S6:S5 4^E4BOTGN7Z2OTD<DT5
M;X)R/I\4VG_\Q7FBW>K?'"C++N)5**ZNJ&Z8OX)A\E<JI*=Y,G$BW7)>::<R
MNF.X0_;1-'<);ZJDRZTF4J=OT"8R*_454JA?O3%_%/5#\58+](5@J@*D0>Y&
M( "_4?!4;W[4P9^Q%A7L0U&O9BY5BM44X3R*8&Z8E "H-^BH7[%Y0M)L> C@
MJ@.2EVXD1SXFX7BKH@*O!7@$0S=F)$69,;=G"7YXZLPJXZB*V[D70')478IY
MHHDYX.5J-4(PLZ/;_$#OP? 4<GJGB/JK84#IR/!/%P4SE6)[5;X)ZIF\0LO!
M?I"?/H5FK.F9O@G^JJ2KOVJP5AX?FK!"K=RH:)J=J\TF[ R_64VKX*X\%^H#
ML3&2J527S59+]28S*_4J29?J7ZE^HJLROU%73"1"_64QF4YFW3-?J/BOU'Q5
M7).:I\T'^!6:S3.W>@\J>"\AKVT3D#Q_- R+$]%Y2$SCQ6163YJP\4Q"J%YJ
M=Q*:,6/-4"&L%RJ@IR&C7IV53$/WH:8@=J\X)7Z2OTGQ3[8TLJ.%TY_CR5@G
M()'1/(,$SU35/852G>JU[V3F/Q5  K@=J\M1\.W\%IFW@K!_!4'Q7FE3DP(3
M4P\I;N"H8]X54-.2K*R/2V2K)NY/$IY6]_@K_%4*K+XE4D7]\T"'7FHF(=.1
M[]B.E C-7/BM+U5&0UMWI@&KS6@6]\UGXIL'+^*L_;5?I"8(D9)PP;HK?%.,
M*#%\=)"!&2K@Z;@KP@\D"S,G =T9<T9<B/B5GXH\#K4_=PU]K6BH7(3\T(]?
MG3%Y(!KX,^&D9XZ8KJ B_-![IH\DP;WY(M?/\T3[W3]ORP/OD@(H&%W7FOGX
MKQ_ARGP/0.@>16D4"+')L >2$2S#&^%;*E,+JI5SX?FK\?F+)C(CN1 -G^&
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M0!/-E8+S 'N3!5XV=&7/#5R0D,D-P!.[)XU"LW>R<EN]UF5IL/?X*OAAJ/\
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MC&1JJVJJ)TPR]@S.^#KTGJ87CN1'Q6WNQM.,3XA:8@K48E/*)_%/&-3W_-$
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M)E3@\HPIB_L 55?"V7OG@V+8D<Z)B$.B8HQ:B?@KAJS"8IPG=:7':OU!4(3
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M#W6+]JT;E*_),5I%$QGKZ#WLA%K.@0"W-#42'6E@@8T*8JQ32IW?)&8+LO\
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M"*\W3II>:!N"AZGT>W* E8QD@\I1)-S,N.YZ]B$"?/&C7K7YH^JD:E \U'=
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M^/;5&7J-H1W/[X>61>GF+$'JX7^S^W2^_P"G!L/-'3RGMU-OZQX46WLS;9W
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MU ZXG,]$XR"D '>BEL\INW:I^H.>E_%>5![V[48B]%+;F:U9>52A+($?@G)
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M@O* _,W1E,@,*!&433((CFC,\D_-.<DRJ@_=B!D$Z).2<BBU<UI"LYP:Z!"
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MEQ.G/$TK9IH6XR3D$\4Q+=^!(R1UHMSP8>P=."Z<TK?DH^E]<6D&$99$9/\
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MN%LG#]P48>K=VK:A6J#.6ZGWYK3FF9D\K_!.Z(^B\H0R 6HY+[>^:\\^PK5
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M6J08@U;-;DMSRDQI'GWJ40P *>-%]O=8@TLOO>E+=.:_R>_5?=A?X(:RZ&X
MA&)<CGR][(%$'@J@.2JG0D#3DF^13/?FF!5?Y(SE3(?17_G^/#1.J>P CE[E
M,6X&)9$P+^_U5D1  %.<\T."F%<*(\\*IL\&DO+54Q89% F_!3!^&F#\/FOV
MI[K437-,,TY#)OFF-,/].=2',>QJ]K76HED6+AN3IHDA,;)I6['*$8R8K5ME
M^CT5*2Y&R+Y53Q(^JZJJTC-,+%:LR47ROR S?DR/I/V__/ZBW.$>I8L3T<*7
MK/W+=.[,U#V'(1%@!V<55U1D;XNHGF%( JB[<'1$LT\:X43[A[E("X'-2CJ
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M+VW14X:853YG OSQ8)SBY>B#Y\+IT($U9UJ%D?#O3%'4M=@4X3G*B P?D51
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M\OCA3AHA]RQ4(9$CP4=JV>'-4HJFN2H4"X<CXIK]RT@T"KC1,F18AUI'@O\
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M7[$Q.F']HR[2F<D84"[$=W;#D5["%N;4R\]N];T^"_US<"IP!S3#^9Y(;FP
M"'=CR"CL^L<1E)@33/ZK[4I1C9W-_?FAHF)/RKW%.@8DF&8YH;NV:\L=-&'U
M32X66D!W5 @#R1B/U1#Q_)68H="AVHHJ17<, UT!+Q1[4.].@#5 $/=:A1
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M+\+<,NU/(U[>5DX5<"8W"UGL[D\23WNF)9>8@MRQIP"(5<U*GZ@Q]\E/8/\
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ML@0F365:JRLK-Q.;Y!:1^=O>J!))IFIR!]ZKR$*I)3$GQ6[#(-^"[*X,>3H
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MDQS7E/Q3ZJJ1>P*EJ+U)1/O[M@2]UY1X)J#L5259TPP8JRLJ!6"H6'5,LO!
ML/# DJA5PK_!4(0,BLT8Y/1,*)TQ]K3V+'B,"&!O^2TC+ATLM)#/@P[<!&5E
M3AKPM(W5$<*XTP?!Q[:N#'&N#FH5 R 3E,J<5DQ#)Y%T^#O:N%4.U"(")Q;!
ML-2.%."BJ&ZJE\SP41ESX 0G0 Q(N^%$P5<'%T2!:ZTC--&W$_ Z@8UZ?1 Z
M:,M.Y%DX%_HBGBM1SXA+F$_)7^"R*+K7+D5N$9'YH9M51=2VMR)$I,8RL QK
M<>9[4MWI^'2J9! $>*Z'PK@QX6*=/ATX@>U>N]:[:Y"/8RD-5!\E*0F1^2&V
M)EBPOUJJR8!3E$N_C12)S?ZJR8E$2HI,BZ'$_&8<QBV!;G[%BM469>8-[*N-
M>*J<\3LL_BJ!V\<*+HO+5. $X P(L3FF3S[O9>:K_%>4,JI^*H6EE3A?!_8Z
MS8*H6J/"RLF%,:!TY#8  TI[#2<L!FC$W(IP/AJX73<TQ 3QHG-^']2&D\-N
M#S%D2$Z:.#@H&6:#V'OWH::]B /+V5$"HZ@XI[]$'A'HQR6J,'([$0-L<[J6
MG,H!:<QQ!DW-/AX?5&/_ !*D!S*,1=1!1].9 [<@8L1J,1SC(U![%54X'366
MDJJ9#CHJ*J; #%UO;T03JG],U*%:NB"[H"/S33&28NI-[W7E%1A]O,(A40X>
M7L*IN"E@,'3^P[\&]I3C?ANKKS65$WT5E^A?I9/^H>"+1:BJ:&O5_P $T4^-
M5Y@K!5%50("-3@\JJBIEQ5X'Q<^T$1B<7*?BJOR3GFOCW85X=37^:;FO*G=/
M&N-"FR6D84Q#)A='5A3A/:GP? :K?/IBR<T"I884.#!,*FZUNX'N4\K#!_8L
MSKRA/)5+]$Q-DQ*)=^Q-*_R3E.+IFJJBB) MBQR&+IS92)+%F'4E2,Q0O7N_
M%#,H%[)Q@RKA1>8K-?<=W5."U> \38L4-V=1N2'<6J%([<:'J*!&4''@H[DP
M2.RW5&4P[?@I1A9^2D66J576F)"D ;?#^:)"#W0/'7B<ARG/P53@P#E5N?8L
MGBJIS;V%4YQ8ITQQIBQ3BGMM)RMP'3=>>^#)L*^Q;!RJX-@WM .N.D&K]ZYG
MXH/17\$P39)@695*&@53&AP/7 Z;JV7N%=75:JZI@_(_-#IB9)N*F6#JJ[*X
M43<)/-.J8:0M(X#"C*JHG3!=3\$8@=%KL#@_#7A,B69.[=J=,0O+9.9?%56I
M#%BJ.G'T39)Y_BM0MBUT!$M^2.Y(U*URH]!R[T\"&5$Q]_!-3XIPGP):@S7E
MJR:62=TQ*H?%<U=<\&]BQ3R#5 7HCNQTRW)/W,#]5YA3Q1+ 'L][JD6[D6:Q
M1END <S]5.&V?YH@29'S?R1U&Z,>?O\ DB?:MA5.P3L/!. J>RTIDPNF/&WM
MZIDV%<DXX*8.B1=DQ3FK*ZU'"F#Y\3E'V-$Z?VC\DZ=:CFB(W)957EPJB<DU
MST1#45,*AW1BR8@>"M[ ]V.D<3HG!@G)9,.-I4>G-,$R?!S4JBK@7+D99HGG
MC0.G1G=Z+5*WSX'-5Y0FP':O-ECY@XLCJIR1BV#%5S3BF+K2+)A1>4!D\AWI
MHQ 3Q+#).;HQ[UYK+4,/@B '_%:9Q/6B_3I 32#JH?I9$P#<A>J();L7GB_8
M@;+3S0 % G94HJU3&BY+4< $V#\8[UM;7.0^:])^P^DD!'T\ *$7Y]$YE7Q7
MGF/ >]%YICP!1<@]P4HB3#MS[%*9D[II2/<BY1!JF.8PT\T_!3AKQU]A3$DY
M!$2-<->8]V]BW#7@KP-["OM*4P<*J!3)O9,NH]L#T3&R9UI%'(JGE4A65&;M
M3,G*:2=U1!SX*E?@F9/&(;J:\%>'DG%ER[,.:=E3+AHM1QLJ\!/)5+\#RK\D
M^+FJ,CX9XT3!,,UYBXPKP45<",@CV)A\5^D*J;Z8'FC7 "*9E54.%T[JI/BI
M:"0U>Y.271 ^2U9G!@*IT\LWZK3$)DTW95*= CMNG =4"LK,KJGR/$Y+)^"G
M$XR7WC>-NWZ=%7<^*I/XJL_BOU_%-.1^*))*S3JE%=5P[/9TQ?VS<S\E3) I
MBFS&+\5/:.C+DAJHXM^/"X"H%EXJP\56GQ5*]Z;BKC?@9.^#8/P.G]L4".6
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MJJI@Z)I7AHFP?V0@;55%U3>SKCI3<N.BK0)AB#'XI\&":9OD$PX66K(HJJ(
M%LT[KS,%4)PX*U2[OS">-54MT7EDG"!/X+M1.%:ITZ)6HW*IQL0X1 #/PZN1
M#>S<HM8T\<#@2R9-$K)5#\^W"BJ75>*N/E++S,%JEFR=Q14D.Y-$NFYHF5BF
M:@X*I@$]_?DK!-!@Z$'R=.*LK84P<JJ.+H]:X (C-DVT'Y(F4*]'^E%H-&0)
M*B_-"/-&;W;X(-7)"/+#PQ 0'(H]B/;A4<3<%4>PIT"A.*J/BB0,;\%<8[/I
MR-?J)" Z/4^ 0A&T0PIR7Y*WP5@G8*R :B,>] ?P%$R<T08N_ YPM@V#A5HK
MJZ9/;A;V-$TE3V3Y<!"KP, LEUYXU*S6D"F.GF4Z<X4JJA63D)J$BR.FJJ73
M)XKS5*<"B8I@.\T1,L\"F" 3%=$QNC)-AH(Z^TJ'^"\I)P:.=%YPQ^?!95P8
M<%$PN4!,,402[*Y7E*I@X7FNM1%U?CHO+?JFZIHCQ0"OAVHDYX!D>P\))S3D
MV3 NKHL4YP'14NB!B<7"( JF(0,LE4%$F/T58=$VD'M"> LA 4P)R1!=PO,?
M<K4?S6H8@\E3M1F;#ZH\/C@>%EI*;E@SJY97.+<-<-F/_P"BVI'_ -4RP/AG
M?DJ)\*J^!=10;+%E15]@V-KIL'XV3<DR8<!(3%/PLM/$"$^1PHFS'L*(XV51
M7FJIQ5L-1%U0,FD5FB!0?%-4^";@.D.M4KJJ#59?R6EGZ+ET"J$05K*IE7N0
M+ICAJ-DPNJ>_Y*@54Y!5E0=^:U&R<%U<>*,!?!RCHNG(<\-.,3HR\Q5_@GN>
M*O&&%EYC5:AYG3'B8%.AJE1/&N%<'* B;_/HGSS5<0F" %_=RG%E147E+'%G
M=,@Q8T3E.*(19@+8.J5P8&N?!J(P9")S^:<<JCDC=TX%LV3&J %A\%J.673
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MH<IB,.MT%V<*SLJ;@LC\AD L,QN:L&0#@[BQ50_J!/NN@'S,I'I)%229&0G
MAUVA"@7VE%P;(>XK%*D@06I+:BAP$=&?<#<-L,RVV]M@MDV[PW0QD2IF5-<*
MK7+FYT4(MQBI382;(4(" PB/<F32DX67-9XY"LWM@H1;0W%0'YB1!IOBN"75
MMSJJ&];"D->_XV=5.8,S&6>1&"#=FYN&UK*DM<)HZE?R[1 .TU!C!@N60MZ
MS2Y!,D)$3% !H2,\"X;*!4(46G0D@L02 %,!JK(J/&9A0IBXZ/(L7&-FVJ2"
MK.X)@&:Z=8.-RWS93W"J/<9B)+2]OT3\SD[>M-,7&]M9+[P?<9KS Q%QP21N
MW'*0)@9##AC;0.)4DRH:Y_\ -%%(W P8]):I@1CW2 7C;!'N6Z$AEVFIB3N<
M#T^.!O&T7"@9MQ=5!]-E0B@9G,CQF@PGZ:6UMWG06SZGWU4F\[;I0^)CSUN"
M]<):!O4#?<M5V[U*B-J"9FN6@.$6A:V?0RE=E\;0&:#3;$,QB3,>.%%P"VJ;
M+SN";@)VEC<*O&^"(S$3.>$417UHQ<AK8^6V$409 )W @?&9P1<N$VV#6D1W
M* W#^=$8T98J!(K3+'_+;M,:A;:!F7<(-LW# FM0N?P."R(&(198R5M2-B(L
M4F2"9T%<+N.]P"QMETVEC VAU$%HJN[(DSICUL]M=SV[8=A;+;C19:223,08
MD"*8VE)87@MS<3<)$%UN0<R:T/\ IBXR!0&4$T5C=+VZ(P:DR))44SK@&W=]
MM0@1%4JMT[5W,5,22QI!%,Z5PY)VB"55 27-OU%F(@$K!$*,\7F57I:!=U<+
M>]N)>[;8^K=F&6LX=]XM[K*(C;P=BW#O(,3M4P 3$EHD# ?U ,%0FXZWF$&%
M1R8@FD::GIC;N"726=&W/N5B23:  @2@J>NLXW6UN76W&XT*BA YD&T34D&/
MF$:84!2NS;M6X4N760L=VQQ),SN\P8IAE$,BL71&;:J/)*J+E6I#541MG!("
M;57:HC]9G0S<OEFH16%2),5RP[@72Z,=Q!]3Q;E$N%M8S%)ZC!VB/;%NX=H+
MH58^IC^7TU+$'/+KAGMVR@+!3>#+&P'U[0T$^J(K6DT.";@5KA**=[*C^ZDI
M<<J12*$C+/ 871<8AV+/N-Q%#2WZBB64@_E$4KA02&+EC<%P;=[7%WFX\0%R
M 83E$#&QBL!=K!7VL%8[DVS(,[HK6,,-H!5B2 H'N;B!M7;(40:L130X56M7
M1ZI!JP!BJP<B"#03,#".BA2OI*7&">S!HT&8+"":X5O;90Y;VH &\:/;5H!:
M)]+#R-<6$5W6XUPVA55%"&MV2)]&XR2I,ZZ8M-=)N[VV&X656E)'I<12FL_?
M.!^0!23)-N'LOO"H%D @1Z3F9^(=E=S 8J994]W_ )'?;)9J29$1TIA5J0I9
M@&/K*AMP8,?EVB3 J!3&U@6:4:++,0H4RKI;S#&9V])T. F[]5B S;MQ=5<E
M9+9@*=O0S J,%Y5END"SO8^X#$>VZQ$@DQN$$P<!R[E55_4%")>.T* 1F,X\
M#\,*R,%8!P%)1W!?(FX#$.*$?''%(0)M8([-</JN#THC$'; !I2LC%EC[6VT
M8I&X7 ?E*L-!G$?9BV\!B#;"TS4U!"U$@S/VXL"@]*Y=-N*C[?M&6 =M,H&7
M6,?\9Z913/U$X!]L9_"G5<+^F1,U.D]#@;A72#E]O7 &D&IK/@0=<&!$ _:,
M\94S,=/C@>F?A,US Q,9@ 32/ X%,O"HQD)CJ/.N,H(@5I&,M)$YYZ#!F)K$
MU\8.#3J) @_9TP?2"<\XGH:X @"/#3,R,*",\_  9@'3PP=00"-(C+[\5!W'
M[:B#.#%3E(ZZ"N(G04(H,?C]FN#3)3%?_IIP9I(^6!'_ *AXX?P$D9Z^'7PP
M<EKX5 K _BF*1-6H<P3\M=1X84 U),R) $1/PQ%!D"0,]6((PQ@Q(C^Z29,X
M,Q$U%8B/XG3!+&AF8G:I\.AUG#MG&XB%.9_-G0#QG!R!D@+("[9(>2,I&7WX
M]3,2#G,F0))/701.   0Q4P!^:8VU^W%0PJ" ,@9@@?TRQ,#T*5:9$@&05ZG
M[\ 5)(W10$+0C<>O0X])'0 D;:B2&W=,?* ,IJ1^.6%,B%Z@$5H&(Z8&>TT!
M:M5,KN'\L36(),F""36?Z8RAC),4(G(G3+3'7*@FA%148.9WY":D$R0#IY8G
M(4F2:]('WXS)])I0,*T]7CXX@B?(Y4Z9?;CR@J*=*BG3SQ*L3!B- 8^43KA@
M'\S\*@+@9$: Q,'QP1,QE0,0#G,:=,3(%3E6:P1BA^62%RJ#U/X8VLP%"#-9
M.I!UZX(UTD'/^,\$R6'0_,=#.!!!Z$:#,D0:@:X(FH$P".LF#U\\"2 -.I)R
M&"9J<IJOC!G!]0&@R-/Y>&%@DT.ZL4(@[?$:XH00#M !%-HBL9X/J%/5(;U-
M63/B=,36"QC(!2V4D_?@@'058P*CTD#\<$ @S- :2HD+XGP&%K)C>U:05FIS
M'3"@@P*SND=?^AP>N?\ Z@:$$YC[,>L[M /EF!0F.IB< ;JR30Y4]2P>N6(E
M0)G6D"IG$$2*,!,&"8)/7$R" 1!@@B<MH/C3 @[B.GI'B&\,'U3M-)%8 Z33
M$R?5 "@Y-D"WPQ$S&C&36A(-)\1A2(%"(W R)@QI_7%-ORP9D02.A_GBLS0Y
M$$C(R.NF)-"1ETD17IY8VM3T0W58Z1J?' ))KJ8$$U63GEC,$P8T@SM :-#@
M%2&J0-L&3GD/'4?' FI$@P=H$B84GKUP).=%,TB=0?CA2" ):8(:2VDC73%%
M @P(B:9+3%&! $D"I!)S\<'H("B0?FI G7PQ )$>E@*5U(G[!BITC7:!G$C+
M$+NK-&%!-)Q(J!,U!@@?FB:8-)!R8D2RZ@#.F!N"@@S2@I6/#KKX8'J.L TH
M#,4RG%8V@ 3G /0?TQ%1.1G<.@'G69P0 :USK,R9P1%#X29ZQUPH*S.FM#$D
M?RP-Q)R-"(,4'X8J:@:FD3%8C'4DURR Z8(D"FIF:YGK&8Q,2,H!I :L37SP
MWIW"2(U,UH<0 /RU"BM/'!$Y&((H:4G!D$$B21-% Z?A@Q$$1F>D5!\,12@D
MD9C3++ @?-!SG7+_ *XRD'.<\OE!P(\S,"H%<OA@=8F3D234 _#%1J3)DCQW
M8I'6DB5\,?&AB!$?=&(FID&?52(!C$E02)!!C(9 $9]9C&LP=-",P3BAD$4$
M1]^*,"AJQ&<_E & 10MF(I0>/W>6(F!4U!S-#7+X'$;@#4$D930./QC$:K.8
MI(]+3TUC%/3MDG6N2F!G_+!4/Z@QKMS)I)BD8@-\H8 Y%J5J-=8P(@B/29/J
M(%2T_;/PQ2DQ-""&%0P/QP0I!) 6DR)G4^>*@U 4P-Q ZKUG$1)^7,P!-"P:
MIKXX*5V-4 !B?328TDY# W3M.Z)4F*1ODUZ8%3)%"%(*QJ>@'7!]) VD209)
M&?Q.#""2:K'I@CTD$&G3\<2-V<&@ A:"0/B<%C;W2"0"!!*B 1^,G!]%#$&-
MRS,?+UUG$>V98",F#.*T(\!4X8%9G, 22I,U_#$;2&R)T6G73!.R <P#!)%*
M >.N&,B5K&TDP15>GGT.(H2H! <@Q&4&,AK@'( $1F?(GH=<?*%5A66R!&<G
M33$K$,8)$Q&A(.0/7/$,XD#,Z U!D^.>%)<@@4=8E3IZ>AUP69O4(W%25%#\
MP K76,':V7JVS(.A!^V <"'J% W$$,Q4?E'A_K@$W(((,-Z@#%8'2M9PH(VD
M-0E=H @Z]/# !.X?-MB$4YC81TUQDORQEKU\_P")PUP7&N*UEE-I'VM<8D&+
M=HA8I$Y&*BF& :!N"A2UPRER8MV4$$ ?W'3,UQL]3[;EL--Q@A4K)#Y*(4C;
M!@G.N+CVE@%53U6HN!739Z4-0S1$5R$5Q/Z1*@HR*C6 +X&XD/,!P*R9F363
MCU%B7#7&VW2I0J,I8S!-2S 173"EIMB5470'<HI6+:BV( )T;/0S.-R>E[()
ME5)8?VN6$^HSNKE7('! : C*H6VN\6V-O<URT[ 4D_GK,ZXA?<!1@XN[5]8_
M-:+M(<M,GU=,(MHJ"HD7 "=B@@%KFTZ" %'6!E@!&!(:V]T0I,;ANXYV0(U,
M=9PZ(SU+^Z&<@JN\,$%X 4!, TZ5RP_SL2N\!V9:JVUG4@26$2MR($5PIY"H
M[(ZV;:@B &$F E&+!=VHG6N @D6[:M=-Q4"V[Y5J *NC$Y-KGA7F[EN6\MHA
M5,M\H0$*=P 4@#.8.$5@&)#$V]I!]PG>I%QQ $SI4U@'#)$?I9JK5LL1NV1$
MG<""1D<QEAI1@6/((6Y+NOMK* G0LHS!-8SDX!<VY4JQX]& W9F3( %00=?#
M!K9E[14B56V0VXMN,@%J4 SI!PENW;VW6MO*JJ/*L"43D-((&X2T@D+4:8]
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M9'7$L 0=LU @Z #.2*U\\1"G=$BOI!_NGJ#23@"H@ D&( B@BE,*IGJ2"PW
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M[%4D -7($FGGCV2EM4&Q61DW*AN#T_JB8(4FI'09C _34+>63=/N*J*P]O\
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M:3!(,"LC% 1]FN0K@36<J5 C4X$:9CS&N/FGJ.I\!@1EETG49XG^/ATP:9U
M%/&DX%8\=?+ K3+.3TDC F,SU^&(^S&=>DBE:@8RCQ)Z>(_#$3FI'2FN(4R"
M3!C4M0_UP=K@&:^8K@%C69^!U)P :29\02<90*1_I&-*P8I]M,3X?A0QB=<
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M!XR--8&%!C/.(($ZC^N(F)$#0-6L8(^4L"I-.N9%,28D4)J:Q3"Y&<ZC/J,
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M7\3B! ,G:0I@5B?&<5KF 1TRHHZY$8! @3,SJ!&F6),G^T3$@F1&W[\&*@*
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MB=I/X'%?]QCI%)8G7!_VP1%09J1/C]V"3 &Z(&M):@_CXX.4UG7:)FGP^W$
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ME] B?2(F>LX ?;^V=#<NK;W%BULR))K!&YF42&KA";UT6G2XF],R+N:LUO\
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M$W.AO&?5N?0D%CJ* G+"H[LJJJJUQ415O%_DN5R"Q!DR9-< ': 6_P"%BP)
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MKX^%,M<?_#^!P/3% 1(&<^&,I,9C+'QJ8B8%13 ,:SG($]<$:DX,"!4^/E.
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M"WC<J50K*HFZ%&W5C4U,UPC +M6;8MPA1E4PX%QXR-216(,P<!&%L@;$6XB
M7%W?*C'4]1DM368P[NLW5*?(0TD1!MP"28-5,:DXN,!M4@7+EM@X"%B=P 0D
MM6"(T)\\$74@A+:^VN\W3ZMY*K)W5.[/*F'W!K2+L=42VXMPHW*SE#0,*L$K
M.<0<>TJAUO#:ZVV(*@+ N7' %=8T%9)PUI5*@K>+$W"UNV"WI+4D;JA0().
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M1\L#P,&<$W+;%/4A5F%L@Q"W&*D$ "K(-:ZXN[@1;%Q@KLR&V[+\VP_-2:5
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M4PBM[I4L'+>I2M20P- JDY>,4IA@')?<I5B 7 "3#N1&6@ IC8A0,H=T]Q1
MNL &]N)($F3I.7AL;9N>-RUW .-D@"D0!7,T!S&+>VS<*[2BMR]UH5EA[=HU
MTCJ!AEO+;9F5 5]ME((&X(S"IE:23G7%JY;;9<6X2A%JF\'>/=*9UI(QQEV;
ME"D"*DDQ"H9IE)D 8LG:0$925(8[:A2N[6)Z9X43\JR>II&WQP1-8I4  1D0
M?MG#0YB@)&=121_3 5G:6/I4=2=VVF>)&_0@DU@FO^F%T.1(K,4TQ(H2 :S'
M@)_#&L'PJ*Z'7&5/[JUD5P-QBM--8SP-03(,TG0_A@CYJZ4CRQ\U9'D5ZD?R
MP(I)Z4CK&)(/023&>48$P/$#*:'!T(,^<UF1ITPP$EZ2!GX"<&,IU$;2-9RP
M=8,F#Z1X$#[\36*R20!\(^[!,F@&5:&IK_3'RG0 -6GYJX%2TR)!VQ%8$8RT
MF#4$99_SQX$01.0ZDXG0BL&1/2,-Y&9R)_UPY_M4@Z!I,@P,2226;,TVF8P#
M4YYZ@U!I'WXKM@_,:%A33'I(EMJTJ3!T_IB4!S^45)$R3'CA1;4Y":$UZ&//
M$&VQ8F@()&Z*D3E(\\'9;JT>F&)R@"=/,X]"E23%5)I.49FN &62""8MELJA
MMWAT&N/^-@5'IA"96*!FC^6 3;,FD[=H6M"/Y=?CB?:<F2/E.9U"X@HP&W:(
M0@^G.<_,8!"%>A5,@#3TG[",&0PKFML>DP?4 <2%8%=I)"#=(H03TQ;N 72
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MMH?"!(\SBEL&(I $4Q_Q*=(( GSZ8DV5 $5(4^7^F/\ C63T \\L5MJ(R-#
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M\]8_ZX&]E$L(%-?36:1A23;.7RF::#"+M#':( @S2((_BN)**3UB8KH<\?\
M"M09/ICX1^& /90[<A"Z_CXX!-A*:J &/4>6/^!(T@=*U/\ 7%.,G^ZGXS@
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MZZ1GUIB?^Y6,XK=417*N@UP2>Y\:/_WHH#J*_C@(.Y\=F/R@7!IK'VQ.&_\
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M!&"1_P"K/.-:], @YFITW$U!/\L!09D:&%,?/_U^&%@H20!28'3<!A0]PFI
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M>W28]+:^?WX*FXT_,8=3 G.<#]1JG,LNE1()UQ*W08^8%Q2M-S=#I@3>0DR
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M/2OP.-QN7&8T4[KFTR*@3EYX!)O5A20S;016(.7A3&T(T$D%5=PI!K()ZZG
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MLSBEE8I'I$D$RQ&4XCV!4G3P@1/AEB6XZ_-.W=$:F<$"R"3# $!0!K,_AUP
M+4;37+U 9,3@[;%0)!@914_'KC_A^803"Y U@BE,!O84$D9025.M:_TP1["#
M[B)^4DC.?# BT II!B%(FJTP1[(,+#93N!RDT\\$^Q-<BW6IFF6%FRN8AER8
M$T !^\_=@Q96:&9!E@9D:^7A@?I6Q H"1 $Q3XR,&;%M@?3$K)&40,AT Z8_
M^=[8DG*#$Y$Q]V(]E-M"1-*Z$'[<0+-J*E:Q3Y=LU^S (LV@<]#,&"I.8P/T
M;<$Q$+!T( C$+;0 4J0#&BTS\L2;5L$B5)BHU\SG&/\ AMK(B0!,M_77!FTD
M $B  )U)G[QB?80S! D+6:"8Q(MJ ,E@;=Q.6WKXX_X!T^9/M_TPQ>^XWE27
M"$V[P<'U/;^8N)H%RH:98VC?=%P.1;@&W)CW=UV9D;8*G6?BEQ5MK;9$4G:0
M&:3;%7]6TMFM#/4&<!&N6@8&ZYL8[VN-(M^VX@JTD%B9$3$XDW6)1$DED.X,
MTNP9<R($+1C\,.0E+J@JB6R6VI6W<-QB2[#YG R%!EC>B,R[) G<BI,*+(-!
MU$ZGPP3:N.EPVF8!MMT0I )(H*$R()C(9U0W+B$ I;;>L.2XEV9Q_P CEI)7
M;MTTP"'+6MWMJF]6A0^YA=%84&AD"#EBVULM: 2RY5;BH A;<4"L8VM("[=:
M^35"LYWGU>L!#,4IN!(W*M"8Q;0* S!0H56+HSSZ'4F((&4@#.1A6BSZF]IE
M4EP@MDLTD0"L28\*>)NR_K!:XBV]MUMIV(2U*"DB) K6,( [^WMVNR(%)4$R
M6=J =#&DG/ 92Z,S>XA'ZB$K#6RIK-,XH#\<&05&^XS;A/MW&.T$>U!SR (%
M13/!N;G%TNQAB!L:@=B)BA'I&IZQABK7+DL'!(4!]K$$W L21EFH,UK@BX ]
MIKBCV[;-L@CU+[>H+"9:G05KO=KGJ5-F[U'VT:%4W2/3L% ")KG@6D1[MH0X
MU,?(P;;$[!,&8C0G!<*3 52-BW#"L R@K5I%3&&1V.]F90^T*EUOF=&1 54B
ME!KGKA64'W"C60'8-L5K9"$D5JQB/"3TP"CPA4"Y9WLI98W$J7DDYB*? #$
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M\5%*%A7RF<5$"M")\<AC("D]:#PP8 !J#2:G01\<4^-)J1E& 3J)IE2I,^&
M23-8G/J,O#'Q/GY=,$"9RSH3G$'&<USZ$9J-<3!J.NG3%(Z?Z '#5FC9R)&L
MGRTPPSTI,=02#TP1N)DS,1-:*-)/7!TBAG.OB,1Z9-*T^T#^6"9,"JD>HB?R
M@T_^$G!1;K0%D#<9J09VY$SXX>7N;& + W'&TF<@3K21UP3[EPRVXH0T+MZU
MF@RPL^Y,$?,?2(G-M#]HP0S7*U,LTD@R*C48$LS0#NACNW5 <Q ,4K@";D!O
M4?<>8CIGM$Y8E3=W$;20[F=2R@TPH]>U48#UD>LG+P'AKA20]&##]0B21HN
MP1A61ZV,_E*GQ,_#$&T1($CW'D"=&6FF/^. &W;1N$J!M$+TRK.*VE @&!NW
M$1G4S-:C%;<+# $$ 4-=I'WC 38"1MVK7:%B2?50D'K@'8-PDP1F&H0?YX,6
M@ HJ=L@4EMOGA0+5/]RY',1/A@_H@&IC;/A)ITUQ)MH01L^0>H3N-?$=,"+*
MD1!W*(@TDS_!P6V*" 5JH8$DR0?ZX4>VFW*8#R3\PG,X!]I)F:V@9 &@.6)/
M'7Y84A0"(%3(U\<*&LKI4!3$C(Q3!+6E(J"-@BIB1_,8@6E@T (D$C2M,']*
M <Q0M J2"V5:8JBYR9H=H_+XZ?ABMI2QT"S F3 R!\<"5&8 D"L_FK7!&P23
M(^51&I/],?* #H -QDU8X V+'6!ZCXS]U:XDHACJH,2:* ,"56H--JTC2E1X
MX$+I%8!^WPZ4P/34"9-#)H*QIG@RN5( @YS0:>6%H2:B,BH)F!'AB0F8](($
M!HC=3*F%8K(RI  \XT_@XG:,IIU!U/A@4 FHIJ:Q_%,40#(T ($F:>?33 &P
M4D"A(W30D=#@ 6Q_N$^EI&L_UQ(M+$"# CKID/#'I12I,&AI(J2#BB*(6GF=
M1^.!" 5,D&H)H?A@[E$&@((W$]8_&,*1;VD"2"01,D@&?OC"CVU)J)U'6//I
MIB&"5\**L1-?YXC:#%*K.W0DBGPG#;D69,-G49TT\\#T"2!3.>M1UQ2VBG<"
M(S!&<DZ4RQ.R3M.LQ(KBB EA($4K!]6*HI 6*GT^-0:S2< A% B2# B,JYR3
M_$8(%M1I036,I.G7[L516R  (42/S3TCK@^A(F5C[MIZ'IUP%]H+20T3X$>'
MA_+ A5GI0@2,YS/7&T*A(G\M,\P#IB"JTU()VZ[1&6/E$A94+6/_ $SGBJ@,
MP!C;("DPV6 =H@F3TD  3K3!A4CH!&XQH3BH ,;H(@1EM 'WF(P 56,VD>K.
M1,?9B2!_NF!)- 3J/AB"M*%10G++RP), @P( J<QXZ>&(  8F3(!WC,&1@Q2
M?#=Z0(T^_ R4-!8"GA0C\,3K('RUF((C&6=9$4.1W1_+&XQYFE,I/A]^ -J,
M.O6,B/OQ.U30Q7,==)KE@, HI4[:UTC^F%W:R!4RIZ/]V#ZAZC/IR.W.IUZR
M,#U+%3M!$M60?+"C*L;LEZQ/XC%3! SB0*Q!\3@M(S@S$;IG7IIB5VE<S4$&
M: 'KY3%,1-!N.Z!K2=IZS3PP5!$ ;8&T$5GU=?# 612#N)FA$4/P-,&?;-08
MBA%"-O2G7!/I -9FE30R/PQM*KF VVIG,F)GX8@E3!(,03!,21I\/CC-3GE2
M1K(F,&2"/FFM#'I'X0<2(.0 D4FD$'[1A0& (,,0?5,Q]A&&^2E#6@K-1@^I
M5I!$"DZCPQ\X,9GI&1"G,]<4N*"34S.6<C6N!#"@I!G/^,CAO5-01D#G)@FF
M(-Q1(@"DS$$">FF-I<0* TSF:#^>"2PD2(I\HZQ6F!ZU,$C=(VDGH1@+O4DG
M1Q%14[CET,X,7$82QC>#Z9CT]*XDO;DR 2X@+H9^W"CW%$3+ @BN1\L5NI0E
M?F!IK/GGBMRVT?[HST,9XDW$H3(W""=3ZLZ8'ZB'=N,%ED@'T[0/O_IAINK4
M%HW#09R,C^.#^H"!+ RL$Q2 ,LA74X^=&,5W. R]2(U\L%ENJ1HM*3ENZ8,W
M;9$4$B9%)*B3&%_64AB3M+#.:BNN 1?MJ 5 ]59!K$'(98 %ZT"3 !=:@U,@
MFAZ8(%Y929]0W&L*5&GQQ)O((F9(8@K0_+J,J8!]U 1.X;P&+&B[1D/Z8,\B
MV))IO494B)FN>"?>M 5VS<&P[>GCX'SQ2ZH BA=9$F/41UH/],?\EOYMG_(N
M7]_EXX2Y<0VV ]HF6N- N';8:T/4I-9=1$D#3%NU=XKI8]W>ALJA*O,W7<-F
M:1GE0X118]L*^\E+1<';\OOVA\P"S69$2,\(;9W BVNS>AWER"-PNP0C ;@!
MZAYX9&W2)+@CW$VJ"RWBA DUBIR,YBC+.[C*%==Q C<?6MM@)7J!,08Q)4I=
M=X2T+?Z:^WZU(1@1Z<_.AQ;%NVJFVJ0J7&]J6:#N!HIW:0*YTP%9$$M-Q07V
MNP4EF)?Y#.3'\:85;98(Y"J4MR;MT01[AN"8K,'"-=4(H=5M"V&95+J2[';,
M*9^!%,\68$$,4%MBI>V Y0,*1+&M0/&E<"2RNGZ3.A&3J"2P7,T]5:#+%VV0
MWK!0$( =JG:SJ1H3 $B, R $ %H,2P:!6V2QDBIG_=D8Q[IA_;!0M<8[6M@P
M1<%<B9  H-<+;.U;:(L-M8D;C.T"8:323D#3P1F5"QDPU;6RFY1&4 T#9S6F
M#M4J=Q4/M$;5(4JZFLU]$99Z8O&3[;$JP'S$L5-MU K7^W2)H<, 2ZA58@0/
M^-3-TABQ )$1F8&E<),;6(#^V$4021[+I%2=!$# M6D9B*6E122OY=GZ< JV
M<'*,&X_N>TX((M':PSG:@$ DF*F8\\!@VQ$2V6%LT9KC!@HW>H01^;(&"0</
M<&YU4N;EQ%B\P<>F_;N-,L,O32*'!+JSFT6+!1M<JD *0U29].T9CSQ$'W+E
MM7.R EL+ WIN]*.=))H#& ZH1%W8!N9B7:X0SMMR -:=<HQ;%Q'<;E3UW(55
M*$#YHD3J1.DX?> SN26LL"./;);:&M^V3!SB?5U."_J*7#++<"H&$2J"T,Q4
MMM.<>6 /;N*I*,6V[RQ9#^HC6S34T&6>6%]-Y&&W<MS:5@$;?984((DEB*FG
MC@G8U&++[9)<VQ7;Z!)!S9II& -LI'I ,;6994+% ^88S\<#:I<VC;N,K6V5
MT!7VUNHOR@F(@?-F9I@0& 6T"LD^C?.YJ1Z3%3]V)MH7+,KAH;;5(.TD@$$B
MH!^[%NRR1<<6]Z[=VY&.[<\B9F0#G6F!<",!LC;1%>*!FW'YH !RG2HQ 0"V
MQ:X,B55O3*EZP(D ^9KB67W&5BHV#VU<@!JKJ8RD5\,2UL/N%TJ@#&4VP453
M(7;KKY5PDVPP8-M 2?TXW$*HR R$FL8+7$VAE6;BVPR.1\M<E(G^4XN/[2LS
MH$#(61MC#VV(F9W_ )1GI(IA]HED8* %6K!1-OUB"0*0>D@SAW4$'<AW  [5
MC=4DR8$[:8(%H 09=MS-"B!5:93N(H?OPP,A%,F%+[MA$;7 D>&I&=,(V;)+
MS<8FZS!8MNCM3:21IA"ONH0]L;"%+"1N?Y3IH223UPP6W)O;@LFELCU/%TUC
M\Q7*)&$4!2& %UE5DW;B/7;S I3^)Q< .P6R&5PI!*A H4'1O[LL!VVV_P#D
MW*REP2[#TL5J!)$D?9@,2J %[A.Q2KECM*!#!$9BA@5RPEM1[8(47%6X/TRD
M>F!):1'J4" 0!.+@*JKL2H*$VP 1[FU"#.DJ2>N&;:[;F6 3M#.+?I(V_F\0
M,IG'Z:-=8 @O+;UVB&M[C&0^6,IUP/:;D6D@E;EFXR[D18DW7J&,_$3TQ9'*
M%Z^M+1920X$289LF$QG7QQ:"K<<ML62Q47+BMD[-7KF*^&6+0?>1M'J9<]Q.
MY8.1T'ABR&!R 44@.3NJ<9$ *HD&I84R'CD<$E9.M*DG/!FW -)45!URU.%4
MVU#)2I!,DUC^6%$0%"Q,DJ1GYXMBD QI,R*4P#(D"<^HJ <4!&I.L1I&",XU
MR)T%,%J0<SK)Q!:I@$Q('A3$U@UGQ&0$],0('CK&9GQZ8F(&616)%1@9YYYD
MC*)UP28V]#2:^.N,Z&09F<I!C!ZY4K C[(P)$ R//J3X8.L4W&!/0QB,Y.0.
M?E.)I6M,\2IR@@169J*XK%:$C+/I@$4$QH3XG%:TF=)BI/\ +!!@GX$1'C@B
M#,2-?/+#D>,F*3&4:QBFT"H F3.JF?PP:D9#*!\(Q29928!W$>JHG+2< $B-
MIEL@TM5?3E'3$1$9#*@F')&4Y#"&AIN.X',C,3H,*= 2X-/4"/F"]#E7&X%*
MJ2)!SF=M<L3MD20)%1N$$$:X%!4RI](*P-1J<$MM!D34';TC;3'I(-:>J!_N
M(.677&XD0.L 03 +>=1@3L()D0=HC5?&/#"MN'@U?5)I3XF,$3(6M67U]#(^
M_P <3O!F#N@2(,B3^ Q.X3!C=M5?,G.1A.-R5M<JZ6V;FO(OZJT(V5H/[L6R
MG$[9L8A2P<;I;(C?6<>Y8X_MEC(>R048:';D9P=K*P6)J$8D4"E6ZX&]3:.0
M#*(/FRX#;A,@*"9H*F/"?]< ET,&-(SH?#!^7TD$U%2! KKB97TU!-221\W\
ML ^DB($P"5(US\<1N$@&#,@F=>@\,#U5.D1_ZA@04(DMG.ZE:??08@,I)KN-
M *QIB VD$93/GBKJ10D3% -/XK@0R0"*D@3(H%;PSK@M21U-<_Q\<-D/5$DB
M(.0,U.O^N%!*@&(BH$>(S'A@Q43E( .E<,=P$ &#FQ)S Z8)E=P!_,!69 CP
MTQ5J YY&>A'\L3F6-2""()DF.F(++0P #,,>DQD,#UJT @3 \3A1NDQ!7<HB
MN9ZCI@P5J0*ZB/E;\<0&3U:3)H>OEG@G>)),D,%TFA\=<3N4ZCU *-(K_7$
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M=2V@B@,1. 1RWG<H)4DNA)"A;C+F#H<,[7@2I8.PN3%/F9LP*P -<L$&^$*
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MZE.WTI4@B:"AH3@,>.59F8,MLN^PV\A#BLF)#4&AQL%L"_<4 H8A?1N(%Q1
MH0"(SRI7"NPA 2=B,AW$$+;%M#0L#41IJ<;?4-ZD,OME-P!_452).Z"0=QF*
MTC"-=MM"JQ)4.6:T#" %J:16M*8.RVBW;@MNQMBDM\J"XV52!TG.F%?8";;_
M *EHSL6&]# )4%C, 4!$SB1;%I3N00Q!;W +K3N!"J30S61XX=66VZ@N@3:%
MN+'KVWBU #!A14 @X4!51RI8 VX"J4@@&LCR-?#/&\64#.LVV6SN>L,$*$T
M,@C=08<JQE_6005LAHVPK2,A10-)!RG!'L(5,;3M</G/I.@_V] -3@7 =X,(
M"RPJ#=M9'3^XZQTZXM@V@6) 0D,"@.0.5>N"S(?42+:J6(N7%$^[,2/$S33"
M KM1R%=MQ 5RNT)<.9D169QNMH&N*-J[OS7)D*X_+'QI%:X"!-ZR3=Z2<HT,
MG('RI3#77M*_J'N" MLEUW 7%:3N@#;U/C7!1U4M;8W Z6]AVL,MQFJDP:2#
M3$[ 6#9E8"@CU*2:!BNIUPOI!8N;@G,I!IM68"B2TBO7#*]FH1&#TVE'/H8
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MQM]V3$G:=WI%,SIUG$^Y)TEB2 QH-NOV8W"X* -&X!JG(1I3KB0R@#<^>W<
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M/[D+LJQ5FN$,A@D'4"E.N(;DE"%9PLP ^VK$M03/PPI')B8&\-!DYJ0T0/\
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M+@C<24;W!<K6*!LH-?'!<60J&6(N*6?<XV, @ !(_+'W X(]L#TE54AC D&
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MK<!2B@F4'H!_^29PH8 ]2!N@J#4@Z S6,\!0S;5$;XSN$2NZ*$^-/PP!%PJ
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M U"8/ZA6"LCU(NZ #X^<8E0"54L"K03N:-H69%((F2< *D"-QW#>&4F&D4D
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M=< =1((K3,Y8DRU3%0:9DUQ,D20),5!%?/QQ)W>,&F<G[,\ DD#.@D5&L8U
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M/2S*:;-PU,#U108(T0;B@@L K4)FDB00/'K@K&U4]0*,<B-Y5&:HK-0,+ZF
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M3[9N: &M,SX8]+$>H!]5?3:A:I^&48+;W"[65E (H.A03!S)/PQ*. 7].CB
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M83'H)#&<IJ1XX$")$R<XTJ,O+ +?+JHS B *X7*@T@^DG,XU%%--=8(QYQ4
M$CSPTFNV2)$%=3 PX,3KT)B5_B,,# ),$5VY[F(^&F(@E23 )RU)$5@X8"%C
MTC<23E,R-,.1!(DU)!CR'WX)(]1D4&VNIVFH\,,)H 9(K/1S.1\<%:P2ZL00
M77T^J.M/YXVA22BG85- [&59"2?XSRPJ258-N>%GVZ@ R).XTGIA7G:01(+
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M#GG@JKE6M@M[8('Z6\*Z"LB1 D4ZZX8&XUT'Y0K('AJFT=I&T" Q*BA&-ZW
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M!@,#M$Q%28(J 8C748IY:$9>HR<2) 'J(K21&35\L4$29)!)#$^>0_GA214
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MH47GMR&BLBM8RP?U3>0L'G<=RJ)%N%)@K/I-/3TI@,H5KJR9NEA!;_D#.E
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M4[<B?L&!-9)@9:9F<  &FXYP<H UPVHB:$SN_N8?B)P^P^H$B#3/, 8N2I9
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M\\?,0?&LJ-)'V98DF8,BNV9I%<16:@^492/+#012 5#P?'X>6&@D 4)D](@
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MN$+2&'6,XPZ$':.,K!D]0"B[M((/3QQO4AHI!/J S.>I\<70&J?U6\"U (T
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M!P[(OL2%<VT692BO=-K;!6LP3K.F')-OVCL16>+ERX%>C$58"21!)@:5P [
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MY3@MI! %2IW>D[B<C]O7#ZJ!D?2 3D:^/3#'6=I5@-E3X&9G_0XV*!).[UU
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MZ'%?2T C<NZ-*2,"0(D^=9K'G7'J))$B361$P#G7&4 $$#=U.8'7PP2"(4,
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M.TP9VZ2,<'G<2ZK)<%LBY8<D7-[#:Z]3G,X6URO59N_+?4C]-Q0(X%(,T.$
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M%:5-:C//&WU &LF*%!,A>F6&@%C!]0A2)RSH1@ B2 02PH2:'.F.AHL$2*U
M.DQB9\Y.X>0'GEB)$$05H:ZFN>&($@3'C6<_B<78%*-O@U6/EG+3#[:'U.M
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M2102 "2"!7+KTQ N1.9F"6.HD_;@@N!Z@ <P#$C[:8]32(,D00L5+$F,\L,
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M=]YJY<QE>SV?B@H%+O<B'+Q15U Q[O)YB\<+:9Q?*&W[>XP$L*VGCGCDGO\
MWR]R+-T/?;=<2U7YT2 9VG(+ G!/;>$E]RI%GVDN-</MT]0 DZDC/I@<_OG.
MXOTWV_D$_MK&ZV>2UAB0+YL@[B8/I0GQ-<18[7<[KQ[U];UGNG+_ $K19$VG
MDWB__) K2FF.+V;BO;N<-$(=K+7K5IG!,V[2VZW-HH!6APW&YW>['8+/*7VT
M_:J7Y!6X0;:.UL!]T$[E$"!4TJO$^G.P=V^I$Y=YA>[O<1^-QW4DK<N6FN
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M;)$001N \0 "&-<;5,6R3[;*[%=P,*=K4F3\L1TG$.+3M E7DH[@R#;VU!U
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MEA3[<DZD"NOI^&)]NH "] <H ZQUQ51 %20L ]3_ $P(  !H-3Y$Y_TQ&6D
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M8]77IBK 5J&@%2:YC,8:#.T3E^6<X.#!^8#:&S,4E9R@'7#DE@H!4!:EB%D
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M4$236%N'4#3QPJT*B!O$(Q&9*L-9)$D860%.?RU8QM%L*H@1K.""@.;4KE4
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M)G;+23D8SC7"Q; I&X#Y@:T'VX_XQ!&TBC3Y8 C_ -!VT'6@TQ50HH#($CJ
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M"!4[@.I(@?;AIW*K@2K97!0 DGP^W7%P[=PDB68G:Q-"?]O]HH?A@JU?4X!
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MW$W %5<F(K( &<5G#[+P7=M$[?;0$0&8"N0H*BLBF$N41@:726)-065%,#:
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MU8(*E2((_P!H8:F)& R$32E()!.U)&@UP"+K5:34,P7(DL#49QD, &ZJLH8
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M!:?IO#0 12 0168PON7;JBV-I9)"@JTO4GKIG7'N(3+KO:Z]4.TG:@45KGN
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MDY%8^PXF# #;:&I4>K+3%"1E"@5,T 4ZS'V8%--I\&!W%0,"- 29F8!D4\L
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MMDXURTO'-SC6B3**ZB=T9FAS&+-_L/8>)W/O"V[7%_<WK37;=E[*A$5!<)(
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M.Y=U1G[=:<#]US;9&Y5XEMX*VI@;R(-8Q<^H/J>\_;/I;AW4/[4E[;\A%/\
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M]FYW6_:N6VO7;CM>X5AV](]MW/J,^EB,M,6._=SXG%Y7(%NV%X5FWO6U6CW
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MGN?;SZD(DQR+! ##'9N\?07,O]V^FKO'_?\ :F*_NN18XZW&Y-A.Y6GCW5W
MH+@]29@ZXL<WBNG'OW#:N\OM;@A^W]RX""SW);;M\R.#N"G0@UPMWCA!;Y";
M@PW.+983)8F0.G3"!@!>)MF:"/5GM'EKC(-2&'YI)UW&!_$8DGY8*U_IX9X'
MI(AJZQ2=TD>.#(DK,JPH)&9.OPTP020:%O3FI,1)R.,R)!.VC;?+P\,#I01E
M6:&N?CAR2!Z:BOJG,08R\)\,22I W!6V_,: [2>@S."!)VEU9B#&UJ$&*1TK
M&&4,HBADU612,P21D/MP49()$$ Y@F1ZEK'GK@O;66+%PLJ"Q^4U&4 5P02I
M 7U5 !)-3OZQ0TTTP I@5V,& O"8)!W"-:_9@[838K/L<JBH=\N&!J)G,_#
M/H#*IV!GWFI_X[4S0Z?'%L&'9E: 852L20S5  RG.G4XML%5V(<!I]MH_+<%
MLT)! 'B(P8VW"8GW=H]X;:,23F#F*81&>XQ8!7(522R_(B1E&50)RQL$;F!#
MP:^H>DD-)H8*QY8+@LN2[8"+19'J$Y1(^PYXN JI2'$@K7TC<^TT$'KETQ\_
M%_Y]^9^3^SR_W9>. 02T#VXND,P93L>"(!H212>F$4E' )2V0K?*-;FZ(/C0
M8*[  OJW;@=VVC-M%00?E&OWX1 98"9](F&DRID5%0 :X#%6MRU=S*HEE&TM
MG!B,AX8!"JK#:2%%9!B/&F6FN#O>K  TC:PK!C\<06!(CYC.^DD?'4BF)HHV
MD*"3N,@D^KJ!K@PZ%0"5$UDK.V1GX_9AF!!823'I6N3= >FAPR!ODHL>HFXQ
M]#@J130@>66(+ ;98BY(0GY2[@ [3T,XND;4)$HI1I+5%MMRC+;G3I."NQBH
M5@[,H;;<@0J@5$D;IU--,.RA'B\URVI&_8K"6:Z6J#3U;HKH<$A=ZL753:H$
M/R[ (E=I(:8K63&##HS(MQ5)4,P"Q[FV?[R*%C3%RU<VLMQ!<EC+/'IAX%8(
MK0FM#7"LNXL5M,A),VT257W%84,F.I F8QM5B6EG65(#*J[C!<'*9"%IUR.$
M7=%A7558.8-H 0D-^53+$UI3&Y7MW+A<!YW$7-2 <E;(5SI6,K;MNM@;Q<MV
M6W2,I TS@@^,9X'N!G&TSM9:VP_Z:[0)$_\ 7&QU.UE!0J__ !B/3<>X<S)B
MF8I0XWFVH*Q;(0!6+V3[;;F)I&8_+42=,#;;.Q%+05!078AFSJV@ IX8* $,
M9:U-4E34,5BH%&)-/'%L*BO(.]6"L-I4-[@9Q'@==<.X_5MMM5W$;)9_<# C
M6A@CYM<L;F 9#;9MKKM" ?\ S0AY$G\NHFN'#2H'ZLS5@]J-S3TBIH"<-Z7!
MW,"H$+;M@#<5ZU$T$U.>+BW!.]@P9@_MP9]P,/R4A5W"3X5P8=E>X!Z@27#
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MO [<]X6^&;CPME+RAHS4+4_OSR_J+ZEY=SN!X5_MW/X7=NS?3Y5;VYG[+RN
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ME3)#-%!B\]FWQ>R]G"[+)VJ>0BJ(!1AF0((@$^,XN7>+SSR^4AW-RN;=%#D
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MIU.M,0)/J+!67<R "6@1-# Z",.6VL]+DW R IE.V@)BE,A&%*JJA32X"2I
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M;+2,W'LVW*\2T@;VU:Y[<222"M(G6N+?=_J;N:\P6KZWWM7BI3D,J;G)0^@
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MNW9<!@2YFLY=<!"P8O99MXMPBD0K;"NL")G.<HP$):Y<)=BRB0SM0N%#10&
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M<4[4E9<MZG!85,&<JZT.%15S0&99"PW"7$CTPVGC(Q/R']15(2 QC:P2: Q
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MSZB&.1&:Q6=#AF4)L5=[;D)"K,!QM$:1Y1%9PBLUP,LYC>Y*FB6Q&X*LYYX
M+L0I)V[_ % GT@NR@ $9+X:":@AW19:R5%QBZ-'J<;JYS,#PRKC<S ;;;E@Q
M+,2X!41,EIKXB8& '8NH) NJWH#$0&*P*S  TS,89RVY;1:XJ[C\B@*ZD+$"
M=#4UQ87C_J7;W(3BVT!"A!>N+M8,@B(,%C4XXUSC[K-X\4\'ANJBTRL]@MRN
M>J$2=T[-QKKE3%WN?)8<GG<CD7+MFU<8N0ZW-PEVUR,?''*[EWJ]<N\CF.6=
M3>+N=PHH&M-I"Z >&(OWHXO%W);LVMP"J?E5Y,.QKN)G/'(642VRW"+: HJ#
M.ITUD$XNKP0%MJNYGNTLV4)@DQ62=!3KB]:MW CRUOE<HD$L)J+9$P(^S7 ]
MKAVN?S58J+MT!]MQ:AH-17+0X?AH/8XKE0UBPI!*BFT%-/A3#V+(]KW-Q4L2
M6B)+;1K,U.";EZ]=(8M-S>Q"G/[#E\,&6?U$^GU0)$J*9B,\;KEME4J"6*MZ
M=U1(_KB!"Q4_F$:3/7RP=S23#+D9GY0@6OD,6T:S=7>!$VW+L,FA5%?P&>./
M>[C8MKQ$*7;ESD.+92V%#%:^$2,SI@7;/,7N'<;=I6;A\%%VERI)B^9&V1#!
M8T@3BU9XMH\#M*VX-FTVT;GSX]P'YFBH D',G'_V#X/LW8%M>3= -Z]M.WT)
M$*"*S,CRPO-[WSK?(Y'N-<M<!;@_;<=@)5N7>9I<M(@9#("<-Q1=>[[A(<(J
MBUQP#M+JNI&5*^<X/(M=MN<JW9<.MV[;E6MG)BSB!3YY\#CB6>1;[9:O"TRV
MQR;MN\O'O.!%QK8@4.3,2LSAN%Q;_-Y]P7':VMEF2R)!F6$"H^4@?##\WN/-
MN\!R5-OB#DL+BVXW)[A,5J=JD36<SA^V</FW+MT@BY<2Z7MVSG!)JY H (VY
M@8N7+U[D3?O%R7O,NY68;9,R!7(Y&(KBW9%_D\;MB7;:NO&-XW;X7_YFK#_X
MBS:TK%<7;79C8[66#)=N\I%?EE=TM )D3,EFRK&+ECB]SY*H#;+KPR+=V^JD
MJRK=SA3)&BS3KA>;:=+E^XS3)#W&044O<:6.88DP9D87A]L5DXEI_P!7EWB[
MVK%EB3<N!!Z<B=H&9F3BR.#VK]YW8\<&[W7DH?W-^\ZB4K$*1UH! $5Q?[G]
M3]T'&<6-Z6D*F_[JYIQD8^K;%0N$3@<B[QP&N>[R+MR;C62NZX'NF@!%2">F
M./VCZ;5[_%[:+G'7N-U)XPNVQMY-U;)J[1D33XXX]FS:NCE<EO;L7%0W(XMQ
M/U;MH$ J<R*UR!D8;G=Q:]9=9_9\5F93<N@"[MO)X""9^;S& @=N,#R!^R25
M=C<DBY?N+F%8[MJY92!CB]]Y]P6>?RN-RN ]HAKKW+9Y!9(4?,VG69G'![/]
M7^W8YG+:VGT[WGD<9K]KM_=.4#N3E/!!M[RJ$9 D'(8^K+7=>+<[6B\Y>P<8
MW(1>[=VLVS?[EWKBVH(8<5']N[=%)*P6ICD\@70.+S.P\?B<:[0?M^U</BA0
M[AQ*&XT&12OPQ]3=Y[ASGL\ W>TKRE!*_P#<+7$XI7D<&VYG>$MP7,47X8[G
MVFVX?BO<O=TM\)9?C-;Y(]RW<5(@DKMV4C::TRYS=FMW+"<ZQR;'.X)<L]CE
MVF'+XO(X[K,J22%!J,C3%KB<T+Q[UX#C+>!'IN6C.]]T ;HAJB"M<\<<V>1<
MXO*1_9N-9NFT[+_R*X6:[X!6D3D*SBUV?NO(#=PM\>T#9N$7%YMF?9')L*V;
M11P*K&6I[0EWDF4O&V_&NNMT<6^HWV'MLT%5==NTC3,XV'<;B^XJG= (+RLL
M<XK##/3 WV/?M&V4Y5BXQ'O6JAR[&@,YD94.%YO;F7D\!XD%9Y7"N&?T>2@.
M0(I<%#]V-L@+<,,:G:^L-J#XXCU1M)(@YQ- N4X4K,EJ$"6'_P 0,":XW;0!
MZX.TJ2)H*:?CCU,#0$$MZI/CK&"))8$D"<Q)]0!Z'48;U 06(6VH4T:E0<C&
M9PQ(]6[=5BH<9S"Y#&]2WSLY"[=K"8.[<,CD9'E7#HBK+"X=C&LL89'4Z10R
M1&F% 8(M-QMDDBV&H 6D;A\OEE@J"&'MH0%VLVUC(:E*_F"X*PI7\R;J#;/K
M"M,D&H$3@@?*) DFXY,P))$&2:Y8@2(FW;#&5$F-P*Z37H1G@%&%!L=6'I(>
M?S9$_F) IH8@84VD FJ6U]1G_C(+-EU#3&-J[AZCM"#W&W*T$*7 F3.9I7/!
M,$(682=K!%2 01H,CJ1\,.($,)>2"&4-N9GVU5LO4!7(8-J7VR6EDW&X3;!9
MI%8C( ]*8VEW"DL9D*2Q,; I/I"BL-G(C#5&ZVWJ:/;3(0&1*,L_--!.N/\
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M=B+>ZXOJM(&$@'4'[<\.0H)1&DLI8$YBS.9'E'7 MNBW+EQI/).XJM,I34"
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MCIH)QZJT1J,!0$)O84,D_, ?*<*OMK!@/L(@P)"A&_+%00?.,++;F!(5X.V
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ME4ZYXM6[UVVJ_M;ET3=V.'WJH=D6N5 8,3YXV6[MJW?XP%Q6LWEM7G4ON@Q
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M*=<7.'<M.J6[C*]N!_QJX,R?RS\I']<"[;MD6W68RJ)D;1]GCY87]+?N3:I
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MY8B-IK )VFO7 DT %-&_](ZXK206%9.?RMB"I-2M9U$?-TP,S'2@IZ8,YC!
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MM4A-R;-MK6=IC;$"#7%M' H/0S2?>V';$F(B!IC@=FLG]G9O\GB6N9RBAO\
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M'W.7R+5LVX*\9S:7:9:@6*G/J=<>]R;M\EAN%RZS%VFA=6)J,J83_M]B^=S
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M>'GADGY84EP%C;0N&77QC*II@#>;;@;AN'N!03"PRYJ1E F,#]1CM(4E:EF
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M:C;%*;G/K(-P&<B3 SJ:X#0;Q*, 59E-"![JAC4Y TT.+3%1D49B"Q"O0W/
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M9"  ^Y;MY76VT@R"%SZXNV=Q;W0JBTJDF%(18:=,H6A--<%N2P_14>D,#[2
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MZ:X3P4Q,$DY5FE,&/2 !6*>1FM=8Q<M\FUZV1IN(J[Y(H,I-:P#&+]SCV7Y
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M,$ ?&G\\1.<QN]0,"09Q"DJ:#4?-D&&OEB2!3TQX]-PI. $($3(.3B-3XZX
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M0JD[&"DD;R-J[E/6.GGUPP602K(Y)<*0 6 2/E\B!F1&-I:XMT* R&-R,5W
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M<C:4*ML%2TDT\#KIE.&%VV"MR+:[BOI60)836HBN/3LV;@DN96WZI9'7^[,
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MI;.TH"WZ=BUQ4]-L0!M&<9X=E=;X<E3;Y%P,IK)/M@RQT'CB;+--;;^X"-I
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M9M9I08M.B@\BY;!1]N][%K/W;*K16<#,_*M<)R>9R=J$>Y9LG<6NL&DO<84
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M!\.AQR^->M&_VOGLKO>M)[IMM&VT[*H,!00).DX86+]SE<.U=%D+'N);MLI
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M7)-\C. C[1FQ&F[H<!O:2 006MD@DZ #76,6[79.UW[REI:];1K=JW&96ZT
M#+Q&+7,[WS^&+J(#^WL#W"UXJ&%MU8TGJ:TKB_:-SW./QI-NW;VJMPK10X4_
M(#F(Z Y1A[_'N+P^+QU*V;A('MHJ&6 @5@2 !6F#[G[CN_.:J6[MQRC%S N.
MC?\ S04($SCC7^Y6DY/>N<0.+QAZKG'2Z 4)LF0L3! _$X#K[S7>2PI;MW$7
MCH]P+^V5Z5G/76N.#](]G9+O<>4]D=ZNVDVO8#@3:#C-A\NN1K2,=]O6G3C\
M*QQ;G%6Z&BW<N7?^=#MAF"J&)5O"M,=H>UL/:/HSZ9Y#6V>X?;N<F[< MBV@
MH7)!N,*D@"HKCEW[X1O^]=\XSC8?_GI>,S7+@1U&:M 8^<98[OR.[AD[1Q^P
M=\[V0EDWEN7_ &O9[?8?? 'N,T$G(5Z82Y[%JV;7.>P4MH ]GB/)944BMLN
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M?9.]'N*QE5*/#;E(B3IBRRO/NVE%T;V/MW"($G0F-HCSG!._:U!\[01&8&@
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M&!$U&HQ_P*8]4!$]3'(D ?#$>Q;J3NBT@"D"A.VGC&N%!L)N 4B5S4&*@9>
MTQ_\[I(R'MB9B!4_QF,,3Q[<^D$[ )@Q $372O6<$BRAD_V!EID/50^>.(AL
MJ9Y*L913N%I&>)(H!G]V.3RA:MCVKGLVP5 &VV ;OQ=C4 :#IAT_;I8!+;[=
MQ$:^P,^E5(H":AC)Q_B/_P (_P#"O:.9W;Z^_P _=RX?'[Z.$COS>5VWA<[V
M./\ 3/&O6H:W;:[<%SN%X0+5L,'80<<#_%W"Y_;FN<9+_?/\G?Y$XUJWS_\
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MM8K6D0<IT--,'W'7],,%,U+T@'[\L$*?E4^D  G=5#+&@T  RIXX"[Y)EY\
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M-;"LJU49= ,LCG7 2 ;;R0!^98D$D5BL8N*U/285[>Y0! D,IJ"! P]EE@*
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MXF[]-40_.H&=<ZTUI.$E-@"  $D,#$'<QF33R&%_3W;A4$4 4>E8./\ C02
M#(#'/*OCKBED+G)CTEC4B34TP(M*!H0 )'61. !:%(RG(F3'GB!:7U22-D$#
M*0?Y8/Z0D"*),+E7Q&/^*JT6@J)^VHPQV*  3E,#J (.+D P&9H*BL9"/+[L
M7U%EC)96.R5%9%W=I/R^ B,?\7_]0W_\J?\ /_;Y^&?A@@(-VV K"45PTLL9
M3TI]N'.YX:%=;81+EQE;U=8 KX1AA<!,D;QM #*HE ZF8R)(T IGBXY06D)6
M"J[C5-RQN!#3G7XXV"V8N(&DD!E4D(F^22(T($URC"N8.X*H)(]10$VGA:&N
MNOCA0\%H#LY)@O$N& -(TB?*9PH5 JBT%W;I)%LEB@<Q,3,:XVA3! DH"AVM
M4*P.5=!E%,0#N:T"S;H526]-&U6-5$Z'!_(#Z2-V\/L^43T-,,K#8S ^RT$D
M;!O$R(]62T/CB@D^HQ[:LB,U5V$Y U,4QL-I%+LPG?+F#N0L09&1&TFOEB]Z
MW.XA-J$#:7$.RS3I) T$3@!"\I[JN1N0$@^V6)!-8^W"(ZRR%]V\E5;8-H50
MPD9 #4_;A610_I0$$#;;,P0 *M4@,/(X5PI4;P!\P]3CU,9S#&8 ^44B#A1M
M*$DA&N;;A;12 *:?&N%.V?3!!>DL8:V!.L3X8RW[J,0"VW7: OCI_KA%$5!V
MH:B29,1]W3";@S;H(:08C0CIT^W!F-!I$9TG/SP&901H!)4 "#0])\L [0%6
M0QR Z9]/Y8$*(.5#$Q$ &N>N-&T$C( U)I\9Q410@SJ#G323@@@$$5429'ET
M^_$D @@@4FN0C^(P( !!$^D'</FTZX#&*EA517=E3^N#%M5I,9,="?&N!* $
M3D/3!K!!RP"HIH1!VC./*E#TQ5? D1\-QS(Z8RU@B)7P)\QJ,9$B-*TF8'A@
M4$DY 09SH/XIBH,5C23&OGTQ1"!J&()G_<?Z8-!\VAH&RW2=.F# HQVS'Q^7
M!!2 !UVU^S ]*9$Q ,@=8^[!A5 .8VR!K3IYX;:N6A@TR/G@C; $R2#)I!$X
MG:#M! D020(I^.(,0T 3&1J<M1]F NTR#4F).A'QIG@4#:]) .4:1E@KM5!J
MT%CXT/P@8)"B9V#=&V)T&F.*[B+9Y-M#%8=U9$'QR\\759 6M\FZP6(.YZA@
M#-?/'*YU^YQK/&X=BYR&O.A+I[:%@HN.8$D113T ./\ R3_\BDY7:^+]2_X=
M_>?^,7^#^9]3=QN/P>']3C@/WS_,7^4>7W#D.EKB\/A6^1RK%[D*"RL-ML-=
M90+7T?\ 0?<.5WZ_P'[AQ>]?6O)1.V=H[GQ+:V^U\/M_TYV"P"EFPZVR4N/<
MN,EHB6-VY=([<JJBV>2_+Y5JXD$<Z^EW]IR.?:#'_CWAEM,:&#MIAQRH_;$1
M#'=<+ [OTQJ-7)I@?M[8MD G<P4K<M@Y!3_<<_#%TK><$JR\A[1]L*E[TFW;
M3)@:2K:"HQ=MWK]U;BZ+^GI(#6U@,"(@_9AB[;W)+LX58$=01H,$F\&3:P8D
M(!M42JJ($#R,Q@-<X]TH@(V6;T/<($C<7G:DU/XX+<4\;ANFUC<Y5ZYR&NWU
M/H6U:MJ=[6SZT2 L@$S@S?N\WENOJ:Y^C86\3,W "7=@:G<1/3 ][:%"PP*[
M+5I115MV%@*#H,;;1*J!LVJWMIM'J+7'$?\ R1 '4XO<A%*\6S87W>;>BWQ[
M*W7E-UUZ5@A566/2,)?LNQ*RUN[L-=^;"T]3/Y:8MVV!M<?C.9"5%HFV76V&
M!K+!3<,_:<*_#MMQF=%6V@N[[JL%_7Y=V\T'<Y)8P! (43$E@P8;51+#NI47
M'- YW9 "2H-3CW[7)X_[NYS/VEJVM]F2SQ;-@7;_ ''E<NX I#7&%JU;4S(<
MQ $[;W-O#D_IQQ[7%VVDM7*7>X\GE7V&Q5!E"4)G22,)P.".=Q>TVV"W.%VC
MAIS._P#>+S$(B=LX:VW1;UP3<#7@=AKZF(4\H\[C]Y^F[5JS?L6NV7+ZCG<^
MZ6/LOW'F]Q146Z%])-JRS;@**:82WS/IQN;R;PL<8=V[M?[KR^?QY;=;L-:M
M*Z67)H&MHHBDU.&O<[N?/O\ %V?]OY?-XC<NVSM>0K?_ '/#YU^X$"+"@LB>
MD0D8M6;O'XUKBV>1O7_M95>YJ<TY%I[=[?+F-Z,L5D@XYG<[EOG<_P#:/8Y)
M[9WCBM^QY3W24L6QW6RI=8>7<"T9 @M!C'MV[W9[+F_>*7A?X%WD<>UR5'N^
MVO&XS72JPOM*J@K6(G'&XUVZ>)?//N/R>9PN%S^3SNYK:.[B7'[CS R\-5S.
MRS;E=9QS>0G:/9[@+@[BG<OJOO7/^K>:$N$)8L\7M[I<XO&-RGL6K=E695)N
M7*";7"7N-GO/U!R-UWN(3B<ZQPN(]I38X?:K5SN.XDP2;]CCVE HJ;X),]S[
MUQ;G=[P(NV.-R+?)_8\54FSQ[5JVL6GBH4QL%(!G#<JQ>;F.92[;+VK5W8U!
MO0DK<!S)'^N+A6P]@C:JBY=VV[CEI(%TJ6$C\HFOAAUY%N_?=MVRXM[D&PKC
MT+:NNR"G4@82TW!*$$D#]Q<6XP VR@8P(T$&</:<\@6;H_4M&ULN*2-I9'12
M T"ARZ@X'#X_)X'*XN\BSR[G&?B<CB._J<<D$!8.K9:@5QS>:;MZ[Q$ONK\A
M![Z=OOVQ;-GDJ;%/9 EB?SB0!3%CN/'^FU^FOJ6UVKM1^J_IBTX'T[]3\:SP
MUXR?5?:[U_T)R.7;]IC>X[[7=F%T;S&.#WKZ8)[OV;O'[FSV2]P%')[HG(X8
M%[D\#N/9T/N)>L"7:V0&:V#<0LH,>VULW+/%YOOWK%D,0W'Y<?N;A!G=9CUC
M;!'YH(C%_E]OO(]OF*ZIR&0>U?MKZ4MW^//S@9DDUJ,=J^L/I#G7>T?5OTYR
MAS>)=4"_:O$@V^7Q>1QKAVWK-]";5_CN-EQ&((D#'"^D.[<NSPO\E_X\XUOM
MW?.R7+K^]=[8LMV[N/;VO5?CE3[*K\ULJ$;0EF5G*.=A16 0^L>DQ60=,;JR
M"(J%7<!&;>%/OQK$!H )  U8SIE@'4E8 6D1D/ZX .T#.IDSU\S@S#G\QIJ<
MR3\":4PXF&DAY(]1T (!^ PZ@01HPF8J((.E2-0?#%Z9*05,&NQAZE(IZIS
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M5K_$[FHX/(1F93;MBX\M[F4NP!I3'<+-A9L\KFKR>.PD>_Q.7=*7[=DG2":
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M:3$17'&X7^)_\/\ UG]7>ZRA.3P>T7[78[98?\_+[SS%3CI I_R3I&.-SO\
M*WUK])_XPL-=M"_P.)[GU)W?C\>?U%MCB[.,EU1^5KA$ZTQQ+_UI]>?Y'_R!
MW6UMNW;#=PXG8.UWKL@LC6>$CNR,156N8[?Q?J?_ !A9[YS.+:4(O<^]]XY5
M]QEZ[=F^D^%!BW8;_P >/I,O:"I;<WNY+>1$!3:$/*GKN,3UP]N[_BN_]+7[
MD*O*^G?J?O\ V=K;QM1E_6N6Y!@U708Y_</_ !P_SOW;A^_-SC_2G^1^-Q>]
M=NN5WV^+;^H.U"SR+:[I]5VRWB2!CC7_ /*W^/\ N';N";E_@=C^L>"X[O\
M1W>[B61;XJ<?O_$!MI=9P#[/(", % !QW+N/=6_<]T[HUKCK<#,;XO<WD;WX
M]M322T:92<J8Y%WG*JWNW_MT2TIASR[W*6X"Y!B;:DB!KT@XX_'2X;SE#W#@
MW!</NW./RF"W[%I^MMAN(&4Y=?J'MW,-R]8[IS."SW-K(W"[KQ[BJE\.U%9
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M+;3F=#\,?IJK,#4DMI\RJ12@&76F+(:?0H#@ !A;6J>X<F\=8.+3>E[:LI
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M 5/G&"%@@ $DF,\H'XX4%H,R8J:#<*X7UDUT;(Y[8.DC[,""="9F@)R/7PP
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MH_EW O /=.$Z/WCZ/Y',NPG!_:]SMK>[=>44L<NREV;++[?U)V_LW9.5WO\
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MT%ZZ@8;<MZ3 G=3U&*Q/D?##3;NT-=SDE0(J!EE08'Z9DF9@F 35HUC\TX]
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M')B:P?AB WIA0WK#6X4P'<Z,"0  <I& MQV%QB#<#$JI8+F\Z14G3XXWLVX
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MG:.+>MIZ7M&9L\BQ*N!5029"\C<+5S>ENX+5LLIWP2S(H.TG\HJ,>W<$;;L
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M;E N**9_*)$S.8P@-\NS':RAR JJ:?-7<6("'7QP&N-.YBI.XM RW7+BG2H
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MTACIH, "NU=Q((W5,$+6AG(=,-M0&6(*K*U6IF<OLS(PL*6>JI4&0YE=I.0
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M"L'-$(N9#H8^.>"C4:U<+,))!&8!W4\8Z5RIAM@ #1<@ NK4JYZ>>$95?:K
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MU'P)C'M!EJ4 #905G8VM:B1K44Q96538%-UBX9T)M[=UM6!ZQ RFN++,P+7
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M,X^.%_\ H=X@/<$1U>Z6.\W0A8-#:R().4YXN\KN=ZXR7&?9QI:"6^8E 3N
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M<JP&9IV;5S/I@:G/(9XN'==!'IAA+@(=S ,*29G./''MMN=Y9QLA2A.2,,]
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M+W#Z!+049R#;23,"-0*Y8+,I=K8)N1<,?W*$+341ZPQP-R$L=WJ0!H#$$VF
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M-? 8%HNSID!GX9"N%69U.GV1@64!($21X&F6$A'"AA434X5;H(($&?NSP?4
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M^$C"E<CZJ5%H*/0%%-I$Q&M#@K<9W2$0.=H \]\;IH6 S-<Q5F")"W/<N7
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M@3KGE7 VHH]-8SF,$*=OPSG/!AB0:23 /F/PP)D36LY3J?'"70TFDU^..?\
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MSZMDD_92,)?N<&TW*/S7;P&ZXS0Y:&'Y16#,YG#[464"VU<(@K&X!8@$ ?+
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M+2?"N-E'<$[I;=<V%89F!E8KF#(B,;Y]PBX C-2:2K(3D8],GXX6V)<VPQ=
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M25)R-,(X,J %)+>L[F@*X0'+.!7QPIC8097<"K71/_$ F0420?YXWVX#%E]
M9 I4 D"IRZG^9PVY@"1)MC<RS;DN06% -2-:80(^_<A",@#,:R%4+2H,@9@3
MKC:BL893ZT.YTMCUJQ7(1%"/C7!+%$DG:P3="L)N@@&ATC2OEB>(O&-Y=K!+
MQVG8QVEKKK0CY?4#3II@\;G*O"_[DMM5>ZY*7KMK]+V[/*M@;2^2DUT7K@<>
M]<9+*KL;C6A[=JXJ" 6<>LJ .HG77%CB<5+*W+JJO'XQ1;=FW()N7[GM4(6A
M,YF*G"\'A[G[>E\OS>?=&Y^X<E&!?8]/2& #.*4@2%QVSZ2XK$\+Z>[5QKRB
MW_Q-[UUU1U7^YO;#,<X(.6+=AK=M[0V#TEH9S?#7&#9$$0!7 N*9MO9Y/'OH
M(8W1:*JGE!$@YTQ>Y#7=ML*Q3<IVL$0B N1,T\,$L%>RM6V@?J/\RJ6S &;8
M#7B[,6 5;8W,[,?1;VU))R _IAM\"X 3=;YDL@B!;8Y;O 8!J%#%D0U.XBMQ
MAK3+#@D!:$%V%=PH9TF<5@B8F#MA:[NIP=MQD6Z%MOL<AF4U@,*@ 9XNV+3M
M:XUXH'L*MH&Y[?\ QCW0-T#.A&=:X-DL?4X9D<5A:@LQ^_K&*EO8ME?3D;MP
M4WP3D-!A5D;]^Y0%@P<Y\Z8LW^3Q#S>*YV<S@7F6W:YEFX0+O#WY#>M%8_*V
MUM,?X?\ \_?2_<NV?6W_ (]_^2?T-Q^\?XX_R=V&Y>N]KYO;^=82U]9_XA^M
M>,;:OP.^=OY"\CM?<^'=0CW;3-:9BGI_QO\ XG_R;]!V_P#(/TE]2]HYEO\
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M:?*:$"<$QZA$S %1ECTB*9_C,X+7+AID9^4^!Q[EJ\2!ZLSIX#&VXY)%#-(
MRKUZX K'YB(J1TP IJ*1$_;C;!$F)-?@0/#%@W'"7+C (I:L&A.$)()8 DYD
M_'')^GN]]NX_/'!Y5GN?#6\NXI>L&2;;"H:,CCT]FL@@-M86U!!8@D Z4$98
M<_\ 8[,,9>1)+!8W(/RP:TP0O:[:C85]0E0I_+L_#"K;[;;38/2%]*KTV 8
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MF!YXY-VQNC>""5V,-BP-TUUF!AN*S>NWPK_(LEU-;]JUO7W&6L$F ,Y^./\
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M:C%USO\ 4($2;;/\K/MMU \ 8CXX]3&9]M;EP%JW1^GZ%HQBNX@] 17%NXY
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M]VX"X8L"2"VVR$$[0=)G*<-<E"ZCJ0651M<!\ZS)(%,A.#NB;;E@4:5V2/;
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MM&4Z$$8<!8J3(K,&!]@TQ:W#])&2_>(_)9M'W+CS']H(GKCEW[89+5^]=:T
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ME%FV*R3,X[]<Y1NW.+],\2UVGLUAQZN$;7&7G<WE75!-6N,6 ,DP 9C'(O\
M<IOWN2G.[IS[[!6>\W+/[;B6;NZBS0URT&.+W#BF[<?MHYO'YKW)"VW[C;_=
M<(*L4A7R)^['!XZW+GL\CC(F9EG8^J(&4C*N/H'N/)]2=J>SSK#7']#,IVM;
M%MB0"""2!F=,=B[AQR"3PFY,N /U%8K<4@9*<@,(]L6T',Y#^]9R"7U4VFH:
MU&77%LVK!O\ ([9W?E\VQM6+AX=XG]YQUV@TVLQJ")C'U>+]B]RUX';+? X_
M*<'W%L\6^U_@A3KL4,"")IUQ]2<)G]P<-.5;M-\JBP/5Q2!.<$^H>&.X]H1E
MME>WW5XH"3;4/RCS+K^!+F21]N&O65MW^6_"_P"VM;!4+>N-9]^[?=5KN-JA
M@4&>+O&N/[O Y&[BE5*@):,D,T356)$'3#6/<&WEP0NX/-U%V7%V+_>(^& +
M3^U>OV;?$Y%?1>''_P"&[?4C:T"F\B00#BZBRZKM#<HBY;6YN6L;"-X8@@",
M\%_9"FU\Q0.;; >D([ZG7+XX)M<8E"2S*J7!MN6Q.\] )SP W$:A#;CO]6ZE
M#EY# 8<5E6K?J+< 8BH  KX0,!+?'>]<#9>W<1")DD301E)PR\@1$'_VN^Z2
MW]C.\*"-8G  X5^XK+O5BU\L;9K.U(&F !P[HW$!%*WANU_-D<>GBW9 +;=C
M_,,\SEY8G]N^X+)5K=P"!7YOX.*<6X=IJ EZ3J8,9#2F#NX=T#54MW7($T@"
MN#/&N&! "6GH3E&A\9P4/#O T##V;FXAOE(V_A@,W&N 0 8M76&[IGE F<1^
MWO1% UMX !@?::8VKQ;S%H@&W<G=,-M(I3*IQ_\ .M[/9_PO\_\ ;G\WA@YD
M"6K0Y9TK/3#$+6LFH62M5@S/6/YX+ K&3[EB>I SSR^_"L!,,R*H,%3D:B-/
MNC$!2R&023#0N1$Y"IP-X-6S $;"/3O)^S/! 6A,@ Y(U%(+3KF,$@ [:"!%
M#2 >ARQMK,4411I^6.HRZ1@DQM@A@6 VG^YLSE3^>)-:#;D9W4@=/ X:"%)V
MU#DH1$,9(C+IF<9AJ[=LC,K(WA002,\,8;;L;>"P4PIA6;0^!P@8[F8"M9<
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M>_R3R8'Z8*WO47\],%8!T8F@@Y9F)ZQCQ(B(!ECJQ/V??B/G,4,Y$"8;^O7
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MSP1$$>H&<FF)C$B#0_E$B<\>D22*T)D'K&#"P:MF823G7*13&XK"[IW$9 5
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MVX7;_P ?I#&!+!?E5!68&IRZF<!JR?5-8=0/0)- =.N%VJSPQS,*DC<LJ<_
MCXTP6JD%6"[MS;IIM5:0<R,,=A%TEC[9&YO;W2(-!F<A498=F"!0I49,QW K
M5\EDS$S&#;"@>EMPW?\ S,4VF:2LZ_ XD@,R_-21#"##$YG.@B=<-FH5=LJ
MU!4RR]* Q\,$C:"C02Q82N06GXC%V4VB^3:42#="'^T9'*HRBN%]L(MY;._<
MTA1).ZY-0:461]F.5Q;-]$MLV^[=<L&NI;]3@,3\D@CPRQW+N?((6RJWV4.=
MR723%NR;9 ^ K-",<T<A?9').XEV6+-M1+F%(!@1'2<YQ:Y%WT\SFV[_ /V_
MC2K7.%V^ROMV6V')KI]0FL8;ZE[N.-<Y/T[]+<ENS6;B6PR]S[_Z.1<M-^9[
M:'U-I-.N+7UM]4W2_P!-?3%SD?MNW700>[=W4EN,K6C-)(E8@*"203CZG[QW
M&XQ[9V?A#M_8^#;,<3_NEUF6VO#MVSE;R4 9?#'"Y]UO<O\ $[GSWY]I/6EJ
M]R>,?VED!_E0-+EC,G[,=SX_-"IQOI;AV>1W&W;>4#=X(;A6 ['U&YZHRZY"
M,6_J_DI<7A]D^B_J+F6[;^CCIR+_ &M^W=LXJB#$[B0L3KECNO)I;?B7>7W,
M,55T#ORVMI90F*&3$'X8?OEM;=S]\UOE6D )N\;EE MST-J9SRZ3A;G&<-:N
M?4/:>%?L@;XWN7<E1\LQ! H:]<=YXMW_ .:WKG#"!25MIQ[:@6U+5BM1UQ:X
M=TEBEWNEH,6HFT^Y96L5&0QWZ]Q;;N]NPO(*>D;UXUT6[MQPVBABTBM,)<WM
M>O=W^G;-E9 4M^UMA&8QF2P&WPQ_E#N=FW=7C=PX/:@YL5N6.5:[TK<T,^@(
M FGW8YG=N1?V<2Q^]O622S+-VU/'1R<FW'Y=<6.6EJ>1QGM[>[)=6Y=Y=GAI
MO%IT,FUM=CZ6@D:QBY:XUX^Y=X+6N4B*&:_?9-R/2DJ:[3D:XX'/M,%:ZL7E
M!.VVZC==8(*Q<J)RDUKCC"RWZ8:XB*[0H9&+[=AU6,C@=P/'V7C:O\>]^W/M
MAQM#DFT*2)D'[,\*HV7"5WD7"H!7\AJ?4T1EAHMJON"/<+;0MLF/;50?3UG
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MG!6VJVK0!]NV N8&T-2?*=</[B&^1!6W%&NFA)C0&LDX#7&%RX\W8#$*JC)
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M0*TH1C].]<+R\L=LI2-K$R)/@)&F'8.QW'VU8)$4 N$F8&>8P=S[FF58LP@
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M%9B)I@035I)!W,I4&*B*#7K0"#B#NVMN6N9(S8 U$G7"[ -L0-H!  ,^'_Q
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M=^^\?E<3E<;M'.X=GE6K?;NU)NOWR]@VK6RZ48$AF(B<?XB_Q)_XP_2W??\
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M/[EFP7ND *Q%!G(@D8N,AM<CD6R5Y%H6[A]HM5!<N+5]H-62=H,3IA[EQ(*
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MM%[ER1"I8='&XP&GU"///%ZT+;;;UD!P6!-A" FZR6.TLI(W%HCQP+=NW<1
MZO;-Q[;*1&UV-Y"VXOD9-/AB[;6ZE\W?6C[U MH 6NH73:"  %D4-*SAF9[9
M5"?U;@<VQ[@&QA%09R:#&N+8N\A-BVRC[G".Q7Y$0).52.LQ3"W$9[A55W/Q
MRRB(_P#FA--RQ#L,Q05P[V[=N]>WO=3VWOVG]NA!>[=)"L%DL=IQ<AE <*RP
M+C2I63><2-M*4 ZZSBZC%7]UKI452W8)8&W<4B@4G*IG%[FW"R7S9N-P[#W"
M+E_D"@M%W'I++62/,S&%[-S>X/Q;?:NX<D<NS<]7L<FSR#:3C(JY^W%9U,U&
M$YO=?J[B\#C<>T$=^1W!+-NT+2F;C<ERH4B) J9H <L#BV_\C+S;^\[N1P>+
MW+F^VH(4.>5;4 ELR>F8Q;YG9N_=H[[VSD7$"\C@<A;=VPZ+M-GEVKWK5H/R
M;5)UI.!RT[KS$@7;TVR+O+>VQ!2U92BEB*;6]/A$XL\?D\SFH]RTC%.1[>Q[
M%UIN;KOSAUH"% !:@@8Y*A[18V;B-;N*V\V[@]08MF\9 &,=L[%Q7%NU]/#Z
MJ^M.595/1:7G6DXG9[0((4 @L[,,LL\<0W"UV]W)KW.<70;I*7B19*ER2OI
MW3U&AP]H@_L_<6\C+ 1'0[B5I69H!GK.+I]H>PMP1:>TKV^0K$#<P .]B1*R
M)$XN6>$C61#-<XQ??:]P_,;9:2I7(KY>6.Q\;ZEY[=E^C>->YOU!]8][8;4L
M=L^G^WOSN/PEND@)=YEV+*N?EDDB1CA_YR[QVI/V7'XJ?2G^"?HE%M7%Y1X:
MFUV_E/Q6!W6"[?N+K9D0?S1CC_1';.0O<?J[ZH>UW_\ R%]0'<W+[S];<K]<
M<%KQW%N-VOW ;B4#7=J$$+&/\A_^5G^8^(O<O\8_^-1?ZF[G=[BQ?C?7'^4T
ML^_V+Z6XI;T\D\2]<LAP"T\N];4K-HX_RI_Y7?YJ[9_WKZ0^C.Z\_P#RK]1=
MFO +P?JCZXY'(+?XY_Q;P+=WT^R]^UQ[+()"\>S<+",?^07^>N]]Y9^]_P"'
M/IGZFXG$[KQ74)W7_P @?\X\WE?3_%L=J=\EX2<SNO)9;=;?'X5N($'';N&Z
MW+MA/8#V;<"[<2S%UU5FH"0#5J#48'<>[=LY?=>=W'ZV^@K/9;?%:P@7CGZV
M7NW?V/$2+;(J<*U>YC%1;M6;1=1)7'#L%R6M!N,^T$*]Y)]Z-:O+ >(P2SL"
MI"DE],A-<!"Y$Q68!/0:X^8DTRK74SX8ECG,YBK") PP)VJ: 5.5#Z?/ J?4
MS2TB1H25^Z, 4?1J@@[C2(R)_P"N/VEU@.)SRMLR:+<G]-O 3$X*DYY$16:S
M(^[%XJ*;#.L@"((.>N&MW"2PNF4D [M\& <M(GRQ99 ?D#&3H%$%?ZXM-'J#
M ,!)SI))T^.) !F" * P)P8B*Q3XP<&(@@=)F:R,$YUD+!DZ3/W8)*^)I7*
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MV31R\/)J(RC'-_R)WJYR39X2MRQPZ6[+W>;N7M7$A@"Y<!6N-F% !&%[NO\
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MSWN/W?\ R1S%_=\_D_4?*L$I<;MIO7>5S2TJ>=>6T/\ C3%G_&GT[R=OT_\
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M3X4C#PAKMVYE3I6*2/LP2=X VU(*D1_:-?Z8;W$:"X0"9]/3H2,\ .A4%3
MAB-:G+X98'I: 94]0U#XG VVV+09],@="9_'%++9R0!KFTCQSG!*VVAH](!D
MN,B.OC@;;)@T"E8 .H!^_&WVW:AZ$&8+ QE'7#'VW))!$SM8YP8SP?0T#=L
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M;<:PS/<;WHMI<LVU'K0T)5_36009..5W?Z=X5_O'9K[OR1Q+'%N'G<&\BDW
MB* +B:!;<L!6"*X>SS^WFTZ^[:OV>3QV#RK2RL&&Y6!,D'IGIBSR;?&:2X"O
M[;;7MSM38<R0/F)^S%KCW.-<XMNZ]A"UT!6N6[C"'1!!$B2/#'8NUWK[-=X7
M:^+8MW78>Y<2W9"'<GYFCYIT^W"^P%5RHN+9MV[CHUI3F%%16A)@S3%E._?4
M_8^Q7N0P7B6>Z]UXG'Y/(Y.<6K%Q@P)_*2D'*1CE]F7DF_R2G&YUB[:N6KEC
ME>S>#!5*R"2BDR#GX8%UK)M6[]I?;1F5D50=Q&^)%8)!%-10G %V+=W:0 +E
M"?G4PHS/V'%[>BN"ILM525W/0V[;"F4@]?LPQ6T_Z#[G<,K%D>5".IR8:@4^
M..%V3M;I8YGUEW2[Q'XO'(0\I.%:_<+;:V(+EG8;;8S<"<7_ *([UW'_ +99
MM\5K22C-P^'SVY"V+5WD6T#3:XI=G=1ZKC[HJ!C_ !9_X]_^,W9.XW_\F_7E
MI.'_ (O^FPC]U^K>?SNXHO:?K'_R+^J^T+NV<_N-\'B?37#VA X0J#:XK.W+
ML]ZYG%[O_P"0O^2N-<[[_D+O_(O+W!/I;A+<)O=FX_=+I)N6>U[B>5RS/[SN
M;,5+6^.N/JW_ #Q]0=O7G_2?T;W!?I7_  G](\RW=NM_DS_*:%.Z\SOW<>(H
M_5[;V54X_,[B3Z%4<?C.9N7 ?I[ZZ[EWCF]Z^J/\C?5G^0?J+_(O=N:UVX;W
M>N#W9DX16YL"[WLNW+NA':-Z@A:#'_Z*;Z&_Q[]%\FW]?=G_ /%;E_4OUUVO
ML'9[W+N<-^[?5?!^J.U#C_\ ;$]C]_W/B<@\E[E^^[W2KLJ;Q!Y-CZ4[593Z
M;[TO9^P>YVX<Z]87C-VY>ZI?Y')Y$/SKO&[E<YW'N<R[;2Y;#>R5 !PMQ;>Z
M**ZH*E3Z@X/S Y$'S%<0+$28,(.GY!'VX/Z%9D%E^R*8 6W!FE!0S2N,M3DA
M (\?QSQZE+  Y@2)\NN!*"ARRB#/I ^S'RDD3ZB#4$Q0=.M<?*- 9RRS,9XO
M]N<_*WOVJRI"^EE3I(C[,,F>Y"1UF/43BS>1"5%W?I$@@B1EA;3UA0 Q@12L
M87;X3U%*SX8>RP@-+K,9G.F!&L$2,_CC0#0C\!@DQ304,]3.-ML@'X$5S&(9
MH,1.0CI7[L-'E)IF=<3T$$F))G^NF#$C.36@\8RP"14$1K]^%NDTV@ ]*:?S
MP9<>KY3.O4850Q920&,_*13;.&4-_P EP!8,K SJ,\6X+(RD;6@"5\3BVRY@
MJ#4@^)QQ;I,M;7VG)K)2DX8UA03(RJ,Q.'49000<\\<:_N/HY5A6C4$[&$?'
M!BE:=,&3E63,'X8D&#%0V3QK R/CBA(/0DT\Y^[!5X((.O\ +#69DH05_P!U
MLY5/3+%<\\?U\\<GA<RQ9Y?#YEB[Q>7P^5:M\CC<OC7E*7N/R;%T%71A1E8$
M''-^M_\ #O Y'*[6F_E=Z^A..3=YG:+2+NN<_P"EA6Y?L"ON<0DO;%4+*-HR
MD@FI'J#;MKAJ9@R",QK@$+4TJ*YU-<\ [8D9G(B?29TQN98 "EAT&K4TP;'T
MG]+=R[M 3W.<+/[7M7&#4]R_W3EE+( F3M9C&F+=[ZT^N.Q]AW;?>[?V/B7^
M_P#,5=WK7]]>]GCABN14$ ]<$O\ Y/\ JG<=^TI]/=D @F4#!KARU-)TC!_^
MAS_)G%OWMLK:^H/IY^/;=XI^KVR[<CS*XN=S[CV.QW;LO%'N<CO7TUR5[MQ>
M+:)@W>98"IR+('5[6T"I(& 0 4,E8 80:DAAG/6<&+0,"*] -(UP3[;$>D%:
M9KZA0_AB?:.I),$QF?XUP!LK43LEB-3YX(-K.((51NI$DGIKBJ4V@_+4P:#!
M!M2I$B@$+G3\,$"VRC<6W%9+#/\ J,':D2(R ,%JU(G/3  MK-(D"/28(;SP
MJ>V!M8$P)5B#N KF#_UQ]*]QYMNP]WB-R.WN]]1=5TY/%:WQG8'(HWI$^&.^
MGDV4WK9NV;+;0'2.0QN!O#*,<A!;MO;N67E2DBHBOQZ8^L@K%TO\ZU>M(\O[
M=O;(B1E)T^['(Y=N@MJ]ZV4'J6_Q_P!;:A\Q\=<%.1]3<+C=R[>E[@<[A\F_
M;6_Q^3Q0;#H4F3)$ #,^8Q>['VRVUWL=GFD7KZ;D:\Y<@7%&BC/;GCC=Z;BI
M[RC>A:VNYPJA+8*F2"IS62*SGAG(!B-JK_:&VGT?FZP<L7"6(55VJ)% "5()
M^_K@0944(89 T),TQ%K<T23),;O$_P  X2M1(8P0K FD+Y_9I@ &9@N/5 %P
M3)RST!P SA9,.=S%0)F@.N@!.&J()C0^E8$@ZF1Y8=JQM"')5/B/$Y$^%,\%
M%&T6U]P9$&*%@<P1GK3"Q<#(2 8/J W;H4]#D ,&VHCU2(,E%GT[EK2L8LU3
M=;=JRHA*?,IJ?C489:$(5](JW0[29H)^S#-[0IM]X@@H=[3$QKK2<,0K"94>
ME2Q4"K$ 3 R@8W;]Y<%D 4S&D]?*!GA]XVV[=EW9V82L"M!,4_-49 X=[!]M
MKKW^.MQ ;FSW'+,P4;IH*F!&@Q=Y%W;9OK;6S;(#!AN0.B);_*"!).=>M<=S
MY*H6;LW!_;B)-L7.0QN,Q51.[217K4XXG<+J&WN 5S;4 C=11ZHHQ$B #UG%
M]49&/)L\<M"B5*,6)C4Y$S3IECN)VP5NV[-Q&0P4*;77?$F@)D5C.@QS+!N-
MLL6[MRT@E546ERWL/B9T$3C_ +YW:V1Q>T?N.?8N. JW.3<N19":Q'7('/#_
M %WWR]NM]IN<R_P.$IF\MN(L/RM%!$ &<S !QR&O6!R.?WGN!YO%XSH&MWTN
M.6MV;@.5*LK0('7')^L>^<:VO)6V.ZW>=<MC;=N(N_B<'A6V&Z%-2:2?A/TY
M]1< <<6^5W6Q_P!VL[5W6>9>_4?CO;ZA54Z$?'';"[)^WY/!L-R$,S9OJ(1+
M9&1!C<3IX8%Y^/*<E[UEG5PJLSVS[#;!F%ZSF?@>X\S<O'%GCWD:V_J=GY5X
MVDN[IEB*D#(3&8QW_NX 4+_V_M0"D>V0+6[=[)$JQ$29(..YV[X)4+R$ D#W
M%]MA<=AT.0Q_CKM_ #C_ +IW3EV[KEC[G[:TRE2@&9FA:)'GC_'7=>Q7#:/;
M.W\&^8N%O>]VRBW%Y"#YK)]4ZD_' >QR2G<^W7=EWA.^YQ:8 -:6V<T/2HRB
MN.1W;M5H\3F6&M<EN785+G)[?>M'=-U6^>P:J:2 2,\+]#7>#?[+>X 8VK%M
M4':[J\<G=?X;""AN07-LB),C/!X]FQ9X_:N+V]45.,I590PUR\Y^9F?0^8SQ
MP&N*K/8N/R5),PQD[U\8RQ;2]<7<5?EWMH E;S&\?.!%<?47#[NEEF[MWOD]
MR[??XSJ;5\?N"+A1IW&;8'I_+X#"W/96Y84M;+[BZHC3[5PU$U,U$4RRQ;[;
MWZY9O6&/)47@ +G!<7/;!16^4$ [A/CA/VO<+EB]?L/=XXOW".#S>"*V;O%Y
M'R&**0U=":8_=<NP_%O[R6;CIL):X8%X)DUD$U($SE(KA.9QK@?VQ')]@%BH
M50O[A$2"%<Q)%%/ABX?2O.L6[:;[<HM]+*?\;"""X_NR,5FAQ<9F:V1!8-1G
M(J -8\?# 8N1;#?\;^HM)JQ.@Z]<9O4A0U&&W4+G2-!]V(+$#T@14( )(IGX
MQ@@$':LR U)-"=\ZB"<,['># B 2IR(B:1K@2%$&"0JD&1Z;D:'.F-ML  L
M6"2L#\YC*>AIKA+?&-NYS^3Z5=E5@J"C.!&G37%OG7^1<OF\^ZY)E27JY J
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M%K,$?'')@LJ%BUJZ!  )]=MDI/6!03/7!] !.^$6)96;;MW1!$U(BD8^C_\
M"?\ @[Z+[S_D3_*/U[W>SVGZ;^D^QV&N7;S^X%Y'=>Z\MA[?![=P4GD<[N'(
M9;-FTK,S3M5N+]0\RQVS_(__ )3?4_9^+;_RA_FB[Q1S;W#YM]!=Y7T1_B:Q
MREW=L[+8<FS[MD+R>;'N\BX4*VU/)[]R']HC?P^S6':UQD0_+_W(*?UGU*$[
M1E7"GEW5M<:U2S97;;M6UR'MJ( %,!+5S<B':)>3/0'$,)BF"($ 09I7QQ,F
M,@)C[< C(UB8^)(Q5AYF)Z 8J0!KUGI@@5/\:QC[=)\#@L()$"LR*3EC822,
MJ$ B1F)P65B PH ,HP"3,_>V&=0WM7(%T+TBCS@7 [D&L%C'43UQ"6I8Q+E1
M).I)_E@AD$VDH2@-;AFA\A7!(4;C/JF&-:SC<2TS/CU]./F9=[HNI)&9GX3@
MN6($$B<XS(Q:>OZR.2)@@@^XLGRQ!!*D1&0^'7!N-2(J=:9C&Q/+P UKBM3D
M3.@SQ)7<!*L/ T!^RF/W5BTRW*N&0$? X2T\;HV29D$>.-I]160=LP>HGPP7
M50D A0 "6D26)&GCAO<4.&)'J(/HB"H<T'EAKG'1FO'U2C$*IB7VVR#EE,8[
M]_A#_*##L;<ODGO7^,/\B-Q#R^]_XP_R;Q^#<L]@^K;"J07X;S^T[IQ6:.1Q
M+CI&Y4(_R#_@_P#RYV"Y].?Y'_QI]0\WZ:^I^V-O/%NW>,V_A=[[3><#W^W=
MRX[6^;V_DK2Y9N(09! V- 43N!KM!ZENO^F+5%(5C/KVF",PV8CPI@("6!DH
MWR[MK3*[IBGVQXXM&YZP-NYMNW<%(="K&G3TMY XMW1?6VXLA[+L=J,0VYU4
MFD'Y0#3IUPUPN%0VU](8E=I8N]MEK!&=3001,8MI8>5N75N/<N6@SO8<DNON
M "3HI%?AA[-QW#V@Z,PME/:)&T6%C+?^=A,$4PJ;?U C"P+3.MRY=*C=0 E]
MP E8@GIB[<39Z%@J5)N6RH@[@U%(:=P%")!P+W(]S:Z!D)0@+N8L1;L5(5@9
M53I\O3"EKL>A38N7"S^W;3TAP(]2B8VJ":^&+S6PK-^Y<[@34 R&1EDG815B
M<HQ;5 Q3<03[F1N$-[;S)#M4T!CPSPVS=M<LR;A[;PK;C;]P'<#- 7DG,1@?
MNK3>XQ)>P FYG(/K!N4*>!/B.F%L<.Y:"*-^RV'M-LWEC:0-"ROI)&\F:4P+
M_)5[+6AZWY#L%4@2JCW 3N,R2  ,I)C">Z0JI:]?(*$+N:4]NU9M$C<TSO(B
MD$3B_?M6386Y;'&MA[RL"Z03<NL@ DT*B?2HC%I^!?'';C)9-V\BW+-E&M@@
M#D.:$O,;V;/-8)Q9M<NY8LFQ9MW+SVP.2;:.!< %[B3"+3_C# Y@P"!:7NC7
MK_$Y'(L*J>R;=VX"WZ-WC7&(4W<B&@4!$ X>_P!QX5BW<8\ADO\ %53^E;=B
M/W+VU.] A,#YU),L:8Y!M64Y?;+5TW.'R'(N7GM(Q#*XM[E&T$2 !U(G%N]<
MXG(N-QN1:3D\<):>[:;87-T/<7> $&XQ( !(SQ:[HO;N3WODNXX_%[=Q^0./
M:/MK[K-RN2RDJI$#TK,&@&.79X_U-W#Z3[ "S6NP?2ER[V:RO$)]M/\ N/.2
M.5R2!1GN7*G\HQQKG>7YO<+_ +MHORNY<GD<KDW51AN?WN6S.P R&X#XX[-Q
M>;8M7./R[/&[5W46MYO<#M]^T+5OO%A "^ZRZI<=0*VMYH!BSQDN-[5PJJNE
MPMO)AR;=W(RGJ5I(8&N&4\@BW;N 63=15Y4FJ&[ VD"FX:Z8NJK);<6MY1#M
M( ,'<HHP8 Y&?+'%XW#X5_N'<^??'&X/%XZF+EPRO[J]<%%L*2=['(^>.P?5
M_P!0?1B=BO\ TW]/<[@<+ZBL\?E\P]Q^KTY(Y/.[R>7>]#\A:64M6V!M@29D
M8[Y_G_ZO[EV/Z[_S5];<CG]M^G/\,<<7N+W3L''XA:YV[D?4MXIOXG Y95>3
MW#D@EVM1QK$WKK,O?O\ ](G_ .6Z7_K'_P L?_(+@\BU_A[_ !_RF3A=R^CO
MIGE\ WNWV>W=NO>CM#?]N*7.1<A;?9>TJ 8Y%TG'.[=8[B[GZEYMOE?6WUEP
M>%=;B\'LOO#@</@=DX  ]OBK*]O^G.VTN<BX?=NCW+MYK7^6N_\ *^F^U</_
M "9]=6_\=_X.^B;UZU:[BOT!],_5GUMQ^=S/IKL_<;P]7,YR<6YW#ZB[NI2Y
MR^62J <>U;G_ !/_ (S-KB<?OOT_]6?YF[I]6/Q[-KF7+/$[[W?@<#LUWF=Q
MXUUDY9_:<.[>MV4"BW:*B6-PL/\ QCX''X_:^2_TG_AK_%EKM_=.-VW@<;C=
MV/;?HKBV>T_4%K]DH"-RN,\NBL=C/$G:#B[;L\=>.;U[D<A+>T+[%[D<D<MG
MA1&[W)8L,R2=<#> S "3M%:5)Q(03Y3'QP3LF1\<&+,3(B($^-,'].IJ2!D?
MAA@$,&1ED/'KA_129!/344Q[-JVSW&;T*@)+&(TK&&O)V\[ LFL,!TKECC#E
MVKEBW<?9> 5BI5SL-8TF3C:Y#+% *0!3/^6$.V:@><',8  B@,5J8H,+6"8U
MU-*C"70#*D21^83ZJ](PCKD0#]N8C!  U(UG7^6"B4G2<M=/AB23,2)B"<B)
M.-Q!I2=9'Y2,4K.8URK7$ 28D&)%/XRQZNLD]#D)_K@!JB-:Q-! Z8"S'I-!
M4MX1XX &W<&-#2/"?# M[9!(F.D9^?CCB611BQ>)@$:1]F%)6-S C^Y8%!!Q
M:5VH6$$FBB<<CB^YO V75R,@C:=OQZ8(SF17703C:9WER  :GQPW(DRO)1P5
M)D*KR OQSPC4AT5\\R5G'76<R.@Z8F )Z4(CS_'&]3+1$&(\C'W8)D[AF#F!
MJ,*X,W+9DC(LA$,AC =31AN'D<IP? QX8W%J"9Q OJCJ05(8!I&1D98YW^1_
M\<<#C\7OMFWR.=]5?3O LBU:^H[0/N\CN_;;%D;5YR $W;2J!=62/7G8[?VW
MB<KN7.Y&U;7!X'&O<KF7&9MH5.+85F%:5$#%GD=_L<7Z([6X1S<[RPY'>+EM
MOG6QV;BDLK156ON@TQ;Y7+X%_P"L.YVB&'-^HRC<&TP$@\?LO&BS\;F\X3B\
M=+/'XUA0MGB\:W;L<>S; A4M6+("*(Z##;:R5 BN9K(. =P!4@DD?-3(X@OM
M@R*3)Z BOD!@!A4J5KDP8;6!0S(.1!H1A_J_Z<XBV_I[NE\GNO!XZ1:['W3D
M/6Y8M(/3Q>29/2V]* C 'MYZ5!7IEKIC99M/>NU_3X]MKMPQ^86T!;!)[5W$
M0)!/;^6%B*S*?A@#C]G[I>)] ]GMO,8%LHHD3/C@?M?HKZAN*P!!/;[EH&>G
MNE3CW>5]$?4"VU4@M;X?O%5)Z668X:WS.W\_C7D!5K=_@\JU=0QD5=!EX8]Y
M^/R5M**W7XO(2TH(GU,RA8&LG/!;?:: 8<$';XTP@&TEZ6Y22]9R_F,49=P.
MW:&%"3!-2*#IBS<MK'MW$9=ABJ,'!4C%SN$M'<D!W-(FX4!=6'G6,)^HMU74
MRP/I 80Q^$_;C@WVY7;N?S>\*S<CMAY*?N+7&L@Q?(MR02?0)%9Q=[%_CO9]
M/]HO)<3D\JTON<F[;N*4O)9NMZEU#,HF33PO]Y[ES;J_N&W\E$9A[[MZKIN*
M#7.9F=29QQM]C?Q;47054OMMN1!9ZR7,"-?#'$L<.P190DW@GI8VPFU=@.9!
M&NDYQ@/L)O.(HQ5C C)3_%<#D7:$@.QT+ S5NAFI\.F&!,%SG0%X$@+-(PS/
MM'KBI]+Z06$GK\<;09*P!_<HF=H&E12OVXW1Z0:P-U6.0:E,L\L\,26A]HVB
M#0&E>M,\;4RD*PD@#<3.ZG3.3XX$P0)8 L:O\JYY$_?BXK,UM6W=),4(!C2"
M#TQ<+LNP;@K+M% ( A:D#^Z*]<(R$^B#!*KN*UF<S.1!RQ<NH =A@#4%A0F?
MC7#[F"K0[FI!R(\LYP 2!ND%08G<2VYP8H<UPTR "VTAC#-I)4@T\,P,$/Z[
MB$NYF%8BA5&!R(-/ZX[D$+ M:9$E@51-M0P,QNT^_3"OR+2)8MW[G(=6!)]H
M#TLIUW$U8UIEKCF45A9>ZZ!F!4HEO<K[0!(,@*#%8&.[<E4<_N><B<NW,7I<
M;S[I4R%!B5TQ=X(_;KQ^,UOD)=.YE]ZWZ/:5%]2QI&F6$O*;MI?8)65&QPB[
MI5R9,&2#KB]RF17]VXO()MC8Y8$(XNTS*U6D 4UQ9>V;?)6]^@;1#.X17AB>
MN8S,1(P>%QK=L\I4 -EE]'NW;4O$:ITRTQ?X_<G+CO%U+]WCF(-M!^A9:/E$
MF1H?OQQ/J'E\7VNS<5K/,YG-O6TMVQ:7_E IZE($+!@9XXG"XZ6_V:BWMX:1
M[;\2PGZ/'MC6Y?< @M7:!$X[@;[(+_?.ZVN9Q7Y&Y[G'[A?)O>S8+004L@I/
M20,\=HY=@;^XW^RK:;W R_J6WWJS!<HB!]F.T<[EVU5[/>5O\BV&_P"7C(LW
M5(;5F@]/"1CZCY=I+;=KX5M.1?N_*MD7#OMVE,E9.0RD91GCOQ 5[M_NMHV;
MJMM4^SQ Z0OD8)IF)QR./R1OM+Q+]M0)*M+'<2Q$DG+'^&+-M%?C6+7U!<YU
MFY!M?M+A 2Z3(.^TP%Q8K(K0G'T<;W>+=CEW/IGA]PXETV_?7E(S[DM7+9S1
M@*N,OL&+W;.U]PY7$[SW8*EKBW+FU>0W')=%LS\I,$A*'8(C"7+-UQR..M[C
M=V[;<7TWK:4Y#)9K(BI6)UQV;_('T;:X_)1P+'-X]@HEVPK$+RK-VV($KF)J
M*X;A\&U[W_<+Z7KO) ]=NPJRG#<"""#)KG2N$8 HQ]NW;D&!0#:1H<MU<-RK
MB;PG9;R/(A3>_9^V 3TFIQS+?(L!?;[F.;V;F>[</(7NMFZZ7./N0,BVKB$I
M<61,@Q3%MKUEPO<./:M%7;;?2Z3!5!<@@!J&<OLQW.PMOB\5%2]:W[6=6+7B
M>1<#,3+,0% !Q9[/]4ACVQ5LG@\K;/+[0+GZ(Y2G_P"I*2N]#1U-,IPPYC#G
M<1[=L\&\NU^#W&W?!:T]DF0B+;_*#G2N/<X+W5W>U?M\=[F][08%+@M.WS M
MZ3::A\<7+W%3VN44]P\-* ONK<X1<_(?S6YH:##$L=Q;VW+MN<$9A6> (-"#
MCB@0UZZ3=)9_4+;+ \R36N7EBVW6@@^I9@!2/QZSG@, LZQZA&CQH16@IB/1
M !W;:;E6I"'Q.8/XX8J%DDG=!(6N8(ZCK7KA4M*'21ZV!"DFL1,D^,9X-M5V
ML5)9]&VU*GP\,<BX"SCB,$AH58*#<R**+2DXN<1V]NX5/M@L<S! 4B:5K\,7
M>%R'"/;8+:9S.4SZ@1X#=UQD/[/E'S_W>>#7U&(8B@!-*'(]<,*@ 2_0^"_C
M@$F5$3-3E(# 5GX8:9D$ G-0"*UIX##STW9;9+4D 3'PI@K(S#;C!-36)U&&
M8DYD K41F<YGQC+ +1ZJ0"(AA W-K6OXX9F:0JA6.^ 6/]BKT.N'W-)))#*Q
ME@,I<4 (I.OVX$L#MD[4 40!ZB1TF"T_9@$[F!DEV,&AA@$84 !!EOCG@T2%
M)  )DW#)72D5D9>."UY__J@8#TB9W#VYH<\S]T8"402#Z4H21&Z3\(.4]:X(
M4DC=;M4S9282ZP-"1D2,\(%&X;=L2"97/=/4:X*7&9B0J$;%)<-E)%10=?##
MRP4 EV)4EF*S -*'6APR#]2 &<%@Q9)W)ZCXU@B:1B]M=+E6,@L X)G8# &Z
M29\HC%YR-K7$"@A]QDM&]8@@ 4,FDXY-IV)#E55$.Y[14R;+[1+&AD].N+C!
MMS00'=E@E:@!%,A34 #I7ICZ2_QI_C3Z:[E]7?Y _P B?4O;?I+Z,^F.WIOY
MO>>^=XY XG#X=LCY%#DW+EYO3;M*[O 4X9+2</ZP_P#)#_(?:.#>_P V_P"8
M>5Q[3<SE\L6QR&^@/HNXVYN%].=MN,;5JU;*MS74\KD[F9%2WR[MN3:)/$22
M I(AKSH<F(^7 8  Y5 ,S6O]<;[<)&[1J';%8C'[:^_H#B"8B-V1;".MQ3N4
M3!!B>IUG /A,1GI%,5^&4^&(&8R-=,A'GB)(U,Q_$8KIK^&!6!%(,^%1@B3&
M6<"GC_3!!(J(DYQ$98)D@!A\3K4?AB#5H- 8,'4G3!61NZ2( \<!78E6$&?'
M'LO)1IV$UVSF(.-W41,Q '7%YA2;FT$P&A% H.F%("N1G%)/C. &@+ )C3JH
MQ:.X!=X$3(]0(KYG#A29"E0 M2S>D5RQ8CY5]R)R@6X@X!8@QH?M@88+2*4K
MY&#IACF9US\IP5IE61EX#$M4;2(\.N'XURT"8(7TT@]3A[PMA S[@ ( $R2,
M$C)AZHK305Q0@S0"/MK_ "-,$N=DB?31PV8:N>"=H;B$_-<;:%),06ZGPQ;N
M<&PCNG+X]Y1L%T$AH8A!*KF:UPO_ )?_ ..^Q3_FW_ 79&XW^0^'VVTMWE_Y
M$_P=Q+S<CE/R+=D![W<?IFX[<WB-ZF?AM?LT6VD6[MAE=+BI<#+#*Z$ [U(S
M!S!Z85@Q$0K C=-9/V'[L*/4#2YN$J0  1M\_P ,6$DD!05*L =D2^T$UC,_
M=GBTWOD,(*VRI#A&_P"3<362:#[*8?W'4+;V6KH4LS+;N6MJRO4_E9OM(PH:
M\VQ0QM%2H&ZB*"P&W*D*/#I@76>EZTX*A$2XXV^MV5@2""3)(QNLWU0( ZL5
M@V75%EE*^J1\TGIF!AKMFW[A87&%!52?1[Q7TLQ 8&)KUQ9$L&5@N_>0Z7?;
M_357(!)$P<XH,6R)-O>R6A<+L#<5=S+:12"(.3M37!06U_6543>NTLH,0P2L
M3()'D<%AZWN^W:O/9,7/;#;DBT<B)BC$Y"<(JO<N?IJ;EL.]OC@A""EU6&TM
MU*ZYUP0EVW8N6PR+Z]RL[@$7&N-N8_V[I(G(",6[UY.1<NBS;BZ&WJC(N[8$
MJ""U6($QYXO7A>%RYS;*HX%UD6SM;W#:MVF8!H:*BL$ Y8%Z\Z>V^];*M^G!
M@H47>1+ZF1TKIBU8:XHMM<5@6N6UL&X$JER20&;\J*LM%8& .Z\G@_L_V]BZ
MO(Y(>RHY-L^TO$XELKO>0:J3$@Q,X[;9O_5O:NV7U>T 'Y''L<I-C[;GMGEE
M5MI!#);=@8TQ8Y7TM]4?37*XO(N7^ +_ !N[\#N*_P#<"0R<<@,!9O&/<"DJ
M(I,8M\<JO+Y!]_;>XJ<4E7<A.;<:]8<HRL00:>DT'7'<5?M0*WWN7W5P[%+C
MCVT>U:'J@?G .?JTG'<N$.'=X-I-R^ZS%WV,\'/.28 +2)S.&L<Q;U\6D4V7
MNE=\M_QF<R\3+BA%*8N<OM95;Y3>ZO;LMO7;M-K:=NY&&8C[\7&YG%XW$O<?
MCW/6>/<<*;2@;3NHLFJC/73%R[:Y')M7.-S+;I=XUYA=#I?BT]QU@E3NV+4^
MF5(C';?H/_(?<5XG,X]VTGTE]4<V\+-KD#DS;M_3_>6H%O6C"\2]<.VZD+1P
M-P0W^/?8; 'L[C99MU?=CYM!(J#3!<@,6#$H E&5C*!3\N>G\\'D,)>REYBS
MHH-KCFEPB\^4@$$Y "3UQ_BS@=J[KQN\_P"$_ISG=V[EW'D.O"_:)]17>;N^
MH./W#@W5/N6"H%L/=4Y[8D@X[A_E+ZD[#]1<KMG [WR^_?1W^)N]<*WR_IM>
M5V0_O^)WGE\B^#Q[?!3:+UJUSV%BR8:+S"W:;ZJ^GOICN/&[7]-=C;@]A_RS
M_EGN2W[?TA_CWZ63F?N^W_0/9N2PA&YEY1=M=FXH?N/=N2%N\L+:MI:M<=/H
MOL]RXG'Y-M^'R>]&SS.XWN?:1N)>^K>^FUOLCN'(4N./Q;;NG"LL+5MC<:]=
M?_"?T+>Y_%['],]__P#*+Z)L_4O<=S7;M[L'8^TW^3WBX.-QR&6SQDN-<(7U
M7;B!000 ?_'RY]1_XB'T'_AC_/O^8/H__('TQ_BWN?;+G,[9R/\  W [+;XO
M$[E]0< 6TMVE[IP.V6^3W"QDESD@M"M7LWTTMI;/'^G[=[LO;K:#:MGLG;K[
M<?L/&5*;?:X@LVB--L"F!2OB!TUQ\H,^&)(&=>GE3'R@=*==3&#Z:FM,OL\,
M&$TU KUJ,3 (J?\ KB=J^-!EIA"4$M<$LU8 :H$X2=C(Z1$#I6<"X.%Q[ET$
ML6*+NH9^;PP5M)MMA0-H,P1G3+"FM'%2-)BD87<3(Z'4Y4ICTTC4CX9X.[I]
MPRC%RR98H2003++H:88 FA!@],I)/\L56:9GSI7QQ#"!J>HTB<  ^.=3H1B)
MI%3%9.4QUP(R^R-9'\\&":G.(.<P<33Q\)$4P2&]*F('A, X'S1/S#6E8P H
MG++.I_-BU:$S:4 QE)$4P-HH0 1F?$CP\)QM!)RA12N<C''LWW**_P"DTFAW
MC+[<$EJ%<P1E&5,;=U$UGU$DY",!A-0"9J-S5 $XX_JK[5NITA1B-U#I19.0
M$X%9!RJ*>!P"#(F.A\R, R 3Z3,"1IN)Q)-)-*:9"<-=@M9)W-$?ID_FCIB;
M;>FM2:?_  G!#.1(_*0(ZF?Y89^-SKA)8$VV)GX#I3%I'ON60+#!@-K"IB:^
M1QS$[)V+LO9>7R^1>YW,Y/:^V<7A<GN-SE7#<O\ (Y/)LJ'=]Q)<;HK,8,D3
MF3X8)4GP;*G7^F(4M,D@[:D=!& =A,?VJPSK)!Q#VV&=2"*161K@.PV &0YS
MD9J)_ECT%212>E:R,7^)R[*<CC\JQ<X_)L74!2]8NKM>VZ&:'_73',Y/>>]7
M;G9+/-?]GVOA VN==XQ.^W:[AS3\H ]/Z8D@3(.+?#['V;MG;K%M0JBQQK9O
M.5$;[E]P;C$ZEFK@L;5L@ D_IID!TB,;+06S62MM%00-: #$-=!UG(Y4J,2C
MG*I#&M*S6N#<Y-CCW02=ONV+3M , EF!-<-Q;W;^!=XS@A^/=XG'N664T(>V
MZP9Z' 2QV3L5E%HBIV?MJA0*#TBWTP/_ +%=I8J1M/\ VK@2LY[3LD?##VN9
M]+_3O)MW&W.K]HX(+-_<61 ?L. +OTIQ>"[,/U.U7^1P+F?2VVV/",?Y)^C_
M *&^OOJWZ?[1Q^YLG"NV.4&;BW!QT)XUHP 0.HTSKC_L5_\ RKW?F\/B@J;B
M2.5?39LM6KI U6M,L\7>^_67<.;W+N3,5O<KF7KG(+*YD6[>\F#D=HI)\\'V
M+*JI1P+NQ0^T 47;U.0 @"9KBWVY..+G!N\H.HJVXN]2J+DH&9G/%NR]I5Y6
MWU;;$PBS<VJ4CTQ0;O(98FW;"6$:8'H,.GHW TSG+KBQ9ML"@/ZC1\X<40$1
M&UIR)Z83TE@H)60=TD;1514:@1A3_MRU B2Q72,L.4, G;6I- 1.H-//"NL2
MQ!,MFZB:1G'0:X-N2S'U1Z=5D$Q0 F@C"@DDM_<0A5I/J,C[!Y89074 0H5B
M3ZOR%<O/77#^I?[&A3$3J3&0Q[2 PLQ<RN;2:@:BGW98*V2Q#[-S$@D[:% #
M!$4.<G*,'V[A+L!O9A"9[6=0=08Z=,(D-&[:[N(<G($ B8R,-YXAPFX*I()4
M#;$/=Z0.F&@S90$,75F$'++.#'VXW%#0M"LL9G;OD&9\,7:>W<<>EP-K,T?-
MU^.7QQ> ;?Q[%K?>5&_YKA$_J%O[9$_UQSV.U$XO/N\>PA]2,P8[O4L>FIW,
M3TH,7K=T*+5]1;-%:/340()!($%H_#'?MY"NG-N,FU9V*@/S#\Q)&U@=#.+X
M+[;-_;<XZF ;4D+>!0&A:K;CK05P4#L6XUJ\"\!;BJ6H2&(D"8 '6HC'+-JX
MI2VE^&"L&_=+1-S-)-?3 Z8XW<2MRSR$L(S6RDW3?#$NC Y'7ICC]U[EV]CV
MGB7GY:WK[MQ[/+Y5P[+'%!N48KFX4&G3')/U/W=>\?4+\I!VWZ8[1>5>%QT6
MZ'#<GE '<8)FW$**5QPN/;2WV?LB/8M7^+Q2+;]ZNH@CMW$6FX F&N#(:U@6
M^\=W]MUMWUN]JX"L6N7N3N(LFXK DV[,$!8S@Y''TMQKRJW)L]TMWFXZU1;3
M0IW!:FX03TCS&+/#]^UQ>+;LV'N.:*+3KN-JV3F0<_B<?5][MUH?O^U)VSD=
MNY(@^Y9;EAN8M@Z,$,DG3SQ:[/P[MQ+S-<7FO<"VQR550UHW=I,[33P7+/';
M>VJZ!.3S>0ES: P)?ACU;YE@<A]N.2MDD>T+UNXXE2SDDB/PICZ<XO9&N6/J
M_P"GNU<CNG$X]M&+]U[<][;W"Q;1:ED7U!HZ T..S_3W,NQW_M'TG9O=M @D
MV[5E5Y'&:R0-Q69C+H#&/IGOO9+[+R./WOM]GN-A7?9:>YRD<O;89$J7%0=I
MTC'=[_:KXM=S[4;7,MW5,>[;YEE;RVKRBA+;HGPQR.Y]A%Y;2BW=^JOI<,6]
MU8&_O/:+1J3G[ML DZ8L\[MEWC6^\GB"Y>M @)S$6=C!'@JRDP1$@R,>W<0N
M#ST6U=(W>JXT,6Z0.N.]<A4/Z'%V-<"[BJNXMMM^$SAN[_3?#X8X [KR+]UV
M-RXC6^'<][D7+U@L/7!(](G*#CMW/BQ</)4<Q$4DV%>YQQ>46E::DFHF)'AC
ME<;N=@N_(<7K?'9[96W<8S9N[V%",]A,9$X1G3=QN;>3CM=5]USV;S-;9G1"
M03Z@>AS&6'_Q]W+F^T>,URW].]XY%D$\/G6;>U++VWDFU<81#&")C3'.[3S+
M0X7>>([W;W#W_IW/<<"R_"NY0\>XDG7X8"<Z;/(0S9Y <HS')K%X'J8 I$^&
M.3S+B>P.&JGE.$-M=@.UA=4?,&, G,$SAQZ@@*(%*D_IA=JDD&E((C3&T@EE
M5 \;@FT'TA3F,+Z:*!#2?32JJ!\VF%6@)+J5H%!S!$2*Z=,&^Z[+!4^II#.P
M_*="?'"V[*!$*RPD S3U%AEX"<7 0 0I6<Y-8 Z^>.[\:X /UB-I]2@[/TC&
MHBAZYUP+MF;92X5=$40('S(Q'RZGQQ:Y"/%_8*E8<M_M3,BFN/F_^9;?_P#)
M_?Y?[\""2"/5K!F# \<9%E!)W&H@T!,?"<?+0*2"1T(@#!)! R,C<#INDYUS
MP36A W9FF4D^&@QZZI4SMH1'I) J)\\$$08)8G,^F 2=#K(P4VG9NF&( !!!
M\Q777PPZF0P;:S. 3N%;DD4)U$4C *;H.Y)9EC<#Z"9S74=,'Y()N;WG:JJ*
M3L,@DU ) D_;@O;R7TB@](+;=UQ3G)T(\\("PW;R2X7("9?9-#F/N)%,;7KN
M5Y> #;7<"Z,!62(KXX+*=S0J*H)]=HU801%!,'+"D71L),@$ !F:$&\4#13.
M<XP5E06)10M5!F0D+%<O 8WDK.THMM3#&X]).W008Z3BX$$!%@P?61M)",&R
MFH,Z89B64$L)5##=4W5W5-*Q\<;+JAI+W!:W%;HV-4(X)&?ID&L:XW*%/MDA
MK0FV&84]P[J0) I7*,707)9=ZR";4LPJSD91_N, :C'(+NH0O<!##:0?=-EV
M)$3-!2N/\L?^6_U5VFWRNS?X3[78^@/\;<KF\47;5GZ_^K^,>3]2]Z[;=<[1
M>X/:@O%%Q!N1N28@G",4VV0(MVH*LS*:.XZ=,22-QDF1(\Z998 F@$5IXQCD
M\6ZOK:T^VE00*$8O]OY)%NX;K^U=:59P#*D-BWP.:&*;A[;DEC!;,-K\<)<0
MAI$@@ZQECT@GPC[R<0?LUJ*X_#.12AQMUC+^TGJ,\&3\/],$@TRF:Y3K3[,0
M!NK.XB@.E<3D<Z@ 2<]A\<1!CK/V&<;H(W^(T./[C.@F#%*M@=14&*SE%<"V
M?F!.E'$9##3,;V@:T,898RK6/AE@D$E1%)@"=3@[?40 003 8&0?$SBT""5!
M-Q@1010*2-9G#9;;2!1IZG]1^P 8K6-!6FA\L%:D$Z&AKJ<'S.D3UH<37PG(
M5\,&1$]1I&6'<(#=MB=L59-#.L8NV+J!+MAB&6,R#$^/PSQ%*D;OAG0ZQIA"
MA@$FD9P:QXCK@6KCJ;E-RN244FNPN:%AT-,%3;2XS *+FT&L3132GECEVVME
M^,S6@K6V"(";PD[=9!FGV8N<3E\6URN)RTO<'G<'FV[=SA<OM_-LGB\SA<JU
M<!%RS>MN]NZC"'1F7'?>P]DX.S_"/^6+O>_\@?X)[A9)>SP^Q\CG?_W!_COE
MO$6^5V/D7/9M(6._B-8NK0G!1ANAMR-)]*@"5.@(G/IBV =P8![8+>I7:FU>
M@(TTQ9+DBVC*P@+_ ,A7T^VQT.1ZSBW;+E0S!UA8"#=!61J32)^^N&D+Z[";
MS!3(%'MM[?S T)C+#(&'N<=[:V2U=MMGE+GM151) .@KGA.2K7@MZW[?(M;P
M+=RZB':6O_,2TDJ :ZB,*MVZ";=NVK!-@(VK"VT<C=&AI)G*E0&NW50M"L0;
M7L/E[9@Q00I8#/[,$M[]^W+#8_MO%T,#[L C[ ?'KC]5;P]BTMNVX*M>6TEO
M=0)1MN<@Y:TQN>P++BYNMW4#/<1+KC;=.P$L 3IJ=,7++%=ML;A*!'M ?\9<
M @L3/J DCKGA=KM!1"X8-7VFVD6Q.1IM H()DXNV]I;]42B"VY?;4,D 1&V2
M!UI7%U;;7KRVT55>Q<V>V0:,RWHW,,FVUUQ<':NZ]R[:;C7&+V>5\@/S6[+&
M2HB"2"3E7&WF]VY_<[.Y49>;R+M^ZH;,6RYJ#F1]F%7N+7N"@ 07[;?HAVN!
M57U:]6DGX8-OMW)N7[3(C!FY%IRKO3:Z7,BH$@],7$XW/Y'&M\QG;E>W==I9
MK8#O<KM!<#;\8PQ[3]2=^XMET0W;/"[I?M([*I'O-9X[ 2M8:)PM[L?^0OJ5
M;CNET<;E]TYK)M)*WA[=QAM!&95IGS..!VK_ "#RG[YVFS?0<BWW!1<O"R!M
M=;7)N*2EQEZL0<B,7^^_1_=.W]O[VZ<;EW&!M/<X',C]'M_."D&#^2X!!U&#
M:[_V_P!RS89K5GF\:T;W&O%&,BVZ?+MD%E(@3G&+BO9?UL59_45J0'2T7IO'
MGY0<7[HWJ+UE9M,&W,I,%MYD^G,DS_/%]F;=#LURRNY=Y8%+@4&-A(@QJ/MP
MG':V_)9PMM[OMREY(&UR&]*D(05))!,Q48M=O[LW(^J_I.Q[1X]AN:3WCAV[
M4V[EGB\V\NRX H$6[C;E(@, 0,<KN/T-W@]WN]IV7>__ $\5/'^I_IYMNU3W
M;Z?O_P#N19(DGDV4N63G[@QVWA=M^FNX_5-J_P Y+9X?%X]TB^SL0H6Y<7:R
MJ/60WH(D,8F.9]$]O_\ %3ZN^J?HSM?;^W<;F_6IYWT']+?XWY?<FXZGN'/Y
M]_ZBY?&]];1(2V_#=KA90&3(X^M?\G_Y7X/?>7VKOG:N^=[^I^V?0_>.)]/_
M /T.?1'8>#<[CQ>VIW#D-RKMSNG)798XUK@V6])-Y6#[6';NRW^P]C_QU]"=
M@[?>O_1/^&/HJ[O^B/\ %7'[L1^Y7G=R4F]W_P"L^ZVC[WU']2\^Y>NH".%Q
M72TMTMP.-VRWP&>Q;XZ>W>?D*@?8$5@G&1F-14"#7/7'^).Z?4/^1K2?3O\
MC'ZL['R^Y_X][#V+B<;Z9[)]*6^8O=_K&[R.X\GWVYG=^;Q[5X!N2&]IGM@6
MRJ['^F/_ "3[!VWOO'^J?HWLG-^F?H?O?U/SKW=>XM](=SNB_P 'M#?OD]UK
M*<)K?'/-<)=<H%5+=I50*  M 2)D"F4XFD>=?(X%?CG@4KUZ]#@>5#GI0XI7
MP\<&E*YC7!H!&O\ K@@+),Q,#,4^&/<5896D0=/,UQ;#4>T A!SE:_TP44$4
MJ#.6I PU_: 9)(G.<Y!QM$2"#X4KG_/%)SD9#X8 ( C4BHCJ,$30QH0"8C/P
MK&%>:'T/T(:@^ P"HGQ(RG\V#Z09,@UF<L\  "OWGJ/Y8J(TI0]#EB3/IBN4
MS08D1.1C/X# ((%?XSPV98BLB! K7#J,R233+SP1$C= I,3_ !3!=B-JH2QJ
M -HDF-0,7+@;<6N-X^D4 ^S"R,CE, IIEA&$L'63M$L#YXLWT8RC*VX4((/X
MZ'%JP6(*IZGF: 9XWD[@]P'=U6<ATPA$$! =L=10G%I23*H!M)(50O3!13M!
MD$*1F<B"?QQLN7(J(C)1KM+9_# .^5(^8F)I,^>M< [T).0W%B%S)VC'H>6$
M B?#KX],;7 ='4@@U!D9,#CVK<BV?5;W$BW$^&NF(:2#_:1$Y2"<"\ VTD D
M$"*R,( 2 (VL005I6 ,SXG"7;;Q=LG<A((FE01T(I@$ JI^9C/I)S!\M<?J
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M'PC($8^ &?QFE?/ F-<J Z",0Q%:]/MQE, >0!%#ABIG::TH"=2-?' -(-
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M(;=C_)'UY8O";?=[EEV_[5VV)XJ/^XO$761$MPI( @DB" : XS G34&(SP2
M=)K4_P!<"@$MF8]7C& "3/RGJ0-?AKB_QG4/OMD $2*C4X;N?#4HB7 [!962
M&W& /M^['&OV+@"W[:W&4M,-$,/]M=,* :P)C*16F(IH:U^(P<SUZ93!P10@
M=!4?ZXS\C%!%9G'B>H $G2?Y8D@,2?E!(%!7+$3  GI,BD'I@U -"*4\@.OG
MB!69)(I76F-X,5K"[ECH#B*FDQ  KH,2QZ3&9/A.6"VGI.4RQ,4'3%"JSF/E
M\001TT./:O$ +078@-%?U&T/CD<+<(I7VU(,*,M[#4G3I\<>V/4B&7N30.IE
M;:'PS:*:8".[7$_+=$3TV7%U\",?\BT&1<"?(-A:R,R('XC\1C:,S!Z$8)!U
MG!($ ^!$]8Q)D5RK'@*XO(4#V[JD'<*!XB1/7%ZPX*K)* YT,P <,[*K,3Z1
M-4!KO)/WXK#+.YG>W1@<C _-H!&#:MU+0J3Z@)U)&4#J,<[ZCXG))Y''.P61
M7>J?J7W+'3= )$98?D"72[87W[2C>PI_R6AFQ!G<,X/7%U[-VV;=;J>XUQ1M
M8_+M,,#I$8[?_P">7^+^PMQOI[ZWY_:_I/\ \A>+P>*MCB=N^MVMKV[Z2_R8
M>.H!5.[*@[;W*]M /)2Q=:MUCCWEE7M*4N*A,,#Z0ZJ)GQ ^)P65C=# ;I$!
M*@%@8!$G3X#K@$,9@+MN!5@J?E!6DFE9\L63O9=C$ARH+( L-Z <CF-QC73"
M?J(C,1;8WV -R%FV0#.?0>.+A#VUI[8MW&VJS%@^UQ6F>V(/3"VKC)8MVW-]
M%N*C![UR=X+-.TD"1.0\\"X#>-ZW13;N*;-VF^X$M@G:<ANJ#TQN:T66XP:Z
MB.NZVY&XFQ=DT,C*22,L7%N7C<"F&<K+7+RL5]=(DY,VL2>N$MVU3TR/:MA=
MJ,6"LMPL?LDYFE,*&7UVCL(MK[ONNQEEM*HF@H0<C04P6LH+9N[F9PVY![H,
M^\ 298 !@!IE@[@&2XR(]NZ0/<5/6RI$"&@09KKCD6V%Q=\?IKM6V%JULLMN
MI*B",O'#'?: "1;(#/=O*/3MO6GR&8W4)F1B]?LHS7;!92$ NLMH?*NX?,%!
MAC$C#61R+O':X/9=K.X HAW.MP&L:4^V#C@);X_+?NO!O6KR<QD6];MLOZF^
M]O\ F@_VG*D2,<[M'?>VKW$\JTG&Y':5M>_QOJ3T[!VP$@HEJ],7%O4 ):I&
M.!]6]GYG_P";SNO.X/)[ARD#'D?2PY-QGN'M@X=XLZHK%;%MK9W'5<ABW_CK
MNGU7]<_3W^-/J#E\+N_&^GN%W_E=P^@N?S['_N.%?L<.[OM\>[;)#BT@MAIJ
MK8XUSZ2^J^U]Q^OOI?@7.1]6?X@[O;_[3]4\F[QU(;OWT-SV9N/W'AWX#>R4
M6[9;<K:$W>-::]Q>0G)/"YW!YEKV.1P>78<B]9Y ?U%T<-(()!$ @8M\KMMQ
MT_:7!=L-;!"T]5QK; >F1G;G:9SFF.T\_FN__=/I^^O:;U\C?=-IK7N\9+@?
M4 06R\HPJ6R'N7+=JV\M[*%F0DV[+B4!,;ID>6/;MS;$,HMJ/<6X+CAP8 BI
M&0\STPBW;HWI#(1;(<VF(%MR13,0"0 #7%H*=UQ0J6PL@W%N^ED57G7/H:Y8
M[9VG_)7?N]_0_P#X]?3/$O<GG]M[,+O$^J_\W_7=E2+W#[:QAK79.WC] 7[B
MQ<O>XZ @*<=B_P >_0OT^O8?HK@7+?&^D_H3L''91>?C\<<6US>ZM;!:_?%M
M1NOWB1;7<9$F>%_D3ZV]KO'?^X=K56O"Q<L]O[-QN?95[W:^SW[A#W;MR?;O
MWUB/RF,7[7!]E7[,O#[6ERS;2SQN/Q^W6-J<"Q9055=VU9KJ:L<<EU"@_JAB
M00528V5%):L3E-<<6]ZE(Y5NU*$E[<U9=^I!,R)!!C/'%)N-\EM0P:$)V@LP
M)UZSEA2;D1%)S\IU\< "Z<QKUSW?' _44$*3&\^D:^D:C"$7) @Q-?(^>$8.
M-K 4U&A'PRP(( .NAZ8%:C61YQ3&=/#+P&#,:]<NN&&6LZ'$'7PC#7!Z0H))
M\!4[C@<5N7;Y%BJM#[C;8G/:/'3 N6[Z75:NU&6A(UC\,>^"U2#$@Q'B, "0
M0,LLL2S&)@3X#0_'##<"HSB*>-,&"29]+5I(Z9X4$C;= !DP-^D#IBOWUC%<
MZ^,&-<30&/CXQ_/$DTJ0 (BDU.#$GU><0-,91^:,\J4PR@-Z2:B1(S-3]F!F
M"2U(!.>?],=3-?#P$XXO%N ^L,Q*Y)MR,>/EA(!VS (H(43,9=<3&8 ],@%L
MQ('\L*1$#*LEAJ:_CA)H !,_>/\ KAKS+4M"R=%I&+4J- 5(D@'.N&V-!@TG
M+"V+-LL[6PRNI]*YR"W36N$]^T22  QAMG3<QS/E0X4W;I0QZQ57(Z03ETG#
M7FMVG<>KW+NUV#90"=<.J+:0V]V1AHG5A3X8]TE#;_)L7:2-6;R\<;+5QTV9
M$R2=  3A[!N>]:O(4-JY4*QH67I@W!#)="N(D[9&[:(I7QP%9?5,0I&@H?'\
M,%AZ=P^: _J_N"MZ<.C,-^^@@,3(+?,*8]IF"E@ U8*QG'C@@ON=,R:DJ?E-
M-#D1AHI3U+6D&""<<=% (8W+@!!B-P$;#6?@<*K)MH* FBQ&0K7&QB8S"F20
M8K7RTQ1CM894;;2G_7 ND2K&!$E09D%H^["W58[EC<"?LGSQ8YR'<;!_64 S
M<X[^BZGB(J/+ "1M(5E89%6$JT^6+JS1E5OOBN*BNGB?AE@VPX%#]^IP':")
MF6GK&%"YP  *4\>GEBIB9I&5,&#+=9_#%&B?$U.40,"16=6H/%< 5K0D 0"!
M-!CZBO6E"?M[W&>ZBJ(N6^19%P7 -8K.'90JW=Y1[;$3,1*D], )<&X$A@6F
M"5W(HZ>%<*B0;C#U!F%"WIH<NE#K3 MVSZ 8:5!)<'Y5ZJ!H/+ .99O4[00A
M8A@R]9U\C@!ED':=S"68;H D^<S3IB(*K$KZFU%&4BGAA2P"LI(#?,H I4&L
MC+_IC=))=B%"D#;0D,"U2<S.&0;2'V@!@3<%"?F,#<3IB"7$+!7:I WTI% <
MZXNFY<FWM$6Y,[@:&Y%('YF.4X]I7) 4)=*;A<N!99=M/,3]@G N/?9#[Q]M
M3170""*D$;=!%:G+"H Q)B1<!#7F4 G](UI,QBWNN!OF3V!0D[I4$35:Y#P'
M7!N<D7;=FU)LV2SHH09ENID_*:&D8MS:A#"J11G>(9UF*3-,L\!;=HJH4$W2
M&78A (6%\>F!N"E]U6:6 (F I-=:$T@X;U;F=]H4G<X9C(JM!\!X89!+.K.8
MW_,QHHWY%201!U.'2\@"*5#O#*J.*+N!R%::G%F\68VN78N(6!4/;V7):XX-
M08$P,QY'%H7#M1UW[[C+)0'<4W":$9 ZZ8]_Z=^B?J+N_%O(5/+L=LYHXZ"H
MMLCN%4]&4DSY8;F</Z-YG#L!22>3RN'Q#<!S7]N[2333*8\,>[WWZB^GOIQD
M"$\&X_(Y?<0XHYN)QAZ7 KK-*XN)]1]]Y?>>WV^(S;NT7;?&OGEW5)-XCEB=
M@$CJ#G2N#Q>'](WE7A['L]PYW(N<Z]R.79)".'^1)_-L$>..#R;O$[?VFS9"
MW5[3Q![KE2D+<OM:$ER!+=*>.+G+*IQ>/?,)=OH 1;,KL"H)RRKZL7SP^&53
MC6F;D<[DIONNS@AKEH& OJH.@SQ;XS\AK?& +.W_ ,WNA6EKJ08 $[9/WXM=
MN[:XMVC;'$]V\X-]4FKW[RY4K ,Z8X]GC75N\UN.]FX6 =0'3U70!D!H*1-1
MF,7?W O/Q[',=WN[[A=+QO[5N,K9^KSD1H,!+5QKR+Q+9L7%:4-H0SK2"(&A
MJ-*'':>^([JW!6S:N("QN!'$I<M!:-EJ)&.W%[QNCV+<EFW7+=Q0&]1Z?ACB
MJ$>T>>R$<^TDFP+#AU#.PR.1&6.5>O6"O*[7],=IY/$[BJ%K1L"PV[CW(!*C
M< 0TYFM)QV3Z_P"P7^7Q+??^%:M<KDV6;<.;QV"H&9#!EHK$&HBN/_&SL?<+
MP_[K]3?1';[W/XD+;?\ =<>R/<O+;6,V-5\3TQPEXUY[?+](NL@9-ES>H12P
MTK6<\7>]<51QN5P.6P[[PM@4<KVG@<GBK2K'U.1F#A+-K<;9X8Y?&,25).UD
M\01G7'[CCEN/S^"58W "OO"!%LLL$$=9KA^+W&VO_<+%IP''HO!P*D16ISQV
MSF6;/)NW.%]2\BSRN+=N7!;YO&Y%O>[->2LR205RJ#CN_;&M6%7MO*6S[=K=
M=*<:Z/=M7$+YI!@&/'%\-;.\F$;<VU]HVJ9C,^.-PM(E?443:S'^U2:$GKMP
M7>MU#N#L#NMW/_J3J:1&1%#BYQ]GI2X;EM54RN^KT:M#ZJ>.'"J)!6Y,DE6J
MIDC6,7;@8-S.*GZB;0!R["+/N &I=!GJP\<);557=D(@G<9+%1KJ , ;MUX-
MZ[C!9! ^55J)\\$SZ<XW 3-5%/"HQ/N"OJEB& W'TF!J?NQLW0I.YFU'1W'X
M##;3\R[F0C; 4QM4:#+/!]NJL?4OJ]M)JQ&K&!0C+KAUOLJ<BOL<L>ET>/0[
M-F:Z5\1@\;N"[N79^1E"I;Y%J8]U,JG/P./S_P##L^5?^/\ ^^Q00:&)S&6T
MX(S&TUR%<P(Q!!&X S%0=#]F&"[5H"*3%,SYUP:+-2"QF :%?LSPU#4$(LF#
M-0/ATQJ95]Q!$!<]S#K]L>>'E9)HX5@0K?*K3I2L89B%!VEI$;76(E#!J2)C
M%"T;&;8$+,=H_6(/Y2-3'6,2P==[';[@+%CMDD-D0P@CRPPMJUL?,NTG?O<2
M =\D!JQII0X4]!$;641;EE9E:A.4GSP7<_,""0RNKI!9E4&) J02?NQ(@!%-
MNE-R%J,HR&E1]L8)*L8.Q@3.1@5(D'0MT\, 7+;$LHD?W35!X&DYY:X]"D-N
M,.(@K'J 5B-HTD_## Y7 Q),JQ4#T0<J9#7#* %4R)426W+MAC68RDBN1I@[
M@0!1MD%5">EU90,B#$"NM<;+%JY?ONZV.+:LV3>O<B_?8+8XEFS;5F-UR0EM
M%7<S$**G'8__ "(_\DNSVV^J>/<X_=_\7?X=YR6N1;^G.0]L7N%]8?Y$L$$7
M.>E'X?:F)6P8>_-P*JF_R"SW;KFXUUR98M4EIK.%!!I6>OPQ$"@R)\*SB #E
M)G."*S@D+ FA59 /1H_'!VT&Z#-!G7'61 CICDW/95YL.*I)F#48[I]/7696
MX/*]VP'+C=QKYJ#71@1A7DGTJ8S44SP),5!(%!X[C_+$&@$^ /08, DTKH/B
M,$D$GPF!U_ZXCP@B)(U@G'ID#*E%-(@C,X'49>>"T9T,-UIGTQM-!H0P$]<J
M1@ *)I701T7P\<1,$&)W9Q_3&Z23$F #7P.%)].X[#J3N^28IF,1F3D$]3'P
MZ",$W3Z)!%M8B<@S1F?NP&)8B:KO8+M.=!^&!M555?2J[0 !X :'!!'IDQ(B
M"-1C:RJ6&9VB/.3B8J/(4C^6"16E 34 YP<#=,$T'48F!\.F7W8W&(T&I\YQ
M<;DW+=FT%.][C*JJL2S%FIBYR>!RK?*M(Y"W[<E69<@*5Z2*8C?+D'Y29$1Z
M6.>(-PUDLSCY%%#<?KT SPY1;BJJDAUD-<8T4!M"3UT^W%_BRR>YQG%RY$ &
MYZW9F&1)FISQ<X8:Z&M<N[:/N>B=P.P*/&)_#!# >XF3>F0IRB:^=<?7?^'?
M\F=K/>OH+_)WTWW3Z1^I^V,B7@_"[K9-K]WQ4N#T\CCW!;Y7%N""EZVC TQ_
MDS_ WUKNY'>/\>]^;B\'NH1_VWU3]'=P4\WZ1^K>+N W6^X<%K=RY ]-Y;ML
MU3"FW<_2NA75CM/LJZ_(768.HSI33"A9'H):2(9DR$G(DP)Z>.'W*R$,"V9-
ML"8H-,XBN%#*854W[S*D@[^F7^X:T.$K-RY-MBR;GA:J^V() R^&+;;[:VKB
ML9W!MH!]6]%R!I$&9\L>\ML"*W)"CV[S!1NN!9D-D-@ !_-BY8<M;%LBZOML
M]X D[Y"V]I+9^GSU& >/<WN[W-EU]H+VE4)<LW$( H1Z?]N>N&!(MFZEJ24A
M-K_\A9V))-8 6F0IA0EVV;99K:&T5]Q&!VAKPIL)-*:&?# LW/;-UU=&M*&0
MJZ-%LVS2GYMQ,QUP0AMBZGI5(]Y#*S;M^O.9]( \3&'(8\=[8?=MA4N*A(9=
MER88 C=!))DSCTV[BWO=AS;N';<C]2R[JPC:,R09C2F+%M[:WDOLR7E=5VA&
M!5U8+1SF0T =<6NY<.R;/;^8+CHP&ZV+F^6 N12,P/(8M6^1Q[1M_P#S8W"O
MZK']5BQ;-B =:82YP>V6E2XKVMG#*/SK;;)#OQA#L,B;ASTC';N+SN9W;D=C
M[/W%KP[<-S<6_>X[;N."DA20?4%G/.<=M_QSWSZ>M\KL8XMMN\<OO=JVMKFC
M@PUFS8<>O]P"JK[M"B" #GCM?>/\9]][KV;O7:3;[MQ[_;.?=M<CZ8[K:BY8
MO=J[G:;W1)SML30>H%6C'*O?6W?>1]0]T^I.78N]P[]W/V+/)Y'-N%>,.1S'
MXEM$D^@LX0$FK$R3A[ :U<MHKVB+=PW'W6@5?D*1*JBMZ2KDUKH!CN)N/<![
MMWFU=X7'**;8M]OL,+U]D>-P:0)TD^&+ESTVF=;CK;4.;=S]0>X;;-4&2*J,
MM,.X6\Y=\S*NMN)*6MI !$%C03I7"*B7/V]^XY"E97;L-P*[16:Q)SQ=O<96
M[A];<WB6>?9X*\=^5Q/I;M'*7V+7=^\+QROMW>2Q*<*T[C=6YM(B>V6_J;F=
MT[UW+O5RQP.P]DY+_P#N5XAF]Q0; $I;526DBHJ*Y_\ T6=Y^D+/=/\ (/?N
M#PU?ZA^H..Y' X%Z\MZ[Q^)P[H_1MWK@56 &\VE 8PQ&+'$%U7Y(MVWOO91;
M=FS;98-JQ:M@*H/Y=0(QRK/'MV&MWKUR[<]47"SF?610SE48Y@:Q=2[8<^IS
M*C<FZWM*RII,%C]IQ88!QLNBL&/36TTCXB"*G'%JZ'VK>Y1F69=S 1A![AG;
MZ9!$@?E8XD,PD;28W*!^:@SP)--2#43X]<("6ZY9_P :X03EM$]?&!X8$GR_
MKA3G&GAC.F8&":],4^!Q]\?ZXN\'B70MUYMM=!!VLU"S*:P,L#DKN(8EPTG<
MS$PS5Z^&%5 P4@!H@DP(R_'"6G 8!JR2&@FLS^& [P%BC$PLQEXX9$,J 008
M \?CTQ[9O*)>(F223D!YX6\C$O!5J$5F,*P-%]0,90:SA7FL0TBL@=,58" :
M@:1)I@P9G(Z'K. ,IB*4CR\ZX]2C6"<YGPP(R$SXTC+^6'$U@R8S&?\ !Q5&
M)F08SI)C[L#*GA$TQ<"L MB;2P <J:5SPJFBPL$4AE.4#"YP(D^&9H/Y8 C,
MP-T0*28."T1,YUIEKE@%BH(@R,S.48MMO#J#M FJ]9 TP-KSEN3,@GQPUPJC
M_J4W@9D4']< JJJT;B!&TD9C'YJ$_E.>H,]/ X-BT\7'! AB"(S9@33PZX +
M%Y;TEC):M0!U\<+Z89@2LC720,\+<8MZB1(69C3PZ$X#%)5F(E"2!U,-GCC;
M("BU;$M58(@3I\<?+N)(90!2-2".G77%3#16L@D^$8M7 PC=#?+N_NH/Y@^>
M$=&VD%@"*2OQSI3".2&8-MN*&.QU_.L-KJ,)?L/-JXLHXB6!TID140<<*\5#
M,I99J&((G3Q%3A94 @"&#4$B9,XW,'.XF&#2HZ$C$>N#XZ=!.>#_ 'H*0! B
MI)$YCKAD+%D)VLI!(*C,#\<-;W;K;JP(J8)R_P!<7N(SAKW =D$F"_')]#C7
MTF5/PQ;>8!])/EH,%R?2JS)$ $BM,.%--Q%2/5&@ P(!@9"/YXWN0('D#Y3A
MK2OZO#./ 8:X9S-"I)936?#  F=0 <O'^F-Q@L ,J2=09QMU!J,XGH<<N^R,
MEON_9>)=!)/JN6%:VTQY ##7MUR+I9BJUC6?'PP+2BZ VYI@@ ;I!+C\PZ'"
M[F:#N52 2"(FK&:SEUPUP(09)V4+$S "Y1&<X4,H<-MA@#0&NV<R3F/QQL5#
M)!R)9]T_*7)B.F!O4 $[,Y4$Z(!FW4882P)],F"5;\U1T&?3'N$ ;5@B)V2-
MPKX4PR@[6DA6N ;C%2K'PS$?#!#2P0!2X,$**$$M^8T.[^N+C[V8JK;V!*JB
MZSG6,S'\\-[3@AF*JS;G*B?00JD5$Q4_ X]5ZTUPD$V]ZNZ/MWJEJVM=S"6*
M@99X:UVGA7+=L-M?G\A'M!X!EDM/7P4X-[N)-_E0NY^1G*KN%M)H%7,D"?CC
M;;+7& 58"JML,IHSAI)SI.#?ND%%MAEM&F9"H+9/]U)'\\*+7I((8E*L(D[;
M:](ZX-P^MUDJ!*%?[PH,R1]F"[$ * S$D(%!8J2Q,5\\%GOHJK5F9BB%V8 (
M22=VXGTC#/\ 1OTCW;N7#"K:?G\FS<[=VM6=QER>4%#@ 1"[AJ,<?N'U_P#4
M:VV)6\W9?IVV&NBTU;EF]W.^L@J#$(N=<6+O9OI+M_.O"W;V\_O:_P#=.>&
M =C?Y@8;J:*,"RG'0V@H4V;-M4MV%!@>VMN #\,&^SW>&S N2FX*(KZE7J<Z
M8O7KMCE,ZJ]KBOQ_;4K9GTW;EU?49S@X#=[Y_.YK\6Q(XEZ^0ME'$*EQ5(!
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M<Y:HHNJL>VL 7=/=13J?S#7,88"059A#TDBA.[PKGA-Q&Y3N)D[7*5&5*"<
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MY':?_HA[EQH:WS._'_N%U;H7;[B6W'M@G/Y::1A;%BW:XW'0 6[26U5+-(A
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M\>W:YM^Y[H%P"T_[9%WJ#<J0#(,ACG%)$<>RU]GY+V2"J@NT<=PS6;E,P/L
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M290R"*$Q/JZ8]Q2%+N483(6%H/Z3@A6A;=TVK@),R5+(K;=#UQ;6%E;*L%J
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M'=1[5ZR0&W1[A.1(GRJ8G2,"VQ(#P"H)+;LC4_;A[MYZA9,994C[Y$8^C_\
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M#2():8 (_ICNSJQ-OC7+';[9%5V\2UMN%2M(+EL(1M/]U/F R$^&"#&Z!$L
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MVV#*[I 7;FNN+MR4^<7&LN4L@W2(("B?50+2G@3A>1=??<*FV_N']P[DJ-J
M+ VQ0;@-!0XW<8&[:W*EH3Z;2W#Z]H,9F5(-?'+!)51<]7Z=JTY4HI!+S(-"
M!6LR:4C ]U4*-M<M5%<'6TJ^HD$R#3H!& U^W<%EU8MO1"6]9==UICZ3J9%-
M>F$-^RANLQ*$76]H@&51;G_I)H:Z@P,?J61;9'5C:OR[FV 2A2Z" @@$R1YU
M,X_XD#6R&M;7471;+E+A8 Q3,[JZ0:8MQ;V6_;4IR+=E4]P"G(8%H@K,@4!T
MPO&XUGDJG*OE!:@LUPJ3Z;=/E>@(DDG+';_KG_)O;6XG;U5>9VKZ2NVGM\GN
MS,!<LWNXVVAK/%D4ML [R:!:GB7.%QK'!M6N*;=NQQ[26;*V5 MVN.EM -JB
M J;13(8M+RD*7K@-YR27M$R%7:P^4 4$^>+?)4AU2!>V:H: D:P:_P L!EDC
M;2!(@YD3BR691^C>8"03.X13.?/ &TK9#$D$0]T@@@4_+K&N#;!7<RFE(4:;
MB,.2@="C+=! &]7$&F@Z=#ECE<-V)_3N-QKQ((OVPI)MWHKOMB/F^85SG'++
M6_=47"[,BPWH,6V&[H&^4"AQ9LN651=WHL(+9E]AD9L8$,=.D8XOJ9I ( DR
M#6"QRRC%J9_+G$B<\ S0'KTH,L0<X$SXZTP* S28D4T&)H/'PP02!$?$8H*
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MF (D;@:FI4"A/EA5,++!?=#15LJ#[*C%MP%(4_*[H6:#,E1E@AH.08;9(8=
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MQ+]NWRPFYK9(#!A4@C48V,"RAM<F"Z"<L,G)L#C<IU*>X J[Y$@$C./' O\
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M\>F!-R(J1)E?'XX6;M")F3(&9!& 0\AJC:1N(T)&)W ^1)J!EYC&D:TTZ8W
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M/$F"2LB=L%9W L>NL^."00""9!D%JU@=#]F!_82"5-3E4L1H#X],;F9HG;M
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M G2N9!)TQ<FV%!4[B%!:0:D2.N6'W*C^E@QU:/E"D349F1AG.V09B0H8DU
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M^H/\V_\ C]]*]P5";/;K:?6??5+@56[W#BV+*+T)"-_+!/#_ ,H?^/G<+@Y
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M&&T2Q).Y8,&A-/NZ8=R"%!8Q'I+)*AJ5DZX=B0&W&))&P,M4$9QK.*.JPTL
M2I# ^HJNIU,_# BX/16"X !_) $B(J?ZX0.X"E9%S<<S3:1KY?'"?J DJN9H
M!-?E_'"['@JJBK DG;4E =:Y?'"%;K025 D(PK!^4X7]7(F=LDY0:#IA1[H,
M$09B9%?3A/U58T]08ZYBM// EY$3G6HUGI@ -)^/QI@=&S&>0IB'16$QE7I(
MC!* -0&L B!_%, -^I;.8-0NGI)_#&^S=5J& :,(J%*^&)-T21!C,5F1C<2&
M)K)I$"=<2P]7YJF2.FX_ACVR6*TFLP8I0Y1U&.5R>[<G]I<XM[]*\89W#+(M
M6E@EF)R K@I;X_-N*&(3]P/VY"3 )7.3XX7<@M@$B ?&@KGB%8H2?49 "@Y3
M&<^& UHD[@I() :@JQV_'X851;< D;6V^GI#?T.&NM:)NW5H%)B8J01]\QAG
MY3>DL62TA!B,@1KCNFV5;]E<V[C (&@ &8UPIDP1^7*!^8XAB &83,5 T -,
M7(]1;H,U'@<=S[:Y9+?>.";]E,E'([?<W3 U*,0?+ MW0NVM)(8J*F!TZG#6
M+;>Y<="H!,*M*B?X.F"[#>=TE9UGTL?+IB\K)NN6MMT ,%_VM]V"+.\A00P!
M4^V*F1&?0B8P#=1P*%F*L#,26$?, .F&_;+:]ZX/6+A??)6KLRU!.@GSQ]#?
M3RH-MWG<SO\ S+0(V_L^THMGC,QDG:U^Z#/48X5@/NDJNRFU5( !-,ACNO<T
M8MQ[7-;@\3T@+^WX _:VR8ZE6,^.-I]7ID"H@D5]/]<(LD ZQ!&W,D:#IA2%
M(-""TF6BGC]N,F8TG:,@.L1AV,"A$2=!T&&M6U1O;SB9+QD=QJ/+#$JI-2=H
M%#$@URC*<!MNY[C2328!DJD9>)&.+VU 2I"VV@D@@F;DCQZX[7VNVH3C]LXZ
M7G184/RKHW6E8#15]7B8P;<  305B*>N*5Q*Y4J<@<I'E@(U6>LC^T#48<@D
MF#Y1/0:8[CRBP4<;CW[H8F%WE=EH ]=Q  &.*G+A^T=CV_4'>C4CD6^/>GA\
M0GK>O[00:$!L,YDL23Z1M )/RJ-!X?#!!J2RF1F/ DXO 5+6R*34E3G&G7'<
MYMJ'LW.+?4;""KVG]1I5@,P,O",?6@N\Q^!VCA]\M\'E<T6_<OLEGCA+EGM[
M,8+^HRQHI( KC@7?K[Z<^H/J>YQB[6[7,^I.X\;C^]=5;=RZW'XVT2 ('3//
M"]E3_!'TPW&V-_[GEOW#F]Q#.9:Z.=>O;PW1M-!B]S/\7W.X_P"+^_6K3"P>
M!>O]R[1R;BI^B.7P.:S$$&)>TRGP..1?^G>\_0'UE^RM7K? 9.9W'MO.Y=MA
M^DBKS5:V+@B02T33KC_(G^2/\V]EY?8/K;OMSC_2?TYV"]S+?//;?ICMQ_<\
MWNIO\9F0GG7R-A4SLMU )C =^3?1I'Y6@D4@"(@89+7N&W'S,").1,'QH< 7
MF"[2(+ TK&<?RPQ-Y2&;T@5.>8&N>>'4-N8"@4$@4I0:8EKC,^[<513M$&@G
MK@BUQK@ ^5=I$J30@=9PZ6^*+" ,3=N@D[0)+!5^W%UK_-]KCPS7PQ"P@26.
M= !ZH.>.[#@ OVWB.EBYW&]O#7+RW/7Q[0J"NVK'/3/%JQ>1+"!#>O<B\W_(
M@7.F@ RQ;MK>:]V/MU\V.!P..KW/?O;Q;6[=)I"E<J@@FHC''[&UFS8M6A;M
M>V5M&S<OK<]1+.)D20)J(J3&+-KF^WRK3\VSQ>-=1S^WDM[:V4+?\KLQVC0"
MITQP>S=FX=VUP?IZWQN%?L(D+<YUV'NC=0,P)FM/&F/H_E.Q1>P\#B"_860G
MM6K8@L=?4 23TQV:Q+>V.1:N*"#ZC;N %MQS!$P?#'+[M[:[T'&>T-9> M#E
M7/"W;E\\7C\AS:Y'.N%Q;L6202.&H]372,GR7%QKEF[=X)91Q$Y(8[KB$>YR
M-F0F)DR3GB_Q>'M#SO\ W&8 R"!M"</W&\KW[S)[?&$R4)-&,ZZC7X8O\WN-
M]W:W;+V[0EVOW[GILVD _--,'ZL[QQKMJUS;WOVT=)(M$3;MC=GU!_ZXN?47
M/-_V MJS8XH+"R;=L;?4M!Y]<?LN,UKC.UG9[@@&UX)CV.Y=X>YN<L5O7-UM
M76J,5\#6.N.#9Y/>4YB\#CI8LV5.U%2T BGJ:#7%].S<'BW.7[>RW=OP0IBC
M*%TPMSOO=N3<XB7T8\#@*UGC!K;;DDI4QXXX]ZT&MW#;5']P&2J4$S]^.0+J
M&U8N(Z,KH=K--'6<R(S&..MWD,B6PMHL PWW#"DL3XXL7'Y*K:OE50.WI(-<
MIPERZMJY(%01-:2"-<%;3KN*Y$B33+#$!MIJ-DT8&C#QQ[@*\>Z%13>K^J10
MM> S.H.$3E7;L*C/=9;>\-<?+VX/R@:G%Q.';N@;2K7+BA9(J J#KAYMK[+#
M]2WM$+*YM.8T..'?4.1Q^61>MI/Z-M#[B7%;\R@B*5RG%WNEBS"\WE7"=2.0
M;FUR0HR98-?AAC>X]VV"H*Q1F1*_.,E.6' MC8KDA?RVP1DH.;322(I@?HW/
M2C!"\,]O7==!$5TD4G%L>W=4LQ=+0 )NLGSMR%>A3QZ?##*+9'NED&XN$#6V
MW/;11UR!SQMM*%2&:Y<<*!;4M%X[UG<9KMQ[?"%T-"^]>V 7;V\  6D;Y52D
M:G,1@ H9'K97E0SL]?<(RF@(I)H1./\ @/R1_P  _P"3IY?=BJUZC-01)J/L
MQ6D@'.8'EBF@US(TW>>&JHI(Z":T)RPYF(! FI!8Y^9PP)- 8F*3_;'\\"&&
M9%:G<*Q'AK@D$?*9D@FA@@>/3$;C)F"1$4B 1E3KG&*,LP"(B36 [1H(ZX!)
M,U!!6L"M <^L_# ))F2 ^52-P5?ZXK$@LR;EJ9])W3H#2,,P:9,4!)9DA2P#
M9]/PP,MJT:),SHQT@YQ\,0"(405ZR)!!U6D_SQ!&[<!O4YB!%!H(RPA8LP!0
M LR0IW#:67,CK&>+(,L"%U$^9 ZSUSPMNX%FD,*R8D,)H<"]8.^SN#+L$^G0
M,!7XX"-,*5 J=3X_CA2:4$DF)\IP*S,?AJ!C2LF"(BL3.(F1%-"/"<!6,CI-
M1IK@BN4B,NF>"#7Q ^V#@G,Y"*$8]8CH(I/6OX8D0C#)M9\L7=PV,J2"10P)
M!KCAM,.UE1.=0*D8J)! R.9P0L#;)H"( J<Z8DO415<C_M/A^& 6@@ :G^6&
M#*&H2D"0/'=UP ZC=NVHN8+C*%'XX2[<<5((6:((R(; ()T$QZ?&!B6)) @D
MU,94&F&6 #4@P($F1(QO529.TAE )W'\NOE3!Y_=&GW 'X_;?E9YJ+G*&@']
MNNM,&Y=)(@!$2 EM!4*BK0#$2#&FG4@SC*#%09 '\>&(("T.Q@1!ZBN-Q, Q
MGG36<:F*R:3\<2#!.F4UH)UP0")ZG+[< UT!.AUKUQ!,FH\)\L&LR"(I \\0
M #&@!\OC@TU-8 (!T$X&C'-HD@9Q@S$&L&2#X'I@A2REJYSG4YY8O<7E(#[M
MMK8,$ @Y,>OVXN\GB05-UB;4D@@31)Z88(0'C:ZS&UAG).4>&+?*OW";270[
M@-"KMK$=,"[8N<?C]UL*$L\IO38Y841;X_.9:_\ IN9C)J8O=J[[QO9[A;9]
MI<%;MIS\C6MWI9",B*$5&+M_V+K\8.S6[]H,R;9F-XF9&<Q& I/ZMOTM( DB
MLL-('VX#WKZV+2P-[G/_ &QKYX_P'_Y4_3W#"VO\D=A[E_AS_(W/XME-G)^J
MOHBU_P!Y^BN=S[UL1[MWM-[D<1;CF7''51.TQ],?X2_P7](\KZV_R)]6WKG[
M#MR7EX7;>T=JXQ4]T^IOJCO%[]+M_;."A]SE<JZ8%$0/<95/9O\ )7UZ.)_G
MO_R>XEBUR3_D#O?!%OZ&_P <<V_8V\GA?XF^EN4"+;VY:V.\\T/R[@DH+"MM
MPEY[G(]P;0ZA]J%4$! HR&5!BXXL*=\ [3DJBA,SGXXW-:DDA=L 5C.<56I-
M9S(F)G!NW7MJ=M9C<=8!S)I3%SC66:UQ6K=-5NW1%=QFBZG!LVS5055EJRDF
MA&ZA\9Q=[IW>^EGA=O5N2U\R"@02(/6?E'7%KO-N]RCV_GLW M6KCW2W'XJ)
M[=A7#&(<&2#KCNG9;]^ZRVN3>M%68AU5'(V$BL1H,+W#@EPR,KJZL2P@DD3]
MV.-W>P[6;TI:Y90P$O*(#.HT.I(Q;XW<7"F1[?*MR;3 U!#:?'%WM?.%I[S6
MR>%S%V^[;N 2A5Q45^W%_LO=;-RW<LW"+%[*WR^-/HNVB9!,1(TP9\$(! (8
MZK'3\<<=]TA;Z#<&Z@B"#XG%7G<9SJI)J)Z_=BRYDA;@H=0U)_TU. \'=$!@
M(.V9@#29UQ22(D'K-*=<L7EW1MLV%) _NEJ1IC4 "6@[B*T)C3+#&I*Y;M-Q
MR7[O+#U.]E]1.=:D^)ZTQ>!C8%(63%6J<OC\<<@J=P%\W)#'U+4,CD0=HZ35
MO/&WW7]RV]MG7_YIM*C=O5)!BFN>F. TDAD2FXP?.,JUP%:"($5\.H^[!NK(
MFLC\8Q#/!&<$DCJ<4>%D '<*^-,+^J="),0=0/ X+*Q5@A9C,0,R!7[<?LSR
MD#L[;B6 8L,\_P <L(?>MMN)EU::Q('X1&+AY-RTQ*FFY29.4C3%][EGBAF]
MQE=DM-MD;I4F8ZR!B][#I=O-[AMA&$A V998-10?ZX_<7[S^RKI<2T-VTEG,
M7%!D BFX&:^&..]QMK"TC>N 6)$+,TJ3_KA1<OV]Y50RAJK(S)8Y>.+I6_;+
M;3!D$ GIK43'C@M9OH89R3,*!MA3M,>K[<,1?_O9=T[JK"B<J_;@_.FZ-EUV
M"VVN26*ATT(DS&5-#C-V2%]RYN@+<689=01TC2M,6U-\/O;:DLQ!VK,"X/ 0
M>O7"1=&V5#$, ;=( *BHK]N+0]R08$@B4:/4WJ- <ZXMD'<?E@-NDD9D>.=,
M*R,6;.9^890"33X^6+?K^8!IF)!S&[QRIA8N P(B9 BH!PNZ["C4F8DQ$C"?
MJB1MJ33S\L";@!@2=!&@&!#3(F3$ ^0Q.X9$FOAXX)6)$C.F><85E],$$Q6?
M#%L6[1"L8>X5("',1UQ)+F[MG<1,$#YH&&M7V!$RLK -?F'^N/14&01U!-3)
MQ;MO/['M@;]O:S5N6XAKQZE<@<!T261F!*[MR[J@[LP#%0<L*'9Q0 @^IA2
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MI &N #M!4 5RK\T 95P3^F-HU !,4\<2;'N$S54&?S%:]>HP+?$XZ6V)JQ0
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MV%-GM_'7_P!O:45V;1,J!F3F<6;W'M>P65=O'VCTG,*%7+#6UXIO\EU.RS9
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MNUM76#NWSNVS3TC.#B;-NWN&< %0#FI_@8"E5:XI#&(-L5T'E485E15B"58
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MYX/JSB 0:F8K&"345H/+Y@>N":R8J))I_NZ884(D !>H'X=,&(],K.X@"?\
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MCZ?X=J[8)VOW3N=YN#VY!D;ME"IN<@+TMB#HVN&'?>X<GZCO$-NXUU6[=VA
M3\J<#CD-<C)6O7&,:#'L\7A<3C6X.RQQ./;XMGTK 5O; ]656F<$D06)#*T
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M0)U,"8RD?RPP+$_W_P!Y$Y5U\,.L@BC"2 )G7\,,?F:@))9@HUIT(S)PZJY
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M*=,<CB7]G&OV6:S<0%?;#*2H58-&),@87B6I#$HUQ#M"@&Y*U_+ RC+,4PA
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M;)!)J0(R:E,NF&:A!,5(-9IY5PQW)KZO[03J#]PP_P HR 98^7)X&=1E@@$
M-K)DD:%EDR0!EA@=K%6"AAM-5.]6+"I.@I&)1H*L&HX VL9+.IH9&?CAP226
M$NNX!CZ8]L(T$ @B@URPH +EE"@LVX^E*A5:,I@_SQ#.@8WB4MWB4MN%.UMH
M4:'.-:YXW$,H*D%-=A)% \B5SB1GD3A2+A9G'N,#47%^6"V0*URS.>/3.4 R
M) C) ,VF8I7H!@, 9#>D*"0H(K(&1- , HK[1!"00*F2&.DU-, R=RCY5]4,
M/3\, F0 0/GR*D47^*X <ST%9+-7,9^.),[B HW#?I4"#2N>*@-) VA2LPHI
MY8#6F*G-B#12--Q_#"6.1M0_*&/HVGH?Q,G&[CN8F:,=O]U/AA+5[U"@7<6!
M3QC[:G%DM?4,!$;H4B8B,)<!!! D"#33!^7<,C(KX>?QP6:A$[2#GH33%_BL
MP.]&5@V1$0!..^V44A.1R%O2U!)&TD1I.N!!S&<T$>7CAUZ",\_'!I-9EB*:
M4_IB!!8R:]8U&"QF2: "2QZ 8^2D5]((4CH=?PP"*[6@[H=C7*E9\,6>]=Q
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MJQ!9&:(])DL@!-!4B.O3%BQ^H%+E3 DLX7_B@&&$0Q$T^T85V1HB-Z6Y:XS
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M_I?_ !_W3N_T;_C'CWK<HSO?#?4_U8@.=WE7$7BVG!I:MQ^8X4!86(B)DD3
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M#+4^&&6WM5A\S^E@TY5_I@VKC J2(:8)BL&<OQP+JG>*PT;J3-3AE<GTT$Y
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MDX4W$#"H*L"":AD"^!K-*8XSD$"XX.V-P1PQH3;,"E0?YXMVQ$%"=T2/49+
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M<=K[2I8([+[?N).8RBFIP.W=IW<_DC;[O(4DVK9% 2<B9_UP_+[E=7E<Z[;
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M>@,?=B#Z8I(R)B9CI@UT%($@9BOEC,_+.0R_K@*25VU)^:&.0KKX8SR%?MS
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M]LYW-M7+:$&J;EV D#IGCOWU=S%:Y?[EW:_:MO<W,UQ;(VW+JLV8=O'3"J-
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MR@UGJ?+ 58'WP,4--<\L3UGS\Y&>(!IE4Y^&*M2)CX^&*E=#'AUI@4'6=9P
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M=@(&4B/OP"E5:5=03$YAOMSPQV@J).Z,IS.5<."P123M/S!I F!IG2<&!3Y
M"VYBQ_VC2,!F F-S4!W-D:4IUP=J@DG:H$3UGX8DH(!8G4DY#<1@E5)KF/*
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M2=LC,U^W ]E 44L2RQ\K+ZE@9Q@0D%#F94 Q0?;6N&@&E'.9%9;<.G]L>>)
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M%@YBOA%:3TP#(&8/XZZ=<;<UBH\QGB["@[U(ZURD'^>+EMU9;)(*,1,2:H<
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M 2RAN,6G+(YXL]R;:_N=][GS2#D+ESENP='U$'TQICTGH:C(Y1@@T_&#F/\
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M[-\#]PM ]21Y@8%AY*LSD,8JL9K@J[;@P#J3JG3R\\.^V%H?0**(]/H)TQ(
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M!8@@@%AZI)$_#!&Z9+1$^<1]^! )!4'=341GBT*$@YP#E$@?SP09,L#,?*2
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MF-M;:@MZF@ P :91URQ8[[W3B7):'M6+JG;;47 ":2"QJ0130XL@6 H5%54
M E5$A?ZG @CTC+*HIKT&F&)J#4$ZQ\L=,$$ F#]HJ/\ 7!\00!$D'H3B@@"F
MN9.DXA5C.8T&7^L8^,QY"H^W"R9D $$?-T-=>N%'RD=*F!2AUP!(@FDZZ C
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MQD6Z&F+O%O+M*_(Q'SJ#-#J</(!MP9$9S6 #TZX8^RH),^D0Q&1@KEA";2D
M@25B1) ,"GEBME P () .[33#3;&I@BD^!T\,7$2UNDU4@5ZJ"1ASR^!9NJS
ML6#VPRR:LQ5IZ?TP#V_MUFSL*BXPLJ"\M7<0*ZX5;-@(0D0J$1 J0=2?'#0=
MNV3$9#+(Z^&+A+; JDE]QG<9:/3T\<7>*EPL+8/R^I2$D6W63,L9KX?'#O/N
M6T<HJDP%KZFFFNAQ\S &8VS,C,L$RUPQ8F)49$ R(R)G/_7 (VL"22XDBH!@
M'3*N!<M7+ELDE=Z.Q$D>ES!%)$1A!;Y_(:RH)VLX=9D*2$N2)Z1XX2SW'D;M
ME)"[69@9VL"0:FA(-/&<6)[K8L[]L6^1<V3-53U:?'3"*_*XSR#!6Y;$Q!F<
MCG2/Y84K> 'IVGW;?H@0-PZ_P,,]J\D-\OJS),0HRTJ<,;9HQD%8]1-681/P
M/2<(!;#&3 I1ORL3!S^\84[8)G:6$ 2)W"WD((.+?'-EWXZW+37(8A=X-2#&
MNI/PQQC[050ENBH!\@@ ],*BJ$4  5B@R.((RSZSY?TQ,&8@D0(&9H<\4$YR
M03(,UF<"F6G7R)ZXB0,Z:B!^7^>),@Y00#E0$_#$F33U$FH'B<;LA-:28C,3
MA:3!D$ZG28_# DS/2 ))ZX$&% ],9T.N%@B:9&C"*8!WG\8KE/\ 3"F9.?3X
MX!TZ&IZ3A9)\O], YY>/Q\L ?'_7$%!,:1'D9P#[:FL_+]V"#;2#I @^(Q>M
MMQT5KDC>HRG6F+EWAA[UA=S% #N@5(6GWX:U>5D9#4$$,#- !U'3'IZZ$L"2
M<J=-3@+<=B3!@L!M:?[AU.F"C-"L"I#'<(-"J_Q&&L!I6S<8(0) MNQ=!3S(
MP3(J9(U"Z5\=,<[F2![]WVK9B/38SCKZB:XX':..3[G<>79XD@4M>\X#W2!H
M%DSICB\"R%%GB\:QQK* 0HM\>V+5O=TRF1@SMD44'/\ W3&F!(&X&N5(/Y2=
M(\<*2N?J!F01/R$??B9J1J:#S.(FAKTK&I&?@,/ZB3 B1,":D'%!7=(H)_W3
MX=,*S)(VK#>,3Z?Z8@#,'X4R_K@Q\T&!,F(B!_7#,21+!2)R@5'CJ:8VI$ Q
M) /JRW=/A@S0A8,F*FDC$3(,&".N+FT0-IEI^4@Y :XX'%)VGF_4%DG0,O%X
MSW8^_7&\BMKB7&J<_3"^0@GQQI!K,&1)H1@+$B1)DQCN?+8P+'"NQNU)ME57
MS)QW7O#VXO\ ?>\\JYO(]1LV'VL2>GX82T!"HH4+&<" 8&!!BOE3 DU )H8R
M\_PPHI7*.A$SYYX.6HS.6E#BH%<QU)UG'4T@5J?+^N,SUC3[\)Q5G;<?,3*2
M9DQ]F-NVH59,"01_NZQ@H@)8R)('JV^>-UU#"L698 #0:>4X;WD]FRLQ; S1
M10@_;C@VK"0.);6RB*)65B<LR0!C_NG.M*+@'Z2. -FVH)&$LA1==B B32F4
M^6+K<MEG;\BP?5H -<)R+Z+NN$^W;$;FZ%E;+ _24*:JH @#0+T P)H<S00(
MP(K44UKJ<!E4P%SZ=<;W$"?A'A. %MK/7:*F=,: 17(#RICU,)%)/VTP?74
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M+$H&9K*RK2"'+)# -3U+-!I@T!925B NV 1,93&9BNF%!EV:/4ZG(K#+=W5
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M_$X0'//P/C.%(!-!4:STPN[Y8$Q$$3,#"DK _IG.*#.N@^V=,"!Y"/OP)/\
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M'0S,#7 KYR:FN0Q62,B"#($::'$S$S%""!K,X4,1D*P:Z$",3$Z>!$3.#!!
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M (J)D ?[?ZX&FUQD(!7H,(,MA]+1,*V:_P#I.HPL9173X'\<;(.9FLUZB,"
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M8DDQF*9D#*3BH&E?A$C!@"0.A/P\<".I.D3-!A08I K-(J<M#EA! H :5RR
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M"<Z0(,3TC!G/PSC6F*G/,0<HJ1.)$9&/[OA@QJ34@U_](P3'J$1"D^5!IC:
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M<UC*/#&V (D$^?\ KBZ0))FGE_+%"3N:D5]/0=<(I6L@D'\TF8$Q!PB[/3M
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MF&!4$[:R 9!&8P]_BVXNSM2/22[M"BE<\<3@B$_;\5+4- *,+<,:TSF,9@3
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MXMJVLW&%V^1;XYMJ^TLS2,C0YX^@?IE[?_N^W?3':EY>Y0COS+_%7D\EF"B
MWN.P,:C"V$MLMN2S$DQ(&4_><,@1BS*?4#1B,A*Y>&&9T<$$P2-PJ:&N=<L+
M( F:Z+J23G/^N+1-6TU\*#QP!02OJ6(,Y :T\,!E;<H@M B:2 #UQF6 @2-
M*Y8 !SB)C.9GQQ"DD_9$YB<+)UB,_OQ&X3 @F::8,D9Y&:1@@TI,YZ1B0P@
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M1-1EU &/3I0U'I(RP 20/L\<"*#2A$^9P0:ZF33Q^&-R](C\,L&:Z_+23I7
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M3!*FH),CIT P '(R$S]F(]P@Y4:F?V84^[TK)!SUG  N0P@034QH,*">E9C
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MX!S6:@Y >$XG= Z1D? X'JGST^S$[:G4SKF0,$Q05D4@'+;.> RT%/FBI%3
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M5\*0L"!TPUI' C(3E7.,$^YE_N@P:4&&&\><TCSP2KTJ1T'PP3NH:B8T&9Q
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MTFL.YSIX#%17K7TCQQ0"G\\L#[(J:Y8K0Q,P!3&N>M<NF"#%9^WPP9$Q]N*
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M@ HWMJ(VH!N B0Q&HPI=F15CY\V)^;:!Y8]%R! B(R-(!P"+DQ4UK73 *EO
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M=4-"LS"DU:OD,6]]R% V@*2S@'.TB@B#U)SZX>;Y1CLW^LCW25)E5K3K'B,
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M-&Z3@*^8)@G)AU_H)PJP<A(&43%=/'"L PG+*)\\*MPD@D:C.8@3BA!F*?\
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MYUTQRKUL%M]]FN3[:KLMM^I:8J02( W,<\CUQVO_ ,BOK;@\KM7T;].73?\
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MH\\$D1GF#E\,$^.HU.GATG"UG0UB!J)P-!H3/VXZ[ISS^)P)SG.H TK@")-
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MCFY8?CW^0>-?X;-;]2I!5C;< @SM!PIMJ]S@N/<M\>\5N'BEQZ[:7$ ^7*5
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M!# $5W5Z?ACMK*Y1N4MIE6V]2)!*1,US'V8L\7W22"IV%MI!,!9\3A!<8;F
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MD5!*S]U,>K;.V"6 ,"))/\ABF]':69J*-JY^D^&8\L.D*&EO5M$@ P"1^ &
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M1U'H;Q'3#!U](G:8@1%)QSK4;OW/%Y5@!S _6LM;4,#H9@X[YR?\D6N5]/\
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M@'^*C -L5%0,_ #"!P0122:-X5PL&2.A$8&@,369Q&9-(\?/$@$S&0G7.,L
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M4&X%6.8D8( (ZQ- <A'],"A#+KEZ8H =<5$1 J:T%,&!!)!(-*R>OVC!523
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MX)(4"(J,ZQ)'CC:AF)F)IXTZX.YHFAB9\R<$L <H J9F,;3$])]0@3N /XG
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M8&U@&(A8) G_ %Z'$G,S!J"*Q4_;GB&)DG1AH,R!]F%.T+01!!D:B= ,L#8
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MTQ,4/2HI@D4H8B<\71Q^0UMBK!3-01D<7;/-N^Y>W,9)JP)H9.N+=BR3OO&
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M1;$CJ":#+!)%*T\QF!@Z"*"<AI@H168G/$&O0SH<5TCXQX8F9%(BF(8C,$]
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M]8_F0<$#[LHF*$8J<_N.> "<NN?6<$3 T^R@!PRM# BNGAEBYNMH9##(5@4
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M)V'LG![;:M*ENW^UX]FV51%] *VQ4C4F<>@B2:LWS1&49C$'.A:,S TG ((
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MT/Q&!!KG4T\L&I)Z"M.F-?Q(Q))!I7P^& 34C33X8@$9Z>.M,&IH1)T)UF<
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M6K2R4ME9Z2-(\\*!T'\J8(($"GCU (P3N@'SJ/+'N77(45SR\2<.#>5W4?\
M&KJ28H*8<A?;*&""!,:1&+B.X 9H \33/IC:"))G,1+93B0-V4L2*3E6N0P)
M40?E@ $R)RTPQ]M28)D@?#^F+@M6_37*/(!CYU.+K$226,B 0>HVY>$XN%F+
M$AF]/RDZ!AK/_3!W/LB2QF26)D0N16*",$FZPMRQ1MTF#65F(K\<'9R+JL+N
MW:K$BHG<HZ'.O3%L/<=I4 P3X$L-#Y8(>X2(!)K^72N.7;4P^Q@S&2%5@<S6
M9ZG&TJOMN;@9B (9]Q! &1,!1U&-QW"#D$:6 4; %@@K)BOPPS*OM7@H56VR
MMLD[CN4R"5J0!EYXNW!*O13<VB3)R*1%3+"M =,(0D[67VB=IV5&YF$1ZNID
MX2\MIE5R?<NE2CLP]!N-XZ"(D8!WD9E+L5KZ0K]0!2<(+8)(K< 9@% H6+9F
M<S'W8N?,/4)B1;)/IVH9-8RDX7,$0\+),#(D_B=,L'=<5 0J@EOG9<CE0:4U
M\\."6 4$U=2",B%$Y>&6$4OMKLC^]30'<.AJ>N7C@.K) I&Z2 * -.0GPIB2
MS1MJ!69$T/2/'#D7@-R@!9 (6)(<'KKK.(5QL&862"6),HOP\\6E9B'@ $,1
MD0% \#G49XM<*[?3)0DT!5?25 ,9=<+M96)41!!,QI&-R9 S!)9?XSP 3(S.
M0IIGI@]9D:B(TQG,  &8) -)QZL_+[03A34B2)Z@U,8C2,_#I]N'DZY2:SG)
MRC$L()$>G48R@ US!C4GX8 !D28Z[M*?=7"ZD&0)F*_9. 03'7*>L_SP*F":
M5S/2N(RSGSZUJ3@S6FHRI,CQ&)@KTR%-,J'P&!2*@3!R/]L98FLY$:Q!J/Q&
M)\NLD>$??B9(KH=08P)82"8(,36@(. %N$1MU,CR.%6ZQVY$>/G.!M<2:P36
M8UQ .?\ $+@7$+%)H08  \<+9OF'!$S/J&4R<2' F*S3KAH;\I-3UT&(!I-!
MXY5Z8D 3G_04PHG.(H8\3& #ET\\!KB*8@CTB9PH"J(R&5-,1 \8_GC,= ,Z
M?#/!B ?,3,9XS.V8.>!($_?(UP?#(G+KIC.!,1)K'EC, '+^5?YXR'C7/XG!
M].F/EB? 3\3_ $Q5?*GXG'RK'4BN6"5MC+*,Z4C#[4@D&!H?+%UAQR8W?E)R
M-"9PZ7;1)7+<)F:B8PQVD 9 BI)H"8_@8$ R)SZY"NHP=TFH$&M8K!^S/ (-
M<H$@FM3N_KBA)C.)$S_&>%+&!G4F3_=. S02(FNNLG[\484-!U\1UP:GR&A-
M-HP;7'M7+CF0%16::T C%MKEM^-98B2Q(<5F=OX86]S%%ZX!)+B:S/YONG$!
M;?Z8@" :=!&#:XVV 8!$C+.<$L3)!]-3$X).4@DYX$'[1XQ7_KCPFO4 :UQY
M@?=6N,X$:'ITC$ QKY:Q@>LP!2,S/08$DP*3-/'/%:TI6*=1BM2<9D$STBF"
M:QI!IXX)+@3.3$$]1&>(4L 2<S29R.#NDDS"D$[JS.[PTP'-'(U%*UF(UUQP
MQM+$W1<8]%7U&9Q41'4?&1@#P&6=-,5SZG/XX(RD1,9^1Q#&*?>.LX8$>7^L
M8+P/4<P,XRK@;-HH"?CAG+!50;AI/7%WA<KEI;955H:X$$$Y@_B,!;UZP=XJ
M&OK7=(FN8I'48-VY["K4SOML014[8^W#6^"W%N,WIB%-&$J((SGI7'R<;Y?>
M^1?DZ?ZXCTZ$Y;>@A1U\\"!!F5,2*4@'QP)42=TU&1HP+&H^&./RU$-:OI*[
M95@#^4^6L^.$N(059$80)@/6"?#3KAB/RSMB"9U,>.4XC;$1,?E&:GRSPO)*
MP=]3D NZ28SP+E@*U)H)KA6<0  "#F8J:8N!W50H)(I(FIRQ=6RX>6,LM0H.
M1 Z]<*1<WV Q;:Q;1H)!'X8]GEN+5T +NW09:@.X]/#!WW&O<!W,.(*H&( /
M]<3:<,VW=0C(]!E\3@ 3 IN_-6F%MDT!!!-3G!PD D.!H2,I_B,*[VUI7U :
M8/;^WP>5?FVNRIMS^:G77 YW-M%[SG>S.*@M6DX6% @=!3&U:@2?OKGB!6?M
M@^5,;0LZ95CPP&:F5//SQ-)'AUP56GB!\*QTQ5H^X&M<\4K\8F?''JZ1TGI3
M'JCI%8_Z^.)K2HB:^<X@Y13X]< ^,1&>E,1$2L?'/+!]->AR\,2?CG-,_P#3
M% )UK-=,3<=4&NX_#+!5KZL5I"P3(-(C$6+-U^L(Q^ IBG$OF<HML2?#+'_S
MER!J ;;?B,%>1P>1EG[;-^ P1Q>)>0$S)ML,\/;L<9@ID%F!,",EG"K=W[[K
MC=(("UJ3X#%JTB[BH +9 P)G_7'RY4I3[1AV-"%,2/"N'<&1)'4=:8(G.OPQ
M)URJ(I@S68T('41B9IGU^V,09^Z:>.%CJ-?B(G%UK(W!4:I$_#TZ],;#)8-M
M(U$T$G3"]('JJQI6K8.9SZM%9%, &8TRTI,8,#QRB(,5U(I,8B#\,CXQ_4XZ
M#*AJ/ 88;>@)T.DP?QP#3PI \!TQ&TC.LTZDXKF/XG%-*BI(F:G%QF/I*-NI
M)$+&6.Y\V]847+%FZS7$3<T;2=K[:U&N>.0G#]H\C@7;MNR&=5MB)$A]& J0
M?YX*7.\):M%K9"F^XKMJ&5<S,Q%/MPMQ_J!2[K-+AVJF>0(/2E17KA/:[LEU
ME%LP+IAK8G>88Z:4IG@<7ZC[)P>;SK36U/(OV[=ZY#.0"[)\PSK$BFF.,%^F
M>T[3;M@$\6U.7RR/QPO[;Z=[;:VCT@<:PK2,C&V<*MK@<.VP 9=MFT(K^6F.
M5<2V9%HJ %4#?>/MH)%-TG'#1;01>'Q[2Q&]D(2 (^W W2-X@[9D^ QN* [I
MJT$F.I_KAO89K8)DJ0#(ZJV/96Z6M$PUFY#VF $$-;:1!\1@F_QAVJ_)!O\
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M!Z:X/I8C(G;G!G"V^!Q;K*3'N,I]L"=6:/MPESG<APQ 8HJ1MU($Z8#$768
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M@-=,$O8L,2(F%/V8N/QE4",H&6=/'!46Q[I.U20/2)SIKBV (](KD9BN-S4
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MBN=?+6,$B/  T)U_Z8,5(K44^'7RP34UB(%3%<?+&<2"(T!G7&1 G.3,#.F
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M9H/NP6:6+#-J5F@K3$DSK2/E&8^&  OIH#NUK44_' MR%.49> ,X6\0!7>P
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M10@CI KX8Y'%:#;NJ+EJ/E5AG Z1AG629!AJCU&C@#33%$-3#B?EW&=]>O3
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MJM[C57G[L)>YK!# ;VU%1/A^.*%45!.YB/M)Q<2PX+J#$561U.+BF[-YY]M
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M6DM+<;:[7&N5]52(!^_%CE=TLS?;VVWM;("0-J!5:2*4)&9Q;7]K$JLD)!)
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MDF9 _GX8DL:D29@8W08DY"D=,;CEG!S\B?YX\]8!!\,& !&O3QG^6"(,TSF
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M+BFWF"/E&FAC'ZW"M,0Q(+6Q2= ")/A.6$Y%OMMA;AC<WL(:=*#[,6PO'2
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M(9LE@SH-(\9PX?\ ,,XRI-#AKEMG5ANJ!(8DURR_EAVM<FZ #Z0&?3,QKT.
M+]Q[BAR226UH/36/ X2"QH(.DQ,G!$R:3(H*:$X@!2)-*SYX(@Y:9>4X,F3Y
M:CPP:P!$?RI@?P >@C%R0=VUB3)H8QW+AW+9=>3;<;0S#YE(/JR!SG',Y0[>
MBB]?)W'C(%.UH!55'45(Z=,*_P"PVDNA+-: W;3N>*2N[.:UH<72G"2V/:="
M J@$[2"_IR<Y?RQS'MH5]HW%9BF0$AKAMFLT'F<<*R2I1^19MOM5A<4+=VMI
MT-5B<YC':[@)%NY8LGYJB4SFM#&1G'=.X/=]I;7 OW&=-Q@"T30#KUQ_B?\
MQ_R+3<CC_5WU']+<_OUB\;0LW.R=MY=SZU[W;YW'N@B_:N+:MV7M$5+*9IBS
M=2PO&M\BZ]RS:LHEFS:XJQ8XUGC6D 5+:(D*B@ #(8A6!,Q.D9R>N),@G^VH
M)8T,ZS@AR16)!U.GE-,>HR) T,14P1BXX$#;$D0Q,=?O&F.;>X3$.@N, &:
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MVJB,D91K_$X_3L#<64A]H<90ZAB,B:]>F+",#,[H>!))A 3X?Z8M*!_;).I
MG $ 9$B!&51\<L05VP8$@#;)DTP( ,$>,P/N\L*2 ,H% (USPLB@ &VE*9X%
M-!6/CGC*DDD=)I(Q(44SH?YXD**1(\<?* .L?;&!0 12D C6,&F>@Z1_$XD"
M#4_Z#$Q(!\YQ_*OG@4C^FLC\,0/MT$8)ZQ,T$'IB"(H:C^F#!C,B3G/A@BE*
M3Y>>!$5K\2:8J::^/E_+$#.1K^& #E)H)U-)Q$^>5?#'W?;X8B)ZC7XXJ33[
M/AC^E/+!5ANS$D=-2#A[R)E)8@?,/&,%2L$'Y<YK@P*1(ZDC+$Y$SF17K^&!
M0ZC,Z:QX8J*23!I$:G#?VR6@"!G!'PP94[1,&A\O4?Y8@5DZ]"*2!TP($_$@
MD@]/#/$5F12%@5H0!]^#IG77H<_QP#6 <A32OVXI.9$'\I/W3@D 2* G.@@F
M--<&"U2*'+P!/CF<?F)$"IZC,>&F*BL$30@": ?A@5,D#($SF:C -8STST'Q
MQ!H08G,TU^.(($F:G[NN#2<]K1E3495PY56VB:U.9T\L#=/IZUB,HPDT@"<J
MGPZ8@$0<M3USP'!FNE0?+ #4F*YTQ\PGI'\CB1MRST/F,"&4P8H0(Q!N 1XC
M\,3O0S69^ZN#Z@(KI'B!."%:9D2"/Y8#;JDFNI\\"302#7./PQ :3'6<%@0:
M$4K'QP5@R6@#I7K@-<7:)G/[\5B0/"1\,0A!(ZGQP/5TUUT Q5I(I_UQ!,?R
MGSP*CX>5(!P)(^,8DE0:]/L&#ZA0$T@_9ADM-))IM-(BM<.68A9I7/I'B,-Z
MCU-<X,ZTP0"8),5\)/\ 'V8.@&14P3MK$?CBAW3$9'_Y4XEC)FHU U!_$G$9
MP/F$Q!.!!\21H3K/6<5&76DZ_# VTG= -#E4DX\!$3,921UQ))$"FH6E",:#
MSK '3KK@ 1T$22:3D<4&@%=*9_TPTQ \HIF*:X8@F9( R ,4RQON9,:J3 D9
MQ@F9I$R 0<P< !H/6<IUCRP9).D=3.N/F$,>E#U_TKC>P&XR%(&1'I!RPS5W
M%9 FDZ_'!GU0\DR3.ZNV<91!B8K)TKBYW&\D\+ML"T&RN<MAZ0 <]HJ?A@RL
M:Q^)P8'0@1IK@B(.==.IK@T.1^,TTQG!^_.)KB3I6#&@DFF+MM'CTFH;(@4C
M[<XQ>#W?<:3 S%*1Y>.+D,: EMK*-I-2IC#EV0C<8! 4ECJ2(F30"/A&(DU8
MHWIVKN.6TD0<XI\<#:\E1)V$J01"[F)T$U(P4#5,DHJL!N%"!N%:QXZX$@O%
M I4BH'S!JG4SXZ8L[C #*6&TP"2 %4G037&2_P#SCM^9OLQ\HS/QP*"#4R!K
MUPL*&BGCGK@0 ! ^W6?],#(:3G&.X\!E#F[QKAMTRN(NY3'GB]QW7:]AG1P=
M&4D,*Z4P"3%.LST/_3&8B)B:B:R<$DP=M3U\!YX@D4R%3 S ).()_*>GRY"I
MRG3$-"[09'AKN_EB?2 2#U CU473XYX(5@ Q*[HD'</EKK_$X1F/J@ 'Y@K"
MHDG\,^F TSMB6$"F>F?E@[*1)F0<ZD^(QF8I#$U,FN6N !&D J8Z"(^W#\^Z
M/39(%N8^8B2U,%LU!U\*1@Y"@(Z&O48I4Y*,X_E@F9-1 Z="<4S$4)\<JYX\
M2<CZB*SGXX)H>I9I^[&A(VDC(&:4.""PU,$GXQ& )F221-:B@IY9X])@J#K,
MR.F*?&-"* #SQD?@3$Q),G$FL_"II(']<  #PG(?' D = 1UQ4Q UH!(UP8B
M3T/36<&H$^.7\:8!)FLF<CX 8(D?:,@-8Q$URGS\_NQ$_?,#SP #()I&9KXX
MM7'1A;D2:4 /3ICVK9 VH!0BO^F'(8D,QI)-/PPLU_C(8'2:@ZQE3%:5IK@D
MZ5@Q@UI/_43C7J1TBLXDD>$:SE@U$C,0:>6" *&:C.)SQ0:SE.6F%FA\L^A&
M'FXMMRC &:S$P<7_ &;S>ES5IK)F /Q."N]FB ()^T Y8]19H (6<I-*C\,>
MJUN%3)I$>?QRPS*IDL"#4$'/RQ:2Y'A4@A9\<XPOJ/R@]/XZXHVG3[1@R---
M1.":P&JL8BDSE\<YT."!4] =173#-J%8P<HBL8N!C19ZD0WRB=?'"@DUI*S-
M#%033SCQIA: ,K4SUH:+^.+I,,/;*[J'/0@_ACN 4 $V[XW%1\Y5G8#JL&1.
MN5<6[PD>WW95V(#Z]MX H2""?]K4GR&.T>Y<9"EFR?;+ RA7TAB($C(XX_#:
MX;C7BBD1_P FY=NP_A./I+ZVX0[A]+]Q[=WRSW7E7/I+NG<OIP?4'&X-MK]_
MMWU5Q>T7K/&[AQ;IVB]:YEFYN$"9P5NY2T%!L6IF@\,3!9C%:C[\;6,EAZBH
MF/,Z1C?OD:"8IE/CAC"@@%1%3X$8Y%M6!MJK34>HQ)GH/+%WW1NAB!ZA\TZ
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M Z4I^8">N (!)-3I0SE^&-0*$P*@]*XD@ BHZ3I7RP2*R,B,A$^& (BD DF
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M%IJ!H0H=S 16X9.F1&%/NA%@&!,P: IH/Y8^9?\ AV_\HR_K@;6))!G<QZQ
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M+%J$+MK(&/90D<=9@29;Q(^\85F6!G288#*O6<*Q2/3G,"!4Y9Y8@14&I\I
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MRLT+ZJ'/(]<L,0*D4(Z'*,&:1G.M8.Z?MPP]58RBD=8Q )$ 5\NHP!!T+14
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M_;@= ,XJ1J2<13/($:4KAJ@*,S7**DB=,'9ZS6# SU$#!]3"9/12)@01Y]<
M$S(/RR,J 4P:UV9ZTSD?=@T(D4J3G3\<"8W:0*@=>D_ACYB#N! %8$2?Z^.,
M@(:5!E9,?F.<=<2T$-.V( DFL@^>6$,2TDY"$ R G"DYD105I# "=,%MP%Q_
M0L321D?+$MMH)9B?&22#^.#;1BMFS15'YW!D[AIX8VK0P#3^X"@W=#CG<L@'
MWN6MI#6=EFU7U'Q.! IM! QI]NFF+Q+96VUC3*>N.>Q'K-@C< 2I(?:0Q%<C
MH()SP4J]N7M;/<4!3(.VVI!)8FHTIX8V'>/4R@$$,C!R^VA(>"8))H10:X&^
M^[W"I0$$BW-R0P6VWJ# 'T08UTC!9K]PP&MA9N,HM[-CWK*K0NL%8Z$SBQQA
M>0&[< 2X=UPW5<*I>8&T%2 3$5UQQO<VN@-LJS(69&8!:',10@ Q,$X!:VMQ
M5V"'0?D,*BD9@GYB<LL?\-I2JM!2 5#?E!&>W,1Y8D!4(#2[)!6:#T4,M6:Y
M>.'--RPC E49H/I<M04Z9:X#>C:1M9MQ)G^Y8FNIP1(G;!*!;8 S!V=(RZXS
M/V6O^/[?F\,\;I+!AN\ #\VX==8PTG^T@T@4G7% *?,3E)B P_I_/!H6-3H
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M"<@"2- #()DU$X+#.1))CTG-1I3I@C(23Y$9 CQI&!*SN,UGX$;<JUP %B:
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M-<1M^,DY90,1&HKG,TI.*@>4?=C(TSBOPC'6H,>&8)& 2!!\CGEA0:F*P:$
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M#<N1S/QP&44(D4H1'\:8DA=0:TB>M,0WS@U( H#ZJQ,2-3]V ZS+E0(,A0-
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M232.F!"A0(.E!@K\V?S  5T@8ALC(S.N9C[L4G7I,GQQ&[R.4CIXXI0"::]
M0<3N-/YUSQ$1$9&:Z8EFK$U-3K3!">4@33KB34GITGIB8Z2(S ZX@D&0/.N?
M_3&O02)BM)(Q!( R-#.<0//#@:(: >F/YG'.N)**MN[OD1N $4;213'=D1;F
MQKY-K],@,2^Q0(],Q0'%LM;N_,1M%LK;9!^4*VI6K*"#.6>%)XC39-NFUO6A
MHRSF6URH,):>V$(! VAD8H;LM9$2&%8&[7"W[=D*L%]K,TA@VVE=H SIKKC=
MO&ZS;MW+:"0R(AJAN5!ZTJ=<,C<J\#O (  LEU>6N(&^50##$_#%NRG+:V')
M1U(;;&P$K;*U]4@ '+SG''XXN>YN;(L"I#M#?$1E'F<L6G-M7]Q49MR[O5\N
M[U=< 'C@@TR%8I-<O(8/Z"P*SL!'C((PQ/$0ES)](,@95.(''I$Q%)Z$0/AB
MX4M0H0@TBF4R-=,<D;2MI;=Z@!?U RA(.8Z2:XN>Y  O7=MP$[!;:H#I!+1I
M7/%N01N)+.\!F8@*S;)Z>.<8M@$P+BI<;:$N-N!VM)S4F5C+7''MF]<MA[]I
M65&*@JAGU]0L:8 &Z#J)A7)]("B34F@,_P!+2P'):V9.Z5]4Y#29W #QQ:8!
MPI(;<)5%)H$&<J!EBT66XK #:8F8'09 X&[6(&9$^D&/NKA)5*PK&)D3(S\/
MMPFY 5S,Q6F<]1A6VJHR(BD9PWPP0!M@'(32<E\<"!X1'QSZ#$"3$@R:DY9C
M^N.0T@W+=EW10*[R/01'0X=[H9[UYS<9V(=F=B2=TC0F2<*)4'2,@0(W+Y84
M;LP&(K))/J)G3STQ0E16($;AIXX(A2($14'<TU\O'%=L@:Z> GXX$"%)F%@D
M$M J=<\\6Q!)@ ]0 ,L"@DF"0-0,VGKTP 1XP=.@$8R -#Y^)&%4#+7(FFHT
MP# (&=9UU\M<*?#.F$5 3)SU'E@.Z[BT1(RQ!@$ #P/QQ?NLVT);8SX 3'CC
MEW3<4K;N,EL UI4[L @@ZS4R=#/A@5K0?[<M9^^,481(  .0RR/W8,L*9UF!
M,%?CUP=S Z4)B8RW>>>(H/C)D=1A2:4,R9C0R3^.(W$9$"=)KA1, F%/0C*,
M5)B1YTK'GX8.D9@Q4=#@ D&,LJ'PG!@@EB !(&?CB"QD"@-5C/!]0SD@$$C6
M:_?B=P6?S3-3_MUQ2@ZZS%8UC D".NM-#Y]<3'IZG+*1C-CKGUU)UQ0C^WPI
MF2.O7 $R"(,>&9&DTC @B/O,TD ?RP9,UT,&=*?SP8H,NM/$FN 9,9K7TF/#
M ,F2,A40=!.#!8&&UZ]1_+!)+3&1H)G7PQF1YF1&L$^.#%QI)@26$#^73$^Z
MU2*$F17IB-["0 3!J,CB!<: *UJ//^F(-PTJ<YCSP +S4T!,QF8!Q/N-TS-<
M"+A#:2U>A!G!BZ^T9'=N$"D]?#!_4;+/'*4W&@V2F6>^D?CAI)SK!A2&&48I
M$23$5\:S!QP;;PRCD"ZTB"MNS^HQ\R0!C:J9M)@%29,T/7SPK&A7<R;8"R!4
M03-/' 5R03 &HW"A)&DZ8SJ1G&1%8P2 :R(SGK/\L$QJ2 QJ1G@FH-2>HZ9X
MKGG-,AGYXS F(\NF 9.NH,C.O7 !F:Y'6(B,L995I0[<QB9(R(TUKC3,FE(,
M=3@F#0D;@-I@]3_/$Y0) '7Q&!X DR*?=IXX^6OCH!6,33_<#6*:G$$5I 7I
M,@XRRI4SYQ_K@$4AAG0",OMP0Q.4Q\)PSQ!B?&O0X-L$F0?ES@&!0_RPEQU8
MDL-H;YOO_#"EEJ )/PH:8@#,P(I &4#!T'3.N=#AOMZS2JD"F"%,3]M,$&3-
M:&/C'W8H<ZP) ,>6!!@S.6<8!.8,G*36)P 8,2#-9 J< 3!\Y@=!B3$UTZC'
M3H?YXSZ5@_'RP*SD*FM>@PQF1%3AB<HTC/#0(B?/.N =V4Y5-3!,# DQ7QHL
M2!@0P^,F2,P!IC,L22() USC!%3)Z9'6>F)) B)DT(SSP5W@D5B<]02<2;NU
M9)@T)G(3@CW)H28R@TSZ8@-Y@F5G62?^F&AAJ?FS@^D[?X^W&TM6:G=-,]Q4
M_P \;P=Q]5*G</"*XW%@NTY4+>&T="<\3.T$;C4QU8>60)Q ,D@1G-*UC*N6
M()!TH?EIF#UTP?7EM8;:DP/2K$_RQZ3!!J!).YL]P/X8:[S>99XR#U2[ $*N
MJ@F3X",>UVY;W/N[RON%?;M(0*LP(DYY=*Z89O>7C6V'IMV&4*-Q!67&@RDR
M#IC:>877)I8C:<]IVT$Q_/"/[GN,I'N&6'0E0S9@TDZX7U25!@@C;#&#3PU.
M-S$#2%AIA:*IZ^.-10 J)]))@ D_?&.9W&\-UOMW%;9EL7D<GT!@=2%F,2H@
MGQF=,L&L9]-!I&/F6N1C.<&"N5*9CX8<MM,!B1G2)($_?BYQE"@,Y_3 -5#S
MZR,YSTPQ*IM"[0=I&U2VX^DUSRP J);.2 CU;2)99B"(\L%$6:7+8VAV :2S
M[A2*??AHD,(HFV1< E0O^X4.?V&F$)0!ROIAE8$EO4#NCYC45C3 #6P@0J;J
M))!W'Y6_N%!.%#6EH<D"AE4F-LDU%8'3$[01ND,8  "Q50:@"0!EC<',L0LD
M "%DAB-#H*_ABWNH#.TJ2N^%DMZ<RISG/X82X:!V#D$"FLB/O^_'S_\ X#&>
MO],16 P(B#&XB%D9^.*@4/J(I,91$B,2#6L;J$@UJHD#SQ,B#TIZC5@2=-#@
MF,B&$U%5H(T_GBZ58;H)(RD UB-03(Q5B&5BJ*/2'(]4"M"9G[L!20)/S!BU
M3YZSXX6XA!*.OJ$[@%- 8Z]<6;I@W$46G %591D9UZ=,$C2222(Z $88J&,D
MDA@T[08W,?XI@$VCZ3($'I4S6/##[054"6)S'JJI U\1AT131S60(!KO $DF
M* '"W[EMX(,$0!0[BAG,D33"A5(,#:<MHG)@/PQO( $,&/JH>L4^ &6" %S(
MW14_[::8@*2LU7-F)K0>5,#T$U"T4F.NZ<CT_KB"&8 U,9D'./Y8:)RR(H3H
MQ!R&=,,M8@Y Y])Z32#B-U) DB345&F& )K!K5=PU)&<>&%!F0T@@0)_*?*N
M6!0.TR3! &[6, "#H2=1,F?],4(ZB6 &=/5Y8J8 U(BFL_UP8<1D!GN@5)/\
ML#:5<L"*U(DYC^6*JPH=K9Y&H!Z=<46I- <I.AT\C@2/(^J&)^85T'CA6(!R
M ,0M,B!J8PH( RIX34,3G@KXCTJ1'45T.%$0?$#+H<:9BL@:Y8JV?CD,XZXC
MW 3^:#]T_?C,:](/0XW=#(BI&,NM0?M,8&U2( S)BO3 !@J:9:?#$M/IUB9\
ML2%K!F3EXQG\,?"I4@0"/# I$GJ/O/\ /&9-.E ,HK@MGYF(/3_KEAK_ "'6
MW;0&=T28% !KCD<:R@'%87% $%V)!F2)CPP_)/#M7-S@EGMG<SJX:28RH8(-
M,SA8XB VX:VP!.T!BQW,10CP%<.HX]K;<42OM;3,"66:U&7\#!(LJ3ON3O25
M(,0S1J,HC*N&M@,54M&X;("CUIZ()$T# U&+OM[D#  HA5X+)$*#0B0*_P \
M<B_[MXVOW-WW$MHS[_<8"T?34!=8$G,YG%@^[<VVW/M0EQMS*QV- - 2#1LS
M C+'#6[^HY:WO#2#[N3!IB&D91 QQO146TDQF0*@$YX3TBJC,5'6F)-L$DB9
M.G7S.*J"!0Y&#IA@J+T(,@[9K'],7008 :GA%#(^W')"B2V\0#MH,F4@>8'X
M8O-;L7&3?=184L+9DM;4,V8+$&3F!7!-U%=AMW!#1C\J[5(FN<"OC3"V[H6Y
M$,%-;B,YHK!LH-"QZX2[:MJUV4(<DL-P)8A=Q^TC[,6U4$!&&X&V"Q']JD0%
MZ^&.+[R!MS)0"BR1ZPQ_NZ''%8 ,=J[%*$%#F9\L@<\\+2LQ K! ]4:Q.6 (
MG(R:-$T()&%8 2"-) GJ1UPI*C+*I\H&/4(,46L@ZE<2*VR(@"9,U,G B( R
M/7K7\,-<+#=YU  J1X1A7M.%Y?<^=:X]I6,GV;8]R] Z  3@7+S%F%2!(0FA
M$*<OMQN-/5)K13$0(KYBHPA D B-:,*F3]M,#U C2HF37;\, J:$@ "D>$8)
MD !9@_*T],5_,=U!2IG/IU.+8D,(C4DB)-?YXH#(KUFE1(^T8F*Y^ FI!G G
M6N6OE@ 2!2A%(&8P) FE:5TB,*@$DZ5Z9X5[B:3T\<\"!!BNF65,$B@Z33'<
MG!(%NRY!!ZB#.+[,2OZS^HL/42:1_7!&\B#\-QJ)S^S ]=0?EH8IKK@'?,F3
ME4'JOPH,26VY$ZT&L9TR&/232M?N$C3Q&,X%)F3YFN/FJ"-U:0WAY8!#?+ ]
M1RK0CSP"6BN0UG(UQGKN])%!J3@J#0&*D2&.HBN> 2X! H"=9J3$X W5!S!$
MUT)P)@C(EFR!S'C7$#2D]#X@9^.#((%-I'YO]RX)+9"M8&6)W9U!BI&@&/F.
M<1I05].*M0G5AGD "-,$$D0:BE>E1J<9ANM:YS_I@&1MUVFHBI/^F#-"#$"H
MK_<3@S&7F3'08,$U'D& R7^>(!),DSX=)Q6*&2"*0=:8!!$S4 @9GQS,X,"D
MT@T/GY:XD-EE03 P#N+170R/ XZR,H &<"N*'4B"*GP!&#45DR)R\9P8,D#J
M(ZS&!$94@U(U;K@5$$TH*4@Q@@[2)D5H#U \<4*Y03.LT"XD"MUC;/B LT(P
MS4(528(J230M'W8:GIK$1(K)$?Q3'*OS3C6EM05)W/?,M)'^T5P)50X^4Y%1
M% PZX:0 88;MH7Q@,:^>$,>D1X'H:^> KUR$U(+1(\J8(C/RH1U_K@D*<_ B
M3J3@L5BI!$3-(P0H((/JG0#2/P.*Z>%).@&*[=($P:UG C5NN4:P,9QH:Y#*
M<$D=2/&>N.L9].@CP\<$2.D$5!)S,8FIC\PZC,P<\ S%3(_$8&A)II.AD'[\
M>1@G^N (H#6#4GQGPP)DY_Z?=B(DF0"0('E@;21%"3XB8C!6&@R:YDS%3^$8
M#.NLF0#GUG&58$4%*Z^>,@*0)_G@U$SGEEB/O/7H/Y8,&IJ-?,B/PP:UF0,J
M$5_UQ4ZTR&F5, R)G(: &@G'J.4^76K?SP* T%9I!ZC$TTU$@Z# G0B3_/$K
MJ///(Q@J9%2/AG3QQX =/B9/CA2&@$^5)K P%G3,FH\<,1TD=2,YIALATJ*S
MK@@>)ZT/0'77'S10#. -=-<&&RK02(B9.E=, 2*P8)BN50<&[><+DT;LQ/CT
MZX9+#PDQ(($B<;FNECN,9DP3J#GJ,5N"03 :8"Z3Y?;@LER9G>58T.>V,H'7
M#'<8@ F2:GY=R_Q&&AH]523NJ)Z?;!PI+E6<&:_,1^8D9C6,LL$*PB)$23Z3
M)@C7J,$[I8;H J(FD@].N "TD;B1,BIR5LO,X)9B-TD F-H(I)B:G&VY<10%
M!+,P11M']Q-=0<&W8NCDM4'890=?4:_9AO;:W: ]+%0921 +3TI2,.YY#W2&
MJ:EE7;!8!X$S(@#%YU9C;5U*[B$"HI+&5$@ Y5^_$7BVR98'<S%V$VT!2@6N
MT$4S.6$1KNXM)9X])01#FI'_ *H/W83V[S N 0<ALS10M:P/3,4PA-R#*M )
MEE8US/G,'"I:*[5D S ('4Y-^.%N&LD")A?(C^/&N.7Q[5@.>5=2[=N2%90J
M;52!]V(/%8;?FA\P?[9/V$8 ?C7/[I%PD$>)&!/&N@$T!)GQ&73K@[[-Y0%)
MH:+X-3[,,NUY@E:DGTCRUQ^E<*3<#;8/KU GS^$5Q+L"L$$F6]2T"E169\/C
MAE)RF!56928BN1.>[IA3:W#>"NR*(@,+M7.=1!\\-%M"KJI*'TB7,@CS-<\\
M?J0%)02D2&S#*8K) .7B<-(K:!;UQZT-2P8#*: #.N#7>J03LF2L5!0F).53
M]^!\D7-%)9+<5ER8J!E@Q1J*@$$,8!RK0Y^=,6X$^K+Q !E@#4",YQ8+M+&Y
MZAZ2DEB5(8:5@XS7_P"=(TS_ +<*452IG;%9C, Z>9Q*J67YMQSJ*D8 "EM6
M%6)&H_GYX)"GINS-.BZXHI$@@DT&T9">OAC<JNI)8T$G:1!$ZCS& WN7H:A+
M#TY[B2<_C& US]58!D@B"3+T'7[=<*=C+ F9SE:B@H:8N6_U/9NB3(_-%"%P
MJJK."9 @2"P@@K@M=XZB!_;!,4J!X],&+ %9$ 9QTPUSC6]NZ3<3:"&C+:3K
MBO'((D$$0)F#NG"H$(.8,2H.0KUZG/ !&M/1!,#,QI@K\Q)B2L@=33$LM"(D
M5@Z??@0.@$ZZF!H1B8TR(&IF*X$*ISI I3\TX.VV"2(G;,1E'GA@+2@B@)4P
M9$C:<Z'$-;D"DG.E(E=/#$[3J#Z6 ^;+U9?# +!]Q^8D&*'6/PP/21%.M#3!
M@,)I,4\1&F!N&1H#!%=#@C.FV? :1K.N"%4@F!Y:5Q,&A@$S$141X8&X2M(V
MKEIZ3@$H!X$5(R&XG_IA9VT)STIE'PQ&]* -$^F!TC!V@FD@ >$3XC3&VW;@
M"5))D@: ;L2& @3Z008!H:_ACYS4D"N<UD?UQZG8 TDL?.*?=@>HGH2214S%
M,$==1*R"?Y8H3!S]6>M/'$FHT%?OQ+0HI0 #X&<\4SBF0+4U)Q)&6O3R&#49
M25_W'08,01$^=)@G!I)C^6N 20!2N@$:SAD+K?NA:6K9! K^9O/!-UC:M*24
MMB0JKHL:^$UPQ8 Q))I,:1_+#)M2I,B-Q"R(!)S FISTQN"R&&T0H8"-0!KY
M8<A%DB7$0A(%#7*=8IAX&UD@& 1N694M&F0\L'=M*R0/RG:: ,GQD>7CBY:J
M"-K,& )4S^6!0'*M12N+@>T@WD.X6VNXL')##6="1XZX*JN:J"I$S!D/741-
M*YC%K:@(FTI($G;;:"5?4S6D8XZY0BT'R@1H?XK@$TR!BN6DG!H,@2/CH< C
MKY2.@QKX_$?FQ=BLHT^)S->F+Z "0[1(!(FN60\<71<LL4N D@D,"A! VTI-
M0,7/VW&4%V4;G##_ 'B")  R 'G2,,B<:\ I78P0D;MTA6&9 G^> CV)]NVN
MTHM'LAMI#(^M09'P%<&X>.",F6X@(#(\RDUD3,^.4#%EGM$((:&0#>#!!*B:
M4D#KBPI43$;0-0D@R?YX$BI KUG,B,SY8!/I@01D8G(@X4 &"9IG,P,]:80J
M"143J3H9&6*F((JU2(S'EYX('RF1T^)_KBI!ID3 D5*F<"V*(H]68RTK]V.#
MV/>/V_:>TIR&"D$#D\]I+,.I50(.F&*@_E8?F]0R+1H*C$T!)S !B<HZ4_@8
M6(.8+4W?_"VAF:?#"23!% 9)(U,8602HB32)&6T#/!C+U0<JG\M?''13340)
MT!^,XMJ1,10'*DC+RRQ4D@@G6@B3Y3@B9 /6#3J3B<Z1G2F9Q53H23X:5ZXE
MA$1&7PP;URV1:MG:K,I ) T!P%2@70]?XRP?4(T\2,%)W1T(.>0..Z7%D%K3
M**P8"DFN-Q+ SN%34DDJ#'3K@0(,D3HTT)('3 B3M!I\() Z= 3B 2 1%2>D
M&#X"GW8H*G7408!G^6/S$?>8&X3/X#!() @T-?/YL%@)BGS$3 SKIUD8)J#$
M3N.VHW3.M<30CH!%*B -#."Q)@[0#$0X^8 3EBXI96!(K,"M&(/X8D-D=P))
M  'YO/3K@>HR6I-(BH_&G7 8DP8S,FN1."0Q-! $ 4ZGXX !!B@F:4\?'PPP
MW TF(KMB"<&21G )B8J#.  U(ZY'($'7%&@3IG44%?MG&;9?W29FI \>F/F,
M99Q7HH'XX@$P-21*CJ<!=U<Q6 =03.F)#5H:S _W#KY=<&6&?VSHP&!)R!U(
MIU$>.!41D#,@3H1B0V@@$PW0[0-!XX"AO3.>0)&<XDF0I$QF:TDX@D0QS$UK
MU'73'S$B?5)@QE0 XSC,S/Y8])@>.!#K H02/F/6/Y8S@BE#0]1& -\3 !G4
MU]1TQ)8^J(,B1B"TYY&"0>IQ((T(_ @^/7'%6"&-H7&!S'N>N'\<$JPSD;I+
M.>NW^F%4 [W&AJ8KN\/X&'OE2KW[]UR0*DJ D$],\+"Y>LS$$Y1N^^!BYN+>
M@"=P,%F;/_4:XVDBHD-H8T& 4)$@D37S\< /Z% !-2U#J2,08;=$5T \<$@=
M*4^ P?017^*_RP1%:P1USG (S!.<P?./PP)$4K\,_#%)D1I6<A3I@F!E0Q,_
MZX!!.6F49"N!(B14=9RS_GB&DYUT\8.48$B2!2:4G%:BI \-?QP* 4SUZ?;B
M:@0-VA$YP,"(RB9,$>/6FF!$D3'EIKBHK62/Q& 2@Z"<_&N! \B!'XXDT%0#
M,1C-9ZT) TG!$_?.=#'WX)F3!.E-*G[\-)H()F<CF@_KB((G4U,8W95'0&E)
M!Z8-,@9C,'IYQB8\Z3GE,_C@=9 IJ,>)CQ(T@G^> ?LDC,F#4?;C:<]-<;E0
M[9HI$?&1@@T.2Y@SUQ68^Z?Z8@S6!,Q%<P#UP5+0:P<XTKABF9S/]H-)\?+#
M DT+ ":L"<SCTS Z D Q%!@58:B=1,BG4:X;<X+D#(@D$G,+D3X8:+C"W(A0
MU(FLZ8*R8TJ#3Q./FDLT4KF*"=/.<&+L@2H&II.6?A./4Q'0 R#)I_3!VE@%
MDL9(4*PVG:"?AC:7*R"558G:! (<:X)D;MR06E14B)@TQZR,Q!4R 9R,T@94
M\\%W:#!ALE"ZBA\S@ORN=8)$>FVZ7&N 4@JAD33 3M]I+%DR&O\ (:;@ F 4
M% )SU^Z2_)Y-YBQ.QBY6TP(]9]-%7+;NSPUU6+0@ERU#M-1<!C0U ,32<&[=
MN(L2$_4)"@#<T@YQ)DS@^WR(18968.Q]MC *F1).8)T IABS(5*PY&YCT!E#
M,K,D$9^&&C.Y;:+MN'#(/4 #\H422&BF ]F[<.X &3*27+JRI(-1&T@0=<*K
MM<,BW<<D4"F/S&!33. 8\<6@A=MK(C DF /E*,VHB" *XMEB'W*BLP4"NL@&
M)%,&HC; 4 2.L:^,X%6F2!(J.H>-?/&V)62 23 .1CRRG!.\(2T1.T  9,?'
M[<&@ 0PS":[LH7PZX*VV)G<",V92L$$G.>F&7< #,@1("B:3E. =I"[94$P-
MYK ^'YLM,!04HP#-$@*9@0:Y4))\L%59@2CJ4!7<5I*29@^6?EBZ4)4W&!@K
MN#1\Q&H! R773"-L!&_U*!+,J@H&1YTF3/7#-"DN20\F6&7JH :'Y?Z864V@
M*0?7*@Y,:3.0-?N!PK2#DJP00JS-"8G2A \,-LACNAV"G?;D^IE!Z_=B952)
MVPL$',JU3F,V_GC>0WZGJ+9#*A!$@01F=,(O&N>VH1501Z8!D$AL_/3'_P ]
MM_P;/^1\_P"W++QPHN9]!.TP/5'2L3]F%!DT$K&H$;IP650N>0D 90/AA950
M-LY"LB)KB-JS04 R&:Z84;5G.3G\<)*)3P&?D<$A5@K- !/D,.0J169VYYC%
M#;!F3$2/'%JW"PVM":5@1C>BKT.4QU).'5U *'U"*QUC#KN0Y]#$UD'#7%*R
M&FD1'E_3!#; *T!&?A&/4RQ0>.>7D<>IU$F@:)GH(SP(N(-T4H8T&6%EUC+T
M^(^:<*-RD#J1EC2:4$?Q3&E2?"8TPS@0(I !)^)I3!<VU><O0 :>.#^DG4@#
M7J1ECT6P),SUC.>N"1; 4]!,T@Y88A2-F0)@%8H#UQ!@YR!$&!J<IP0T QH8
M$'(CI@DD9B),&M/2.GG@FA@3NU GH:8.T+N6 *@5!R\M<0K08)!.43I\< L[
M DFHDYZX 8S)/CD*+@1%)"F="8J?PDXG6*TS\< BN8/5LLQT\,'TQ(_'./#%
M3F#((Z9#^F*M)$ @ QTR_G@UI6/YCRP(H)UH/(8J#*B8D@2* C^F ,M8 %:9
MDG'_ *1,@3%<CB)IE!,P,M>F)N7T0K!]=Q>FAP?=Y]D5)HX8^D21 .(XEI^2
MWJVE@41B<C.>-J,.-8@G99E2!-0Q&)=V<LP.Z2Q+9[?^N%DCTF86?4T1\1UG
M%\R =IR@!5U'WYX(80Q9DC<<II!%,*9)UBJYB:@_RPQ: "# C4#(3B\!-/75
MC$*/G@5(!\?Z8"J*28_M(/\ =2<JB<L;T5F<.5V23<+$T<,!!.5#YX+VU+ N
M&+[B1M(.UCMK']PR)J9Q!#EU,,65@I!$KO.5#4^!Q;E Z^Y;!8KL*$7*!=OY
M9TUQQ9$.;:$@4$!?' (!!IK,GH1XX],@S&?PF, ZUF3-9ZGPQ,Y0-QIKF<7B
M9HI&8UI 'CBX ""7VA2* @;CN^S33"LUF,Q#K5@:,Y4TS%!3RUPTV@\!H8J"
M?68*A1G28IA@UI,QHH+;0-J BN>8P MA)+,3N55#DKG"U\P?",*1;4[4@0H
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MIUP25(R6)F!HQ)ZX@YAML9Q DD1]\8#23I4 @&*U&6F5,"2Q#$26FM=?AK@
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M4R60OJ":U\!@+N>2IEMI*[0(0AE, C2DX;8P1(=V+3,&@6.AT'W8%&])WY@
M4@0,B(ZB:4P5+D;B1-Q9=M-I/2?^N#+&0;8RD!K@@!@*5B*99X VU:XY]3-N
M0S$K UFE/AGA3(*+<*EUS"&K-N69.<12, @G>Q]0JPRK/E37,SCYU_X=G_P_
MVY??@P#J* SE-"?'!]97/8#6=21&%L76EX(LLQU42;+QX98N$%M JGJ3,3K/
M7#LU2"5@U])&G]<!K68N J,JH8AA]Q^_%FVYVW;:!+UNDH1!)'AXXNE6VP95
MAF"?XRPY9B0ETJ4K (>9Z82-A)0,08%0($#SP8VS!(&6DU/A@]DY=V3QPS\)
MRP!-LU>P9S*YKX8B58.IH3U%)PRD2-U&H9 \!TPT)!-=Q4#U')OLP[* XS@
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MI1^9#RUQAZ6E@%.4DD@XX9NEGFQ9VL6H=R@D@ZF?FQ;?QR UC,DZ8$QIF:D
MS7;I\,*3\T:" 30C<N(B!N( ,4@4_'+"Y@A8#'YH%(C^6!!($"L$DD#/&<YP
MQ(_B<$J1ON#VT@FA_,0/ 3@"H$YF)$G/ICN=POE8/&3\M;AV9^(G 1"!6&J!
M!R&6LY895F26E@,@L1"=!@Y5HI@0:1Z6\3GC:20"")K%*4/4:X7SE0S"1I$^
M.DX5!\Q 8@*=I('Y</.1$DD3*YMEGI&+MT[@;:L5@FL9R?'I.+'%#,%N7PH8
M&1M,,(!I7IH<<;D71[]]D4S=AM*[%/VC 5=BB*%8@ " (P5%P@YBM/CKX8(:
MY%:RQ'QW8D/(_-!D]<AB7AB:K6D1X8D28K4R1'\4Q0!8 @:D#QQSNY\NZMKC
M<#BWN1>9R%54M(6,L<LM<?57_;^[V;G:>R<^_P!JX16^S(@XKE+SM#%&]0 /
MV:X46^ZK<<B8:Y 8&%$H20H&:K$@5PZ_]P42J$W3>-X;B(N%@TP0*0N0,SI@
M%NX2920MXKO#*=K%\@L:F8&=3@%N:J,#6T+J[K8R$R1/C7+I@6VYGI("NP9"
MSA265E0F1N/RR8TGK8L#EE\HW7S0*^T@@4F:12M.AQ89.0'D#Y&W4(E0",V\
M/^N+<//Y@1D6'JKY8!SKEI)K'VY8V[3(@D& !6:@]?QP:4!_-.YJ44]8TPP]
M1!.YH )36"9P32-H$@]=&UF," :TI(DL8D$1 CPP!%!$$TH!&F<X%#'S"AH"
M,ZX(F*09FHFID=<,#(C0YDDTAOZ899F:23N,'J>N"=Y.9SA2JTV@FHK7#$N6
M%*@QY+T^S$;@L4(!F:Y>!PLW,V(SH0P@ 3K@!C/R& /5,1%/#3'@2:*:P*F2
M<SB90"%]1H0"-H4C^9P3N(H 1F2<AKEXXH]!229B!!7;K77$%R>D$9^,]3B=
MP# E5D?*Q%:?TUP )U(&I)H T>-?# 4NN@&XU!SC2AP=S@5&1!'0#QKU^&-H
M8B#, J9FH"D866JT$!LHS(,:8,+\V5 ?2!!@]8PL@0!!H:T_-.!*$C.1^;=F
M1&&]!,B"1 G*M?AE@C82#,TD$9 2,<JX!%[ENEGY8;V[4DB36I\<-?N2 3OV
ML6:&R@3H>@IC9;E0M8,$F,Z?RQ:O$ )QK5RZVI_M0QYY8)@@@-G/RQ.OXX!4
M22 )!@$ Q'C7KBVID,QW4$+4S&('@-PDR-8)Q,G.@/6IF!C5B20TTB*#/KC0
M^EIZC2F)D5T G;TG!]4G0QEJ #XX0B!^HU *0(F9QE,Z@?"N"0#$3,"@U_KA
MH$17(#XXU\CXC.F)K37XP1/\L10DG.) @37PP3!V],C73$5BIIF-?OQ-0"N>
M>VDY8( /S#*E?' 7++H-)B1@>7V&)/GB-)!\*Y$C$Y:D_P :X(\#69!I(P8D
MD &), $P333 DL9.N?@<$DP%%(Z>.*ZDT-"9Z8-9$=,QE3%33Q(GX].F%'V"
M/MF,2),4@?SC[\"@!(J1U.1I@",AEG36>N 2(#=!4QEB@SZUKTG Z4SB"37!
MF!,QIXQ@-;8Z$+AD:2VI)$&D1ABS *29DF(F/LP3?O*E3,,#/]HKD=<.../=
M?PD[1,2QTZTP0+I0+\J+Z0%FK/D02-<>IR'9BQ!?2-HB>N(9X,@E1(W23Z-K
M91 D_'$EF:0K"08+K0^9!H-,4<'9):(.V1N.T:R#480;R"Q ],FFJ+&9\3@H
M;BB6('KS!S.L@&@(_#!!<$@DP:&%S) TBDCPPUSD<FW8!MN$#%6NW#JP45.@
MZX8=LM/<<AA;O7R4M@Q-+-OU,)%<H Q?3D=R>ZS$$VP_Z=L20 +-N@ @K028
MBLX;];=M+,4W%6%D+,7-V2D9*-*D:86T',W-P'MN=JV]LE+0(!+$4G**YX>^
MEV")57MD"XC%-K58YY4&JF,$-?:Y99=EJRUY9MH#M 5EU!]84FIT Q)NNRVT
MW*36X'M>I]H8^J3!6/A3#V1R;EPJ!=4,5#!F,NH*"#N%"0*?#&Y;^]K;,A0.
M1;*[?59E8]73=TW&N$6R[ONW2?5M<@B3$Q $U!$CSPI=ROO-N5BY9;9:F^Y$
M2*2-M 1X85GO^]M+2'*JEC< 6$.29'S"16?+%L>@PMK9MN%&V7&#@D[98,0:
MQT'6/U&<.0?;MLS'8H/ZEE[B>D^DQYZFN$5@Q8 FTHEP 8V@^&=)IY'%O:T^
ME6W225R!VJU&4FL@?RQ;FYMA6!8P/F;TD4VD$9D9X!F %8Z@2OY0RY@9#^F"
MUR?<9I#4&L*2BS6<S@[VVC<3(VJP.WU- K]L3AOF](IZ86 *B"*5J"=3 IB)
M4*26E0WID[88YD3$CIK&%HI"T:/3N""H);K^7!*J:UVP%8*^=%I-<OC@$_\
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M@F1T($:G$C(F*,21N_+M6O6=,$K)$@S 9IRC;_3+"[H@$DB:3$,3K2APLPP
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MQDYN7+2N8HNT,KB"A/6?#!</<VI5 I$@F[#7$2,AGUP?69DA@7IL@PB,<B0
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MLA1N4"2Q&V:G9\-#7X85;D%7 B6F-X@+M'4Y@>>%4J/D93NDD*E%*[(B@K7
M=%53MW*3DIG,*-3TUQ:8*"'<5554E?F&72LTQ;4#\JP9H!MH9.&.IH!.1SF<
M&:R:2H_##  Y3( GXS@TI&7PQ<%!Z-ITJ17/#30P9(]1%8VF>DX2@(F0#G.1
M43_I]N.2!FMIF5RL2=2"#0GY?NSQW)BL*=WMH0R@DWO<8L/M!KE$85B%D\N
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MAU@X\ :Y0 !@AKBTB8KG6)P0"#TK]D8/MB@!()@ZYQC:MS;7,Y^=,$W+IDU
MW$@3E08^8-U),F9R&" VZ3%?/#[K@4*,\ZBI"_QEAL\O5LB""* $Q0Z8/K&9
M  (W4]4S\(SPQ#U*LS!R !M, [E_D,7+8NJI^>"RU&3  9SI)IAOUP2TJU0)
MD3LVY@ T$4^W%P>\[7E5HVL@(@PJEIDP9D=,-:Y7<K=J\@-L64/N7MI>6!63
M23FT9@&<,O;]EH6EN;7=X8C=#A<UE=2)@8+<CFW+FSW @8,EDA3)<6U(4ZD%
MA$DQB[LO,S7'#,#N="5F+NYO.LZQ@L+P(@!2&O2^X;=K6/E6"/LUQM4-;VG9
MLMM!AY5=M):3.5!KA%WN3+VV%V+>Y2=Q]VW7<(J ,J8N;;@8-O*+$AF#$."<
MYH!TZ8<77>(A3NA9=C\\@G?KI2/'#G==8L%;W5](MH6V[(U,4IXDXN;59_<
MDL&,M$D*=5%#/EUPOJ)#1 *PZHOJ(NQ\I/0#+QP5-JYZE<@>W)N$-0@Z B@I
M)SP@_:W)]#*6"D@$U)=H)(S*@4 SPI_:;UWVT0[3\[KN$3^4Q(SBAQ91^,5<
MF&;;M9IB!<(]0 CU #U81?VMJYL6V+BLH*7;;/)(C;*GYO#//%LA-R$I="FV
M/3/Z9381Z=H$A<B)K.$;VKBB;9-U57;:CU!BQ%0N0B,L\$7+)<R-P-MQ0+"G
M?.Z&DR8J8R&+7Z<DE0# 'MH3N!0F I413[\*H6C?+%LP>H>-3F3A5"KZ%!)@
M L)]3.= /[<SB@*UD!E@;<Y!'X##D"%$PN:S,L",ZY%AB5F84"L$,?E4D$T)
MH :8WY!3$(GYE/R; ).59P',JX6/4P8$9P#UR!C(X@!9,,(.[:I^=1/V'H<!
M6782=I+*%HAIMVBD1$B9I@&J,02^X"L 5U@X!*@;=R2P(^83$: 010X(,-)6
M4AV"[5D&#DL229PI(B=Y 5BQ90)&PR0,IC.F> \>K:S+O!6:[=P/E432N"P"
M$;R =L#>WJ+DKD -3GA05.TCT5!DG.2?E&H!P5D@L#)VC=L4098QIJ#T&-X8
MLH> S+N$C(  0.@/6<24) <N5BA@2VY]6UZC3I@$2$CUL!L)D2/4M8R-<Q@E
M#.Z'+))'I,0R'(1K&LX)5/;)#%A#NP11N]LN3N)&FT9],9WODW_./E_^^\?N
MP5V,VX1N&:F)(C ;2003^4G0"N+*WG6;=M;8@^F!\I.>>#:H4+$JN8$:XW'(
M]!Z1/CG'B, #: (DF:S2@P%F@%( F1F03BT&;T[PL$P:B)CXX8,%,@P:&!@L
M$4[6-1T/]W\\&5!$$$#^[$%0 2(.G4# ( $:8W!1!@3$5\1B4.RLDJ8$ U).
M(8[@/[A!!&5<4@%12H^T:XSJ#!,T$G/_ %PCNYVC.33P)PME^1;6[; 4@G_D
M $;EF-,Q@,MQ9C,$$&#AC[@C/YH\ZZ9X,W%FHC='A@G<*4$.*X_3:9!B33[<
M4;K$$^9(&!-PP=)\*X!+=)+$FIU\3AZP '8 S)@0-VW! &X$@S.WU3_=T^["
M^D3FD EIG\X; MJ"" HVP8):K0Q_$X!:9% :G;TDCJ-,&64 -$QM$L?42#G3
M$[RM9@_+'2:T(P%;21M(J9:H+&IG7#.@]#E2A!]0_M -!0S@7 P'JE2*0)@A
MB<IK,84@#<9VF1,K3<WAH,!^1=95W;AL-6 :#01$>./<L!F 80<ZBD#7%Q@"
M5JLU/J$PLGIGA9:& ,DGTU$&1U\<%F*PQ&0DSF:ZQ@ R*JN4UB8#$SYG#$K!
M/H@U.8,2/'/!VA030S5?EDF5T\,*&%%$F:#>: 4\,9$!9 "U\@? :C!C04D"
M% K2,ZXW1):0#D*&: TQ$&!$FIUBI.OE@0<IRD1 I0^'3 43$SG4&<@!D9SP
M1%!,9$2#0#KAR2H.<B00 *"G0YG!<"992=NT#YHD@?;K@_)$R6!B&J(IIAO5
M$*0% $%@04,G,9TZX<L1N]TA=Y.UB6A9>2 L"NN$8$E54!A#+N.L#0 ]*X7:
MS,0 5C:'AYRSR_-_7 7>2Q!,[9*B)-&SP5!#,0"*L /][,9B=?+%DF&)*M)B
M!)@#_IIA5B94><D33RQO<@32I)G6F",\M,HU!Q$?Z=)PX40:Z3,YDXNLH$A#
M^&F+FY2"&)!8$[1M,FNDT@X&9EI8#YR6_M.G\L7DMQM".VRI7>5/YCUC;EGC
ME%+=]V-RXTA![9*J90H<FW&%G4=,*UW@W;8'*5C^FVV5O[=DF,I&1SJ9&.&+
MGN!RJ&YO!^=1#C:**? 8M2/4P7TJ2 M-!E7"J1J#'YLJ;I^RF#7.!)J(!\<$
MB#&FH_W;CXZ8J-!D,A,B>LXM$&9D$] 14_9K@JIE%)  D*VTPQ\\!H/I$L=T
MQ%9I]^'N34W"%/5!0#^F._=WO=S?MOTYPK/![=QS9W7.3=]BU%U$<44 U(BF
M+-VWP?WO+M*O_NN7_P"XNS%75KDUIE@644*B+0  *6%:1T&>&W%:F34F(;U$
MZ^$X&D^L$^HLV7P&4X G0 22=I!K'X?SPPDP1)!!D#0#2.L]8Q=AMI]RJG4;
MO4=N0$8LHVWU,)(DZR1.+#SGL! H#J9G"D,M%]/2HD$3CUN%74Y21(^_ _44
M^ 8',QB X@=35NM=*8(&D"= "9G .\A3 !!_*!($9^. 0WN-0QD 9F"?/!)(
M4+N)'Y=HJ3AKERP.7V_Z5[8>%QV9&:V+W*O;KJ(<I 45F<$KV[W5VO='HHML
M?G?:HF"*5!ZYSAX[6-Q9H'M)<0@"B"GYLY% :3@*>U2P7UVCQ@VUI@$D"H-8
M!_EAQ^R4 2S!;8"0ZY$K(+ U4"D4QO'#>V%6#-A91MVL@4VS0:ZZ8(3A$.3)
MFPS[5!H-IB06J)_GA+[\,J4VBV?9 #.S0R $3*BJ@Z^ QPTM6/;5?;M,8 +0
MH)MJ"-34E3\<6%]ME!10QK %"H$98KMG;ZA^810QUQ0Y:,8,3M@C3 W,"5K&
M8"3$K_3#&)F:S,^/C3(#IC4@DP!)!I/VG3 (J,HD"&C(=.D8TEC6 8 %1$XB
MI@B&)R)%,L_'%RBF#Z=2*9CJ/'%:D'_X8B-S 5PS4FH.T9QE033R&-NTLT>F
MH!VAORL:4G45C )"@?,*!=U(V+&0U_TP9#21N4C)C&2>(T7"&*FH'J"R!\A(
MIXP1]V$&Y2663(@ FIVDQ\,$ME7Y6 .=!)U&=,33<0=\"E# G3*"2,..A*@#
MYO28,>$]:8<!(,_J,& /J!JP;2,HP7@0I@';(G0;>NM, ^A@&:8688&6H<A%
M*X4?E/J(V3:*JTJL"9_]6#<W@4@K383$*GB#X^&N* '=4!B!K+,&&8J8PI!
M$(H4L2XG):YTZ'%F%I"Z12*@+I&+<90*Q() H/B?#&@W 1K& !4D"-1UK@&.
MAKK\#CD7!%0% Z;C! C7IAYB1%-8.A'3K&"2=\F0# DDQ'W82V!N)*P-0&;:
ML@_TQ;M4FS:55!R+*H7<2/LP%(JQ@:!>IG+"P:!ETB5GJ<&(*KF#2#,TG&65
M!-9^.?QP9.IJ9BI\,4BH R@0:S@ C<#J*$GI7+#')0)98J">HU&&>9($"%(
MCH,6R0 2#IE7,_TP*P)G/2:FF%TH*CI@3KURH.F/ ^,TZG#0!X^6"4&?V3X=
M!@B*36<Q)RC!\S/\#%!,$CPDTP*5-3/7KCY?C_( ?SQ0$UD=9_#&70>>#"D$
M^=?'%0OC(J3X8J,ZR: >$C !R-12 #YXJ5\*Z^&*D$$_;IEC-09,20)QZ(:,
MXS&DG!]H9D@>FH&E>O7!FX8,1!K&9G!EVJ-T!LYUQ,UDBID[8F<9@'\P\/\
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ME(4P 0I,J)I_%?/ +* &8-)4EMT2_P!E,\\ ^V&4DOM%2":"H^814_9@L+0
MJ"*[9FA!-12337!)W02N9D@@U(VYTQ"VP*[6A00K'(J0 *]!AF9,C^F29)7(
M^6D_TQ4 ,1!(K5C+01D*:>6%$,=DM%*J3(-/MFD8T:"2E*]3M.?Q^T85 L%&
MTAG<%?3ZM<HQN>V)D"&?8NU?F;S%!UP5U_,U595+9!\HPH )W;A 0**"3$2-
MHR(.F-K!<Y52&"N2=H0&I$]"(TP%"$2&7;$#<#-3J)H"*93B8,E=Q"I\T+2
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MSGKK@^AB (D@O.T>N9K(ZXHH&A4200#Z0"(\P.N" LSX2%!I!G7Q.!2(R(4
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MP-9.723D<7C,;5:?_2*YXYCVU6Y<5'=="67*:T\\<B+Q10;L+O9 67H0"(I
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MY0/4H"M;.[<"(S^(ICCPTR0(#5D$D1T\\(2Q@@$: :9YX'(N)-I88.PD,0:
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M#\,"VM8&Y5FNX&@GJ,.H<EU " G=NUFDQAR=XAB 3ZC!:0#&9/X8 &X$U!W
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M<,-Q](/II,FM67RP%,[B 57\N4C%=!)&GAEIB"9-#(T.<XZ3J)CS Q2IJ9-
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M1;<%$" '<LS^H0)J3GIY8519.UMX(9=JR**TU)/CG7 5[;;D9G+@;=K E@I
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M7&4D4H#F*$D8J#G62/O(^R<9#U 4B9I7;XXH 3#9>5,OQ&)I%* 4('S"<4$
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M@$[ICI."PN$$S %%VYB/(=<.J7U^9B2TR-LL^T^(URP69]I 6"0A:(F2#0@
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MPB0Q!^?Y"I ^& ((0[(#QFU6_@##*21MN%A-!)J"L_'!,%GVB" 1M(C.1G3
M?;-?6" !.Z(!\QIEBVL@ (C@"E#0X45.E(II3 (G;0%=(U!P0[$0*4J"-0,"
MI-*;IS\>N" 1XFLY^&+H:?4IRZ1 SQ<<@ "6]0(F# H=<Z9X4,_J&<&)/3S\
M,;GN?*H@D@ P*@#*AQ![C:E' ^< @#,C=2/''M?NU:6A1N =B1,U_+&OPQ^G
M<!W+4@JT@Y'9-)ZG (,[C%) G1AXCQQ\V9$#*A-:C[<3) T)@&0/#3! ^8K0
M&@)%0#]DSB ZB!,0*@TJ/]<7'V>E"EP0*"NTCRQ*W"A8U;3TGUU.D:X[[_D)
MN0J=^[C<L_3WTG:N%6+]VYR$KR/;8^H6QZB-!4Y8'8?I'NG=>W_3_([@O</K
M;_(=];W['M-N]=]SE6^$9B_R;P+"T@^40:#' ^F?HCM8_=LEOD=[[]W-_P![
MWKOO<"DW^?S^;>EV+-)53Z5R  P/U%()4A) %<@<&WN4LH,J#):!,2?QQ?55
M W[P5"@@=9C7[L73*CW&*9$*HDG.L348"*[+H <V6:>EO[<I.>)N+1AE$EE.
MI#>GPB.N%8V+3.Q#1L7:L'<@,Y 5G#^U9M* B@^D*#&E,ISPVQ0%#D"!"T,$
M,,Z^&F+7N E0P,U!))S'GIA0CL[BV(M,0VXH)V#QPEQ0MVQ>00&@W++1!%:Q
MA^1V\&_;)+%!)(S)@##W.0CVKC':JN(,Z>C/'*XU[U78:XBM&1&Z,<TE2H2W
M<CTY*>@&.8ZZW5$4_**D]0<_# -:T 4;3T@CRSQZ00/S3-8J4)Z??@@'(#U2
M!K.X'RI&-L[=LF6% -Q-/YXI!! #P(-?E!#=?#$;=I'QB:A_'I,XDC:K'S]1
M,!('@,3N #*S5(# D@,!-/XG  !,Q&8DQ0F,X$P<L0S:#H .@@T,X$ ZGTQF
M=3_,X$R3H(H <X/3H<\#TF),4&X2: DZ>6'.I:AB8Z"F9ZG!!W$EHB@+:,03
MTUG&[\JD[88$9Q1=3AB ?$1# KE3Q\,9&:&(DE3_ +O'II@P*>F#EX4D$8N>
MDL/49T<DQ-=?/#!MTJM21  VQO &@Z=<-565MI,#:S"-R,!\)PK&5(!W5"E1
M.W;37$[&: 2(,[03D6!^4:TPKF  P(8R8))!I2/'KG@$[:J NTQ5:[1.1\<1
M(6?4\S,S51%3_%,957TE6*Y'2OPR^W%Q:0%,&#) $S76?+!]1"NS."\_*:^E
M8@&8 /C@T80Q99)! (B21TR@]<>D;)D%3!M1^628()KYT\\0Z,//YKE(ER"8
M$Y 8/ZC58;B:M(I4C,: ?;3"D*SD2AV^DL6,+(%*Z:8M"=P#KD"<F W&<_(9
M8M[( !!E0("B@V@810P$30F3&8$]?NPM21,="Q R@8]+G,4::>%-/'!:X6]%
M*$EF+" "!IBAD$Q0Y5D[B#EX:8:X1! G3H: ZD#*F#=(@6%8"2%8L17<.G\\
M+N@OD8 @@9DC$@A1T/J!;_;BN2UK4L1G.":B6(@1,92!@ &HZ4W4K@'Y6B3%
M# Z8($Y00=8ZXI$-(R ,3EB-H](G6"-).'9I":1F*2*X0D0 P 'CUC I)$$S
M2D9CXC$D> 'PI. RYKEJ(F<;LLHZ3-<+-#0 C\<"#2E/AE]N/&,I%(SG$CSZ
MBN=,'I!@4K.GVX@GPK]D?TP21 FLZ8N7G8*JH6+90!J1CD\UF86 VQ* Q;0^
MB)ZYX6W:7:5$08$TP:3 C,$DZUQMZAOA2GVG3# D3)FH@R*@XG*N1_,,\] ,
M$@ U(893%08&"!G%>HG11KXXZ-\H8$R3_MP:$E0PK,-YS]V 2)!(""*F1H#E
M&"/$Q%#!U:<AK3!I.E *4K$9GK7I@2!H3T(SR.6)@0#ZI7+19\_'IB"I;6HE
M3U@: =<$;0:J9J2#$3(T&)VQ3+4L!4F::UP1L$"AVK&D"@P"$C4>G<)(])VY
MX@KD")0#(U8D'\<#]-08(JM,JFO]<"$! )(E95IK"SK@'9HH- <C6F48) "R
M9RI0YJ-/' .T$FE!0GPQ&T1!!4"AG0@]<;0!&45@4R\<?(!F*B@$P3_I@';'
M4"D]/]<05H#(\2=8ZXHE!,&(SI_!P,AZ0W4GJ(&6)@$T@^'EK]N(*D16N1)U
M^&,I\M?'XYX]2B2=1J=23@P #EK /2!EBJBD3EF/_3I@T%,Y\?'!'C$T$_9I
M@Y1]I)%,"DR-0?L\QB8$F:]:10G$Z4D]>I,?RQ(&N<X ((D9"01I6<L$Z"H$
M5%-?Z8Z])%)\9^Z,?TKK_/!$$QF(^_ @93\#E3!D S%<QYD#'Y:3,Y$>/CTP
M:5TFE.L8!^Z*S,R9Q, YUU!/7 &TY:130",&H-(@ U/\NE<'2!3*<\10S6F7
MV8H .FOA-<4U\!TP:$2,P?DZ@#[CBH$"<YTRD]?PP1$@'/3J"I\,$[6,B(Z1
MG,]<$Q,1.Z!'D-<20!4Y":G+X8^5<O[C\WV88C=D8 (H8S,?C@"8 , 4SC^[
MI@M50:B#0'R."8!?=Z@*@L#3U'*<XQ)@&29@0 <A'3[)QD<_E;-HKNIUKGA8
M8L!)$95ZG3XX5H,$DUI30 84/GXB/.9_G@&D1I$F3T^&.IF #%)_EB@J)R-1
M6# Z8+ TDU\?(8!9029-),GK(UUQ3^SQE03G'G@L:?"<J$?P,5RRTF)@?9@[
M8#1$]!F9&#M(@&H%8!I/X8W:[@,B9&E,(I/I+ >,@ZCXQ3 ;:8VC2@I&F1P0
M8 $@&,JQ77QP])-8C=!G,$#7H<""%FJ@G+3,ZX@*<OY5#=)T.'!,"*S-(KMZ
MX9F5JQ495,13**:8(H().Z2-H6L3XY8(DJ P52"#)TW3]F  (/7*IU$]:S@*
M# 8QD 3MI^:,\ 57:H &2&:'<,],!@*^H%VR)S)$Z8D;:YDR#_N,9>6%F0*_
M,($1)!'CXX))]1B"*Q2E/NP6=2#,$@SN8$"FL^6"*P3$FNYIZL<_'$@%Y: %
MVR)RD'49SA0U:2R@U('Y:U@YG'J(($GT"DD#TP<NF""3H *35?OF@Q4$03)I
M,B@$^6  OS'(B!4Q]^N(#5S\1'\HS\\(216>IJ:[?]<$Y1ZA $'HOEGA=A.0
M828F,J>&N ^1) $>(RKC<2!4L8-230C;]E<%I.X_,"?Q)^\8F1,^1 BE=?LQ
M!"^D@*:S02)C!W "C#<1 +:TQ=+ MGM!$""#N!(^W#&VLDF&.>X3)/CX##BG
MJRFA!(TF8&@Q<W0P( 7,IN#4%<B- #7"+M'J;<I;TP%?4Y?=TPI4'(&H$L%'
MI5IK0^'W8=H!C8XVDP1/J(!K&&$M)%?;G<%-%VC0BDSYX!"R X!+Y#U58+&7
M6M<6QM!D(944\HS^&)!.4,(DGIB"23KK/A&! (S%3.0\=, 4!"Z@:BF?W8C,
M1-1GUIAP*$J3)%!K(!P;8N;00S02?4=*B(D'^N-VXBI)VDE@%-)4Y$G48O,+
MERWZ"WH9E)(0F"#EH2HTQR7/-OVUM7&8C>X8ADHBJ#6&]4=,X&+=BWW)KNZ^
ML&Y==V96@[6*SMCH,<:ZUQSOMJ)<G=!T6<QIA6F2V230&/G_ *X4@4R)FL"H
MH=.F *$'49Q$*2.G7$1%8G, 9$;O'2<;8,BDGIF 3^&.39S]RU=V@4]93TS'
M^X8OB\ZA$O75)+'VK10[;F\F@ .9F!CZ-_PE] =XYI_Q5_C3AVT[_P WAW'N
M]IL=UY%X#N?=-Z$I<O1-FPADTW$13'8/H/Z*[5;X/;^S\3CK>Y 1/W?<N8ML
M#D\[F7T&YKC-)#$T%! &'2VS&VGI6*,I#4(.4]<0;A,M),FH;(4_$8EF8D2#
M)SA8,,33/XX=2ZR4()4G=%: G0BD_;AB"34S%!!J OGKC=221 !!4@>DME4#
MIEA&6-T>GHT9*N=/+ ,R"PHI+ '.!K3#$$DA?E! !&>YCIUP2I,"Z1NB *4]
M/E3%L+Z1$1E!'A_/"/;<HR$.#,$,*S P/VI3B=R2#<XS'9QN?U:T,E<ZC(G$
M74V.IV/98>JW<Z$'3';^V\;;;"KNO[<J0%H/'#NE H56V008$&G7SQR^>%@^
MR9(S(BJ^..4PDS>N;0#($':"3GH<2 &$5/A)@% ,]*?;AJ%H@$DF))H(U/C@
MC,22%R/0J9Z4P!,&0 U<XF!.<#/"P"#)4-I&H(-3G@&5'Y0I(@@&I.VL=,>@
M$T(@.)(;YB VGG\,- !B*1/_ *1/WFN XD;H%2#ZO[P!EK@"*2 =-I DA(T(
MP!$#-2:F#F8QE!@B@DQ$T_U_E@T]&E)@1.[7+KBY$@R0#)(,F/CG@@BE1!)#
M&M3 K\<2 3)@CY6@_P!NF "I^8S621I,8#;2*A0/,R,ZX)@@$U!4P9$SX&<\
M-"YL34CU$R=QG*,:^3""30;RWAXX%3600QCU$P3(B@@4Q VD#TL=OIW%84W
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ME0H8& #_ !E@"0-1&<#,[3GXDX+1!?TVU/B(+U^SPP7)W7'()FOS'Y=V=/\
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M7PSVG7*F#J54$ &&\0#AC,C,$&1\1K@DF-)(FL26.D>>  9 ,Q$D%JF, AJ
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MJ1!B#3SQ456@6)!FA'_7$@&8Z ^4>7AC<09@DZ9#K^.*Q7.<XZ'I@L1-*"D
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M<&FXF6(Q.T#7QRZ_RP !-/'3(3@0!6<P8G7X=,$G/QZ ?Q7&6T9TRJ.F"-I
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MN8Q!! SFHDBI$ZX! IEJ-1/VX%"V744/AIX8R@BAU$'*<3MTRI.4R)P"(_W
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M8*BBC_7$01-)SJ?S"?#PICY*&HZ@1*KTP=P.1( 50-T0?33/!DC=E6DD"%G
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M7%P1NFL!0I"@$ K&OA@ER<@YED)@&94C7RPP"D%ANS .TTW!A\/Z8JI!!)V
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M>G;&A .9B# ^TX  @4&6?@2.N/&D30$ Q((Z8C301TP":$ P(F2?#[\1$S6
M('C3!@#*,R9 K$#"R" =8!('3%!,UF,_ _UP"1]FD9UP":QI $SE3&43K%".
MAG E3T$K) S&6!G_ "\9_E@G0? FNGX8->HT@G.N!EH""09\YP0*@TBE?//[
M,5*SF2=/#&:@FA'CYC4ZXD;0*91$Y#/#5 _])K(Z3X8+ :]"=:?P,00#L J0
M 3TF<R>O3"BXH4R #0DTD1T\,2-OA,?97\<" LF(,")(F3@T4@^ !#9P!B5
M+ 20#(^.# S!Z&9TD_"F"2?@:?AK@CTQH-1.=1]N#" @$$5\:U'CGB$&768
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MTPJBJ("3((@Y13\3B3Z10^JLG^U?/K@J1Z6I!/VYU^.%D44!1M-# R)UC!H
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MSQF>F4"G48CH,C,9>&/CT^_"L").U30>@141-0,A@$@U(DB9!S$^,:80JTL
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MQF;U[D ,;!$K_/#@P?:8)()H0).!($#U;E, U@P/+ *P21I(.=#)K3!<[9
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GO&[5&ST@D8^4R0:!<ATW' HP\PU/AC(Q$+0Q.AKC7.,F^;KEC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>biontech_logoxforestgreen2.jpg
<TEXT>
begin 644 biontech_logoxforestgreen2.jpg
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M^S8%58U6!8J6PJC+@52CCPA?=![_4^JX^OZFRZK0*CR*&%*-%V,.FFIP Q4
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M*5H.JAX)V0";MA1*/4CA)"A![*SZ:WS47?LQ=58]7\SFQI?#MYWU0Q6$5 $
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M5 JS7:8"()"WV/GX][IK+V)'9&?)A,20:NRDNN_0 0  8/Q2TX0+T[P  $!
M%6 3SG1T@W%9*@#^K@ (Q7F9NJD>.UHF9#=U4A52!0  @!%+-:NK5,," (#)
M$U %V(SSNFL%!F $4F!< 1#*%D>B_5IW;:^;*A.RDT*J;HP"  " D8DUJEBK
MBC4KX_P! .!O JH F[&30JK/["<\C2^ZIBH PC2\T$V5B8F?;[_W0W7DX $
M & <4FWJ,M6J  " )0*J )NS%T.J]A,>7]VUC:ZI,%DWW50OW"C"A)SU0R68
M#0   $]HJ6F"KJD  ' + 56 S7I9=ZV.5O"(ZJX]#2&\4P"$R8L!]:L46(<I
M^+4?*C=' 0  P!/0- $  .Y&0!5@\T[KKGUN7V&[TMWI<6S2:UL-)#&H_J[N
MVA,;PD0<"JD"  # XTJU)TT3  #@#GZP20 ;MY-&_>O@!EN2[DZ_4  $;O%S
MW;7[(82CQ6Q^;9,H7 RIQM=[TU2#USL   !L26R:D*[_Z)H*  !WI(,JP':\
MJ+OVV-["YM5=>^3N=. .XH6"/@55H71[\?7>#]4S)PT   ";EVI,O7 J  #<
MCX JP/:<&/4/FU5W;;P[_<RV G>TET*JNIHS!?'U?IFZJ0(    ;DFI+??KM
M#0  W(. *L#VQ.Z.I_87OE\<G51W;2P 'MI.X)[BY_&[U'T92K>;.JD*J0(
M , &F.@%  #?1T 58+M>ZMH&WR>&4]/=Z2]L)? =SNJN=>,(4["30JH'3AL
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M.!4  +9 0!7@<0FHPAK"J< 3.Q1294+B!;>K?JCV'3H   !3EVI"AU/?!P
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MWY5 WO8L[>UG1=6Z:V_"JDWJMAH?NP4]]1S%&VDNX@6+%#Z&*?@YA52/G#8
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M$=#H)/C"TLC_-Q/=&UU4)RR%5*<<TOZ:&%*][(=J?[Q+!   ( <3[IZJ+@T
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M"MD!#Y#>/\W$0JI3"_%SBZ8:XH6S7^S/6C&DZB(;    ]S&ER37JT@  9$]
M%2C)E=.$1S.ECF>*@+ !B]G\<F(AU1=UU^Z/8!V,0%,-)ZF3,*M>]T/E<Q8
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M '!7QP7OU"^+V;P?P3I@DE*'B*/4,:)4I8?\^4XII/J+?5PKAE1/1[@N
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MH^[:9TX3-JO0\?[O%[/Y^0C6 7Q;B1TE!.FXMZ60ZAN[MR*&5-_U0Z4##0
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M2+!9I;RG3A>S^?4(U@%L2!J-]K&0_?3]A:UHJN%(2/569T*J    HZ4N#0
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M!P%51J/NVE(Z^1FC!--0PGM=((Y'DT*J\37WP:ZO$%(%  !X6B7\'E.7!@"
M+PBH MFJN_9Y(9T>!509DQ**@&\7L_GU"-8!;-EB-C\O8&1Y"=]ER$A3#=>I
M*XV0ZJJ=%%(MY88=  " G.QE?EKJT@  L(: *I"SDT).KQ_!&N#&\P)VXF($
M:P >3_;O^;IK=6SD4<60:E,-\77WQLZOB"'5=_U0'8UL70   ,4JI#:B+@T
M &L(J )92L6*PP).[\-B-K\:P3K@AD(@D)L2WO,EW!Q AIIJ.!)2O=69D"H
M ,"C49<& (!"":@"N3HMY.1T3V5L<A\U;8P23,QB-K\H8,R_#JH\F112_;<3
M6"N&5,]'N"X  (#2Y%X;49<& (!;"*@"V:F[]J" $-T-%[P9C;IKC?<'<I7[
M>[\9P1J8L*8:XLU?K[P&UCH44@4  -BZW .JZM(  ' + 54@*W77/BLHU/EQ
M,9M?CF =<$- %<A5[N]](_YY<DTUQ._8_RJ@(_$VQ)!JWP_5L_*>&@  P"@(
MJ ( 0*$$5('<Q OG.X6<VND(U@#+<N_@]\$8)9BF-.8_9[M>NHQ!4PT7Z?N
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M:O1A,9L?CV =\#4YAR@4 H%E.=\0HH,JV6BJX3*]9C\XM14QI!H[J>9\ Q
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MF"K7Q2;B?Z:^ 0 ;%L>ZN.!,;IJ,3\Q=A< Z_C; $TJC[%\Y@[4.^Z$RZA\
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M<)%"F?PM[L=5"JE>VA<      ."I":@"N3M,CS_571O_>9^Z*ETN9O,+)PP
M .5HJN%JJ9.JD.KG=I8ZJ0JI @      3TI %2C1B_2X":R^31V6+A:SN7&7
M  "0N3C&/H54XS2%E\[S,S<AU>.F&L[O\?\/      !@H_['=@(3$"]8G\5Q
MEW77GM==N^_0 0 @;S&DVE3#00CAC:-<$4.J9_U0'8UL70      P(0(J )3
M$B_2'H80_JB[]K+N6A=K 0 @<TTUQ._UOSG'M6)(]62$ZP(      "9 0!68
MJKUXL;;NVBM!50  R%M3#<<AA%>.<:V?^Z$RZA\      'AT JK U.T*J@(
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MPOS@'%?$D.IE/U2^<P$  /S-;R0  +@' 56 S1%2)5>YCE+:&<$:@/%ZX6R
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MU@ \O:PO"BQF\]QO%H!):ZKA,OT=^CCUO5AC+X54GX]N90  P),IH!:B+@T
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MG19R>L:_,!8*@4"N2GCO7XU@#<"6--40?[N\LK]K'0JI @# I)50$U&7!@"
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MGHU@#1 $5(','!=R8*7\[07N*894FVJ(8?LW]FY%#*F^ZX?*]SH  "B?NC0
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M#3O$H)NQKY"!NFMCZ.IU@6>E>RJP,4TU7*:0:HD7<+_77@CALA^J_;R?!@
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M0G77QDY_KPL_ P%5X-&ED.I/A7<>>J@84KWLA\IW0   &*?2:RGJT@  %$]
M%2B)'_"P/5,(5>V%$$Y'L Z8G'232>GO/^/]@2?35$,?_Q%272M^!^R%5 $
M8'PF,.8_J$L# % Z 56@)"XHPI8L9O/SB00:#M.(<>"1I'!JGSI&E,P8:>!)
M-=5PF4*J'YS$BGA!.'92-94#  #&9PHW_*I+ P!0+ %5H"0N)L)V3:7SW^LT
M:AS8LC2^['P"X=0@H J,@9#J5^VF3JI^5P( P+A,);BI+@T 0)$$5(&2Z* *
MVS6E<-698B!L5PJG]JEK7>D^+F;S2R\I8 R::KA.(=7W#F3%3@JI'HQL70
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M&$ZX3!TA@:^HN_8TCB*;Z!Y]6LSFNEL V4DAU?@]YX/36_'G]\!^J'P/! "
M)Y!J+5.]H4Y=&@" + FH B4X<(KPN%(A<(KCE&[$4'R?.D,"7XC='.JNC=V6
M7T]X;TY'L : !VFJX2IU4A527;6;.JFZ* P  $]CRC47=6D  +(CH J4X+B
MYW U@C7 ?4U]='4<5WX6.T0:K01_J[NV29]K+R:\+9\$5('<-=5PG4*J;QWF
MBIT44G6S)   /+[3"7=1#>K2  #D1D 5R%H:99+]>/_%;"Z@2G9T4?VOU^FN
M=5VTF+PTTO]=*I1/V>EB-K^>^NL!R%\,J3;5$$.8;QSGBOA9]WL_5#H7 0#
M(THU%S<&JTL# ) ) 54@=R5T3X6<3;V+ZHV]$,(?==?:#R8I%L+KKKV<^$C_
M&[JG L5IJB&&,']SLFN=]4/E=RD  #RNJ7=1O:$N#0# Z FH MFJN_9Y".&P
M@!/4@9)LZ:*ZXN<8TG/7.E,1QXBEKJE_I((XNJ<"A6JJ(88P7SG?M7X=X9H
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M[BP6!%_47?LQA! [59[[F\!326'IX_2ZY.Y^2P%]@,E*(=6#?JCB;[9#KP0
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M?_/PWOQ^;Q>S^47N3P)@&YIJ..^'*OXOG]E@  #@L<1:3:JEOK3I#Z8N#0#
M1@FH J-4=^VS]*.W]%'# JH4:3&;QY% )ZF0Q?=[F1YG2T7!/NZSO>4VZ;.T
M$4K=BD\Z<@!\70JI7J:I$3Z#  #^7WOWDQNWD<4!F#.8O76#Z9S ;>Z%T">(
M?(*TEKV*#&@?>T\@RDK+2"<8^0330N\YT@WD&T@W&)3]&)<4*=:?)IO=_#Z
MD T9L%+E-)NO?_4>T)=4L[GR'+(2ZM(  +R8@"HP.+O'AU4\Y&Y[\>"SAWBV
MV7)>'T7'QFT/FO>M+0JFU\O+[ 2[P#M%C-[:BV"J3A'=,=H?X!&JLKE8-&4E
MI H  /0EU6QVCP]32/4_%GVEU*4! '@6 55@,*+36^JX^,M(=F4Q@)\!NK;G
MM'JG7L?UZ^[QX4V\KBRB,"@ /P(12*VRZ]]C7Y,>G!KM#_!X$5*=Q'N4UY8.
M  #H6HSZ/RV*XF>+W0EU:0  'DU %1B$W>/#@PBGCBG$)J#*UG-:O5>OLE/L
MO]TI#%XLY[77G"VP>WPX+8IB*I"Z-JD[Q,%(_]L!GJTJF^NLDZJ0*@  T(>#
MJ*-Y!NF6NC0  ']+0!58F^B8F@H$LY$&;'1?8Q3BM/KO(^J./!2O[HQ=2E_.
M4U&PO8Q?&K8(HTZR0.J/8U^3-;LQVA_@^;*0ZI$N1@  0->RY@D+$[YZI2X-
M , M JI [W:/#_=B[/?>B(L"EP(NC,ER7A_L'A]63JNOW8]YR#&*@Y=1&+R*
M8NV5,4S]BC'][:C^]M?"J,-SH'@.\#(II)K"_HNF+(14 0" KJ5:3DSP^\-B
MKY6Z- # B FH IV+3JF54.HM)P/Z6: O512;O 8,R^LL./QK<;M >!W%P>LH
M%EX+Z#U/=$/=B6ZH[7UQ1VA[8YPNY[5[-\"*5&630JI7[7L/  " KJ2:3C1/
M<$AN6-2E 0!&0D 56*EXR"\B>#.-:XSC^[_'>']&)T8JI=>&_]G]C= 6!V]U
M\HPB81%CF8H(';<GVQ?9'[T80Z?H[+Y7Q+VOR(*HA4ZH6R%U/9^-?1$ 5JTJ
MFP\14M7)"   Z%2J[<0!<H?%AT]=&@!@RVQJ0'6Z>WRX>,2? _HQ$4)]DDMC
M2ABK&*FT+XBP%=H"85XHO-4%+2L:WL1)]UQ>0+S/][Z_"NTX_8?<]_VI+L"C
M<I,%CP%8L:IL3F+<_Y'[*\!PW#F(!\ :+.>UST%7SX2O[; -=6D8"H%N 'JQ
MJ0'55[I1 1O,B&!&+48JI9#?+V-?BQ&Y[[V;]W(,W9=P:.&,.@  "=-)1$%4
MJ@(=0+<BI'H1'6]\4 PP#/^U#P!K]P];L%K9A"_/'N.A+@U_[^V=#L0 T(E_
M6E: WAGOS^@MY_5!412G8U\'8-!FJ>NS+0+H7E4V%]'-Z,9R P  78E:S\P"
M P! ?P14 ?KUR7A_^%,*J5Y:#F" ]I?SVH$2@!Y%2'7B_2$  -"EJ/GL6V0
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M1 [' 0# B@FH G1/\ 6>( NIGELWH$/[#I  ;(X(J59"J@  0%>B5B2D"@
M*R2@"M"M\^6\7EAC>)H44EW.Z\I8): #*=CT3C@58/-497,AI H  '0I:D;O
M/'<  ,!J"*@"=$OW5'B!&*OTT1H"*Y(^6*B6\_K,@@)LI@BI3HJBN+2%  !
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M@"K TZ33KN^$4V&SQ*GU--YUORB*S[8/-DH*E[]-(]*,\P?@)2*D^MXB @
M?8BQ_P?IT+4#<P  C)6 *L#CI7!JM9S79]8,-E,*ER_G]410%39"&TQ-]]Z%
M+0-@%:JR.8KW@@   +V(25_IP-P;D[X  !@; 56 Q[E,HUB6\_K">L'F$U2%
M01-,!:!35=FDB1COXA B  ! +])G3#'IZZV@*@  8R&@"O!]I]$Y]=I:P781
M5(5!^228"D!?JK))DS$J(54  *!OJ?850=4W1O\# +#M!%0!'I8^J-Q/8U>$
M4V&[94'5=TZN0Z]NH@C_PW)>[PFF M"GJFPN(J3JH!(  -"[Z*B:1O__$#4R
M!^@  -@Z JH ]TL!M6D*K5D?&(_EO#YS<AUZD8) [XNBF,1!D"O+#L Z1$AU
M6A3%I0T   #6(=7&(JB:FBA\=(@. (!M\B^["7!+.IWZ83FOCRP+C%<ZN5X4
MQ6SW^/"@*(ITI>+@O_V3@!=+8_Q3Q^(S2PG 4%1E<[UHRG1(*77R?FUC  "
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MKZ*KO8,^    ][C36.'O&BSD]>>[M>B\3EUHN   ,'!%4?P?RW%GH"=*P5\
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
